Toxicology Research Laboratory

The University of Illinois at Chicago

Department of Pharmacology (M/C 868) 1940 W. Taylor St. Chicago, Illinois 60612-7353

Task Order No.: UIC-15B UIC/TRL Study No.: 152

Title Page

Volume 1 of 2

Study Report for Task Order No. UIC-15B SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

Sponsor: US Army Medical Materiel

Development Activity

Test Article: WR238605 Succinate Contract No.: DAMD17-92-C-2001

Study Director

Barry S. Levine, D.Sc., D.A.B.T.

In-Life Phase Completed On

February 2, 1996

Performing Laboratory

TOXICOLOGY RESEARCH LABORATORY (TRL)
University of Illinois at Chicago (UIC)
Department of Pharmacology
1940 W. Taylor St.
Chicago, IL 60612-7353

The views, opinions, and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy, or decision, unless so designated by other documentation.

CECHIDITY	CI ACCIEIC	A TIONI OF	THIS PAGE

		RE	PORT D	OCUMENTATION	PAGE	BAF		Form Approved OMB No. 0704-0188	
1a. REPORT S	ECURITY CLASS	IFICATION			1b. RESTRICTIVE MARKINGS				
2a. SECURITY Unclassi	CLASSIFICATIO fied	N AUTHO	RITY		3. DISTRIBUTION	/AVAILABILITY OF	REPORT		
2b. DECLASSII	FICATION / DOV	VNGRADIN	ig schedui	E	Unlimited				
4. PERFORMIN				R(S)	5. MONITORING ORGANIZATION REPORT NUMBER(S)				
	UIC/TRL Stu	•							
Toxicolo	PERFORMING ogy Research ty of Illino	Laborato	ory	6b. OFFICE SYMBOL (If applicable)	7a. NAME OF MONITORING ORGANIZATION U.S. Army Medical Materiel Development Activity				
6c. ADDRESS	(City, State, and ent of Pharma	d ZIP Code	e)		7b. ADDRESS (Cit ATTN: MOMR-	y, State, and ZIP Co -RMA-RD	ode)		
1940 W. Taylor Street Chicago, IL 60612-7353					Fort Detrick	ck MD 21702-5014			
8a. NAME OF	FUNDING/SPC	NSORING		8b. OFFICE SYMBOL		INSTRUMENT IDE		TON NUMBER	
ORGANIZATION U.S. Army Medical (If applicable) Materiel Development Activity MCMR-UMP					DAMD17-92-C-	-2001			
8c. ADDRESS (City, State, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS									
Fort Detrick Frederick MD 21702-5009					NO.	WORK UNIT ACCESSION NO.			
63807A 30463807 QC 073					073				
Six Mont	h Oral Toxic	ity Stud	ly of WR23	88605 Succinate in R	ats				
12. PERSONAL	AUTHOR(S)			-					
13a. TYPE OF Study	REPORT		B. TIME CO		4. DATE OF REPO	RT (Year, Month, D	(ay) 15	. PAGE COUNT	
16. SUPPLEME	NTARY NOTAL	NOF							
17.	COSATI	CODES		1B. SUBJECT TERMS (C	ontinue on reverse	e if necessary and	identify	by block number)	
FIELD	GROUP	SUB-G	ROUP						
4				and identify by block nu					
aminoquinol mg base/kg/ lung lesions	ine derivative w day, and were be were seen at 6 a	hich has de ased on a th and 18 mg b	monstrated a ree month to base/kg/day	antimalarial potential in pre- exicity study with a three m	clinical studies. Dos conth recovery perior y was the no-observ	se levels studied were d in rats (UIC/TRL S ed effect level. In the	tudy No.	R238605 Succinate is an 8- le control), 0.5, 2.0 and 9.0 098) in which anemia and study, the animals were ≈	
clinical sign significantly and high dos due to the p	The primary toxicities of WR238605 Succinate were to RBCs, the lungs and the liver. Mortality occurred in one high dose male rat. Treatment-related clinical signs in high dose animals included rough coat, hunched posture, labored breathing (males), and piloerection (females). Body weight gains were significantly reduced in high dose animals and mid dose males. Also, food consumption was decreased in high dose animals. High dose males, and mid and high dose females had decreased RBC counts, HCT and HGB concentration, suggestive of mild anemia. The anemia may have been hemolytic in origin due to the presence of Heinz bodies and increased methemoglobin levels. Microscopic lesions observed in the spleen, bone marrow, kidneys and adrenal glands may have been secondary to anemia and/or hemolysis. High dose animals had elevations in mature neutrophil and lymphocyte numbers. Mild thrombocytopenia was seen in mid and high dose males. Pulmonary lesions in male and female rats in the mid and high dose groups consisted of foamy). Body weight gains were High dose males, and mid we been hemolytic in origin arrow, kidneys and adrenal mphocyte numbers. Mild		
macrophage centrilobula TBA. Simil near the lov	accumulation, region of the line clinical chemy dose of 0.5 mg	chronic interver were so istry chang base/kg/d	erstitial infla een in high o ges were seen ay.	mmation, and hemorrhage dose males, but not in fema	(high dose groups of ales, and were accom- ne no-effect level (N	only). Apoptosis, p npanied by decrease OEL) for WR23860	igmentati d serum (5 Succina	on and fatty change in the GLOB, BUN and increased te is considered to be at or	
	TION / AVAILAB		ABSTRACT SAME AS R	PT. DTIC USERS	21. ABSTRACT SE Unclassifie	CURITY CLASSIFICA	TION		
	F RESPONSIBLE		_			Include Area Code		FFICE SYMBOL	
the Real Property lies and the Real Property lies in	S. Levine				(312) 330-	1343	1 1	/ A	

DD Form 1473, JUN 86

Previous editions are obsolete.

SECURITY CLASSIFICATION OF THIS PAGE

Task Order No.: UIC-15B UIC/TRL Study No.: 152

DRAFT

STATEMENT OF COMPLIANCE

Barry S. Levine, D.Sc., D.A.B.T.

Study No. 152 entitled "Six Month Oral Toxicity Study of WR238605 Succinate in Rats" was conducted in compliance with the Good Laboratory Practices regulations as published in 21 CFR 58, 40 CFR 160 and 40 CFR 792 in all material aspects.

The protocol for this study was approved by the	ne UIC Animal Care Committee.
Signature	
Study Director	
3.	

Date



QUALITY ASSURANCE STATEMENT

STUDY TITLE: SIX MONTH ORAL TOXICITY STUDY OF WR238605

SUCCINATE IN RATS

STUDY NUMBER: 152

STUDY DIRECTOR: BARRY S. LEVINE

INITIATION DATE: 5/15/95

This study has been divided into a series of phases. random sampling approach, Quality Assurance personnel monitors each of these phases over a series of studies. Procedures, equipment, documentation, etc., are examined in order to assure that the study is performed in accordance with the Good Laboratory Practice regulations of the Food and Drug Administration and the Environmental Protection Agency to assure that the study is conducted according to the protocol.

The following are the inspection dates, phases inspected, and report dates of QA inspections of the study.

INSPECT ON 5/15/95, TO STUDY DIR 5/15/95, TO MGMT 5/15/95

PHASES: PROTOCOL REVIEW

INSPECT ON 7/19/95, TO STUDY DIR 7/19/95, TO MGMT 7/20/95

PHASES: ANIMAL RECEIPT

INSPECT ON 8/2/95, TO STUDY DIR 8/2/95, TO MGMT 8/3/95 PHASES: BODY WEIGHT, DOSING, CLINICAL OBSERVATION, FOOD

CONSUMPTION, ROOM ENVIRONMENT AND ANIMAL IDENTIFICATION

INSPECT ON 9/11-12/95, TO STUDY DIR 9/12/95, TO MGMT 9/12/95

PHASES: RAW DATA AND DRAFT REPORT FROM THE ANALYTICAL LABORATORY

INSPECT ON 9/19/95, TO STUDY DIR 9/20/95, TO MGMT 9/21/95

PHASES: TEST ARTICLE ANALYSIS

INSPECT ON 1/30/96, TO STUDY DIR 1/31/96, TO MGMT 2/5/96

PHASES: OPTHALMIC EXAMINATION

INSPECT ON 2/2/96, TO STUDY DIR 2/5/96, TO MGMT 2/5/96

PHASES: NECROPSY AND BLOOD COLLECTION

INSPECT ON 5/1-3/96, TO STUDY DIR 5/3/96, TO MGMT 5/7/96

PHASES: RAW DATA AND DRAFT REPORT FROM THE ANALYTICAL LABORATORY

INSPECT ON 5/6-7/96, TO STUDY DIR 5/7/96, TO MGMT 7/1/96

PHASES: RAW DATA

INSPECT ON 7/1-3/96, TO STUDY DIR 7/3/96, TO MGMT 7/9/96

PHASES: DRAFT REPORT

ald Solvenherk

Task Order No.: UIC-15B UIC/TRL Study No.: 152

Signature Page



SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

Test Article.: WR23

WR238605 Succinate

Sponsor:

US Army Medical Materiel

Development Activity

Fort Detrick

Frederick, MD 21702-5009

Sponsor

Representative:

George J. Schieferstein, Ph.D.

Testing Facility:

TOXICOLOGY RESEARCH LABORATORY (TRL)

University of Illinois at Chicago (UIC)

Department of Pharmacology

1940 W. Taylor St. Chicago, IL 60612-7353

Barry S. Levine, D.Sc., D.A.B.T. Study Director

Date

May 15, 1995

Dosing Initiation:

Study Initiation:

August 02, 1995

In-Life Completion:

February 02, 1996

Task Order No.: UIC-15B UIC/TRL Study No.: 152

TABLE OF CONTENTS



VOLUME 1

TITLE	PAGE			1
REPOI	RT DOC	UMEN	TATION PAGE	2
STATI	EMENT	OF CO	OMPLIANCE	3
QUAL	ITY AS	SURAN	NCE STATEMENT	4
SIGNA	TURE 1	PAGE		5
TABL	E OF CO	ONTEN	its	6
	1.	SUMM	MARY	8
	2.	INTRO	DDUCTION	8
	3.	MATE	ERIALS AND METHODS	9
		3.1	Test Article	
		3.2 3.3	Animals	
		3.4	Experimental Design	
	4.		LTS	
JK NM JK RB JK MM	3-1-12	4.3 4.4 -4.5 -4.6 -4.7	Dosage Formulation Analyses Mortality and Clinical Signs/Observations Body Weight Food Consumption Clinical Pathology Ophthalmology Organ Weights Pathology	14 15 15 15 16
	5.	DISCU	USSION/CONCLUSION	18
	6.	PERSO	ONNEL	20
	7.	ARCH	HIVES	20
	8	REFER	RENCES	20

Task Order No.: UIC-15B UIC/TRL Study No.: 152

TABLE OF CONTENTS (contd.)



TABLES

1 2 3 4 5 6 7	Summary of Toxic Responses2Dosage Formulation Analyses2Summary of Clinical Signs2Summary of Body Weights2Summary of Weight Gains3Summary of Daily Mean Food Consumption3Summary of Clinical Chemistry Tests4	2:20
8 9 10	Summary of Hematology Tests	72
1 2	FIGURES Summary of Male Body Weights	
A B C D E F	Analytical Chemistry Report	-
	VOLUME 2 APPENDICES (contd.)	
G H I J K L M N	Individual Hematology DataG-Ophthalmology ReportH-Individual Organ WeightsI-Pathology ReportJ-Pretest Clinical Pathology DataK-Statistical Analysis DataL-Protocol and Protocol AmendmentsM-Study DeviationsN-	

Task Order No.: UIC-15B UIC/TRL Study No.: 152

SUMMARY

DRAFT

This study evaluated the toxicity of WR238605 Succinate in rats following six months of daily oral (gavage) administration. WR238605 Succinate is an 8-aminoquinoline derivative which has demonstrated antimalarial potential in preclinical studies. Dose levels studied were 0 (vehicle control), 0.5, 2.0 and 9.0 mg base/kg/day, and were based on a three month toxicity study with a three month recovery period in rats (UIC/TRL Study No. 098) in which anemia and lung lesions were seen at 6 and 18 mg base/kg/day whereas 0.5 mg base/kg/day was the no-observed effect level. In the present study, the animals were ≈ 7 weeks old, and weighed 216 - 289 g (males) and 160 - 204 g (females) upon initiation of drug treatment. The results are summarized in Table 1.

The primary toxicities of WR238605 Succinate were to RBCs, the lungs and the liver. Mortality occurred in one high dose male rat. Treatment-related clinical signs in high dose animals included rough coat, hunched posture, labored breathing (males), and piloerection (females). Body weight gains were significantly reduced in high dose animals and mid dose males. Also, food consumption was decreased in high dose animals. High dose males, and mid and high dose females had decreased RBC counts, HCT and HGB concentration, suggestive of mild anemia. The anemia may have been hemolytic in origin due to the presence of Heinz bodies and increased methemoglobin levels. Microscopic lesions observed in the spleen, bone marrow, kidneys and adrenal glands may have been secondary to anemia and/or hemolysis. High dose animals had elevations in mature neutrophil and lymphocyte numbers. Mild thrombocytopenia was seen in mid and high dose males. Pulmonary lesions in male and female rats in the mid and high dose groups consisted of foamy macrophage accumulation, chronic interstitial inflammation, and hemorrhage (high dose groups only). Apoptosis, pigmentation and fatty change in the centrilobular region of the liver were seen in high dose males, but not in females, and were accompanied by decreased serum GLOB, BUN and increased TBA. Similar clinical chemistry changes were seen in high dose females. The no-effect level (NOEL) for WR238605 Succinate is considered to be at or near the low dose of 0.5 mg base/kg/day.

2. INTRODUCTION

This study was conducted to determine the specific target organ toxicity, dose-response relationships and a no observed adverse effect level of WR238605 succinate in rats following six months of daily oral administration. WR238605 Succinate is an 8-aminoquinoline derivative which has demonstrated antimalarial potential in preclinical studies. WR238605 was discovered at WRAIR, and is being developed as a prophylactic to replace primaquine. The study was conducted in accordance with the specifications of the Sponsor as described in Task Order No. UIC-15. The rats used in the study are a standard and accepted rodent species for regulatory toxicology studies, and was specified by the Sponsor. Oral administration is the intended clinical route and was also specified by the Sponsor. All methods and procedures were conducted in accordance with the Quality Assurance Programs of the Toxicology Research Laboratory, University of Illinois at Chicago and Pathology Associates, Intl., designed to conform with FDA Good Laboratory Practices Regulations. No unforeseen circumstances affected the integrity of the study. Dosing was initiated on August 02, 1995 and the in-life portion was terminated on February 02, 1996.

3. MATERIALS AND METHODS

DRAFT

3.1 Test Article

WR238605 Succinate (Bottle No. BM12562), a pale yellow powder, was provided by the Sponsor. It was received on December July 10, 1995 from Herner & Co., and was assigned an in-house chemical number (0720614). The chemical name of the test article is 8-[(4-Amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-(3-trifluoromethyl-phenoxy)quinoline succinate and the mole fraction of the base is 0.8. It was stored at 2 to 8°C and ambient humidity, and protected from light in an amber bottle. The chemical structure follows.

The Analytical Chemistry Report is contained in Appendix A. The test article was initially identified by GC-MS and the purity was determined to be $99.52\% \pm 0.21\%$. The purity was re-determined following completion of the in-life portion of the study. At that time, the purity was $99.98\% \pm 0.02\%$. Thus, the test article was stable under storage conditions.

3.2 Animals

One hundred and twenty-five male and one hundred and twenty-six female CD® Virus Antibody Free (VAF) rats were obtained from Charles River Breeding Laboratories (Kingston, NY) on July 19, 1995. The animals were approximately 6 weeks old (date of birth June 10, 1995) upon arrival at the UIC AAALAC-accredited animal facility. Each animal was given a study-unique quarantine/pretest number following placement in cages. Animals were singly housed in polycarbonate cages with Anderson bed-o-cob® bedding (Heinold, Kankakee, IL) in a temperature (65-78°F) and humidity (30-70%) controlled room with a 14 hour light/10 hour dark cycle. The cage size, 840 cm² area and 20 cm height, was adequate to house rats at the upper weight range as described in the Guide for the Care and Use of Laboratory Animals, DHEW (NIH) No. 86.23. All animals were routinely transferred to clean cages with fresh bedding weekly.

Certified Rodent Chow No. 5002 (PMI Feeds Inc., St. Louis, MO) was provided ad libitum from arrival until termination. Tap water from an automatic watering system in which the room distribution lines were flushed daily was provided ad libitum. The water

Task Order No.: UIC-15B

UIC/TRL_Study No.: 152

was not treated with additional chlorine or HCl. There were no known contaminants in the feed or water which were expected to influence the study. The results of the bimonthly comprehensive chemical analyses of Chicago water performed by the City of Chicago are documented in files maintained by Quality Assurance.

3.3 Experimental Design

All animals were quarantined for approximately two weeks. During that time, the animals were observed daily for signs of illness, and all unusual observations were reported to the Study Director or Clinical Veterinarian. Hematology, clinical chemistry and coagulation parameters measured in five rats/sex indicated that the shipment was suitable for use (Appendix K). These rats, however, were not used in the dosing portion of the study. Animals were examined and approved for use by the Clinical Veterinarian during the quarantine period prior to being placed on test. Near the end of the quarantine/pretest period, 100 animals of each sex were randomized by sex into the groups shown in the following table using a computer-generated randomization program, stratified on the basis of body weight.

Treatment Group	Dose Level (mg base/kg/day	Dose Conc. (mg base/ml)	Dose Volume (ml/kg/day)	Number of Males	Number of Females
1	0	0	5	20 + 5*	20 + 5*
2	0.5	0.1	5	20 + 5*	20 + 5*
3	2.0	0.4	5	20 + 5*	20 + 5*
4	9.0	1.8	5	20 + 5*	20 + 5*

* Five satellite rats/sex/dose were utilized for the collection of blood samples for plasma drug level analysis and were euthanized after the last set of samples were collected in week 25. All other observations, tests and measurements were performed on these animals except for the collection of blood samples for clinical pathology measurements, ophthalmology examinations and pathology evaluations. The remaining 20 rats/sex/dose were used in the core toxicity study.

During the test animal selection process, each animal was assigned an animal number unique to it within the population making up the study. This number was coded on a subcutaneously implanted microchip and also appeared on a cage card visible on the front of each cage. The cage card additionally contained the study number, test article identification, sex, treatment group number, and dose level. Cage cards were color-coded as a function of treatment group.

The test article dosage formulation was administered by gavage once daily for at least 26 weeks beginning on August 2, 1995 (day 1). Control animals received the test article vehicle (aqueous 1% methylcellulose/0.2% Tween 80). All animals received the vehicle by gavage for at least 3 days during week -1 to acclimate them to the procedure. The animals were dosed up to and including the day prior to scheduled necropsy on days 183,

date?

Task Order No.: UIC-15B

UIC/TRL Study No.: 152

184, and 185. Dosing volume was 5 ml/kg/day, adjusted on the basis of each animal's most recent body weight. Gavage needles were cleaned with 100% ethanol and rinsed with deionized distilled water after each day's use. The rats weighed 216 - 289 g (males) and 160 - 204 g (females) on day 1 and were approximately seven weeks old at initiation of treatment.

Dosing formulation calculations of the test article were adjusted for purity of the test article and the base mole fraction. The control materials were assumed to be 100% pure for dosing calculations. Formulations were prepared weekly and were administered daily by gavage, at 5 ml/kg/day, 7 days a week. The 1% methylcellulose/0.2% Tween 80 vehicle was prepared at least weekly by placing the required amount of deionized distilled water in a beaker and then adding the required amount of methylcellulose and volume of Tween 80, using its specific gravity of 1.08 (1.0 g of methylcellulose and 0.2 g Tween 80 per 100 ml of deionized water). One lot no. each of methylcellulose and Tween 80 was used. The mixture was stirred while being heated until homogenous and then refrigerated.

The test article dosing suspensions were prepared weekly. Stability data from a previously conducted dog toxicity study by gastric intubation demonstrated that WR238605 Succinate suspensions were stable for at least 28 days (UIC/TRL Study No. 47). Homogeneity data also obtained from UIC/TRL Study No. 047 demonstrated that the test article suspensions were homogenous (coefficients of variations for sampling in the top, middle and bottom of several test suspensions were typically less than 4%).

Each test article dosing suspension was prepared individually by adding the appropriate amount of WR238605 Succinate to the required volume of the 1.0% methylcellulose/0.2% Tween 80 vehicle in a pre-calibrated beaker. The contents were mixed with an Omni-Mixer homogenizer, for at least 5 minutes. All suspensions were stored at 2 - 8°C. All suspensions were allowed to warm to room temperature and stirred continuously before and during gavage administration. Samples of all dosing suspensions prepared weekly were analyzed, and only suspensions within 10% of their target concentration were used. Weekly samples were also analyzed for test article concentration after use. Tolerance of sample analysis after use was also 10%, i.e., of the "before use" assay value.

Non-fasted body weights were recorded in week -1, on day 1, weekly thereafter and at scheduled necropsy. Clinical signs were observed and recorded for all animals once daily, approximately 1 - 2 hours after dosing. The general behavior, posture, locomotion, breathing pattern and coat were observed for all animals. The animals were also observed immediately prior to dosing and in the afternoon for moribundity/mortality. Physical examinations (clinical observations) which included examination of eyes and all orifices were conducted weekly starting in week -1. Food consumption was measured for all animals weekly commencing with week -1. Core study rats were examined by indirect ophthalmoscopy prior to study initiation (week -1), and during week 13 and week 26. The animals were treated with 1% atropine sulfate eye drops prior to the examination.

Hematology and clinical chemistry parameters were measured for 10 animals/sex/group in the core toxicity study during weeks 4, 13 and 26. The same animals were used throughout the study, with the exception of animal no. 558 (Group 4-M) which was found dead on December 16, 1995 (Day 137) and replaced with animal no. 561. The non-fasted animals were anesthetized by carbon dioxide inhalation (70% CO:30% O₂),

Task Order No.: UIC-15B

UIC/TRL Study No.: 152

0)

and approximately 1.5 - 2.0 ml of blood was collected from the orbital sinus to measure the following parameters. The samples were processed in the same random order as collected. Clinical pathology methodology is contained in Appendix B.

Hematology

^aErythrocyte count and morphology Hematocrit Hemoglobin

Leukocyte count, total and differential Reticulocyte count

Mean corpuscular volume (MCV) Mean corpuscular hemoglobin (MCH) Mean corpuscular hemoglobin

concentration (MCHC)
Heinz bodies

Platelet count

Methemoglobin

^aIncludes nucleated RBCs

^bMeasured with a Co-oximeter (Instrumentation Laboratory Model 282). The assay was performed within one hour of sample collection. The specimens were kept on wet ice prior to analysis.

Clinical Chemistry

Alanine aminotransferase (ALT)

Albumin

Albumin/Globulin ratio (calc.) Alkaline phosphatase (ALKP)

Calcium Chloride Creatinine

Creatine kinase Glucose Inorganic phosphorus

Lactate dehydrogenase (LDH)

Potassium Sodium

Sorbitol dehydrogenase (SDH)

Total bile acids Total Protein

Urea nitrogen (BUN)

Activated partial thromboplastin time (APTT) was measured in all rats for which clinical pathology measurements were done. The blood samples for the APTT measurements were collected from the vena cava at scheduled necropsy in week 27.

Blood samples (1.0 - 2.0 ml) were collected from the orbital sinus from the 5 satellite rats/sex/group designated for the determination of plasma drug levels in week -1, approximately 24 hours after the first day of dosing, and approximately 24 hours after dosing at the following timepoints: weeks 3, 7, 18 and 25. Blood samples were collected immediately prior to dosing, i.e., approximately 24 hours after the previous dose, due to the anticipated long half-life of the test article. The plasma samples were stored at -65° to -70°C, and sent in two shipments as directed by the Sponsor to Dr. Emil Lin, University of California at San Francisco (UCSF) for measurement of plasma drug levels. As indicated by the Sponsor, the UCSF plasma drug level results will not be included in this report.

All animals which died on test were necropsied on that day. The surviving animals were killed and necropsied in random order over three consecutive days at the onset of week 27 (days 183 - 185). Euthanasia was accomplished by carbon dioxide asphyxiation, and

Task Order No.: UIC-15B UIC/TRL Study No.: 152

MRAFT

an extensive necropsy was performed under the direction and supervision of the pathologist. Terminal body weights were collected prior to routine sacrifice.

The necropsy procedure was a thorough and systematic examination and dissection of the animal viscera and carcass, and collection and fixation of the following tissues/organs in 10% neutral buffered formalin (NBF). The subcutaneously implanted microchip was also saved from each animal with the NBF-fixed tissues.

*Adrenal glands

*Brain (fore-, mid-, hind-)

Cecum

Colon

Diaphragm

Duodenum

Esophagus

Eyes with harderian glands

Femur with marrow

Gross lesions

*Heart

Ileum

Jejunum

*Kidneys

*Liver

* I ~ /D...

* Lungs/Bronchi

Lymph node (mesenteric)

*Ovaries

Pancreas

Pituitary

Prostate

Rib with costochondral junction Salivary gland (submaxillary)

Sciatic nerve Skeletal muscle

Skin with mammary gland

Spinal cord (thoracic)

*Spleen

Sternum with marrow

Stomach

*Testes with epididymides

Thymus

Thyroid gland/Parathyroids

Tongue Trachea

Urinary bladder

Uterus

All tissues and organs collected at necropsy were examined microscopically in all control and high dose animals. If treatment-related lesions were observed, those tissues/organs were examined microscopically within sex for mid and low dose animals. The one high dose male found dead was also processed for microscopic examination. Gross lesions were examined microscopically in all animals.

Femoral bone marrow smears were prepared from all animals at scheduled necropsy. The myeloid:erythroid (M:E) ratio was determined in control and high dose animals. Since treatment-related changes were not seen (Section 4.8, Pathology), M:E ratios were not determined in mid and low dose animals.

3.4 Statistical Analyses

For each sex, Analysis of Variance tests were conducted on body weight, weekly body weight gains, food consumption, hematology, clinical chemistry and organ weight data. Organ weight analyses considered weights relative to brain weight. If a significant F ratio was obtained from an ANOVA test ($p \le 0.05$), Dunnett's t test was used for pair-wise

^{*}Weighed at scheduled necropsy. Paired organs were weighed as a unit.

Task Order No.: UIC-15B UIC/TRL Study No.: 152

comparisons with the concurrent control group (Dunnett, 1964). The level of significance was $p \le 0.05$. All statistical analyses compared treated to control animals at each time point. Data were not corrected for baseline values, except that body weight analysis included absolute values, weekly changes and total weight changes. Dose levels for all summary and individual data are expressed on the basis of mg base/kg/day.

Statistical analyses was performed on an IBM™ compatible computer using the commercially available LabCat® computer program.

Quantitative data were tabulated and are presented in the report. In addition to the written report, summary data tables of parameters and variability were transmitted to the Sponsor on magnetic media (computer diskette) in "ASCII" form. The transcribed data on disk were no longer considered GLP compliant.

4. RESULTS

4.1 Dosage Formulation Analyses

The Analytical Chemistry Report is contained in Appendix A. Dosage formulation analyses are shown in Table 2.

Test article dosage formulations were within 10% of their respective target concentrations both prior to and essentially after dosing. Minor exceptions were in week 14 (0.1 mg base/ml postdose dosage formulation was 129.5% of the predose value and 123% of the target concentration), week 22 (1.8 mg base/ml postdose dosage formulation was 111.1% of the predose value, but 107.1%, i.e., within range, of target concentration), and week 25 (0.4 mg base/ml postdose dosage formulation was 110.9% of the predose value, but 109.0%, i.e., within range, of target concentration). Thus, out of 78 post-dosing analyses, only one sample was slightly (13%) out of predose or target concentration range.

4.2 Mortality and Clinical Signs/Observations

Summaries of clinical signs and clinical observations are presented in Table 3. Individual clinical signs and daily incidence of clinical signs are contained in Appendix C.

One high dose male (No. 558) was found dead on day 137. One day prior to its demise, labored breathing was seen. Treatment-related clinical signs in surviving high dose animals included rough coat, hunched posture, labored breathing (one surviving male), and piloerection (females). These signs were generally seen during the middle-to-latter part of the study. Clinical signs of toxicity were not apparent in mid and low dose animals. Hunched posture seen in one low dose male on one occasion and rough coat in one low dose female on three occasions were considered spurious observations, as it was not apparent in mid dose animals.

statistical, but clim inside rand

Task Order No.: UIC-15B UIC/TRL Study No.: 152

4.3 Body Weight

Summaries of body weights and body weight gains are presented in Tables 4 and 5, respectively. Individual body weights are contained in Appendix D. In addition, summaries of body weights are graphically depicted in Figures 1 (males) and 2 (females).

Body weights and body weight gains were significantly reduced in high dose animals and mid dose males. Reductions in weight gain were first noted in high dose males after one week of dosing. For high dose females, this was first apparent on day 22. Beginning on days 15 and 22, and continuing until the end of the study, body weights of high dose male and female rats, respectively, were significantly less than the corresponding vehicle control group. Beginning on day 85 and continuing until the end of the study, body weights of the mid dose male rats were significantly less than the corresponding vehicle control group. Total body weight gain for the 6 month period was decreased 12% and 39% in the mid and high dose male rats, respectively. Total body weight gain in the high dose female rats was decreased 32% over the same period.

4.4 Food Consumption

Summaries of food consumption are in Table 6. Individual food consumption data are in Appendix E.

Food consumption in high dose male rats was significantly less than the control group during the first study week and generally throughout the study. Food consumption in high dose female rats was also less than the control group during week 1 and was periodically decreased throughout the rest of the study.

4.5 Clinical Pathology

Summaries of clinical chemistry tests are presented in Table 7. Individual clinical chemistry data are in Appendix F. Summaries of hematology tests are presented in Table 8. Individual hematology data are in Appendix G.

Clinical Chemistry

Serum globulin content was decreased 10% in week 13 in high dose males, resulting in a 12% increase in the A/G ratio. Total protein concentration, however, was not significantly altered. Similar changes in globulin and the A/G ratio were noted in high dose females in week 26 and total protein was decreased slightly, however, these results may have been incidental as significant changes in these parameters were also seen in low but not mid dose female rats. In week 26, significant elevations occurred in total bile acids in high dose males. Corresponding increases in high dose females occurred, however significant variability may have been responsible for the lack of statistical significance.

Serum BUN concentrations were slightly, but significantly reduced in high dose males in weeks 4, 13 and 26, and in high dose females in week 26. This suggests a drug-related affect on urea synthesis by the liver.

Task Order No.: UIC-15B
UIC/TRL Study No.: 152

No other clinical chemistry changes were considered related to treatment. Sporadic increases and decreases were seen, but were not considered biologically significant.

Hematology

High dose animals and mid dose females had changes in erythrocyte parameters suggestive of anemia. Erythrocyte counts were decreased 4 - 7% and 5 - 11% in the mid and high dose females, respectively, in weeks 4, 13 and 26. During the study, the hematocrit (absolute) was decreased 1.7 - 2.5% and 2.0 - 3.8% in the mid and high dose females, respectively. Similar decreases in RBC counts and hematocrit were seen in week 4 in the high dose males. Hemoglobin content was decreased 7 - 10% in the high dose females during the study and 5% in week 13 in the mid dose group. Hemoglobin content was decreased 5 - 10% in the high dose males in weeks 4, 13 and 26. decreased in week 13 in the high dose females. High dose males had decreased MCHC in weeks 13 and 26, and decreased MCH in week 26. Reticulocyte counts were elevated slightly during the study in high dose animals, and Heinz bodies were present in week 13 in the high-dose males, and in weeks 13 and 26 in the high dose females. Heinz bodies are formed by precipitation of oxidatively denatured hemoglobin. administration produced methemoglobin in a dose-dependent fashion throughout the study. Slight increases in erythrocyte anisocytosis were seen in WR238605-treated males and high dose females.

Male and female rats exposed to 9.0 mg base/kg/day of WR238605 had changes in white blood cell parameters. Total leukocyte counts in high dose males were elevated 59%, 62% and 77% in weeks 4, 13 and 26, respectively. Total leukocyte counts in the high dose females were elevated to a similar extent during the study. These changes were due primarily to increases in mature neutrophils and lymphocytes. A slight increase of immature neutrophils was seen in weeks 4 and 13 in the high dose females.

In week 13, platelet counts were decreased 10% and 15% in the mid and high dose males, solution respectively.

No other hematologic changes were considered related to treatment. Sporadic increases and decreases were seen, but were not considered biologically significant.

4.6 Ophthalmology

The ophthalmology report is contained in Appendix H. No treatment-related changes were seen.

4.7 Organ Weights

The summary of organ weights expressed as relative values (% brain weight) are presented in Table 9. Individual organ weight data are contained in Appendix 1.

WR238605 administration resulted in increased relative weights of the kidneys, lungs/bronchi, spleen and adrenal glands. The relative weight of the kidneys were increased 10% and 13% in mid and high dose males, respectively. The relative weights

Task Order No.: UIC-15B UIC/TRL Study No.: 152

DRAFT

of the lungs/bronchi were increased 46% and 100% for mid and high dose males, respectively, and 55% and 97% for mid and high dose females, respectively. The relative weight of the spleen was increased 25% and 168% in mid and high dose males, respectively, and 19% and 127% in mid and high dose females, respectively. The relative weight of the adrenal glands was increased 34% in high dose females. Mid and high dose males and high dose females had relative weights of the heart decreased 8 - 10%.

4.8 Pathology

The Pathology Report is contained in Appendix J. A summary of gross and microscopic lesions is shown in Table 10.

Male and female rats in the high dose group had pulmonary lesions consisting of hemorrhage, foamy macrophage accumulation, and chronic interstitial inflammation. Animals in the mid dose group had foamy macrophage accumulation and chronic interstitial inflammation. Hemorrhage was characterized by the presence of free erythrocytes and fibrin in the lumen of alveoli in the affected region. Foamy macrophage accumulation was diagnosed when lumenal macrophages were very large with copious foamy cytoplasm. Chronic interstitial inflammation was characterized by the presence of alveolar macrophages in alveolar lumens and thickened alveolar walls which stained more basophilic than normal in the affected region. Minimal changes in the lungs were seen in the low dose groups (foamy macrophage accumulation in 2/20 males) compared to the control animals.

Both male and female rats in the mid and high dose groups had pigmentation in the cortex of the kidney, with lesions being more prevalent and severe in the high dose animals. Pigmentation in renal cortex was characterized by the presence of brown granular pigment in the cytoplasm of renal tubule epithelial cells. The pattern of pigmented cell distribution was most consistent with specific accumulation in proximal convoluted tubules. Pigmentation of cortical epithelial cells was considered to be a sensitive indicator of chronic hemoglobin resorption by the kidney.

Male and female rats in the high dose group had increased congestion in the spleen which was characterized by increased prominence of red pulp regions due to pooling of erythrocytes in the splenic sinusoids. In male rats, there appeared to be a mild dose-dependent increase in splenic erythropoiesis and pigmentation. Erythropoiesis was characterized by increased number and size of erythrocyte precursor cell colonies in the red pulp of the spleen. Pigmentation was characterized by the increased presence of focal groups of macrophages that contained dark brown granular material in their cytoplasm. Splenic hyperplasia of reticuloendothelial cells was seen in the high dose males and one high dose female, and was characterized by an increased thickness and prominence of the lightly basophilic zone of cells at the interface between the red and white pulp.

Apoptosis, pigmentation, and fatty change were observed in the centrilobular region of the liver from high dose males, but were not seen in female rats. Apoptosis was characterized by the presence of condensed, deeply eosinophilic round bodies in the centrilobular region of the liver. Pigmentation was characterized by the presence of brown granular material in the cytoplasm of the hepatocytes. Fatty change was diagnosed

Task Order No.: UIC-15B UIC/TRL Study No.: 152

when cells contained discrete round vacuoles in their cytoplasm. These vacuoles were generally empty, but sometimes contained lightly eosinophilic homogenous material and displaced the nucleus to the outer margin of the cell. Centrilobular fatty change was also

Pigmentation in the zona reticularis region of the adrenal cortex was notably present in high dose animals and was seen to a lesser extent in the low and mid dose groups. Pigmentation was characterized by the presence of cells that contained a variable amount of brown granular pigment in their cytoplasm. Adrenal gland congestion was increased in high dose females in comparison to the other female dose groups. Congestion was

diagnosed when vessels in the adrenal cortex were dilated and filled with erythrocytes.

seen to a lesser extent in mid dose males. Congestion in the centrilobular region was seen in 2 males in the mid and high dose groups each, and was diagnosed when blood filled sinusoids were observed in centrilobular regions that are generally occupied by

Bone marrow hyperplasia occurred in a dose-dependent fashion in both the male and female dose groups. Hyperplasia was diagnosed when blood precursor cells were increased at the expense of lipid cells. Bone marrow granulopoiesis was observed in one high dose female and the high dose male that was found dead on day 137. Granulopoiesis was diagnosed when the number of myeloid cells was increased at the expense of lipid cells and suggests that an inflammatory response occurred at some site within 1 to 2 weeks prior to necropsy. No treatment-related effect on bone marrow Myeloid:Erythroid (M:E) ratios were seen in the study.

DISCUSSION/CONCLUSION

This study evaluated the toxicity of WR238605 Succinate in rats following six months of daily oral (gavage) administration. Dose levels studied were 0 (vehicle control), 0.5, 2.0 and 9.0 mg base/kg/day. The results are summarized in Table 1. One high dose male rat was found dead on day 137. Labored breathing was seen one day prior to its demise. Treatment-related clinical signs in surviving high dose animals included rough coat, hunched posture, labored breathing (one surviving male), and piloerection (females). These signs were generally seen during the middle-to-latter part of the study. Clinical signs of toxicity were not apparent in mid and low dose animals. Body weight gains were significantly reduced in high dose animals and mid dose males. Also, food consumption was decreased in high dose animals. Treatment-related ophthalmic lesions were not seen.

High dose males, and mid and high dose females had changes in erythrocyte parameters suggestive of mild anemia. These changes included decreased RBC counts, hematocrit and hemoglobin concentration. As a result of the mild anemia, compensatory increases in reticulocyte counts were seen in high dose animals. The anemia may have been hemolytic in origin as Heinz bodies were present in high dose animals. Heinz bodies are formed by the precipitation of oxidatively denatured hemoglobin. Also, methemoglobin was observed in mid and high dose animals. The production of methemoglobin indicates an oxidant nature of the drug, and further supports the mild anemia as being hemolytic in origin. WR238605 administration resulted in bone marrow hyperplasia in a dose-dependent fashion in the male and female rats, and is a compensatory response to the anemia. However, no treatment related effects on bone marrow M:E ratios were seen. Male and female rats in the high dose group had increased congestion in

ORAFT

Contract No.: DAMD17-92-C-2001 Task Order No.: UIC-15B

UIC/TRL Study No.: 152

the spleen which may have accounted for the increase in splenic weights. Mid dose animals also exhibited splenomegaly. Splenic hyperplasia of reticuloendothelial cells was also seen in the high dose animals. In male rats, there appeared to be a mild dose-dependent increase in splenic erythropoiesis and pigmentation. The increase in splenic erythropoiesis may be an adaptive response to the anemia.

Treatment with WR238605 resulted in leukocytosis. Male and female rats in the high dose group had elevations in total leukocyte counts in weeks 4, 13 and 26 which were due primarily to increases in mature neutrophil and lymphocyte numbers. WR238605 administration also resulted in mild thrombocytopenia in mid and high dose males.

Administration of WR238605 for 6 months resulted in pulmonary lesions in male and female rats in the mid and high dose groups. These lesions consisted of hemorrhage (high dose groups only), foamy macrophage accumulation, and chronic interstitial inflammation and are most likely responsible for the increased lung weights. Minimal changes in the lungs were seen in the low dose group. The pathogenesis of the pulmonary lesions is unknown. A possible mechanism could be a primary lesion to the endothelium and/or type 1 alveolar cells resulting in hemorrhage. The presence of erythrocytes and blood protein could result in accumulation of macrophages in the alveolar lumen. Macrophages may develop copious foamy cytoplasm as they attempt to digest the lipid membrane component of the erythrocytes and may release mediators into the alveolar lumen resulting in interstitial inflammation.

Administration of WR238605 resulted in hepatotoxicity. Changes in clinical chemistry parameters were suggestive of mild liver dysfunction. Serum globulin content was decreased and the A/G ratio was correspondingly increased in high dose males, and low and high dose females. Total bile acids were also elevated in high dose males. Serum BUN concentrations were slightly reduced in high dose animals, suggestive of a drug-related effect on urea synthesis by the liver. Clinical chemistry changes were supported by histopathologic evidence of liver injury in high dose males, but not females, and consisted of apoptosis, pigmentation and fatty change in the centrilobular region. Centrilobular fatty change was seen to a lesser extent in mid dose males. The centrilobular lesions are consistent with classic cases of chronic congestion. However, congestion was only seen in 2 male rats in the mid and high dose groups each. Alternatively, these hepatic lesions may have arisen due to circulating free hemoglobin in the blood or direct test article toxicity.

Both male and female rats in the mid and high dose groups had increased kidney weights, accompanied by pigmentation in the cortex, with lesions being more prevalent and severe in the high dose animals. The pigment is most likely hemosiderin arising from the reuptake of free hemoglobin by the renal glomeruli. Circulating hemoglobin may have arisen from the pulmonary hemorrhages upon hemoglobin release and return to the blood via direct resorption or lymphatic return. Hemolytic anemia would also result in circulating free hemoglobin.

WR238605 administration resulted in pigmentation of the zona reticularis region of the adrenal cortex in a dose-dependent fashion in male and female rats. The identity of the pigment is unknown, but may be either lipofuscin or hemosiderin. Adrenal gland congestion was increased in the high dose females and may have accounted for the increased weight of the adrenal glands in this dose group.

Decreased heart weights were seen in mid dose males and high dose animals. The significance of these changes are unclear as corresponding histopathologic lesions were not observed.

Task Order No.: UIC-15B UIC/TRL Study No.: 152

In summary, the primary toxicities of WR238605 Succinate were to RBCs, the lungs and the liver. Mortality occurred in one high dose male rat. Treatment-related clinical signs in high dose animals included rough coat, hunched posture, labored breathing (males), and piloerection (females). Body weight gains were significantly reduced in high dose animals and mid dose males. Also, food consumption was decreased in high dose animals. High dose males, and mid and high dose females had decreased RBC counts, HCT and HGB concentration, suggestive of mild anemia. The anemia may have been hemolytic in origin due to the presence of Heinz bodies and increased methemoglobin levels. Microscopic lesions observed in the spleen, bone marrow, kidneys and adrenal glands may have been secondary to anemia and/or hemolysis. High dose animals had elevations in mature neutrophil and lymphocyte numbers. Mild thrombocytopenia was seen in mid and high dose males. Pulmonary lesions in male and female rats in the mid and high dose groups consisted of foamy macrophage accumulation, chronic interstitial inflammation, and hemorrhage (high dose groups only). Apoptosis, pigmentation and fatty change in the centrilobular region of the liver were seen in high dose males, but not in females, and were accompanied by decreased serum GLOB, BUN and increased TBA. Similar clinical chemistry changes were seen in high dose females. The no-effect level (NOEL) for WR238605 Succinate is considered to be at or near the low dose of 0.5 mg base/kg/day.

PERSONNEL

Study Director Barry S. Levine, D.Sc., D.A.B.T.

Pathologist Robert L. Morrissey, D.V.M., Ph.D., D.A.C.V.P. Clinical Veterinarian James E. Artwohl, D.V.M., M.S., D.A.C.L.A.M.

Ophthalmologist Samuel J. Vainisi, D.V.M., D.A.C.V.O.

Tox. Lab Supervisor Soudabeh Soura, B.S. Lead Technician Nancy Dinger, B.S.

Clinical Pathology
Chemistry Specialist
Quality Assurance

Maria Lang, A.T., C.V.T.
Thomas Tolhurst, B.S.
Ronald C. Schoenbeck

Report preparation was assisted by Dr. Alan P. Brown, Ms. Soudabeh Soura, and Mr. Mukesh Pitroda.

7. ARCHIVES

The raw data, specimens, test article reserves, and final report are archived at the Toxicology Research Laboratory (TRL), University of Illinois at Chicago (UIC), Department of Pharmacology, 1940 W. Taylor St., Chicago, IL 60612-7353.

8. REFERENCE

Dunnett, C.W., 1964. New tables for multiple comparisons with a control. *Biometrics* 20:482-491.

Task Order No.: UIC-15B UIC/TRL Study No.: 152

DRAFT

Table 1

SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

Summary of Toxic Responses

Dose (mg base/kg/day)	0	0.5	2.0	9.0
Rats/Sex	$20 + 5^2$	$20 + 5^2$	$20 + 5^2$	$20 + 5^2$
Deaths	0	0	0	1M (day 137)
Body Weight Gains	-	NE	↓M	↓M/F
Food Consumption	-	NE	NE	↓M/F
Clinical Observations (Signs)	-	Hunched Posture (1M) Rough Coat (1F)	NE	Hunched Posture (3M/1F) Rough Coat (5M/2F) Labored Breathing (2M) Piloerection (7F)
Clinical Chemistry ^b	-	↓ GLOB (F) ↑ A/G (F) ↓ TP (F)	NE	↓GLOB ↓TP (F) ↑A/G ↓BUN ↑TBA (M/F?)
Hematology	-	NE	↓RBC (F) ↓HCT (F) ↓HGB (F) ↑METHGB ↓PLT (M)	RBC
Organ Weights	-	NE	Heart (M) †Kidneys (M) †Lungs/Bronchi †Spleen	Heart † Kidneys (M) † Lungs/Bronchi † Spleen † Adrenals (F)
Histopathology		Lung - Accumulation, foamy macrophages (2M) Spleen - Pigmentation (4M) - Erythropoiesis (4M) Adrenal gland - Pigmentation, zona reticularis (1M/1F) Bone marrow - Hyperplasia (5M/4F)	Lung - Hemorrhage (4M/9F) - Accumulation, foamy macrophages (20M/20F) - Chronic interstitial inflammation (20M/20F) Liver - Fatty change (6M) - Congestien (2M) Spleen - Pigmentation (8M) - Erythropoiesis (8M) Kidney - Pigmentation, cortex (4M/7F) Bone Marrow - Hyperplasia (11M/7F) Adrenal Gland - Pigmentation, zona reticularis (3M/2F)	Lung - Hemorrhage (20M/20F) - Accumulation, foamy macrophages (20M/20F) - Chronic interstitial inflammation (20M/20F) Liver - Apoptosis (11M) - Pigmentation (11M) - Fatty change (10M) - Congestion (2M) Spleen - Congestion (18M/17F) - Hyperplasia, retriculoendothelial cell (4M/1F) - Pigmentation (11M) - Erythropoiesis (8M) Kidney - Pigmentation, cortex (16M/20F) Bone Marrow - Hyperplasia (19M/13F) - Granulopoiesis (1M/1F) Adrenal Gland - Pigmentation, zona reticularis (10M/18F)

CONCLUSIONS: The primary toxicities of WR238605 Succinate were to RBCs, the lungs and the liver. Mortality occurred in one high dose male rat. Treatment-related clinical signs in high dose animals included rough coat, hunched posture, labored breathing (males), and piloerection (females). Body weight gains were significantly reduced in high dose animals and mid dose males. Also, food consumption was decreased in high dose animals. High dose males, and mid and high dose females had decreased RBC counts, HCT and HGB concentration, suggestive of mild anemia. The anemia may have been hemolytic in origin due to the presence of Heinz bodies and increased methemoglobin levels. Microscopic lesions observed in the spleen, bone marrow, kidneys and adrenal glands may have been secondary to anemia and/or hemolysis. High dose animals had elevations in mature neutrophil and lymphocyte numbers. Mild thrombocytopenia was seen in mid and high dose males. Pulmonary lesions in male and female rats in the mid and high dose groups consisted of foamy macrophage accumulation, chronic interstitial inflammation, and hemorrhage (high dose groups only). Apoptosis, pigmentation and fatty change in the centrilobular region of the liver were seen in high dose males. The no-effect level (NOEL) for WR238605 Succinate is considered to be at or near the low dose of 0.5 mg base/kg/day.

"Satellite rats for plasma drug level analysis

TP = total protein, GLOB = globulin, TBA = total bile acids, BUN = blood urea nitrogen, A/G = Albumin/globulin ratio.

^cRBC = red blood cell counts, HGB = hemoglobin, HCT = hematocrit, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin concentration, RETICS = reticulocytes, HEINZ = Heinz bodies, METHGB = methemoglobin, PLT = platelets, LEUK = leukocytes, MNEUT = mature neutrophils, INEUT = immature neutrophils, LYMPH = lymphocytes, MONO = monocytes

? = Possible or marginal effect

NE = No effect

M = Male

F = Female

DRAFT

Contract No.: DAMD17-92-C-2001 Task Order No.: UIC-15B

UIC/TRL Study No.: 152

Table 2

SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

Dosage Formulation Analyses

	Target		Predose Analysis			Postdose Analysis	
Study Week	Concentration (mg base/ml)	Date	(mg base/ml)	% Target	Date	(mg base/ml)	% Predose
WCCK	0.0	Bute	0	70 Taiget	Dute	0	701100000
1	0.1	08/01/95	0.105 ± 0.001	105.0	08/08/95	0.106 ± 0.002	101.0
	0.4	00/01/00	0.409 ± 0.002	102.3	00,00,00	0.385 ± 0.024	94.1
	1.8	ł	1.770 ± 0.069	98.3		1.777 ± 0.019	100.4
	0.0		0			0	-
2	0.1	08/08/95	0.100 ± 0.001	100.0	08/15/95	0.098 ± 0.003	98.0
_	0.4	00.00.00	0.391 ± 0.002	97.8		0.397 ± 0.007	101.5
	1.8	1	1.789 ± 0.012	99.4		1.822 ± 0.071	101.8
	0.0		0	-		0	-
3	0.1	08/15/95	0.100 ± 0.001	100.0	08/22/95	0.099 ± 0.002	99.0
	0.4		0.411 ± 0.004	102.8		0.401 ± 0.001	97.6
	1.8	l i	1.909 ± 0.009	106.1		1.818 ± 0.016	95.2
	0.0		0	-		0	-
4	0.1	08/22/95	0.098 ± 0.001	98.0	08/29/95	0.098± 0.001	100.0
	0.4	1 1	0.388 ± 0.004	97.0		0.387 ± 0.007	99.7
	1.8		1.790 ± 0.003	99.4		1.781 ± 0.029	99.5
	0.0		0	-		0	-
5	0.1	08/29/95	0.100 ± 0.002	100.0	09/05/95	0.104 ± 0.009	104.0
	0.4] [0.400 ± 0.006	100.0		0.395 ± 0.002	98.8
	1.8		1.818 ± 0.039	101.0		1.825 ± 0.027	100.4
	0.0		0	-		0	-
6	0.1	09/05/95	0.096 ± 0.003	96.0	09/12/95	0.101 ± 0.005	105.2
	0.4		0.406 ± 0.006	101.5		0.397 ± 0.013	97.8
	1.8		1.799 ± 0.022	99.9		1.882 ± 0.069	104.6
	0.0		0	-		0	-
7	0.1	09/12/95	0.098 ± 0.009	98.0	09/19/95	0.105 ± 0.001	107.1
	0.4		0.405 ± 0.012	101.3		0.433 ± 0.007	106.9
	1.8		1.787 ± 0.031	99.3		1.866 ± 0.026	104.4
	0.0		0	-		0	-
8	0.1	09/19/95	0.100 ± 0.006	100.0	09/26/95	0.093 ± 0.004	93.0
	0.4	!!!	0.406 ± 0.005	101.5		0.391 ± 0.003	96.3
	1.8		1.873 ± 0.042	104.1		2.037 ± 0.038	108.8
	0.0		0	-	10/00/05	0	-
9	0.1	09/26/95	0.096 ± 0.001 0.395 ± 0.011	96.0	10/03/95	0.097 ± 0.005	101.0
	0.4	1 1		98.8		0.404 ± 0.004	102.3
	1.8		1.720 ± 0.034	95.6		1.876 ± 0.055	109.1
40	0.0	10/03/95		93.0	10/10/95		100.6
10	0.1	10/03/95	0.093 ± 0.001 0.404 ± 0.004	101.0	10/10/95	0.098 ± 0.003 0.405 ± 0.004	108.6
	1.8	1	1.844 ± 0.003	101.0		1.788 ± 0.036	97.0
<u> </u>	0.0	 	0	-		0	57.0
11	0.0	10/10/95	0.103 ± 0.006	103.0	10/17/95	0.101 ± 0.003	91.8
''	0.4	10,10,33	0.400 ± 0.006	100.0	10/1//35	0.101 ± 0.005	97.8
	1.8	1	1.788 ± 0.003	99.3		1.728 ± 0.015	103.5
	0.0		0	00.0		0	
12	0.1	10/17/95	0.110 ± 0.001	110.0	10/24/95	0.099 ± 0.002	90.0
	0.4	1	0.395 ± 0.006	98.8	1	0.395 ± 0.004	100.0
	1.8	1	1.827 ± 0.003	101.5		1.849 ± 0.011	101.2

Task Order No.: UIC-15B UIC/TRL Study No.: 152

Table 2 (contd.)

SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS



Dosage Formulation Analyses

	Target		Predose Analysis			Postdose Analysis	
Study Week	Concentration (mg base/ml)	Date	(mg base/ml)	% Target	Date	(mg base/ml)	% Predose
	0.0		0	•		0	-
· 13	0.1	10/24/95	0.099 ± 0.001	99.0	10/31/95	0.096 ± 0.001	97.0
	0.4	[0.389 ± 0.003	97.3	[0.372 ± 0.008	95.6
	1.8		1.788 ± 0.009	99.3		1.786 ± 0.017	99.9
	0.0		0	-		0	-
14	0.1	10/31/95	0.095 ± 0.002	95.0	11/07/95	0.123 ± 0.008	129.5
	0.4		0.432 ± 0.006	108.0		0.453 ± 0.009	104.9
	1.8		1.707 ± 0.035	94.8		1.854 ± 0.040	108.6
	0.0		0	-		0	-
15	0.1	11/07/95	0.102 ± 0.001	102.0	11/14/95	0.104 ± 0.007	102.0
	0.4		0.403 ± 0.007	100.8		0.394 ± 0.010	97.8
	1.8		1.672 ± 0.024	92.9		1.739 ± 0.041	104.0
	0.0		0	-		0	-
16	0.1	11/14/95	0.101 ± 0.004	101.0	11/21/95	0.104 ± 0.004	103.0
	0.4		0.412 ± 0.050	103.0		0.420 ± 0.001	101.9
	1.8		1.768 ± 0.050	98.2		1.890 ± 0.024	106.9
	0.0		0	-		0 .	-
17	0.1	11/21/95	0.106 ± 0.002	106.0	11/28/95	0.106 ± 0.006	100.0
	0.4		0.413 ± 0.001	103.3		0.392 ± 0.034	94.9
	1.8		1.842 ± 0.011	102.3		1.774 ± 0.026	96.3
	0.0		0	-		0	-
18	0.1	11/28/95	0.106 ± 0.001	106.0	12/05/95	0.100 ± 0.001	94.3
	0.4		0.408 ± 0.007	102.0		0.398 ± 0.001	97.5
	1.8		1.861 ± 0.033	103.3		1.737 ± 0.023	93.4
	0.0		0	-		0	-
19	0.1	12/05/95	0.102 ± 0.001	102.0	12/12/95	0.103 ± 0.002	101.0
	0.4		0.377 ± 0.001	94.3		0.381 ± 0.004	101.1
	1.8	1 1	1.910 ± 0.034	106.1		1.877 ± 0.036	98.3
	0.0		0	-		0	-
20	0.1	12/12/95	0.098 ± 0.002	98.0	12/19/95	0.101 ± 0.003	103.1
	0.4	1 1	0.390 ± 0.019	97.5		0.412 ± 0.009	105.6
	1.8	1 1	1.828 ± 0.001	101.6		1.873 ± 0.018	102.5
	0.0		0	-		0	-
21	0.1	12/19/95	0.102 ± 0.006	102.0	12/27/95	0.111 ± 0.004	108.8
	0.4		0.414 ± 0.009	103.5		0.396 ± 0.009	95.7
	1.8		1.831 ± 0.027	101.7		1.816 ± 0.018	99.2
	0.0		0			0	-
22	0.1	12/27/95	0.098 ± 0.004	98.0	01/03/96	0.096 ± 0.004	98.0
	0.4		0.417 ± 0.009	104.3		0.398 ± 0.012	95.4
	1.8	1	1.735 ± 0.099	96.4		1.928 ± 0.041	111.1
	0.0		0	-		0	-
23	0.1	01/03/96	0.094 ± 0.006	94.0	01/09/96	0.103 ± 0.006	109.6
	0.4		0.411 ± 0.011	102.8		0.403 ± 0.024	98.1
	1.8	1	1.798 ± 0.037	99.9	1	1.795 ± 0.022	99.8
	0.0		0	-		0	-
24	0.1	01/09/96	0.098 ± 0.005	98.0	01/16/96	0.099 ± 0.008	101.0
	0.4		0.396 ± 0.010	99.0	1	0.392 ± 0.004	99.0
	1.8	1	1.803 ± 0.059	100.2	1	1.805 ± 0.041	100.1

Task Order No.: UIC-15B UIC/TRL Study No.: 152

Table 2 (contd.)

SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

DRAFT

Dosage Formulation Analyses

Target			Predose Analysis		Postdose Analysis		
Study Week	Concentration (mg base/ml)	Date	(mg base/ml)	% Target	Date	(mg base/ml)	% Predose
	0.0		0	-		0	-
25	0.1	01/16/96	0.105 ± 0.002	105.0	01/23/96	0.104 ± 0.067	99.0
	0.4		0.392 ± 0.005	98.3		0.436 ± 0.004	110.9
	1.8		1.845 ± 0.036	102.5		1.709 ± 0.034	92.6
	0.0		0	-		0	-
26	0.1	01/23/96	0.102 ± 0.002	102.0	02/02/96	0.100 ± 0.002	98.0
	0.4		0.421 ± 0.006	105.3		0.397 ± 0.007	94.3
	1.8		1.708 ± 0.007	94.9		1.774 ± 0.010	103.9

Task Order No.: UIC-15B UIC/TRL Study No.: 152

Table 3

SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

Summary of Clinical Signs (Males)

DOCE (me honeller/don).		0.5	00	00
DOSE (ing baseraguay). GROUP:	W-1	2-M	3-M	4-M
Scheduled Sacrifice	20	20	20	20
Animal Found Dead	0	0	0	1 (137) ⁸
Hunched Posture	0	1 (11)	0	3 (62-84, 136, 169, 171-181)
Labored Breathing	0	0	0	2 (136, 167)
Rough Coat	0	0	0	5 (48-102,104,117,124-125,134,173-176)
Total Number of Animals ^b	25	25	25	25

Summary of Clinical Signs (Females)

9.0 4-F	20	1 (92-96) ^a	7 (67-73, 76-77, 86, 94, 100-102, 126-128)	2 (92-97, 132)	25
2.0 3-F	20	0	0	0	25
0.5 2-F	20	0	0	1 (156, 158-159)	25
0 1-F	20	0	0	0	25
DOSE (mg base/kg/day): GROUP:	Scheduled Sacrifice	Hunched Posture	Piloerection	Rough Coat	Total Number of Animals ^b

RAFT

 $^{\rm a}{\rm Number}(s)$ in parentheses indicate the day(s) the adverse sign was observed $^{\rm b}{\rm Includes}$ 5 satellite animals/sex/group

Table 4.1

DRAFT

		SUMMA	RY OF	BODY WEI	GHTS (Grams)		
	TUDY: 152	2		S	EX: MALE			
							- to (lon (elev)	
PER	_	OSE: ROUP: 1		0.5 2-M		9.0 m 4-M	g base/kg/day	
DAY		MEAN 2				248		
		S.D. 16 N	25	13.5 25		14.6 25		
				23	25	23		
DAY		MEAN 3		298	299	291		
).7 25	24.5		18.1		
		N	25	25	25	25		
DAY						320*		
			5.9	28.0		19.4		
		N	25	25	25	25		
DAY	22	MEAN 3	90	378	379	338*		
				33.2		23.8		
		N	25	25	25	25		
DAY	29	MEAN 4	19	409	411	358*		
				36.7		29.7		
		N	25	25	25	25		
DAY	36	MEAN 4	46	438	438	373*		
				38.9		32.5		
		N	25	25	25	25		
DAY	43	MEAN 4	85	472	466	395*		
				41.0		36.5		
		N	25	25	25	25		
DAY	50	MEAN 5	06	496	482	402*		
				40.0		38.4		
		N	25	25	25	25		
DAY	57	MEAN 5	30	521	502	414*		
				41.9		46.2		
		N	25	25	25	25		
DAY	64	MEAN 5	648	544	521	426*		
				42.7		53.8		
		N	25	25	25	25		

P less than .05

Table 4.1 (contd.)

SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS_

DRAFT

			SUMMARY	OF BODY	WEIGHTS	(Grams)	
S	STUDY:	152			SEX:	MALE	
DE	RIOD	DOSE: GROUP:	0 1-M	0.5 2-M	2.0 3-M	9.0 mg base/kg/day 4-M	
PCI		ukoor.	1-10	2-m	J-M	4-H	
2.4	. 74	***	F.70	F//	£27	/274	
UA	Y 71	MEAN S.D.	570 54.2	566 45.0	537 34.1	437* 60.2	
		N	25	25	25	25	
DA	Y 78	MEAN	583	581	552	444*	
		S.D.	60.7	44.8	34.7	55.2	
		N	25	25	25	25	
D.A.	Y 85	MEAN	5 99	598	563*	458*	
	, 03	S.D.	61.7	46.7	36.5	50.8	
		N	25	25	25	25	
DA	Y 92	MEAN	606	600	564*	1 - 1	
		S.D.	65.1	50.6	37.4	49.4	
		N	25	25	25	25	
DA	Y 99	MEAN	622	622	577*	474*	
		S.D.	63.7	53.5	39.4	52.8	
		N	25	25	25	25	
DA	Y 106	MEAN	630	631	582*		
		S.D.	64.1	56.1	40.9	49.7	
		N	25	25	25	25	
DA	Y 113	MEAN	644	642	592*	488*	
		S.D.	64.7	57.4	39.4	53.2	
		N	25	25	25	25	
	v 120	MEAN	450	457	596*	492*	
UA	Y 120	MEAN S.D.	650 62.6	653 56.9	40.4	53.9	
		N.	25	25	25	25	
DA	Y 127	MEAN	653	659	598*	494*	
		S.D.	63.4	59.4	37.8	53.2	
		N	25	25	25	25	
DA	Y 134	MEAN	662	668	607*	499*	
DA	1 134	S.D.	65.5	60.4	39.0	58.3	
		N.	25	25	25	25	
		14			2,		

P less than .05

Table 4.1 (contd.)

SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS_

	\mathbb{A}	5	7
UU	7	Ц	Ш

				SUMMARY	OF	BODY	WEIGHTS	(Grams)	
	S	TUDY:	152				SEX:	MALE	
	PERI	00	DOSE: GROUP:	0 1-M		0.5 2-M	2.0 3-M	9.0 4-M	mg base/kg/day
	DAY	141	MEAN	673		682	618*	510*	
	DA.		S.D.	67.2		63.4	40.3	56.8	
			N	25		25	25	24	
	DAY	148	MEAN	683		693	628*	522*	
			S.D.	65.5		65.5	42.1	57.7	
			N	25		25	25	24	
	DAY	155	MEAN	696		703	642*	530*	
			S.D.	68.4		67.6	43.8	58.9	
			N	25		25	25	24	
	DAY	162	MEAN	703		709	647*	528*	
			S.D.	73.0		71.4	44.1	58.9	
			N	25		25	25	24	
	DAY	169	MEAN	705		709	652*	527*	
			S.D.	76.2		75.7	46.1	61.1	
			N	25		25	25	24	
	DAY	176	MEAN	715		714	656*		
			S.D.	73.9		78.1	46.2	61.5	
			N	25		25	25	24	
	DAY	182	MEAN	717		700	659*	530*	
			S.D.	56.9		62.2	52.1	61.7	
			N	20		20	20	19	
# Dilece	thor	0.5	,	and wais of Wa		ina	DIMMETT/C Doc	and in	

Table 4.2 SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

SUMMARY OF BODY WEIGHTS (Grams) STUDY: 152 SEX: FEMALE 9.0 mg base/kg/day DOSE: 0 0.5 2.0 PERIOD GROUP: 1-F 2-F 3-F 4-F 179 DAY 1 MEAN 182 182 182 S.D. 10.2 11.0 10.3 10.6 N 25 25 25 25 DAY 8 MEAN 204 203 202 198 9.8 S.D. 12.6 13.8 12.6 25 25 25 DAY 15 MEAN 222 221 221 212 12.7 S.D. 16.0 14.5 12.6 25 25 25 25 DAY 22 MEAN 236 234 235 223* S.D. 14.4 16.7 15.4 13.3 25 25 25 25 **DAY 29** MEAN 247 247 249 237 S.D. 15.4 18.5 19.4 14.0 N 25 25 25 25 DAY 36 MEAN 252 252 236* 253 S.D. 16.1 19.3 20.0 25 25 N 25 25 DAY 43 269 251* MEAN 268 267 S.D. 16.0 22.6 22.4 15.6 25 25 25 25 254* DAY 50 MEAN 273 276 277 18.5 25.8 15.1 S.D. 24.4 25 25 -25 25 260* **DAY 57** MEAN 284 287 285 S.D. 20.9 27.8 27.6 15.7 25 25 25 25 DAY 64 MEAN 294 293 294 267* S.D. 22.2 26.9 29.8 15.4 N 25 25 25

P less than .05

Table 4.2 (contd.)

SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

DRAFT

		2	SUMMARY	OF 1	BODY	WEIGHTS	(Grams)	
	STUDY: 1	.52				SEX: 1	FEMALE	
		DOSE:	0		0.5	2.0	9.0 mg	base/kg/day
P	ERIOD	GROUP:	1-F		2-F	3-F	4-F	
								•
D	AY 71	MEAN	299		298	298	270*	
		S.D.	22.7 25		28.4	32.3	16.2	
		N	25		25	25	25	
D	AY 78	MEAN	305		306	301	274*	
		S.D.	24.9		29.9	34.9	16.6	
		N	25		25	25	25	
D	AY 85	MEAN	313		312	308	280*	
		S.D.	26.2		32.0	34.2	18.2	
		N	25		25	25	25	
D	AY 92	MEAN	317		313	311	277*	
		S.D.	27.5		31.1	31.4	22.1	
		N	25		25	25	25	
D	AY 99	MEAN	315		312	308	281*	
		S.D.	26.7		30.8	32.8	17.7	
		N	25		25	25	25	
D	AY 106	MEAN	316		314	311	280*	
		S.D.	27.2		30.3	31.2	18.6	
		N	25		25	25	25	•
D	AY 113	MEAN	330		330	324	290*	
		S.D.	27.6		33.5	33.3	17.5	
		N	25		25	25	25	
D	AY 120	MEAN	337		333	330	292*	•
		S.D.	30.9		34.7	36.6	18.7	
		N	25		25	25	25	
D	AY 127	MEAN	341		337	335	291*	
		S.D.	31.9		36.5	39.3	16.9	
		N	25		25	25	25	
D	AY 134	MEAN	347		342	343	295*	
		S.D.	33.8		35.5	41.3	18.6	
		N	25		25	25	25	

P less than .05

Table 4.2 (contd.)

		5	J

		SUMMARY	OF BODY	WEIGHTS	(Grams)	
 STUDY:	152			SEX:	FEMALE	••••••••••••••••
PERIOD	DOSE: GROUP:	0 1-F	0.5 2-F		9.0 4-F	mg base/kg/day
DAY 141	MEAN S.D.	34.7	348 36.9	41.8	17.8	
	N	25	25	25	25	
DAY 148	MEAN S.D.	358 38.7	352 38.7	353 42.3	300* 18.9	
	N	25	25	25	25	
DAY 155	MEAN S.D. N	364 40.D 25	353 42.1 25	358 46.0 25	305* 18.3 25	
4.603						
DAY 162	MEAN S.D. N	360 40.7 25	353 42.4 25	355 45.5 25	304* 21.1 25	
DAY 169	MEAN S.D. N	365 42.6 25	359 42.3 25	359 44.0 25	307* 21.3 25	
DAY 17/	MEAN		7/0		312*	
DAY 176	MEAN S.D.	375 46.4 25	369 44.5 25	367 48.1 25	22.9	
	N	25	25	25	25	
DAY 182	MEAN S.D.	386 44.4 20	370 51.9	374 44.6	317* 17.4	
DAY 182						

P less than .05 Analysis of Variance using DUNNETT'S Procedure

Table 5.1

			SUMMARY	OF WEIGHT	GAINS	(Grams)	
 ST	UDY:	152			SEX:	MALE	
PERIC	no ^a	DOSE: GROUP:	О 1-м	0.5 2-M	2.0 3-M	9.0 4-M	mg base/kg/day
DAY 8	b	MEAN S.D.	54 6.1	49 17.0	50 6.9	43* 7.3	že.
		N	25	25	25	25	
DAY 1	15	MEAN S.D. N	46 7.7 25	6.4 25	5.2 25	29* 6.6 25	
DAY 2	22	MEAN S.D. N	38 6.2 25	36 7.0 25	36 4.3 25	18* 8.7 25	
DAY 2	29	MEAN S.D. N	29 10.9 25	31 10.3 25	32 8.6 25	20* 15.2 25	
DAY 3	36	MEAN S.D. N	27 9.2 25	29 5.9 25	26 11.1 25	15* 12.9 25	
DAY 4	33	MEAN S.D. N	39 9.3 25	35 7.5 25	28** 7.0 25	22* 9.3 25	
DAY 5	50	MEAN S.D. N	21 6.7 25	24 6.5 25	17 7.2 25	7* 8.8 25	,

DAY 57

DAY 64

DAY 71

25 Analysis of Variance using DUNNETT'S Procedure

25

6.8

25

23

3.3

25

22

5.0

20

5.5

25

19

5.0

25

16*

5.8

25

13*

10.6

25

12*

25

11*

13.3

12.5

MEAN

S.D.

MEAN

S.D.

MEAN

S.D.

N

N

24

7.6

18

9.6

25

22

10.4

P less than .05

 $^{^{\}text{a}}\text{Weight gains compared to the previous period}$ $^{\text{b}}\text{Baseline}$ is day 1

DRAFT

 									 _
			SUMMARY	OF	WEIGHT	GAINS	(Grams)		
SI	TUDY:	152				SEX:			
 PERI	00 ^a	DOSE: GROUP:	0 1- M		0.5 2-M	2.0 3-M	9.0 4-M	mg base/kg/day	
DAY	78	MEAN S.D. N	14 21.2 25		15 7.1 25	15 6.8 25	7 23.8 25		
DAY	85	MEAN S.D. N	16 6.3 25		17 5.9 25	11 5.6 25	13 21.1 25		
DAY	92	MEAN S.D. N	23.4 25		1 26.6 25	1 8.3 25	13.4 25		
DAY	99	MEAN S.D. N	17 10.5 25		22 23.9 25	13 8.2 25	14 8.3 25		
DAY	106	MEAN S.D. N	8 8.2 25		9 9.5 25	5 8.6 25	2* 8.0 25	•	
DAY	113	MEAN S.D. N	14 6.9 25		11 6.9 25	9 7.2 25	13 6.5 25		
DAY	120	MEAN S.D. N	17.1 25		11 5.9 25	9.6 25	3 8.3 25		
DAY	127	MEAN S.D. N	3 5.3 25		6 7.8 25	9.6 25	8.9 25		
DAY	134	MEAN S.D. N	9 10.7 25		9 4.8 25	9 4.7 25	10.4 25		
DAY	141	MEAN S.D. N	11 7.6 25		15 6.5 25	11 5.8 25	7 7.4 24		

Analysis of Variance using DUNNETT'S Procedure

P less than .05

^aWeight gains compared to the previous period

DRAFT

 		SUMMARY	OF	WEIGHT	GAINS	(Grams)	
STUDY:	152				SEX:	MALE	•
PERIOD a	DOSE: GROUP:	0 1-M		0.5 2-M	2.0 3-M	9.0 4-M	mg base/kg/day
 DAY 4/0	MEAN	44		44	11	42	••••••
DAY 148	MEAN S.D. N	11 4.7 25		11 7.6 25	11 5.4 25	12 5.3 24	
DAY 155	MEAN S.D.	13 6.5		10 7.4	13 5.4	8 9.4	
DAY 4/3	N	25		25	25	24	
DAY 162	MEAN S.D. N	7 8.3 25		6 8.7 25	8.0 25	-2* 8.3 24	
DAY 169	MEAN S.D. N	2 7.1 25		-1 25.2 25	4 6.3 25	-1 21.7 24	
DAY 176	MEAN S.D. N	9 9.7 25		5 8.9 25	5 8.6 25	7 10.0 24	
DAY 182	MEAN S.D. N	6 4.9 20		3 7.3 20	3 7.2 20	9 11.9 19	
TOTAL GAIN	MEAN S.D. N	466 49.2 20		453 57.9 20	412* 52.0 20		

^{*} P less than .05

Analysis of Variance using DUNNETT'S Procedure

^aWeight gains compared to the previous period

Table 5.2

DRAFT

		SUM	MARY OF	WEIGHT	GAINS	(Grams)	
S	TUDY: 15	2			SEX:	FEMALE	
PER		DOSE: GROUP:	0 1-F	0.5 2-F	2.0 3-F		base/kg/day
DAY	8 b		22 6.4 25	21 4.5 25	20 4.5 25	19 4.9 25	
DAY	15	MEAN S.D. N	17 5.7 25	18 4.3 25	19 4.2 25	14 5.9 25	
DAY	22	MEAN S.D. N	14 4.9 25	13 4.0 25	14 5.3 25	11* 4.9 25	
DAY	29	MEAN S.D. N	11 6.2 25	13 4.1 25	14 6.3 25	13 3.4 25	
DAY	36	MEAN S.D. N	6 5.9 25	6 6.0 25	3 6.3 25	-1* 6.9 25	
DAY	43	MEAN S.D. N	16 8.4 25	16 6.5 25	15 8.0 25	15 5.7 25	
DAY	50	MEAN S.D. N	5 5.8 25	7 6.7 25	10 8.0 25	3 5.6 25	
DAY	57	MEAN S.D. N	10 5.7 25	11 4.7 25	8 7.2 25	6* 6.2 25	
DAY	64	MEAN S.D. N	10 5.0 25	6 6.9 25	9 5.5 25	6 4.3 25	
DAY	71	MEAN S.D. N	5 3.7 25	5 5.2 25	6.3 25	3 3.5 25	

^{*} Pless than .05

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period $^{\rm b}{\rm Baseline}$ is day 1

Table 5.2 (contd.)

SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

				SUMMARY	OF	WEIGH	T GAI	NS	G(Grams)			
	STU	JDY: 1	52				SEX	:	FEMALE			
			DOCE .	0		0.5	2	.0	0.0		has a then televis	
	PERIO	o ^a	DOSE: GROUP:	0 1-F		0.5 2-F		-F		mg	base/kg/day	
	DAY 78	3	MEAN	6		8		3	4			
			S.D.	5.0		4.9	5.	. 1	3.8			
			N	25		25	2	25	25			
	DAY 8	5	MEAN	7		6		7	6			
			S.D.	6.3		5.6	3.	.9	3.7			
			N	25		25	2	25	25			
	DAY 92	2	MEAN	4		2		3	-2*			
			S.D.	5.6		4.6		.4	10.6			
			N	25		25	2	25	25			
	DAY 99	9	MEAN	-2		-2		-3	4			
			S.D.	10.2		4.8		.6	10.1			
			N	25		25	2	25	25			
	DAY 10	06	MEAN	1		3			-1			
			S.D.	7.2		5.4		.6	6.0			
			N	25		25	ā	25	25			
	DAY 1	13	MEAN	14		15	1	13	10			
			S.D.	11.6		7.2	6.	.2	5.0			
			N	25		25	3	25	25			
	DAY 12	20	MEAN	7		4			2			
			S.D.	8.9		5.6		.8	4.4			
			N	25		25	2	25	25			
	DAY 12	27	MEAN	4		3		5	0*	t		
			S.D.	5.8		6.7		.7	6.1			
			N	25		25	•	25	25			
	DAY 1	34	MEAN	6		5		7	4			
			S.D.	5.8		4.7		.4	8.0			
			N	25		25	4	25	25			
	DAY 14	41	MEAN	6		6		4	0*			
			S.D.	6.1		6.9		.3	5.3			
			N	25		. 25		25	25			
* Pless	than	.05	,	Analysis of V	arianc	e using D	UNNETT'S	Рг	ocedure			

^aWeight gains compared to the previous period

DRAFT

 			SUMMARY	OF	WEIGHT	GAINS	(Grams)	***************************************
 STU	DY: 1	52				SEX:	FEMALE	••••••
 PERIOD	a	DOSE: GROUP:	0 1-F		0.5 2-F	2.0 3-F	9.0 4-F	mg base/kg/day
DAY 148	3	MEAN S.D. N	5 8.3 25		4 5.1 25	6 4.5 25	5.8 25	
DAY 155		MEAN S.D. N	6 7.3 25		7.3 25	5 7.9 25	5 7.1 25	
DAY 162	!	MEAN S.D. N	10.5 25		0 5.2 25	-3 7.1 25	-1 6.5 25	
DAY 169		MEAN S.D. N	7.3 25		5 4.6 25	3 5.5 25	3 5.5 25	
DAY 176	•	MEAN S.D. N	11 9.3 25		10 7.1 25	9 8.5 25	5 6.4 25	
DAY 182	?	MEAN S.D. N	5 9.5 20		5 10.4 20	6.7 20	3 5.5 20	
TOTAL G	AIN	MEAN S.D. N	203 38.7 20		190 46.1 20	192 37.6 20	138* 15.9 20	
					and the second second			

^{*} P less than .05

Analysis of Variance using DUNNETT'S Procedure

^aWeight gains compared to the previous period

DRAFT

SUMMARY (OF	DAILY	MEAN	FOOD	CONSUMPTION	(Grams)
-----------	----	-------	------	------	-------------	---------

 STUDY	7: 152			SEX:	MALE	
PERIOD a	DOSE: GROUP:	0 1-M	0.5 2-M	2.0 3-M	9.0 mg base/kg/day 4-M	
 Ь						
DAY 1	INTAKE (g)	24.3	24.3	24.3	23.8	
	S.D.	2.26	2.01	2.36		
	N	25	25	25	25	
DAY 8	INTAKE (g)	25.1	24.3	24.5	22.5*	
	S.D.	1.81	3.58	1.47	2.25	
	N	25	25	25	25	
DAY 15	INTAKE (g)	26.2	24.9	25.3	20.7*	
	S.O.	2.28	3.15	1.68		
	N	25	25	25		
0AY 22	INTAKE (g)	26.5	25.8	26.6	20.3*	
	S.O.	1.80	2.32	1.91	1.99	
	N	25	24	25		
DAY 29	INTAKE (g)	26.1	26.2	25.8	20.1*	
	s.o.	2.67	3.56	1.96	2.51	
	N	25	25	25	25	
DAY 36	INTAKE (g)	26.4	25.3	26.1	20.3*	
	S.D.	2.92	2.71	3.84	2.66	
	N	25	25	25		
DAY 43	INTAKE (g)	28.7	27.1	27.1	22.1*	
	S.O.	3.06	2.63	2.25		
	N	25	25	25		
0AY 50	INTAKE (g)	28.4	28.4	26.8	22.4*	
	S.D.	3.06	2.59	1.98		
	N	25	25	25		

P less than .05

Analysis of Variance using DUNNETT'S Procedure

 $^{^{\}rm a}\text{Calculated}$ daily food consumption for successive period intervals $^{\rm b}\text{Baseline}$ is day -6

SUMMARY	OF	DAILY	MEAN	FOOD	CONSUMPTION	(Grams)

DAY 57 INTAKE (g) 29.4 29.2 27.6 21.6* S.D. 3.44 2.56 1.77 3.56 N 25 25 25 25 DAY 64 INTAKE (g) 28.5 28.5 27.8 21.1* S.D. 2.96 2.52 1.89 4.22 N 25 25 25 DAY 71 INTAKE (g) 28.8 29.3 27.8 21.8* S.D. 2.90 2.85 1.83 4.90 N 25 25 25 25 DAY 71 INTAKE (g) 28.8 29.3 27.8 21.8* S.D. 2.90 2.85 1.83 4.90 N 25 25 25 25	
S.D. 3.44 2.56 1.77 3.56 N 25 25 25 25 DAY 64 INTAKE (g) 28.5 28.5 27.8 21.1* S.D. 2.96 2.52 1.89 4.22 N 25 25 25 25 DAY 71 INTAKE (g) 28.8 29.3 27.8 21.8* S.D. 2.90 2.85 1.83 4.90	
S.D. 3.44 2.56 1.77 3.56 N 25 25 25 25 DAY 64 INTAKE (g) 28.5 28.5 27.8 21.1* S.D. 2.96 2.52 1.89 4.22 N 25 25 25 25 DAY 71 INTAKE (g) 28.8 29.3 27.8 21.8* S.D. 2.90 2.85 1.83 4.90	
N 25 25 25 25 DAY 64 INTAKE (g) 28.5 28.5 27.8 21.1* S.D. 2.96 2.52 1.89 4.22 N 25 25 25 25 DAY 71 INTAKE (g) 28.8 29.3 27.8 21.8* S.D. 2.90 2.85 1.83 4.90	
DAY 64 INTAKE (g) 28.5 28.5 27.8 21.1* S.D. 2.96 2.52 1.89 4.22 N 25 25 25 25 DAY 71 INTAKE (g) 28.8 29.3 27.8 21.8* S.D. 2.90 2.85 1.83 4.90	
S.D. 2.96 2.52 1.89 4.22 N 25 25 25 25 25 DAY 71 INTAKE (g) 28.8 29.3 27.8 21.8* S.D. 2.90 2.85 1.83 4.90	
S.D. 2.96 2.52 1.89 4.22 N 25 25 25 25 25 DAY 71 INTAKE (g) 28.8 29.3 27.8 21.8* S.D. 2.90 2.85 1.83 4.90	
N 25 25 25 25 DAY 71 INTAKE (g) 28.8 29.3 27.8 21.8* S.D. 2.90 2.85 1.83 4.90	
DAY 71 INTAKE (g) 28.8 29.3 27.8 21.8* S.D. 2.90 2.85 1.83 4.90	
S.D. 2.90 2.85 1.83 4.90	
N 25 25 25 25	
DAY 78 INTAKE (g) 29.2 29.4 28.8 22.9*	
S.D. 5.19 2.63 1.88 4.00	
N 25 25 25 25	
DAY 85 INTAKE (g) 28.4 29.0 29.0 24.2*	
S.D. 3.27 2.80 2.95 2.72	
N 25 25 25 25	
DAY 92 INTAKE (g) 27.3 26.6 26.1 20.9*	
s.D. 3.75 5.07 2.22 3.27	
N 25 25 25 25	
DAY 99 INTAKE (g) 27.4 28.0 26.3 22.5*	
S.D. 2.94 3.04 2.24 3.41	
N 25 25 25 25	
DAY 106 INTAKE (g) 26.9 27.1 26.6 22.2*	
S.D. 2.51 3.39 2.88 3.24	
N 25 25 25 25	

^{*} Pless than .05

Analysis of Variance using DUNNETT'S Procedure

^aCalculated daily food consumption for successive period intervals

DRAFT

SUMMARY OF DAILY MEAN FOOD CONSUMPTION (Grams)

 STUD	Y: 152			SEX:	MALE	
PERIOD a	DOSE: GROUP:	0 1- M	0.5 2-M	2.0 3-M	9.0 mg base/kg/ 4-M	day
DAY 113	INTAKE (g) S.D. N	27.1 2.72 25	27.2 2.87 25	27.2 2.14 25	23.5* 2.82 25	
DAY 120	INTAKE (9) S.D. N	27.1 3.55 25	27.5 2.47 25	26.1 2.68 25	22.8* 3.01 25	
DAY 127	INTAKE (g) S.D. N	25.8 2.73 25	26.8 2.53 25	25.1 2.09 25	22.0* 2.55 25	
DAY 134	INTAKE (g) S.D. N	26.3 2.78 25	26.6 2.01 25	26.6 2.06 25	21.8* 4.61 25	
DAY 141	INTAKE (g) S.D. N	26.1 2.77 25	27.8 2.89 25	27.3 1.99 25	22.7* 3.36 24	
DAY 148	INTAKE (g) S.D. N	27.6 2.43 25	27.8 3.72 25	27.7 1.95 25	25.7 3.68 24	
DAY 155	INTAKE (g) S.D. N	28.0 2.41 25	28.0 2.98 25	27.9 1.88 25	24.3* 3.30 24	. 8
DAY 162	INTAKE (g) S.D. N	26.0 2.98 25	26.1 3.51 25	25.7 2.20 25	22.0* 2.38 24	

P less than .05

Analysis of Variance using DUNNETT'S Procedure

^aCalculated daily food consumption for successive period intervals

DRAFT

	SUMMARY	OF DAILY	MEAN	FOOD COL	NSUMPTION	(Grams)
 STUDY:	152			SEX:	MALE	
a	OSE: ROUP:	0 1- M	0.5 2-M	2.0 3-M	9.0 mg 4-M	base/kg/day
	NTAKE (g) D.	25.6 3.03 25	25.7 3.70 25	25.6 2.02 25	21.8* 2.80 24	,
DAY 176 I	NTAKE (g)	26.3	25.2	26.2	22.8*	

2.09

27.4

2.92

20

25

3.58

25.8

3.17

19

24

DAY 182

4.29

25.9

3.49

20

2.84

27.2

2.30

20

S.D.

S.D.

N

INTAKE (9)

^{*} Pless than .05

Analysis of Variance using DUNNETT'S Procedure

 $^{^{\}mathrm{a}}\mathrm{Calculated}$ daily food consumption for successive period intervals

Table 6.2



SUMMARY OF DAILY MEAN FOOD CONSUMPTION (Grams)

	DOILLING OF	DHILL I	ILLIA I OU.	D COMBOIN	L L CAY (GI BIIIS)
 STUDY	7: 152			SEX: FEM	ALE
 PER100 a		0 1-F	0.5 2-F	2.0 3-F	9.0 mg base/kg/day 4-F
DAY 1	S.D.	20.6 7.21 25		18.3 2.49 25	18.2 2.55 25
DAY 8	INTAKE (g) S.D. N	18.6 2.69 25	17.7 1.67 25	17.8 3.06 25	15.9* 1.55 25
DAY 15	INTAKE (g) S.D. N	18.1 2.65 25	17.7 1.94 25	18.4 4.21 25	17.7 3.09 25
DAY 22	INTAKE (g) S.D. N	19.0 3.59 25	18.4 3.10 25	19.6 3.62 25	16.2* 1.77 25
DAY 29	INTAKE (g) S.D. N	17.5 2.05 25	17.8 1.66 25	18.3 2.24 25	16.2* 1.25 25
DAY 36	INTAKE (g) S.D. N	17.8 3.14 25	16.9 1.53 25	18.6 4.12 25	15.9 2.39 25
DAY 43	INTAKE (g) S.D. N	17.7 2.07 24	19.4* 1.95 25	19.2* 1.89 25	17.1 1.65 25
DAY 50	INTAKE (g) S.D. N	19.0 3.77 25	19.0 2.18 25	19.7 2.86 25	19.5 3.41 25

^{*} Pless than .05

Analysis of Variance using DUNNETT'S Procedure

 $^{^{\}rm a}\text{Calculated}$ daily food consumption for successive period intervals $^{\rm b}\text{Baseline}$ is day -6

SUMMARY OF DAILY MEAN FOOD CONSUMPTION (Grams) STUDY: 152 SEX: FEMALE 9.0 mg base/kg/day 2.0 OOSE: 0 0.5 PERIOD a GROUP: 1-F 2-F 3-F 4-F INTAKE (g) 19.6 19.6 19.6 16.8 DAY 57 2.08 1.97 1.99 S.D. 2.65 25 25 25 DAY 64 INTAKE (g) 19.4 19.1 19.4 16.7* 1.35 S.O. 2.34 2.55 2.12 25 25 25 25 INTAKE (g) **DAY 71** 18.9 18.6 18.8 16.7* 1.45 S.D. 2.59 2.22 2.13 25 25 **DAY 78** INTAKE (g) 21.2 20.7 20.6 18.3* 5.52 2.44 2.73 2.17 S.D. 25 25 24 25 INTAKE (g) 20.6 19.9 20.3 18.7 DAY 85 S.D. 3.47 2.32 2.05 3.25 25 25 25 25 **DAY 92** INTAKE (g) 19.3 18.8 18.9 15.1* 3.30 3.41 2.25 S.D. 6.11 25 25 25 25 DAY 99 INTAKE (g) 17.8 17.1 17.5 15.6* S.D. 4.14 1.56 2.44 1.37 25 25 25 25 17.8 **DAY 106** INTAKE (g) 18.6 18.3 16.0 5.21 2.67 2.52 2.01 S.D. 25 24

Analysis of Variance using DUNNETT'S Procedure

P less than .05

^aCalculated daily food consumption for successive period intervals

Table 6.2 (contd.)

		[.]		57
	1-1	141	13	1.1
U	131	1-1	11	11
	الماليا	LU	L	ш

SUMMARY OF DAILY MEAN FOOD CONSUMPTION (Grams) STUDY: 152 SEX: FEMALE 2.0 9.0 mg base/kg/day PERIOD a DOSE: 0 0.5 GROUP: 1-F 2-F 3-F **DAY 113** INTAKE (g) 18.9 19.4 20.2 17.8 4.69 1.83 S.D. 2.20 3.28 25 25 25 19.4 19.1 20.0 17.6* **DAY 120** INTAKE (g) S.D. 2.33 2.08 2.53 2.99 25 25 25 25 **DAY 127** INTAKE (g) 18.7 18.3 19.2 16.0* 1.95 2.09 1.72 1.26 S.D. 25 25 25 25 **DAY 134** INTAKE (g) 19.7 18.9 20.0 16.6* S.D. 3.74 1.80 2.55 2.52 25 25 25 25 INTAKE (9) 18.9 19.1 16.5* **DAY 141** 20.6 S.D. 3.00 1.78 3.29 2.67 25 25 25 25 19.6 **DAY 148** INTAKE (g) 19.9 22.0 20.0 3.83 1.95 S.D. 4.63 4.57 25 25 25 25 INTAKE (g) 19.5 18.6 20.3 17.5 **DAY 155** S.D. 4.81 2.44 2.58 2.05 23 25 25 25 17.6 15.8 **DAY 162** INTAKE (g) 16.0 17.2 3.81 3.31 1.87 S.D. 2.42 25 25 25 23

Analysis of Variance using DUNNETT'S Procedure

^{*} P less than .05

^aCalculated daily food consumption for successive period intervals



			SUMMARY	OF	DAILY	MEAN	FOOD	COL	NSUMPTION	(Grams)
	S	STUDY	: 152				SE	EX:	FEMALE	
	PERI	00 a	DOSE: GROUP:		0 1-F	0.5 2-F		2.0 3-F	9.0 mg 4-F	base/kg/day
I	DAY	169	INTAKE (g) S.D. N		17.2 4.14 25	17.5 2.52 25		18.3 2.29 25	16.2 1.82 25	
1	DAY	176	INTAKE (g) S.D. N		19.0 3.14 25	19.0 1.90 25		19.6 2.53 25	17.4 1.86 25	
	DAY	182	INTAKE (g) S.D.		21.1 3.53	20.9		23.1	20.1	

Analysis of Variance using DUNNETT'S Procedure

^aCalculated daily food consumption for successive period intervals

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 4

DRAFT

STUDY ID: UIC-15B
SEX: MALE

TUDY NO: 152	130								JEA. HAL
1001 NO: 132		ANALYSI	S OF VARIAN	CE FOLLOWED	BY DUNNETT	'S PROCEDU	RE		
TEST(s):	ALT	SDH	TP	ALB	GLOB	A/G	TBA	ALKP	LDH
UNITS:	IU/L	IU/L	g/dL	g/dL	g/dL	-	umol/L	IU/L	IU/L
Group: 1 M :	0 mg base/k	g/day					$\langle A \rangle$		
MEAN	53	15.5	7.7	4.0	3.8	1.07	24.7	368	171
SD	8.7	8.40	0.78	0.36	0.49	0.097	7.58	98.7	146.3
N	10	10	10	10	10	10	10	10	10
Group: 2-M :	0.5 mg base	/kg/day							
MEAN	52	18.7	7.8	3.9	3.9	1.02	34.1	340	163
SD	9.8	8.53	0.48	0.23	0.34	0.089	24.94	41.0	101.5
N	10	10	10	10	10	10	10	10	10
Group: 3-M :	2.0 mg base	/kg/day							
MEAN	53	16.3	7.7	4.1	3.6	1.13	33.8	364	176
SD	7.2	10.71	0.41	0.25	0.44	0.200	20.01	122.7	159.6
N	10	10	10	10	10	10	10	10	10
Group: 4-M :	9.0 mg base	e/kg/day							
MEAN	48	19.0	7.9	4.1	3.8	1.09	33.0	325	188
SD	6.3	6.02	0.45	0.15	0.41	0.132	11.72	96.8	111.1
N	10	10	10	10	10	10	10	10	10
	3,0 10	30		6.0	/				
	5	10		J,	47		25		
				and a	2				

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 4

DHAFT

STUDY ID: UIC-15B STUDY NO: 152 SEX: MALE

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

TEST(s): UNITS:	CK IU/L	BUN mg/dL	CREAT mg/dL	NA mEq/L	K mEq/L	mEq/L	CA mg/dL	IP mg/dL	GLU mg/dL
Group: 1 M :	0 mg base/k	g/day							
MEAN	242	18.3	0.54	144.3	6.20	105.2	11.3	9.6	161
SD	173.4	1.67	0.069	3.47	0.489	2.53	0.49	0.57	39.1
N	10	10	10	10	10	10	10	10	10
Group: 2-M :	0.5 mg base	/kg/day							
MEAN	304	17.3	0.56	146.9	6.18	104.1	11.4	9.4	145
SD	293.8	1.62	0.094	3.35	0.552	4.09	0.51	0.58	11.1
N	10	10	10	10	10	10	10	10	10
Group: 3-M:	2.0 mg base	/kg/day							
MEAN	170	17.0	0.52	145.3	5.67	106.5	11.1	9.6	151
SD	140.2	1.31	0.042	2.21	0.476	2.92	0.34	0.54	23.8
N	10	10	10	10	10	10	10	10	10
Group: 4-M :	9.0 mg base	/kg/day							
MEAN	167	15.8*	0.59	147.9	6.40	104.7	11.1	9.2	135
SO	182.7	2.52	0.125	3.67	0.515	2.36	0.33	0.90	11.7
N	10	10	10	10	10	10	10	10	10



^{*-}Significant Difference from Control P < .05

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 4

DRAFT

STUDY ID: UIC-15B STUDY NO: 152

SEX: FEMALE

JUT NO: 152		ANALYSI	S OF VARIAN	CE FOLLOWED	BY DUNNETT	'S PROCEDU	RE		
TEST(s): UNITS:	ALT IU/L	SDH IU/L	TP g/dL	ALB g/dL	GLOB g/dL	A/G	TBA umol/L	ALKP IU/L	LDH IU/L
Group: 1-F : 0 r	na haca/k								
MEAN	51	14.9	7.3	4.1	3.2	1.27	25.6	213	253
SD	7.3	3.48	0.41	0.29	0.26	0.133	13.51	44.4	211.0
N	10	10	10	10	10	10	10	10	10
Group: 2-F : 0.5	mg base,	/kg/day					10		
MEAN	48	14.8	7.2	4.0	3.2	1.24	(22.7)	237	240
SD	8.4	1.60	0.56	0.28	0.35	0.104	7.13	70.5	110.8
N	10	10	10	10	10	10	10	10	10
Group: 3-F: 2.0	mg base	/kg/day							
MEAN	49	15.2	7.4	4.1	3.3	1_23	29.5	242	392
SD	3.5	6.40	0.40	0.26	0.19	0.065	16.51	116.7	254.2
N	10	10	10	10	10	10	10	10	10
Group: 4-F : 9.0	mg base,	/kg/day							
MEAN	57	18.8	7.2	4.0	3.3	1.21	36.8	260	183
SD	9.3	2.49	0.41	0.28	0.20	0.083	18.47	100.6	86.7
N	10	10	10	10	10	10	10	10	10

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 4

SEX: FEMALE

STUDY ID: UIC-15B

STUDY NO: 152

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

TEST(s):	CK	BUN	CREAT	NA	K	CL	CA	IP	GLU
UNITS:	IU/L	mg/dL	mg/dL	mEq/L	mEq/L	mEq/L	mg/dL	mg/dL	mg/dL
Group: 1-F : 0	mg base/k	g/day							
MEAN	211	18.4	0.55	144.1	5.47	103.5	10.8	7.8	129
SD	167.9	1.50	0.028	1.20	0.241	3.63	0.33	0.88	18.2
N	10	10	10	10	10	10	10	10	10
Group: 2-F : 0	.5 mg base	/kg/day							
MEAN	147	18.3	0.56	143.9	5.46	103.7	10.8	8.0	133
SD	47.2	1.85	0.047	1.29	0.288	3.74	0.23	0.52	14.7
N	10	10	10	10	10	10	10	10	10
Group: 3-F : 2	.0 mg base	/kg/day							
MEAN	260	19.5	0.57	143.8	5.69	104.6	10.9	8.4	146
SD	216.3	1.72	0.054	1.75	0.417	2.91	0.41	0.97	24.4
N	10	10	10	10	10	10	10	10	10
Group: 4-F : 9	0.0 mg base	/kg/day							
MEAN	149	18.0	0.57	143.7	5.63	104.2	10.9	8.3	139
SD	48.7	2.44	0.023	1.06	0.272	3.16	0.37	0.63	23.3
N	10	10	10	10	10	10	10	10	10

Table 7.5

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 13

STUDY ID: UIC-158 STUDY NO: 152 SEX: MALE

ANALYSIS OF VARIANCE FOLLOWED BY DUI	NNETT'S PROCEDURE
--------------------------------------	-------------------

TEST(s):	ALT	SDH	TP	ALB	GLO8	A/G	TBA	ALKP	LDH
UNITS:	IU/L	IU/L	g/dL	g/dL	g/dL		umol/L	IU/L	IU/L
Group: 1 M :	0 mg base/k	g/day							
MEAN	65	20.1	8.3	4.3	4.0	1.07	44.4	236	473
SD	14.3	13.31	0.60	0.40	0.31	0.108	20.18	80.9	515.2
N	10	10	10	10	10	10	10	10	10
Group: 2-M :	0.5 mg base	/kg/day							
MEAN	62	16.4	7.9	4.1	3.8	1.09	46.3	222	413
SD	13.1	7.08	0.37	0.21	0.27	0.088	24.88	46.8	289.8
N	10	10	10	10	10	10	10	10	10
Group: 3-M :	2.0 mg base	/kg/day							
MEAN	60	18.2	8.0	4.2	3.8	1.11	67.3	236	333
SD	9.4	8.55	0.57	0.36	0.32	0.101	26.35	98.0	142.3
N	10	10	10	10	10	10	10	10	10
Group: 4-M :	9.0 mg base	/kg/day							
MEAN	(77)	16.7	7.9	4.3	3.6*	1.20*	62.2	222	460
SD	20.7	6.10	0.49	0.26	0.33	0.101	26.53	54.0	193.4
N	10	10	10	10	10	10	10	10	10

^{*-}Significant Difference from Control P < .05

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 13

DRAFT

STUDY ID: UIC-158 STUDY NO: 152 SEX: MALE

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

TEST(s):	CK	BUN	CREAT	NA	K	CL	CA	IP	GLU
UNITS:	IU/L	mg/dL	mg/dL	mEq/L	mEq/L	mEq/L	mg/dL	mg/dL	mg/dL
Group: 1 M :	0 mg base/k	g/day							
MEAN	312	21.0	0.57	145.1	6.01	105.7	10.9	7.8	170
SD	249.1	3.61	0.071	1.20	0.493	5.14	0.41	0.98	51.3
N	10	10	10	10	10	10	10	10	10
Group: 2-M :	0.5 mg base	/kg/day							
MEAN	456	17.0*	0.52	145.2	5.88	99.9*	10.9	7.4	143
SD	392.0	2.73	0.044	1.48	0.559	4.38	0.34	0.74	47.3
N	10	10	10	10	10	10	10	10	10
Group: 3-M :	2.0 mg base	/kg/day							
MEAN	381	18.1	0.58	145.3	5.75	105.8	10.8	8.0	165
SD	335.6	2.91	0.079	1.34	0.533	5.73	0.40	0.44	34.2
N	10	10	10	10	10	10	10	10	10
Group: 4-M :	9.0 mg base	/kg/day							
MEAN	226	15.4*	0.57	144.3	5.95	108.6	10.5	8.1	134
SD	159.0	2.54	0.055	1.42	0.446	5.64	0.24	0.93	19.6
N	10	10	10	10	10	10	10	10	10
									*

^{*-}Significant Difference from Control P < .05

Table 7.7

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 13

DRAFT

STUDY ID: UIC-15B STUDY NO: 152 SEX: FEMALE

ANALYSIS	OF	VARIANCE	FOLLOWED	BY	DUNNETT'S	PROCEDURE
----------	----	----------	----------	----	-----------	-----------

 TEST(s):	ALT	SOH	TP	ALB	GLOB	A/G	TBA	ALKP	LDH
UNITS:	IU/L	IU/L	g/dL	g/dL	g/dL		umol/L	IU/L	IU/L
 Group: 1-F : (mg base/kg	g/day							
MEAN	64	12.2	7.7	4.6	3.2	1.46	45.1	128	444
SO SO	13.4	4.18	0.65	0.30	0.44	0.188	30.14	26.5	197.3
N	10	10	10	10	10	10	10	10	10
Group: 2-F : (.5 mg base,	/kg/day							
MEAN	60	13.1	8.0	4.6	3.5	1.34	86.6	176	457
SD	8.6	6.69	0.55	0.40	0.36	0.189	89.41	90.7	242.7
N	10	10	10	10	10	10	10	10	10
Group: 3-F : 2	2.0 mg base,	/kg/day							
MEAN	68	18.7*	7.7	4.5	3.2	1.42	59.7	151	320
SD	11.4	8.11	0.73	0.43	0.50	0.253	25.49	79.6	163.4
N	10	10	10	10	10	10	10	10	10
Group: 4-F : 9	0.0 mg base	/kg/day							
MEAN	71	17.4	7.7	4.4	3.2	1.40	90.2	171	375
SD	15.6	2.40	0.65	0.33	0.47	0.198	38.40	76.5	190.0
N	10	10	10	10	10	10	10	10	10

^{*-}Significant Difference from Control P < .05

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 13

DRAFT

STUDY ID: UIC-15B STUDY NO: 152 SEX: FEMALE

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

TEST(s):	CK	BUN	CREAT	NA	K	CL	CA	IP	GLU
UNITS:	IU/L	mg/dL	mg/dL	mEq/L	mEq/L	mEq/L	mg/dL	mg/dL	mg/dL
Group: 1-F	0 mg base/k	g/day							
MEAN	427	16.8	0.60	144.8	5.81	99.4	11.0	7.9	142
SD	461.4	3.18	0.088	1.69	0.438	2.46	0.66	1.08	30.3
N	10	10	10	10	10	10	10	10	10
Group: 2-F :	: 0.5 mg base	/kg/day							
MEAN	489	18.3	0.55	144.9	5.45	100.6	11.0	7.7	144
SD	525.6	3.89	0.107	1.52	0.391	2.80	0.56	0.73	23.9
N	10	10	10	10	10	10	10	10	10
Group: 3-F :	2.0 mg base	/kg/day							
MEAN	408	18.8	0.63	146.1	5.47	102.3	11.2	8.2	166
SD	242.1	2.26	0.075	2.85	0.457	2.91	0.47	0.54	43.0
N	10	10	10	10	10	10	10	10	10
Group: 4-F :	9.0 mg base	/kg/day							
MEAN	240	15.6	0.57	143.8	5.54	101.7	11.1	8.0	147
SD	142.1	2.76	0.074	2.39	0.214	2.79	0.34	0.96	45.1
N	10	10	10	10	10	10	10	10	10

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 26

DRAFT

STUDY ID: UIC-15B STUDY NO: 152 SEX: MALE

ANALYSIS OF	VARIANCE	FOLLOWED	BY	DUNNETT'S	PROCEDURE
-------------	----------	----------	----	-----------	-----------

TEST(s):	ALT	SDH	TP	ALB	GLOB	A/G	TBA	ALKP	LDH	
UNITS:	IU/L	IU/L	g/dL	g/dL	g/dL	-	umol/L	IU/L	IU/L	
Group: 1 M:	0 mg base/kg	g/day								
MEAN	75	13.0	7.6	4.2	3.4	1.32	59.8	204	516	
SD	15.7	4.44	0.56	0.28	0.78	0.375	35.22 °	76.0	359.7	
N	10	10	10	10	10	10	10	10	10	
Group: 2-M :	0.5 mg base	/kg/day								
MEAN	81	16.0	7.3	4.0	3.3	1.26	48.2	173	421	
SD	42.5	7.60	0.61	0.24	0.75	0.327	19.59	56.5	321.1	
N	10	10	10	10	10	10	10	10	10	
Group: 3-M :	2.0 mg base	/kg/day								
MEAN	65	12.4	7.6	4.1	3.5	1.25	60.3	191	405	
SD	14.4	6.57	0.45	0.31	0.65	0.365	31.87	90.1	210.9	
N	10	10	10	10	10	10	10	10	10	
Group: 4-M :	9.0 mg base	/kg/day								
MEAN	(89)	15.8	7.3	4.1	3.2	1.34	95.0*	* 203	460	
SD	29.7	7.62	0.48	0.21	0.60	0.324	37.05	55.5	255.3	
N	10	10	10	10	10	10	10	10	10	

^{*-}Significant Difference from Control P < .05

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 26

DRAFT

STUDY ID: UIC-15B STUDY NO: 152 SEX: MALE

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

TEST(s): UNITS:	CK IU/L	BUN mg/dL	CREAT mg/dL	NA mEq/L	K mEq/L	CL mEq/L	CA mg/dL	IP mg/dL	GLU mg/dL	
Group: 1 M :	0 mg base/k	g/day								
MEAN	502	18.1	0.60	146.6	5.89	103.1	11.5	8.6	192	
SD	397.4	2.48	0.046	1.43	0.387	2.73	0.47	0.90	43.4	
N	10	10	10	10	10	10	10	10	10	
Group: 2-M:	0.5 mg base	/kg/day								
MEAN	378	15.5	0.57	146.4	5.80	103.1	11.7	8.5	184	
SD	358-6	3.38	0.049	1.35	0.316	3.67	0.31	1.06	52.5	
N	10	10	10	10	10	10	10	10	10	
Group: 3-M :	2.0 mg base	/kg/day								
MEAN	333	15.8	0.62	145.8	5.84	105.3	11.6	8.8	186	
SD	380.8	1.95	0.102	2.04	0.418	3.02	0.37	1.33	54.3	
N	10	10	10	10	10	10	10	10	10	
Group: 4-M :	9.0 mg base	/kg/day								
MEAN	606	14.0*	0.58	144.4*	5.60	105.6	11.3	8.4	161	
SD	654.3	2.23	0.042	1.17	0.251	4.40	0.32	0.90	32.6	
N	10	10	10	10	10	10	10	10	10	

^{*-}Significant Difference from Control P < .05

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 26

STUDY ID: UIC-15B STUDY NO: 152 SEX: FEMALE

TEST(s):	ALT	SDH	ТP	ALB	GLOB	A/G	TBA	ALKP	LDH
UNITS:	IU/L	IU/L	g/dL	g/dL	g/dL	-	umol/L	IU/L	IU/L
Group: 1-F:	0 mg base/kg	/day							
MEAN	113	8.7	9.9	4.7	5.2	0.91	93.9	110	483
SD	51.6	6.12	0.85	0.28	0.76	0.121	44.84	36.5	270.4
N	10	10	10	10	10	10	10	10	10
Group: 2-F:	0.5 mg base	/kg/day							
MEAN	(98	8.7	9.2*	4.6	4.5*	1.03*	82.3	114	550
SD	72.3	4.19	0.51	0.23	0.47	0.123	34.15	50.0	249.7
N	10	10	10	10	10	10	10	10	10
Group: 3-F:	2.0 mg base/	/kg/day			6				
MEAN	117	7.0	9.8	4.7	5.1	0.94	82.5	136	486
SD	73.2	5.30	0.56	0.20	0.49	0.089	38.92	93.3	243.2
N	10	10	10	10	10	10	10	10	10
Group: 4-F:	9.0 mg base	/kg/day							
MEAN	89	5.8	9.1*	4.7	4.4*	1.06*	153.9	153	487
SD	28.6	5.70	0.58	0.31	0.37	0.085	164.18	62.3	218.5
N	10	10	10	10	10	10	10	10	10

^{*-}Significant Difference from Control P < .05

SUMMARY OF CLINICAL CHEMISTRY TESTS PERIOD: Week 26

SEX: FEMALE

STUDY ID: UIC-15B STUDY NO: 152

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEOURE

TEST(s):	CK	BUN	CREAT	NA	K	CL	CA	IP	GLU
UNITS:	IU/L	mg/dL	mg/dL	mEq/L	mEq/L	mEq/L	mg/dL	mg/dL	mg/dL
Group: 1-F:	0 mg base/k	g/day							
MEAN	298	18.8	0.65	145.5	5.61	104.4	11.1	9.2	153
SD	232.5	1.96	0.096	2.07	0.671	3.86	0.32	0.84	32.5
N	10	10	10	10	10	10	10	10	10
Group: 2-F:	0.5 mg base	/kg/day							
MEAN	479	18.1	0.65	146.3	5.58	102.5	11.0	8.6	139
SD	462.0	2.18	0.066	1.64	0.448	1.58	0.32	1.13	26.5
N	10	10	10	10	10	10	1D	10	10
Group: 3-F:	2.0 mg base	/kg/day							
MEAN	653	18.8	0.67	146.1	5.51	104.7	10.9	9.1	157
SD	921.2	2.10	0.065	1.45	0.465	5.38	0.24	1.12	38.9
N	10	10	10	10	10	10	10	10	10
Group: 4-F:	9.0 mg base	/kg/day							
MEAN	589	15.9*	0.63	144.6	5.74	102.1	10.9	9.0	137
SO	707.0	1.72	0.086	1.26	0.413	1.91	0.31	0.91	31.7
N	10	10	10	10	10	10.	10	10	10

^{*-}Significant Difference from Control P < .05

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 4

DRAFT

STUDY ID: UIC-15B STUDY NO: 152 SEX: MALE

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

TEST(s):	RBC	HGB	HCT	MCV	MCH	MCHC	RETICS	HEINZ BOD.	% METHGB
UNITS:	10^6/mm^3	g/dL	%	fL	pg	g/dL	% RBCs		% HGB
	10 0/118/1 5	9/42		,	P9	9, 42	74 KUC3	A ROCS	A Hub
Group: 1-M	: 0 mg base/kg	g/day							
MEAN	7.56	15.7	44.2	58.5	21.0	36.0	0.7	0.0	0.6
SD	0.460	0.73	2.19	1.41	1.23	1.48	0.28	0.00	0.25
N	10	10	10	10	10	10	10	10	10
Group: 2-M	: 0.5 mg base/	/kg/day							
MEAN	7.69	15.9	45.8	59.6	21.6	36.0	0.8	0.0	0.7
SD	0.270	0.67	1.34	2.44	1.37	2.10	0.25	0.00	0.27
N	10	10	10	10	10	10	10	1D	10
Group: 3-M	: 2.0 mg base/	/kg/day							
MEAN	7.31	15.4	43.7	59.7	21.3	35.6	0.8	0.0	1.2
SD	0.183	0.38	1.91	2.07	0.87	1.23	0.38	0.00	0.19
N	10	10	10	10	10	10	10	10	10
.,									
Group: 4-M	: 9.0 mg base/	/kg/day							
MEAN	7.19*	14.2*	42.1*	58.5	20.7	35.3	1.6*	0.0	6.5*
SD	0.350	0.66	1.75	2.34	0.82	1.12	0.46	0.00	1.22
N	10	10	10	10	10	10	10	10	10

6.5-9 13-71 40.5°

€.1.5

^{*-}Significant Difference from Control P < .05

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 4

DRAFT

STUDY ID: UIC-15B STUDY NO: 152 SEX: MALE

ANALYSIS OF \	VARIANCE	FOLLOWED	RY	DUNNETT'S	PROCEDURE
---------------	----------	----------	----	------------------	-----------

TEST(s): UNITS:	WBC 10^3/mm^3						Eosinophil 10^3/mm^3	Basophils 10^3/mm^3	PLT 10^3/mm^3
 Group: 1-M	: 0 mg base/kg	/day							
MEAN	16.5	0	2.8	0.0	13.1	0.5	0.1	0.0	955
SD	3.01	0.0	1.26	0.04	2.56	0.19	0.22	0.00	99.1
N	10	10	10	10	10	10	10	10	10
Group: 2-M	: 0.5 mg base/	kg/day							
MEAN	17.0	0	2.2	0.0	14.0	0.7	0.1	0.0	1019
SD	3.43	0.0	0.85	0.00	2.85	0.50	0.20	0.00	108.7
N	10	10	10	10	10	10	10	10	10
Group: 3-M	: 2.0 mg base/	kg/day							
MEAN	18.8	0	3.6	0.1	14.7	0.5	0.0	0.0	945
SD	3.07	0.0	1.66	0.10	2.03	0.37	0.06	0.00	85.0
N	10	10	10	10	10	10	10	10	10
Group: 4-M	: 9.0 mg base/	kg/day							
MEAN	26.3*	0	4.1	0.0	21.2*	0.9	0.1	0.0	998
SD	6.28	0.0	1.88	0.00	4.98	0.48	0.13	0.00	108.6
N	10	10	10	10	10	10	10	10	10

9-18

800-1400

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 4

STUDY ID: UIC-158 STUDY NO: 152 SEX: FEMALE

ANALYSIS OF VARIANCE FOLLOWED BY OUNNETT'S PROCEDURE

TES	T(s): TS:	RBC 10^6/mm^3	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RETICS HE	INZ BOD. % RBCs	% METHGB % HGB	
Gro	up: 1-F	: 0 mg base/kg	g/day								
MEA	N	7.39	16.0	42.9	58.0	21.6	37.3	0.6	0.0	0.8	
S	D	0.201	0.52	1.91	1.37	0.36	1.23	0.19	0.00	0.14	
	N	10	10	10	10	10	10	10	10	10	
Gro	up: 2-F	: 0.5 mg base,	/kg/day								
MEA	N	7.41	15.7	42.5	57.4	21.1	36.9	0.7	0.0	0.7	
S	D	0.275	0.51	1.35	1.70	0.49	0.95	0.23	0.00	0.21	
	N	10	10	10	10	10	10	10	10	10	
Gro	up: 3-F	: 2.0 mg base,	/kg/day								
MEA		7.12	15.4	40.7*	57.2	21.7	37.9	0.9	0.0	1.2	
S	D	0.290	0.77	1.97	1.04	0.48	0.66	0.38	0.00	0.26	
	N	10	10	10	10	10	10	10	10	10	
Gro	up: 4-F	: 9.0 mg base,	/kg/day								
MEA	•	6.61*	14.4*	39.1*	59.2	21.9	37.0	1.4*	0.0	5.9*	
S	0	0.248	0.40	1.67	1.97	0.75	0.85	0.51	0.00	1.39	
	N	10	10	10	10	10	10	10	10	10	

^{*-}Significant Difference from Control P < .05

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 4

STUDY IO: UIC-158 STUDY NO: 152 SEX: FEMALE

ANALYSIS OF VARIANCE FOLLOWED BY OUNNETT'S PROCEOURE

 TEST(s): UNITS:	WBC 10^3/mm^3						Eosinophil 10^3/mm^3		PLT 10^3/mm^3	
 Group: 1-F	: 0 mg base/kg	/day							•	
MEAN	15.9	0	2.7	0.0	12.8	0.3	0.2	0.0	1089	
SD	3.41	0.0	1.72	0.06	2.26	0.18	0.14	0.06	139.2	
N	10	10	10	10	. 10	10	10	10	10	
Group: 2-F	: 0.5 mg base/	/kg/day								
MEAN	15.9	0	1.7	0.0	13.7	0.4	0.1	0.0	1066	
SD	2.91	0.3	1.07	0.00	2.51	0.41	0.08	0.00	130.9	
N	10	10	10	10	10	10	10	10	10	
Group: 3-F	: 2.0 mg base/	/kg/day								
MEAN	14.9	0	2.0	0.0	12.5	0.3	0.2	0.0	950	
SD	2.63	0.3	0.93	0.00	2.03	0.15	0.21	0.00	216.9	
N	10	10	10	10	10	10	10	10	10	
Group: 4-F	: 9.0 mg base/	/kg/day								
MEAN	27.6*	0	4-4*	0.1	22.4*	0.7	0.1	0.0	1118	
SD	6.01	0.0	1.30	0.19	6.05	0.48	0.11	0.00	97.6	
N	10	10	10	10	10	10	10	10	10	



WBC corrected for NRBC = or > 10

^{*-}Significant Oifference from Control P < .05

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 13

DRAFT

STUDY ID: UIC-15B STUDY NO: 152 SEX: MALE

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

TEST(s):	RBC	HGB	нст	MCV	MCH	мснс	RETICS HE	INZ BOD.	% METHGB
UNITS:	10^6/mm^3	g/dL	%	fL	pg	g/dL	% RBCs	% RBCs	% HGB
Group: 1-M	: 0 mg base/kg	g/day							
MEAN	8.26	15.7	43.6	52.8	19.0	36.0	0.4	0.0	0.8
SD	0.556	0.89	2.65	0.94	0.51	0.48	0.25	0.00	0.23
N	10	10	10	10	10	10	10	10	10
Group: 2-M	: 0.5 mg base,	/kg/day							
MEAN	8.31	16.2	45.5	54.8	19.5	35.7	0.7	0.0	0.8
SD	0.387	0.56	2.18	2.75	0.75	0.70	0.42	0.00	0.34
N	10	10	10	10	10	10	10	10	10
Group: 3-M	: 2.0 mg base,	/kg/day							
MEAN	8.13	16.0	45.2	55.6	19.7	35.4	0.5	0.0	2.4*
SD	0.184	0.39	1.03	2.16	0.63	0.66	0.28	0.00	0.59
N	10	10	10	10	10	10	10	10	10
Group: 4-M	: 9.0 mg base,	/kg/day							(=1
MEAN	7.99	14.9*	43.0	53.9	18.7	34.6*	1.1*	0.1*	7.3*
SD	0.645	0.65	1.85	2.95	0.79	0.65	0.52	0.15	1.47
N	10	10	10	10	10	10	10	10	10

^{*-}Significant Difference from Control P < .05

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 13

DRAFT

SEX: MALE

STUDY ID: UIC-15B

STUDY NO: 152

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

TEST(s): UNITS:	WBC 10^3/mm^3					•	Eosinophil 10^3/mm^3		PLT 10^3/mm^3
Group: 1-M	: 0 mg base/kg	g/day							
MEAN	16.5	0	2.3	0.1	13.8	0.3	0.1	0.0	1041
SD	3.08	0.0	0.98	0.13	3.27	0.12	0.09	0.00	100.4
N	10	10	10	10	10	10	10	10	10
Group: 2-M	: 0.5 mg base/	kg/day							
MEAN	17.1	0	2.5	0.0	14.1	0.4	0.1	0.0	986
SD	3.62	0.0	1.10	0.06	3.15	0.28	0.21	0.00	100.9
N .	10	10	10	10	10	10	10	10	10
Group: 3-M	: 2.0 mg base/	kg/day							
MEAN	20.6	0	3.2	0.0	16.8	0.4	0.1	0.0	932*
SD	2.70	0.3	0.73	0.06	2.70	0.34	0.15	0.00	91.4
N	10	10	10	10	10	10	10	10	10
Group: 4-M	: 9.0 mg base/	kg/day							
MEAN	26.7*	0	4.4*	0.0	21.6*	0.7	0.1	0.0	886*
SD	5.95	0.3	1.44	0.09	5.57	0.59		0.00	106.0
N	10	10	10	10	10	10	10	10	10

4-18

WBC corrected for NRBC = or > 10

^{*-}Significant Difference from Control P < .05

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 13

DRAFT

STUDY ID: UIC-15B STUDY NO: 152 SEX: FEMALE

ANALYSIS OF	VARIANCE	FOLLOWED	BY	DUNNETT'S	PROCEDURE
-------------	----------	----------	----	-----------	-----------

 TEST(s): UNITS:	RBC 10^6/mm^3	HGB g/dL	нст %	MCV fL	MCH Pg	MCHC g/dL	RETICS HEI % RBCs	NZ BOD. % RBCs	% METHGB % HGB	
Group: 1-F	: 0 mg base/kg	/day								
MEAN	7.90	15.8	43.6	55.3	20.1	36.3	0.5	0.0	0.4	
SD	0.375	0.62	1.89	2.07	0.68	0.66	0.21	0.03	0.27	
N	10	10	10	10	10	10	10	10	10	
Group: 2-F	: 0.5 mg base/	kg/day								
MEAN	7.76	15.4	43.0	55.4	19.9	35.9	0.6	0.0	0.5	
SD	0.509	0.59	1.57	2.07	0.64	0.92	0.27	0.03	0.34	
N	10	10	10	10	10	10	10	10	10	
Group: 3-F	: 2.0 mg base/	kg/day							and the same of	
MEAN	7.38*	15.0*	41.1*	55.8	20.2	36.3	0.6	0.0	1.6*	
SD	0.400	0.91	2.31	1.60	0.64	0.61	0.47	0.00	0.32	
N	10	9	10	10	9	9	10	10	10	
Group: 4-F	: 9.0 mg base/	kg/day								
MEAN	7.28*	14.6*	41.6	57.2	20.1	35.2*	1.0*	0.1*	7.0*	
SD	0.355	0.63	2.31	2.36	0.71	0.72	0.48	0.13	1.15	
N	10	10	10	10	10	10	10	10	10	

^{*-}Significant Difference from Control P < .05

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 13

DRAFT

STUDY IO: UIC-15B STUDY NO: 152 SEX: FEMALE

ANALYSIS OF VARIANCE FOLLOWED BY OUNNETT'S PROCEDURE

TEST(s): UNITS:	WBC 10^3/mm^3						Eosinophil 10^3/mm^3		PLT 10^3/mm^3	
 Group: 1-F	: 0 mg base/kg	/day								
MEAN	(15.3)	0	1.6	0.0	13.3	0.3	0.1	0.0	954	
SD	4.16	0.0	0.95	0.00	3.47	0.15	0.12	0.00	158.7	
N	10	10	10	10	10	10	10	10	10	
Group: 2-F	: 0.5 mg base/	kg/day								
MEAN	15.4	0	1.4	0.0	13.5	0.3	0.1	0.0	950	
SD	3.79	0.0	0.69	0.00	3.56	0.24	0.09	0.00	139.7	
N	10	10	10	10	10	10	10	10	10	
Group: 3-F	: 2.0 mg base/	kg/day								
MEAN	13.9	0	2.4	0.0	11.2	0.3	0.1	0.0	887	
SD	2.10	0.0	0.58	0.03	2.07	0.18	0.13	0.00	79.0	
N	10	10	10	10	10	10	10	10	10	
Group: 4-F	: 9.0 mg base/	kg/day								
MEAN	26.2*	0	2.8*	0.1*	22.9*	0.5	0.1	0.0	1054	
SD	6.74	0.0	1.36	0.14	6.65	0.39	0.21	0.00	162.9	
N	10	10	10	10	10	10	10	10	10	



WBC corrected for NRBC = or > 10

^{*-}Significant Difference from Control P < .05

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 26

DRAFT

STUDY IO: UIC-15B STUDY NO: 152 SEX: MALE

TEST(s): UNITS:	RBC 10^6/mm^3	HGB g/dL	HCT %	MCV fL	MCH P9	MCHC g/dL	RETICS HEI % RBCs	NZ BOD. % RBCs	% METHGB % HGB
Group: 1-	M : 0 mg base/kg	a/day							
MEAN	8.39	15.2	44.3	52.9	18.1	34.3	0.7	0.0	0.6
SD	0.308	0.47	1.59	1.11	0.50	0.66	0.24	0.00	0.12
N	10	10	10	10	10	10	10	10	10
Group: 2-	M : 0.5 mg base,	/kg/day							
MEAN	8.26	15.5	45.1	54.7	18.7	34.3	0.6	0.0	0.6
so	0.434	0.76	2.23	2.79	0.89	0.65	0.39	0.08	0.24
N	10	10	10	10	10	10	10	10	10
Group: 3-	M : 2.0 mg base,	/kg/day							
MEAN	8.28	15.4	45.8	55.4	18.7	33.7	0.7	0.0	2.3*
SD	0.240	0.45	2.09	2.61	0.59	0.67	0.25	0.06	0.33
N	10	10	10	10	10	10	10	10	10
Group: 4-	M : 9.0 mg base	/kg/day							
MEAN	8.35	14.3*	42.8	51.4	17.2*	33.3*	1.3*	0.0	7.4*
SD	0.479	0.42	0.81	2.76	0.80	0.51	0.55	0.03	1.43
N	10	10	10	10	10	10	10	10	10

^{*-}Significant Oifference from Control P < .05

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 26

DRAFT

STUDY ID: UIC-158 STUDY NO: 152 SEX: MALE

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

 TEST(s): UNITS:	WBC 10^3/mm^3			•			Eosinophil 10^3/mm^3	•	PLT 10^3/mm^3	
Group: 1-M :	0 mg base/kg	/day								
MEAN	14.9	0	2.1	0.0	12.3	0.3	0.3	0.0	1001	
SD	2.40	0.0	0.83	0.00	3.15	0.21	0.23	0.00	187.1	
N	10	10	10	10	10	10	10	10	10	
Group: 2-M :	0.5 mg base/	kg/day								
MEAN	17.2	0	3.4	0.0	13.2	0.4	0.2	0.0	974	
SD	4.21	0.3	1.44	0.00	3.04	0.31	0.23	0.00	116.8	
N	10	10	10	10	10	10	10	10	10	
Group: 3-M :	2.0 mg base/	kg/day								
MEAN	19.3	0	3.2	0.0	15.7	0.2	0.1	0.0	971	
SD	3.54	0.4	1.60	0.00	2.37	0.18	0.20	0.00	158.6	
N	10	10	10	10	10	10	10	10	10	
Group: 4-M :	9.0 mg base/	kg/day								
MEAN	(26.3*)	0	4.2*	0.0	21.1*	0.8	0.1	0.0	824	
SD	6.44	0.6	0.92	0.09	5.63	0.41	0.19	0.00	154.9	
N	10	10	10	10	10	10	10	10	10	

9-18

WBC corrected for NRBC = or > 10

^{*-}Significant Difference from Control P < .05

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 26

STUDY ID: UIC-158 STUDY NO: 152 SEX: FEMALE

ANALYSIS OF VARIANCE FOLLOWED BY OUNNETT'S PROCEDURE

TEST(s): UNITS:	WBC 10^3/mm^3			•			Eosinophil 10^3/mm^3	*	PLT 10^3/mm^3	
Group: 1-F	0 mg base/kg	/day								
MEAN	12.6	0	2.2	0.0	10.1	0.2	0.1	0.0	980	
SO	3.82	0.7	1.37	0.00	2.97	0.17	0.11	0.00	133.1	
N	10	10	10	10	10	10	10	10	10	
Group: 2-F	: 0.5 mg base/	kg/day								
MEAN	11.0	0	1.4	0.0	9.3	0.2	0.1	0.0	903	
SD	3.01	1.0	0.87	0.00	2.46	0.09	0.07	0.00	146.2	
N	10	10	10	10	10	10	10	10	10	
Group: 3-F	: 2.0 mg base/	kg/day								
MEAN	11.0	0	2.5	0.0	8.3	0.2	0.1	0.0	942	
SD	1.55	0.3	0.69	0.00	1.24	0.18	0.08	0.00	94.9	
N	10	10	10	10	10	10	10	10	10	
Group: 4-F	9.0 mg base/	kg/day								
MEAN	20.8*	0	3.5*	0.0	17.0*	0.2	0.1	0.0	980	
SD	3.37	0.4	1.17	0.00	3.53	0.24	0.13	0.00	133.1	
N	10	10	10	10	10	10	10	10	10	

6-15

WBC corrected for NRBC = or > 10

^{*-}Significant Difference from Control P < .05

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 26

DRAFT

STUDY IO: UIC-15B STUDY NO: 152 SEX: FEMALE

ANALYSIS OF VARIANCE FOLLOWED BY OUNNETT'S PROCEDURE

TEST(s):	RBC	HGB	HCT	MCV	MCH	MCHC	RETICS HE	INZ BOD.	% METHGB
UNITS:	10^6/mm^3	g/dL	*	fL	pg	g/dL	% RBCs	% RBCs	% HGB
Group: 1-F	: 0 mg base/kg	g/day							
MEAN	7.69	15.2	43.8	57.0	19.8	34.8	1.1	0.0	0.6
SD	0.367	0.50	1.74	1.99	0.58	0.73	0.22	0.00	0.51
N	10	10	10	10	. 10	10	10	10	10
Group: 2-F	: 0.5 mg base/	/kg/day	•						
MEAN	7.54	15.0	43.2	57.3	19.9	34.7	1.0	0.0	0.6
SD	0.272	0.26	0.77	2.31	0.69	0.62	0.36	0.00	0.32
N	10	10	10	10	10	10	10	10	10
Group: 3-F	: 2.0 mg base/	/kg/dav							
MEAN	7.33*	14.8	42.1	57.5	20.2	35.1	0.9	0.0	1.8
SD	0.261	0.40	1.44	1.49	0.50	0.75	0.44	0.00	0.60
N	10	10	10	10	10	10	10	10	10
Group: 4-F	: 9.0 mg base/	/kg/day							
MEAN	7.34*	14.1*	41.6*	56.7	19.3	34.0	1.7*	0.1*	8.0*
SD	0.358	0.76	2.58	3.03	0.84	0.76	0.47	0.16	2.04
N	10	10	10	10	10	10	10	10	10

^{*-}Significant Difference from Control $\,{\rm P}\,<\,.05\,$

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 27

STUDY ID: UIC-15B

STUDY NO: 152

SEX: MALE

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

TEST(s): APTT UNITS: sec

Group: 1-M : 0 mg base/kg/day MEAN 18.2

MEAN 18.2 SD 3.54 N 10

Group: 2-M : 0.5 mg base/kg/day

MEAN 19.8 SD 1.21 N 10

Group: 3-M : 2.0 mg base/kg/day

MEAN 19.3 SD 1.21 N 10

Group: 4-M : 9.0 mg base/kg/day

MEAN 17.3 SD 1.24 N 10

SUMMARY OF HEMATOLOGY TESTS PERIOD: Week 27

DRAFT

STUDY ID: UIC-15B STUDY NO: 152 SEX: FÉMALE

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

TEST(s): APTT UNITS: sec

Group: 1-F : 0 mg base/kg/day MEAN 16.3

SD 1.93 N 10

Group: 2-F : 0.5 mg base/kg/day

MEAN 18.4 SD 5.16 N 10

Group: 3-F : 2.0 mg base/kg/day

MEAN 18.9 SD 3.40 N 10

Group: 4-F: 9.0 mg base/kg/day

MEAN 17.0 SD 3.13 N 10

ORGAN WEIGHT SUMMARY (% BRAIN WEIGHT)

STUDY: 152 SEX: MALE	ALL FATES D. ANALYSIS OF VARIA	AYS: 183-18 NCE USING D		BALANCES ROCEDURE		F	I
	GROUP:	(1) 1-M	(2) 2-M	(3) 3-M	(4) 4-M		
	Adrenal Glands (% BRAIN WEIGHT	`)				 	
	MEAN SD N	2.77 0.319 20	2.98 0.591 20	2.72 0.822 20	3.18 0.812 19		
	Heart (% BRAIN WEIGHT)						
	MEAN SD N	82.49 9.525 20	79.13 7.466 20	75.69* 6.856 20	74.17* 10.710 19		
	N	20	20	20	19		
	Kidneys (% BRAIN WEIGHT) MEAN	187.63	188.21	205.99*	211.31*		
	SD N	15.277 20	18.890 20	20.407 20	34.564 19		
	Lungs/Bronchi (% BRAIN WEIGHT)						
	MEAN SD N	104.54 13.301 20	111.26 15.623 20	205.18* 231.794 20	209.40* 43.117 19		
	Liver (% BRAIN WEIGHT)						
	MEAN SD N	1129.25 106.800 20	1090.79 131.674 20	1100.10 267.811 20	1041.70 188.636 19		
	Spleen (% BRAIN WEIGHT)						
	MEAN SD N	43.44 5.976 20	43.05 5.915 20	54.38 7.282 20	116.23* 31.092 19		
				20	17		
	Testes with Epididymides (% BR MEAN	RAIN WEIGHT 242.33	239.63	248.22	241.23		
	SD N	25.829 20	19.127	24.124	31.324		

⁽¹⁾⁻⁰ mg base/kg/day (2)-0.5 mg base/kg/day (3)-2.0 mg base/kg/day

^{(4)-9.0} mg base/kg/day

* - Significant difference P<.05

Table 9.1 (contd.)

SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

ORGAN WEIGHT SUMMARY (% BRAIN WEIGHT)

STUDY: 152 SEX: FEMALE	ALL FAT ANALYSIS		AYS: 183-18 NCE USING (BS ALL I	BALANCES ROCEOURE		AFT
		GROUP:	(5) 1-F	(6) 2-F	(7) 3-F	(8) 4-F	
	Adrenal Glands (% BRA)	IN WEIGHT MEAN SD N		4.01 0.701 20	3.60 0.881 20	4.69* 0.713 20	
	Heart (% BRAIN WEIGHT)	MEAN SO N	55.29 5.677 20	58.95 7.725 20	53.54 4.921 20	50.78* 5.148 20	
	Kidneys (% BRAIN WEIGH	MEAN SD N	127.15 15.763 20	125.04 15.598 20	126.85 13.871 20	135.90 15.535 20	
	Lungs/Bronchi (% BRAIN	MEIGHT) MEAN SD N	84.71 8.564 20	87.16 10.243 20	131.50* 18.434 20	167.28* 29.464 20	
	Liver (% BRAIN WEIGHT	MEAN SD N	650.58 80.273 20	658.46 104.675 20	653.34 93.187 20	637.60 82.022 20	
	Ovaries (% BRAIN WEIGH	MEAN SD N	5.02 1.204 20	5.59 1.684 20	5.63 1.812 20	5.56 1.504 20	
	Spleen (% BRAIN WEIGH	MEAN SD N	28.11 4.591 20	29.09 4.392 20	33.39* 4.672 20	63.93* 11.515 20	

⁽⁵⁾⁻⁰ mg base/kg/day

^{(6)-0.5} mg base/kg/day (7)-2.0 mg base/kg/day

^{(8)-9.0} mg base/kg/day
* - Significant difference P<.05</pre>

Contract No.: DAMD17-92-C-2001

Task Order No.: UIC-15B UIC/TRL Study No.: 152

Table 10



SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

Summary of Treatment-Related Lesions

			Dose (mg b	ase/kg/day)	
ORGAN - lesion		0	0.5	2.0	9.0
LUNG					
- Hemorrhage	М	2/20 (0.09)*	1/20 (0.06)	4/20 (0.30)	20/20 (1.50)
	F	6/20 (0.14)	9/20 (0.30)	9/20 (0.25)	20/20 (2.10)
- Accumulation, foamy macrophage	M	0/20 (0.00)	2/20 (0.05)	20/20 (1.80)	20/20 (2.65)
	F	0/20 (0.00)	0/20 (0.00)	20/20 (1.95)	20/20 (1.85)
- Inflammation, chronic,	M	2/20 (0.03)	3/20 (0.06)	20/20 (1.20)	20/20 (2.40)
interstitium	F	3/20 (0.05)	0/20 (0.00)	20/20 (1.40)	20/20 (1.90)
LIVER					
- Apoptosis, centrilobular	М	0/20 (0.00)	0/20 (0.00)	0/20 (0.00)	11/20 (0.70)
	F	0/20 (0.00)	-	-	0/20 (0.00)
- Pigmentation, centrilobular	М	0/20 (0.00)	0/20 (0.00)	0/20 (0.00)	11/20 (0.60)
	F	0/20 (0.00)	-	-	0/20 (0.00)
- Fatty change, centrilobular	М	2/20 (0.10)	3/20 (0.10)	6/20 (0.30)	10/20 (0.50)
	F	0/20 (0.00)	-	-	0/20 (0.00)
- Congestion, centrilobular	М	0/20 (0.00)	0/20 (0.00)	2/20 (0.10)	2/20 (0.13)
	F	0/20 (0.00)	-	-	0/20 (0.00)
SPLEEN					
- Erythropoiesis	М	2/20 (0.10)	4/20 (0.20)	8/20 (0.50)	8/20 (0.55)
	F	10/20 (0.70)	11/20 (0.90)	14/20 (1.25)	8/20 (0.60)
- Pigmentation	M	1/20 (0.10)	4/20 (0.20)	8/20 (0.45)	11/20 (0.80)
	F	17/20 (1.15)	20/20 (1.90)	18/20 (1.80)	17/20 (1.20)
- Congestion	M	0/20 (0.00)	0/20 (0.00)	0/20 (0.00)	18/20 (1.90)
	F	0/20 (0.00)	1/20 (0.05)	1/20 (0.05)	17/20 (1.45)
- Hyperplasia, reticuloendothelial	M	0/20 (0.00)	0/20 (0.00)	0/20 (0.00)	4/20 (0.30)
cell	F	0/20 (0.00)	0/20 (0.00)	0/20 (0.00)	1/20 (0.10)
STERNUM WITH MARROW					
- Hyperplasia, bone marrow	М	0/20 (0.00)	5/20 (0.30)	11/20 (0.60)	19/20 (1.25)
	F	0/20 (0.00)	4/20 (0.20)	7/20 (0.40)	13/20 (0.90)
- Granulopoiesis	М	0/20 (0.00)	0/20 (0.00)	0/20 (0.00)	1/20 (0.10)
•	F	0/20 (0.00)	0/20 (0.00)	0/20 (0.00)	1/20 (0.05)
KIDNEY					
- Pigmentation, cortex	M	0/20 (0.00)	0/20 (0.00)	4/20 (0.20)	16/19 (1.11)
	F	0/20 (0.00)	0/20 (0.00)	7/20 (0.35)	20/20 (1.60)
ADRENAL GLAND					
- Pigmentation, zona reticularis	М	0/20 (0.00)	1/20 (0.05)	3/20 (0.15)	10/20 (0.60)
· gamenan, can recuire	F	0/20 (0.00)	1/20 (0.05)	2/20 (0.10)	18/20 (1.55)
- Congestion	M	1/20 (0.05)	1/20 (0.05)	4/20 (0.25)	2/20 (0.10)
	F	7/20 (0.35)	3/20 (0.15)	7/20 (0.40)	18/20 (1.50)

^{*}Incidence (mean group severity score)


⁻ Not examined

Contract No.: DAMD17-92-C-2001

Task Order No.: UIC-15B UIC/TRL Study No.: 152

Figure 1
SIX MONTH ORAL TOXICITY STUDY OF
WR238605 SUCCINATE IN RATS

Summary of Male Body Weights



Body Weights (g)

Contract No.: DAMD17-92-C-2001


Task Order No.: UIC-15B UIC/TRL Study No.: 152

5

SIX MONTH ORAL TOXICITY STUDY OF WR238605 SUCCINATE IN RATS

Figure 2

Summary of Female Body Weights



DRAFT

APPENDIX A ANALYTICAL CHEMISTRY REPORT

Six Month Oral Toxicity Study of WR238605 Succinate In Rats UIC/TRL Study Number 152



Part I:

Identity, Purity and Stability of Neat WR238605 Succinate

Part II:

Dosing Formulations Analysis of WR238605 Succinate in 1%

Methylcellulose/0.2% Tween 80

Analysts:

Adam Negrusz A. Karl Larsen, Jr.

Thomas Tolhurst

Study Site:

Drug Disposition Research Laboratory

College of Pharmacy

University of Illinois at Chicago

Chicago, Illinois 60612

Sponsor:

Toxicology Research Laboratory

University of Illinois at Chicago

Chicago, Illinois 60612

Report

Prepared by:

Thomas Tolhurst / Tolhurs

Report

Prepared:

March 30, 1996

Approved:

April 10, 1996

Eugene F. Woods

Drug Disposition Research Laboratory 6. Sour &

Part 1: Identity, Purity and Stability of Neat WR238605 Succinate

Objective

DRAFT

The objective of this study was to confirm the identity and establish the purity and stability of neat WR238605 Succinate (Bottle No. BM 12562).

Identification

GC-MS System

Gas Chromatograph:

Hewlett-Packard Model 5890 Series II

Mass Selective Detector:

Hewlett-Packard Model 5970

Analytical Column:

30 m x 0.25 mm ID, DB-1 with a 3 micron film thickness.

GC Parameters:

Injector temp. 250°C, oven temp. 70°C initial, 270°C final, 15°C/minute ramp, carrier gas - helium, flow rate 2

ml/minute, split ratio 10:1

Procedure

Subject sample (WR238605 succinate) was submitted by the Toxicology Research Laboratory. The sample was dissolved in hexane:ethanol (4:1) to a concentration of 0.8 μ g base/ml and a 2 μ l aliquot was injected on the column. The MSD scanned from 40 amu to 475 amu at a rate of 1 scan per second.

Results - GC-MS

The mass spectrum indicates a molecular ion m/e 463 (M⁺ free base) and m/e 405 [M⁺ free base minus (CH₂)₃ NH₂]. This pattern is consistent with the structural formula and corresponds to the finding by SRI International (see SRI International Report No. 469, May 9, 1994).

The mass spectrum of the WR238605 sample was previously reported (see Analytical Chemistry Report of UIC/TRL Study No. 097 and Study No. 098 from August 19, 1993) and it is shown in Figure 1.

Purity/Stability

The subject sample (WR238605 Succinate) was supplied by the Toxicology Research Laboratory (TRL) and stored at 0-4°C when not being analyzed.

Description



A fine pale yellow powder, no obvious odor.

HPLC System

Solvent Delivery:

Perkin Elmer, Model 3B

Injector:

Rheodyne 7125 with 20 µl sample loop

Analytical Column:

Bondclone ODS, 10μ , 300 mm x 3.9 mm

(Phenomenex)

Detector:

Kratos, Spectroflow 773 UV Detector, 268 nm

Integrator:

Perkin Elmer LCI-100 Integrator

Mobile Phase:

75% methanol: 25% deionized water containing 6.9

grams of sodium acetate and 8 ml of 85% o-phosphoric acid; flow rate 1.5 ml/min

Procedure

Six solutions of WR238605 were prepared as follows. Twenty-five mg of WR238605 was weighed into each of six 25 ml volumetric flasks. The samples were dissolved in and the volume brought to mark with mobile phase. A 20 μ l aliquot of each solution was chromatographed at 268 nm for purity determination.

Calculation of Purity

Quantitations were based on the assumption of equal detector response per unit weight of all UV-absorbing components. Areas of WR238605 and other detectable components in the subject sample chromatograms were employed in the following equation to calculate the percentage of WR238605 present in the sample:

%PURITY = (area of WR238605/total area) x 100

Stability

The stability of neat WR238605 Succinate was assessed by comparing the percent purity of WR238605 samples submitted for analysis prior to and following completion of Study Number 152. A change in purity greater than 10% was considered to represent a significant loss of potency.

Results



Typical chromatograms are shown in Figure 2. The subject samples were found to contain less than 1% of UV-absorbing impurities. The percent purity of the initial and terminal WR238605 samples were 99.52 ± 0.21 and 99.98 ± 0.02 , respectively, and the assay results are presented in Tables 1 and 2. No loss of potency was found to have occurred over the period during which Study Number 152 was conducted.

Figure 1

Mass Spectrum of WR238605 Sample






Figure 2

Chromatograms of WR238605 (Conc. 0.8 mg/ml, 268 nm)
A - Initial Sample, B - Terminal Sample




Table 1

Purity Data for WR238605 Succinate Initial Sample



Solutions

Peak Identity	1	2	3	4	5	6
A	5571	1	1743	2792	2890	
В	81818	111201	108637	133756	97545	
WR238605	21209642	21198802	21123542	21199894	21095026	21150796
% Purity	99.52	99.40	99.44	99.36	99.48	99.93

¹ - peak not integrated Mean ± s.d. 99.52 ± 0.21



Purity Data for WR238605 Succinate Terminal Sample

Solutions

Peak Identity	1	2	3	4	5	6
A	2105	1188	1221	4620		
WR238605	10257841	12416867	12394351	9416609	11784722	8730453
% Purity	99.98	99.99	99.99	99.95	100	100

Mean ± s.d. 99.98 ± 0.02

Part II:

Dosing Formulations Analysis of WR238605 Succinate in 1%

DRAFT

Methylcellulose/0.2% Tween 80

Introduction:

Sample from UIC/TRL Study No. 152 were submitted by the Toxicology Research Laboratory to the Drug Disposition Research Laboratory for the quantitation of WR238605 free base in dosing formulations. All samples submitted were analyzed by HPLC using an existing analytical method (SOP No. 01MA10-01).

Analytical Method

Regents

Subject sample (WR238605 Succinate) was supplied by the Toxicology Research Laboratory. HPLC grade methanol, 85% O-phosphoric acid and sodium acetate were purchased from Fisher Scientific. HPLC grade water was acquired through a Millipore, MILLI-Q Reagent Water System which was supplied with distilled water.

Standards

All WR238605 concentrations reflect free base value. A 0.8 mg base/ml WR238605 stock solution was prepared by weighing 100 mg of the drug (mole fraction = 0.8) into a 100 ml volumetric flask. The content was dissolved in and the volume brought to mark with mobile phase. A working calibration standard solution of 80μ g base/ml was prepared by transferring 10.0 ml of the 0.80 mg base/ml stock solution to a 100 ml volumetric flask and diluting to mark with mobile phase. The remaining working calibration standards were prepared from the 80μ g base/ml WR238605 solution as follows:

Volume	Flask	Final
Transferred (ml)	Volume (ml)	Concentration (µg base/ml)
1.0	10	8
2.0	10	16
4.0	10	32
6.0	10	48
8.0	10	64

Controls

Control A (0.8 mg base/ml) and control B (2.4 mg base/ml) were prepared by weighing 25 mg and 75 mg, respectively, of WR238605 Succinate salt into two 25 ml volumetric flasks. The contents were dissolved in and diluted to mark with mobile phase.

Sample Preparation

DRAFT

Triplicate dilutions of each suspension were prepared in mobile phase prior to HPLC analysis. The vehicle and the 0.1 mg base/ml suspension were diluted 1:5 and the 0.4 mg base/ml and the 1.8 mg base/ml suspension were diluted 1:10 and 1:50, respectively.

HPLC System

See part I: HPLC System

Calculations

A standard curve was run at the beginning and end of each assay day. Final concentration for controls and samples were determined using a composite standard curve. The composite standard curve was determined by linear least squared regression analysis of the peak areas for WR238605 free base as a function of concentration. WR238605 concentrations (mg base/ml) for controls and samples were determined using the following equation:

WR238605 Conc. = $(Y-B)/M \times (d.f./1000)$

Y = peak height

B = Y-intercept from composite standard curve

M = slope from composite standard curve

d.f. = dilution factor

The standard curves were linear over the range of WR238605 assayed (8 μ g base/ml - 80 μ g base/ml) and had correlation coefficients greater than 0.998. A representative standard curve is shown in Figure 3.

Results

Result of dosing formulations analysis for UIC/TRL Study No. 152 are presented in Table 3. Test article dosage formulations were within 10% of their respective target concentrations both prior to and essentially after dosing. Minor exceptions were in week 14 (0.1 mg base/ml dosage formulation was 129.5% of the predose value and 123% of the target concentration), week 22 (1.8 mg base/ml dosage formulation was 111.1% of the predose value, but 107.1%, i.e., within range, of target concentration), and week 25 (0.4 mg base/ml dosage formulation was 110.9% of the predose value, but 109.0%, i.e., within range, of target concentration). Thus, out of 78 post-dosing analyses, only one sample was slightly (13%) out of predose or target concentration range.

Figure 3
Standard Curve of WR238606






Table 3

Results Of Dosing Formulations Analysis for UIC/TRL Study Number 152



	Target		Predose Analysis			Postdose Analysis	
Study Week	Concentration (mg base/ml)	Date	(mg base/ml)	% Target	Date	(mg base/ml)	% Predose
	0.0		0	-		0	•
1	0.1	08/01/95	0.105 ± 0.001	105.0	08/08/95	0.106 ± 0.002	101.0
	0.4		0.409 ± 0.002	102.3		0.385 ± 0.024	94.1
	1.8		1.770 ± 0.069	98.3		1.777 ± 0.019	100.4
	0.0		0	-		0	-
2	0.1	08/08/95	0.100 ± 0.001	100.0	08/15/95	0.098 ± 0.003	98.0
	0.4		0.391 ± 0.002	97.8		0.397 ± 0.007	101.5
	1.8		1.789 ± 0.012	99.4		1.822 ± 0.071	101.8
	0.0		0	-		0	-
3	0.1	08/15/95	0.100 ± 0.001	100.0	08/22/95	0.099 ± 0.002	99.0
	0.4		0.411 ± 0.004	102.8		0.401 ± 0.001	97.6
	1.8		1.909 ± 0.009	106.1		1.818 ± 0.016	95.2
	0.0		0	-		0	-
4	0.1	08/22/95	0.098 ± 0.001	98.0	08/29/95	0.098± 0.001	100.0
	0.4		0.388 ± 0.004	97.0		0.387 ± 0.007	99.7
	1.8		1.790 ± 0.003	99.4		1.781 ± 0.029	99.5
	0.0		0	-		0	-
5	0.1	08/29/95	0.100 ± 0.002	100.0	09/05/95	0.104 ± 0.009	104.0
	0.4		0.400 ± 0.006	100.0		0.395 ± 0.002	98.8
	1.8		1.818 ± 0.039	101.0		1.825 ± 0.027	100.4
	0.0		0	-		0	
6	0.1	09/05/95	0.096 ± 0.003	96.0	09/12/95	0.101 ± 0.005	105.2
	0.4		0.406 ± 0.006	101.5		0.397 ± 0.013	97.8
	1.8		1.799 ± 0.022	99.9		1.882 ± 0.069	104.6
	0.0		0	-		0	-
7	0.1	09/12/95	0.098 ± 0.009	98.0	09/19/95	0.105 ± 0.001	107.1
	0.4		0.405 ± 0.012	101.3		0.433 ± 0.007	106.9
	1.8		1.787 ± 0.031	99.3		1.866 ± 0.026	104.4
	0.0		0	-		0	-
8	0.1	09/19/95	0.100 ± 0.006	100.0	09/26/95	0.093 ± 0.004	93.0
	0.4		0.406 ± 0.005	101.5		0.391 ± 0.003	96.3
	1.8		1.873 ± 0.042	104.1		2.037 ± 0.038	108.8
	0.0		0	-		0	-
9	0.1	09/26/95	0.096 ± 0.001	96.0	10/03/95	0.097 ± 0.005	101.0
	0.4		0.395 ± 0.011	98.8		0.404 ± 0.004	102.3
	1.8		1.720 ± 0.034	95.6		1.876 ± 0.055	109.1
	0.0		0	-		0	-
10	0.1	10/03/95	0.093 ± 0.001	93.0	10/10/95	0.098 ± 0.003	108.6
	0.4	1	0.404 ± 0.004	101.0		0.405 ± 0.004	100.2
	1.8	1	1.844 ± 0.003	102.4		1.788 ± 0.036	97.0
	0.0		0	-		0	-
11	0.1	10/10/95	0.103 ± 0.006	103.0	10/17/95	0.101 ± 0.003	91.8
	0.4		0.400 ± 0.006	100.0		0.391 ± 0.005	97.8
	1.8	1	1.788 ± 0.003	99.3		1.728 ± 0.015	103.5
	0.0		0	-		0	-
12	0.1	10/17/95	0.110 ± 0.001	110.0	10/24/95	0.099 ± 0.002	90.0
	0.4	1	0.395 ± 0.006	98.8	1	0.395 ± 0.004	100.0
	1.8		1.827 ± 0.003	101.5		1.849 ± 0.011	101.2

Table 3

Results Of Dosing Formulations Analysis for UIC/TRL Study Number 152

DRAFT

	Target		Predose Analysis			Postdose Analysis	
Study Week	Concentration (mg base/ml)	Date	(mg base/ml)	% Target	Date	(mg base/ml)	% Predose
	0.0		0	-		0	-
13	0.1	10/24/95	0.099 ± 0.001	99.0	10/31/95	0.096 ± 0.001	97.0
	0.4	1 1	0.389 ± 0.003	97.3		0.372 ± 0.008	95.6
	1.8	1 1	1.788 ± 0.009	99.3		1.786 ± 0.017	99.9
	0.0		0	-		0	-
14	0.1	10/31/95	0.095 ± 0.002	95.0	11/07/95	0.123 ± 0.008	129.5
	0.4	1 1	0.432 ± 0.006	108.0		0.453 ± 0.009	104.9
	1.8	1 1	1.707 ± 0.035	94.8		1.854 ± 0.040	108.6
	0.0		0	-		0	
15	0.1	11/07/95	0.102 ± 0.001	102.0	11/14/95	0.104 ± 0.007	102.0
	0.4		0.403 ± 0.007	100.8		0.394 ± 0.010	97.8
	1.8	1 1	1.672 ± 0.024	92.9		1.739 ± 0.041	104.0
	0.0		0	-		0	-
16	0.1	11/14/95	0.101 ± 0.004	101.0	11/21/95	0.104 ± 0.004	103.0
	0.4		0.412 ± 0.050	103.0		0.420 ± 0.001	101.9
	1.8		1.768 ± 0.050	98.2		1.890 ± 0.024	106.9
	0.0		0	-		0	-
17	0.1	11/21/95	0.106 ± 0.002	106.0	11/28/95	0.106 ± 0.006	100.0
	0.4		0.413 ± 0.001	103.3	120.00	0.392 ± 0.034	94.9
	1.8	1 1	1.842 ± 0.011	102.3		1.774 ± 0.026	96.3
	0.0		0	102.0		0	
18	0.1	11/28/95	0.106 ± 0.001	106.0	12/05/95	0.100 ± 0.001	94.3
10	0.4	11/20/30	0.408 ± 0.007	102.0	12.00/30	0.398 ± 0.001	97.5
	1.8	1	1.861 ± 0.033	103.3		1.737 ± 0.023	93.4
	0.0		0	100.0		0	33.4
19	0.1	12/05/95	0.102 ± 0.001	102.0	12/12/95	0.103 ± 0.002	101.0
13	0.4	1200/00	0.377 ± 0.001	94.3	121233	0.381 ± 0.004	101.1
	1.8	1	1.910 ± 0.034	106.1		1.877 ± 0.036	98.3
	0.0		0	100.1		0	30.3
20	0.1	12/12/95	0.098 ± 0.002	98.0	12/19/95	0.101 ± 0.003	103.1
20	0.4	12 12 33	0.390 ± 0.019	97.5	12/19/95	0.412 ± 0.009	105.6
	1.8	1	1.828 ± 0.001	101.6		1.873 ± 0.018	102.5
	0.0		0	101.0		0	102.5
21	0.0	12/19/95	0.102 ± 0.006	102.0	12/27/95	0.111 ± 0.004	108.8
21	0.4	12/19/93	0.414 ± 0.009	103.5	12/2/195	0.396 ± 0.009	95.7
					ł		
	1.8		1.831 ± 0.027	101.7		1.816 ± 0.018	99.2
22	0.0	12/27/05	0.098 ± 0.004	98.0	04/02/06	0	00.0
22	0.1	12/27/95		104.3	01/03/96	0.096 ± 0.004	98.0
	0.4		0.417 ± 0.009			0.398 ± 0.012	95.4
	1.8		1.735 ± 0.099	96.4		1.928 ± 0.041	111.1
23	0.0	01/02/06	0 004 + 0 006	94.0	01/00/06	0 103 + 0 006	100.6
23	0.1	01/03/96	0.094 ± 0.006	94.0	01/09/96	0.103 ± 0.006	109.6
	0.4	-	0.411 ± 0.011	102.8		0.403 ± 0.024	98.1
	1.8		1.798 ± 0.037	99.9		1.795 ± 0.022	99.8
0.4	0.0	04/00/00	0	-	044000	0	- 404.0
24	0.1	01/09/96	0.098 ± 0.005	98.0	01/16/96	0.099 ± 0.008	101.0
	0.4	4	0.396 ± 0.010	99.0		0.392 ± 0.004	99.0
	1.8		1.803 ± 0.059	100.2		1.805 ± 0.041	100.1

Table 3

Results Of Dosing Formulations Analysis for UIC/TRL Study Number 152



	Target		Predose Analysis		Postdose Analysis		
Study Week	Concentration (mg base/ml)	Date	(mg base/ml)	% Target	Date	(mg base/ml)	% Predose
	0.0		0	-		0	-
25	0.1	01/16/96	0.105 ± 0.002	105.0	01/23/96	0.104 ± 0.067	99.0
	0.4		0.392 ± 0.005	98.3		0.436 ± 0.004	110.9
	1.8		1.845 ± 0.036	102.5		1.709 ± 0.034	92.6
	0.0		0	-		0	-
26	0.1	01/23/96	0.102 ± 0.002	102.0	02/02/96	0.100 ± 0.002	98.0
	0.4		0.421 ± 0.006	105.3		0.397 ± 0.007	94.3
	1.8		1.708 ± 0.007	94.9		1.774 ± 0.010	103.9

DRAFT

APPENDIX B CLINICAL PATHOLOGY METHODOLOGY

CLINICAL CHEMISTRY

Alanine Aminotransferase (ALT/GPT)

Modified Wroblewski & La Due procedure Ciba-Corning 550 Express Clinical Chemistry System Henry, R.J., Chiamori, N., Golub, O.J. and Berkman, S. Am. J. Clin. Path., <u>34</u>, 381, 1960.



Albumin

Bromocresol green method Ciba-Corning 550 Express Clinical Chemistry System Doumas, B.T. and Biggs, H.G. Standard Methods of Clinical Chemistry, 7, 175, 1972.

Alkaline Phosphatase

Modified Bessey-Lowry procedure Ciba-Corning 550 Express Clinical Chemistry System Neumann, H. and Von Vreedendaal M. Clin. Chem. Acta., 17, 183, 1967.

Calcium

Modified alizarin procedure Ciba-Corning 550 Express Clinical Chemistry System Frings, C.S., et. al. Clin. Chem., <u>16</u>, 816, 1970.

Chloride

Mecuric thiocyanate procedure Ciba-Corning 550 Express Clinical Chemistry System Zall, O.M., Fisher, D. and Garner, M.Q. Anal. Chem, <u>28</u>, 1065, 1956.

Creatinine

Jaffe method Ciba-Corning 550 Express Clinical Chemistry System Larsen. K. Clin. Chem. Acta, <u>41</u>, 209, 1972

Creatine Kinase (CK)

Modification of Szasz et al. procedure Ciba-Corning 550 Express Clinical Chemistry System Clin. Chem. 22, 650-656, 1976.

Glucose

Hexokinase method Ciba-Corning 550 Express Clinical Chemistry System Bondar, J.L. and Mead, D.C. Clin. Chem. <u>20</u>, 586, 1974.

CLINICAL CHEMISTRY (contd.)

Phosphorus, Inorganic

Ammonium molybdate method Ciba-Corning 550 Express Clinical Chemistry System Fiske, C.H. and Subbarow, Y. J. Biol. Chem. <u>66</u>, 325, 1925. DRAFT.

Lactate Dehydrogenase

L → P technique Ciba-Corning 550 Express Clinical Chemistry System Wacker, W.E.C., Ulmer, D.D., Valle, B.L. New England J Med. 225, 449, 1956.

Na+, K+

Ion specific electrodes
Model 614 ISE Na+/K+ Analyzer (Ciba Corning)

Sorbitol Dehydrogenase

Fructose → Sorbitol oxidase reaction Ciba-Corning 550 Express Clinical Chemistry System Asada, M. and Galanbos J.T. Gastroenterology 44, 578, 1963. Wiesner, I.S. et al. Am. J. Dig. Dis. 10, 147, 1965.

Total Bile Acids

3α- Hydroxy bile acid oxidation procedure (Sigma Diagnostic kit)
Ciba-Corning 550 Express Clinical Chemistry System
Mashige, F. et al.
Clin Chem. 27, 1352-1356, 1981.

Total Protein

Biuret technique Ciba-Corning 550 Express Clinical Chemistry System Kingsley, G.R. J. Biol. Chem. <u>131</u>, 197, 1939.

Urea Nitrogen (BUN)

Modified urease technique Ciba-Corning 550 Express Clinical Chemistry System Talke, H. and Schubert, G.E. Klin. Wchnschr. <u>43</u>, 174, 1965.

HEMATOLOGY

Erythrocyte Count

Electronic counting procedure
Sysmex K1000 Hematology Analyzer

Hemoglobin

Cyanomethemoglobin method Sysmex K1000 Hematology Analyzer

Hematocrit

Indirect method; calculated value based on volume of red cells and volume of blood

Mean Corpuscular Volume (MCV)

Indirect method; calculated value based on hematocrit and red blood cell count

Mean Corpuscular Hemoglobin (MCH)

Indirect method; calculated value based on erythrocyte count and hemoglobin

Mean Corpuscular Hemoglobin Concentration (MCHC)

Indirect method; calculated value based on hematocrit and hemoglobin

Methemoglobin (% METHGB)

Co-oximeter (Instrumentation Laboratory Model 282)

Reticulocyte Count

New methylene blue staining procedure Brecher, G., Am. J. Clin. Path., 19, 895, 1949.

Platelet Count

Electronic counting procedure Sysmex K1000 Hematology Analyzer

Activated Partial Thromboplastin Time (APTT)

Electra 700 coagulation machine

Leukocyte Count

Electronic counting procedure Sysmex K1000 Hematology Analyzer

Leukocyte Differential Count

Neutrophils - Immature (bands)

Neutrophils - Mature (segs)

Monocytes

Basophils

Lymphocytes

Eosinophils

Wright stain procedure

Schalm, O.W., Jain, N.C. and Carroll, E.J. Veterinary Hematology, Color Plates Chapter, 3rd Edition, Lee and Febiger, 1975.

HEMATOLOGY (contd.)

Nucleated RBCs

DRAFT

Wright stain procedure

Schalm, O.W., Jain, N.C. and Carroll, E.J. Veterinary Hematology, Color Plates Chapter, 3rd Edition, Lee and Febiger, 1975.

RBC Morphology

Wright stain procedure

Schalm, O.W., Jain, N.C. and Carroll, E.J. Veterinary Hematology, Color Plates Chapter, 3rd Edition, Lee and Febiger, 1975.

DRAFT

APPENDIX C INDIVIDUAL OBSERVATIONS (Clinical Signs)

DRAFT

	INDIVIDUAL CLI	NICAL SIGNS		
STUDY: 152 DAY 1-DAY 185	GROUP: 1-M DOSE: 0 (mg bas	SEX:		
TMAT # ODGEDUATIONS		CEVEDITY	TOC	TIME OCCUPED

		- (5/ 11g/ day /		
ANIMAL #	OBSERVATIONS		SEVERITY	LOC	TIME OCCURRED
401	Dark Material Around Normal Normal Scheduled Sacrifice	Eyes			DAY 177 DAY 1-DAY 176 DAY 178-DAY 183 DAY 184
402	Normal Scheduled Sacrifice				DAY 1-DAY 182 DAY 183
403	Normal Scheduled Sacrifice				DAY 1-DAY 183 DAY 184
404	Dark Material Around Dark Material Around Normal Normal Scheduled Sacrifice	Eyes Nose			DAY 177 DAY 72 DAY 1-DAY 71 DAY 73-DAY 176 DAY 178-DAY 183 DAY 184
405	Normal Scheduled Sacrifice				DAY 1-DAY 182 DAY 183
406	Normal Normal Scheduled Sacrifice				DAY 1-DAY 68 DAY 70-DAY 183 DAY 184
407	Dark Material Around Normal Normal Normal Swollen Left Eye Scheduled Sacrifice	Eyes			DAY 177 DAY 1-DAY 27 DAY 31-DAY 176 DAY 178-DAY 182 DAY 28-DAY 30 DAY 183
408	Normal Scheduled Sacrifice				DAY 1-DAY 182 DAY 183
409	Normal Scheduled Sacrifice				DAY 1-DAY 182 DAY 183

[0]				
	153	181	>	H
الا	ШШ	La	11	- 11

					L	O U	П
			CLINICAL SIGNS				
STUDY: DAY 1-1	152 GR DAY 185 DO	OUP: 1-M SE: 0 (mg	SEX: base/kg/day)	MALE			
	OBSERVATIONS		SEVERITY		TIME	e occui	RRED
410	Normal Scheduled Sacrifi	ce		J. San	DAY DAY	1-DAY 183	182
411	Normal Scheduled Sacrifi	ce			DAY DAY	1-DAY 184	183
412	Normal Scheduled Sacrifi	ce			DAY DAY	1-DAY 184	183
413	Normal Scheduled Sacrifi	ce			DAY DAY	1-DAY 184	183
414	Normal Scheduled Sacrifi	ce			DAY DAY	1-DAY 183	182
415	Normal Scheduled Sacrifi	ce			DAY DAY	1-DAY 184	183
416	Normal Scheduled Sacrifi	ce			DAY DAY	1-DAY 183	182
417	Normal Scheduled Sacrific	ce			DAY DAY	1-DAY 183	182
418	Normal Scheduled Sacrific	ce			DAY DAY	1-DAY 183	182
419	Normal Scheduled Sacrific	ce			DAY DAY	1-DAY 183	182
420	Normal Scheduled Sacrific	ce			DAY DAY	1-DAY 184	183
421	Normal Animal Removed Fro	om Study			DAY DAY	1-DAY 176	175
422	Normal Animal Removed Fro	om Study			DAY DAY	1-DAY 176	175

		1	57
P	16	17	
	LO	Ш	Ш

		INDIVIDUAL	CLINICAL SIGNS		
STUDY: DAY 1-1	152 DAY 185	GROUP: 1-M DOSE: 0 (mg	SEX: g base/kg/day)	MALE	
ANIMAL #	OBSERVATIONS		SEVERITY	LOC	TIME OCCURRED
423	Normal Animal Removed	From Study			DAY 1-DAY 175 DAY 176
424	Normal Animal Removed	From Study			DAY 1-DAY 175 DAY 176
425	Dark Material A Dark Material A Normal Normal Animal Removed	_			DAY 156 DAY 175 DAY 1-DAY 155 DAY 157-DAY 174 DAY 176



	INDIVIDUAL CLINICAL SIGNS	•••••••••••
STUDY: DAY 1-	152 GROUP: 2-M SEX: MALE DAY 185 DOSE: 0.5 (mg base/kg/day)	
ANIMAL #	OBSERVATIONS SEVERITY LOC	TIME OCCURRED
451	Dark Material Around Eyes Normal Normal Scheduled Sacrifice	DAY 178 DAY 1-DAY 177 DAY 179-DAY 183 DAY 184
452	Dark Material Around Eyes Normal Normal Scheduled Sacrifice	DAY 177 DAY 1-DAY 176 DAY 178-DAY 182 DAY 183
453	Dark Material Around Eyes Dark Material Around Eyes Dark Material Around Mouth Dark Material Around Mouth Dark Material Around Nose Normal Normal Normal Nasal Discharge Scheduled Sacrifice	DAY 167 DAY 177 DAY 167 DAY 167 DAY 169-DAY 173 DAY 167-DAY 168 DAY 1-DAY 166 DAY 174-DAY 176 DAY 178-DAY 182 DAY 167 DAY 183
454	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
455	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
456	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
457	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
458	Normal Scheduled Sacrifice	DAY 1-DAY 183 DAY 184
459	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183

(-)			50
1	191	13	
Lil	LU	Li	l i

INDIVIDUAL	CLINICAL	SIGNS	
------------	----------	-------	--

STUDY: DAY 1-	152 G DAY 185 D	ROUP: 2-M OOSE: 0.5 (mg	SEX: g base/kg/day)	MALE		
ANIMAL #	OBSERVATIONS		SEVERITY	LOC	TIME OCCU	RRED
460	Dark Material Ar Normal Normal Normal Scheduled Sacrif	•			DAY 177 DAY 1-DAY DAY 71-DAY DAY 178-I DAY 184	Y 176
461	Normal Scheduled Sacrif	ice			DAY 1-DAY DAY 183	182
462	Normal Scheduled Sacrif	ice			DAY 1-DAY DAY 183	182
463	Normal Scheduled Sacrif	ice			DAY 1-DAY DAY 183	182
464	Normal Scheduled Sacrif	ice			DAY 1-DAY DAY 184	183
465	Normal Scheduled Sacrif	ice			DAY 1-DAY DAY 184	183
466	Normal Scheduled Sacrif	ice			DAY 1-DAY DAY 184	183
467	Hunched Posture Normal Normal Scheduled Sacrif	ice			DAY 11 DAY 1-DAY DAY 12-DAY DAY 183	7 10 XY 182
468	Normal Scheduled Sacrif	ice			DAY 1-DAY DAY 183	182
469	Normal Scheduled Sacrif	ice			DAY 1-DAY DAY 183	182
470	Normal Scheduled Sacrif	ice			DAY 1-DAY DAY 183	182

[C : 2		12	77
	4	Li	

INDIVIDUAL CLINICAL SIGNS STUDY: 152							
DAY 1-DAY 185 DOSE: 0.5 (mg base/kg/day) ANIMAL # OBSERVATIONS SEVERITY LOC TIME OCCURRED DAY 1-DAY 175 DAY 176 PAY 1-DAY 175 DAY 176 DAY 1-DAY 175 DAY 176				INDIVIDUAL CL	INICAL SIGNS		
471 Normal Removed From Study 472 Normal Removed From Study 473 Normal Animal Removed From Study 474 Normal Animal Removed From Study 475 Normal 475 Normal 476 DAY 1-DAY 175		STUDY: DAY 1-1	152 DAY 185	GROUP: 2-M DOSE: 0.5(mg	SEX: base/kg/day)	MALE	
Animal Removed From Study Animal Removed From Study Animal Removed From Study Animal Removed From Study DAY 1-DAY 175 DAY 176 DAY 1-DAY 175 DAY 176 DAY 1-DAY 175 DAY 176 DAY 1-DAY 175 DAY 1-DAY 175 DAY 176 DAY 1-DAY 175	A	NIMAL #	OBSERVATIONS		SEVERITY	LOC	TIME OCCURRED
Animal Removed From Study Animal Removed From Study DAY 176 DAY 1-DAY 175 DAY 176 Animal Removed From Study DAY 1-DAY 175 DAY 176 DAY 1-DAY 175 DAY 176 DAY 1-DAY 175 DAY 176 DAY 1-DAY 175 DAY 1-DAY 175		471		From Study			
Animal Removed From Study Animal Removed From Study DAY 176 DAY 1-DAY 175 DAY 1-DAY 175 DAY 1-DAY 175 DAY 1-DAY 175		472		From Study			
Animal Removed From Study DAY 176 475 Normal DAY 1-DAY 175		473		From Study			
		474	Normal Animal Removed	From Study			
		475		From Study			



DAY 86

	IND	VIDUAL CL	INICAL SIGNS		
STUDY: DAY 1-1	152 GROU DAY 185 DOSI	JP: 3-M E: 2.0 (mg	SEX: base/kg/day)	MALE	
ANIMAL #	OBSERVATIONS		SEVERITY	LOC '	TIME OCCURRED
501	Normal Scheduled Sacrifice	9			DAY 1-DAY 182 DAY 183
502	Normal Scheduled Sacrifice	e			DAY 1-DAY 183 DAY 184
503	Normal Scheduled Sacrifice	е			DAY 1-DAY 182 DAY 183
504	Dark Material Aroun Normal Normal Swollen Left Eye Scheduled Sacrifice	-			DAY 177-DAY 179 DAY 1-DAY 176 DAY 182-DAY 183 DAY 178-DAY 181 DAY 184
505	Dark Material Arous Normal Normal Scheduled Sacrifice	-]	DAY 177-DAY 178 DAY 1-DAY 176 DAY 179-DAY 182 DAY 183
506	Dark Material Aroun Normal Normal Scheduled Sacrifice	•]	DAY 178 DAY 1-DAY 177 DAY 179-DAY 183 DAY 184
507	Dark Material Aroun Normal Normal Scheduled Sacrifice	4		I	DAY 177-DAY 178 DAY 1-DAY 176 DAY 179-DAY 182 DAY 183
508	Normal Scheduled Sacrifice	2			DAY 1-DAY 183 DAY 184
509	Normal Scheduled Sacrifice	:		I	DAY 1-DAY 182 DAY 183

Dark Material Around Eyes

510

SIX MONTH ORAL TOXICITY STUDY OF DRAF TO TOXICITY STUDY OF DRAF TOXICITY STUDY OF TOXICITY STUDY ST

	INDIVIDUAL CLINICAL SIGNS	
STUDY: DAY 1-	152 GROUP: 3-M SEX: MALE DAY 185 DOSE: 2.0 (mg base/kg/day)	
ANIMAL #	OBSERVATIONS SEVERITY LOC	TIME OCCURRED
	Dark Material Around Eyes Normal Normal Normal Scheduled Sacrifice	DAY 177 DAY 1-DAY 85 DAY 87-DAY 176 DAY 178-DAY 182 DAY 183
511	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
512	Normal Scheduled Sacrifice	DAY 1-DAY 183 DAY 184
513	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
514	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
515	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
516	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
517	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
518	Normal Scheduled Sacrifice	DAY 1-DAY 183 DAY 184
519	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
520	Normal Scheduled Sacrifice	DAY 1-DAY 182 DAY 183
521	Dark Material Around Eyes Normal Animal Removed From Study	DAY 175 DAY 1-DAY 174 DAY 176

				57
1111	Ins	181	17	- 11
	шц	L	ш	- 11

											_
1			INDIVII	DUAL	CLI	VICAL	SIGNS				
	STUDY: DAY 1-1	152 DAY 185	GROUP: DOSE:	3-M 2.0	(mg]	oase/k	SEX: (g/day)	MALE			
	ANIMAL #	OBSERVATIONS				SEVE	ERITY	LOC	TIM	E OCCU	RRED
	522	Dark Material Dark Material Normal Normal Animal Removed		_					DAY DAY DAY	165 168-DA 1-DAY 166-DA	164
	523	Dark Material Normal Animal Removed			l.				DAY	175 1-DAY 176	174
	524	Dark Material Normal Animal Removed		•					DAY DAY DAY	1-DAY	174
	525	Normal Animal Removed	From St	udy					DAY DAY	1-DAY 176	175

	INDIV	IDUAL CL	INICAL SIGNS			
STUDY: DAY 1-1	152 GROUP DAY 185 DOSE:	: 4-M 9.0 (mg	SEX: base/kg/day)	MALE		
ANIMAL #	OBSERVATIONS		SEVERITY		TIME	OCCURRED
551	Normal Scheduled Sacrifice			p	DAY DAY	1-DAY 182 183
552	Normal Scheduled Sacrifice				DAY DAY	1-DAY 182 183
553	Dark Material Around Normal Normal Scheduled Sacrifice	Eyes			DAY	178-DAY 179 1-DAY 177 180-DAY 183 184
554	Normal Scheduled Sacrifice				DAY DAY	1-DAY 182 183
555	Dark Material Around Normal Normal Normal Normal Normal Normal Normal Rough Coat	Eyes			DAY DAY DAY DAY DAY DAY DAY	76-DAY 85 103 105-DAY 116 118-DAY 176 179-DAY 182 61 63-DAY 75 86-DAY 102 104 117
556	Dark Material Around Normal Normal Scheduled Sacrifice	Eyes			DAY DAY DAY DAY	1-DAY 177 179-DAY 182
557	Normal Scheduled Sacrifice				DAY DAY	1-DAY 182 183

2	Λ	5	
ПП	M	U	U

•	INDI	VIDUAL (CLINICAL SIGNS		
STUDY: DAY 1-	152 GROU DAY 185 DOSE	JP: 4-M E: 9.0 (r	SEX: ng base/kg/day)	MALE	
ANIMAL #	OBSERVATIONS		SEVERITY	LOC I	IME OCCURRED
558		nd Nose			DAY 134 DAY 136 DAY 137 DAY 62-DAY 78 DAY 136 DAY 136 DAY 136 DAY 1-DAY 47 DAY 85-DAY 103 DAY 105-DAY 123 DAY 126-DAY 133 DAY 135 DAY 48-DAY 78 DAY 80-DAY 84 DAY 104 DAY 124-DAY 125 DAY 134
559	Dark Material Arour Normal Normal Scheduled Sacrifice				DAY 177 DAY 1-DAY 176 DAY 178-DAY 182 DAY 183
560	Dark Material Arour Normal Normal Scheduled Sacrifice	-			DAY 181 DAY 1-DAY 180 DAY 182 DAY 183
561	Normal Scheduled Sacrifice	9			DAY 1-DAY 183 DAY 184
562	Normal Scheduled Sacrifice	e			DAY 1-DAY 182 DAY 183
563	Normal Scheduled Sacrifice	9			DAY 1-DAY 182 DAY 183
564	Normal Scheduled Sacrifice	2			DAY 1-DAY 182 DAY 183



DAY 57-DAY 60

TNDTVIDUAL CLINICAL SIGNS

		TWDTATI	DUAL CL.	INICAL SIGNS			
 STUDY: DAY 1-1	152 DAY 185	GROUP: DOSE:	4-M 9.0 (mg	SEX: base/kg/day)	MALE	• • • • • • •	
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCURRED
565	Dark Material A Dark Material A Dark Material A Hunched Posture Hunched Posture Labored Breath Normal Normal Normal Normal Normal Normal Normal Normal Scheduled Sacri	Around I	Eyes Mouth Nose			DAY DAY DAY DAY DAY DAY	169 167 169 171-DAY 181 167 1-DAY 166 168 170 182-DAY 183 167 173-DAY 176
566	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 183 184
567	Normal Scheduled Sacr:	ifice				DAY DAY	1-DAY 183 184
568	Hunched Posture Normal Normal Rough Coat Scheduled Sacr					DAY DAY	68-DAY 84 1-DAY 63 86-DAY 182 64-DAY 85 183
569	Normal Normal Rough Coat Scheduled Sacr	ifice				DAY	1-DAY 81 84-DAY 183 82-DAY 83 184
570	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 182 183
571	Normal Animal Removed	From St	tudy			DAY DAY	1-DAY 175 176

572

Dark Material Around Eyes

	0	Λ	5	7
6		5	il.	11

TNDTVTDIIZ	LT.	CI.TNTC2	AT.	STONS

STUDY: DAY 1-1	152 DAY 185	GROUP: DOSE:	4-M 9.0 (mg	SEX: base/kg/day)	MALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCUR	RED
	Dark Material A Normal Normal Animal Removed		•	/			1-DAY 61-DAY	
573	Normal Animal Removed	From St	udy			DAY DAY	1-DAY 176	175
574	Normal Animal Removed	From St	udy			DAY DAY	1-DAY 176	175
575	Dark Material Animal Removed		-			DAY DAY DAY	1-DAY	174



_							L . L	
	• • • • • • • • • • • • • • • • • • • •	INDIVI	DUAL (CLINICAL	SIGNS			
STUDY: DAY 1-	152 DAY 185	GROUP: DOSE:	1-F 0 (mg	base/kg/	SEX: day)	FEMALE		
ANIMAL #	OBSERVATIONS			SEVE	RITY	LOC	TIME	OCCURRED
426	Dark Material Normal Normal Scheduled Sacr		Eyes				DAY	179-DAY 181 1-DAY 178 182-DAY 184 185
427	Normal Scheduled Sacr	ifice					DAY DAY	1-DAY 183 184
428	Dark Material A Normal Normal Scheduled Sacr		Eyes				DAY DAY DAY DAY	1-DAY 177 179-DAY 183
429	Normal Scheduled Sacr	ifice					DAY DAY	1-DAY 184 185
430	Dark Material A Normal Normal Scheduled Sacr		Eyes				DAY	179-DAY 180 1-DAY 178 181-DAY 184 185
431	Dark Material A Normal Normal Scheduled Sacra		Eyes				DAY DAY DAY DAY	1-DAY 177 179-DAY 183
432	Normal Scheduled Sacri	ifice					DAY DAY	1-DAY 184 185
433	Normal Scheduled Sacr	ifice					DAY DAY	1-DAY 184 185
434	Normal Scheduled Sacr	ifice					DAY DAY	1-DAY 184 185
435	Normal Scheduled Sacr	ifice					DAY DAY	1-DAY 184 185

	INDIVIDUAL CLINICAL SIGNS	
STUDY: DAY 1-I	GROUP: 1-F SEX: FEMALE DOSE: 0 (mg base/kg/day)	
ANIMAL #	OBSERVATIONS SEVERITY LOC	TIME OCCURRED
436	Normal Scheduled Sacrifice	DAY 1-DAY 184 DAY 185
437	Normal Scheduled Sacrifice	DAY 1-DAY 183 DAY 184
438	Normal Scheduled Sacrifice	DAY 1-DAY 183 DAY 184
439	Normal Scheduled Sacrifice	DAY 1-DAY 183 DAY 184
440	Normal Scheduled Sacrifice	DAY 1-DAY 184 DAY 185
441	Normal Scheduled Sacrifice	DAY 1-DAY 184 DAY 185
442	Normal Scheduled Sacrifice	DAY 1-DAY 183 DAY 184
443	Normal Scheduled Sacrifice	DAY 1-DAY 184 DAY 185
444	Normal Scheduled Sacrifice	DAY 1-DAY 183 DAY 184
445	Normal Scheduled Sacrifice	DAY 1-DAY 183 DAY 184
446	Dark Material Around Eyes Normal Animal Removed From Study	DAY 175 DAY 1-DAY 174 DAY 176
447	Normal Animal Removed From Study	DAY 1-DAY 175 DAY 176
448	Normal Animal Removed From Study	DAY 1-DAY 175 DAY 176

			3	T
--	--	--	---	---

						שם ביו	ט ט ע
		INDIV	IDUAL (CLINICAL SIGNS			
STUDY: DAY 1-	152 DAY 185	GROUP DOSE:	: 1-F 0 (mg	SEX: base/kg/day)	FEMALE		
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCURRED
449	Normal Normal Animal Removed	From	Study			DAY DAY DAY	1-DAY 147 149-DAY 175 176
450	Normal Animal Removed	From	Study			DAY	1-DAY 175 176

E S	3	7
		1.1

		ك	ШЦ	LN	и п
TETTTTAT	OT TATTORT	CTCMC			

INDIVIDUAL CLINICAL SIGNS									
STUDY: DAY 1-	152 DAY 185	GROUP: DOSE:	2-F 0.5(mg	SEX: base/kg/day)	FEMALE				
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCURRED		
476	Normal Scheduled Sacr					DAY DAY	1-DAY 184 185		
477	Dark Material A Normal Normal Scheduled Sacra		Eyes			DAY	178-DAY 179 1-DAY 177 180-DAY 183		
478	Normal Scheduled Sacr	ifice				DAY DAY	1-DAY 184 185		
479	Normal Scheduled Sacr	ifice				DAY DAY	1-DAY 183 184		
480	Dark Material A Normal Normal Scheduled Sacra		Eyes			DAY DAY DAY DAY	1-DAY 177 179-DAY 184		
481	Normal Scheduled Sacra	ifice				DAY DAY	1-DAY 184 185		
482	Dark Material A Normal Normal Normal Normal Rough Coat Rough Coat Scheduled Sacra		Eyes			DAY DAY DAY DAY	1-DAY 155 157 160-DAY 177 179-DAY 184 156 158-DAY 159		
483	Normal Scheduled Sacr	ifice				DAY DAY	1-DAY 184 185		
484	Normal Scheduled Sacr	ifice				DAY DAY	1-DAY 184 185		

DRAFT

	INDIVIDUAL CLINICAL SIGNS										
S D	TUDY:	152 GROUP DAY 185 DOSE:	: 2-F 0.5	(mg bas	SEX: e/kg/day)	FEMALE					
ANIM	AL #	OBSERVATIONS		S	SEVERITY	LOC	TIME	OCCUF	RRED		
4	85	Dark Material Around Normal Normal Scheduled Sacrifice	Eyes			ماتر ا	DAY DAY DAY DAY	1-DAY 179-DA	177 AY 184		
4	86	Normal Scheduled Sacrifice					DAY DAY	1-DAY 185	184		
4	87	Normal Scheduled Sacrifice					DAY DAY	1-DAY 184	183		
4	88	Normal Scheduled Sacrifice					DAY DAY	1-DAY 185	184		
4	89	Normal Scheduled Sacrifice					DAY DAY	1-DAY 184	183		
4	90	Normal Scheduled Sacrifice					DAY DAY	1-DAY 184	183		
4	91	Normal Scheduled Sacrifice					DAY DAY	1-DAY 184	183		
4	92	Normal Scheduled Sacrifice					DAY DAY	1-DAY 184	183		
4	93	Normal Scheduled Sacrifice					DAY DAY	1-DAY 185	184		
4	94	Normal Scheduled Sacrifice					DAY DAY	1-DAY 185	184		
4	95	Normal Scheduled Sacrifice					DAY DAY	1-DAY 185	184		
4	96	Normal Animal Removed From	Study				DAY DAY	1-DAY 176	175		

SIX MONTH ORAL TOXICITY STUDY OF D A F

			INDIVIDUAL	CLINICAL SIGNS		
7	STUDY: DAY 1-1	152 DAY 185	GROUP: 2-F DOSE: 0.5	SEX: mg base/kg/day)	FEMALE	
	ANIMAL #	OBSERVATIONS		SEVERITY	LOC	TIME OCCURRED
	497	Normal Animal Removed	From Study			DAY 1-DAY 175 DAY 176
<i>V</i>	498	Normal Animal Removed	From Study			DAY 1-DAY 175 DAY 176
	499	Normal Animal Removed	From Study		,	DAY 1-DAY 175 DAY 176
	500	Normal Animal Removed	From Study			DAY 1-DAY 175 DAY 176

000	Λ	5	1
UU	507	Ц	В

DAY 179 DAY 1-DAY 178 DAY 180-DAY 183 DAY 184

•						- L	
		INDIVII	OUAL CL	INICAL SIGNS			
STUDY: DAY 1-I	152 DAY 185	GROUP: DOSE:	3-F 2.0(mg	SEX base/kg/day)	: FEMALE		
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCURRED
526	Dark Material A Normal Normal Scheduled Sacri		Eyes			DAY	178-DAY 179 1-DAY 177 180-DAY 184 185
527	Dark Material A Normal Normal Scheduled Sacri		Eyes				1-DAY 180 182-DAY 184
528	Dark Material A Normal Normal Scheduled Sacri		Eyes			DAY DAY DAY DAY	1-DAY 178 180-DAY 183
529	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 184 185
530	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 183 184
531	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 184 185
532	Dark Material A Normal Normal Scheduled Sacri		Eyes			DAY	178. 1-DAY 177 179-DAY 184 185
533	Normal Normal Swollen Left Ey Scheduled Sacri	ye ifice				DAY	1-DAY 177 180-DAY 184 178-DAY 179 185

Dark Material Around Eyes Normal Normal Scheduled Sacrifice

534

DRAFT

						ח ח	7 1	u		
	INDIVIDUAL CLINICAL SIGNS									
STUDY: DAY 1-	152 DAY 185	GROUP: DOSE:	3-F 2.0(mg	SEX: base/kg/day)	FEMALE					
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCUF	RED		
535	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 185	184		
536	Normal Scheduled Sacri	ifice					1-DAY 185	184		
537	Normal Normal Scheduled Sacri	ifice				DAY DAY DAY	1-DAY 69-DAY 185	67 7 184		
538	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 185	184		
539	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 184	183		
540	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 185	184		
541	Normal Scheduled Sacri	ifice					1-DAY 185	184		
542	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 184	183		
543	Normal Scheduled Sacri	ifice			C .	DAY DAY	1-DAY 185	184		
544	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 184	183		
545	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 184	183		
546	Normal Normal Animal Removed	From St	udy			DAY DAY DAY	1-DAY 69-DAY 176	67 175		

n		1	P	57
	IN)	61	1	Ш

 								3 13 (1
		INDIVI	DUAL CL	INICAL	SIGNS				
STUDY: DAY 1-1	152 DAY 185	GROUP: DOSE:	3-F 2.0 (mg	pase/k	SEX: (g/day)	FEMALE			
 ANIMAL #	OBSERVATIONS			SEVI	ERITY	LOC	TIM	CCUF	RED
547	Dark Material Normal Animal Removed		-				DAY DAY DAY	1-DAY	174
548	Normal Animal Removed	From S	tudy				DAY DAY	1-DAY 176	175
549	Normal Animal Removed	From S	tudy				DAY	1-DAY 176	175
550	Normal Animal Removed	From S	tudy				DA'S	1-DAY 176	175

	5	1
_	 -	1.1

INDIVIDUAL	CLINICAL	SIGNS
------------	----------	-------

STUDY: DAY 1-1	152 DAY 185	GROUP:	4-F 9.0(mg	SEX: base/kg/day)	FEMALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCUR	RED
576	Normal Scheduled Sacri	fice				DAY DAY	1-DAY 185	184
577	Dark Material A Normal Normal Swollen Left Ey Scheduled Sacri		Eyes			DAY	178-DA 1-DAY 181-DA 178-DA 185	177 Y 184
578	Dark Material A Normal Normal Swollen Left Ey Scheduled Sacri		Eyes			DAY	181 1-DAY 183-DA 181-DA	Y 184
579	Dark Material A Normal Normal Scheduled Sacri		Eyes			DAY DAY DAY DAY	181-DA 1-DAY 184 185	Y 183 180
580	Normal Scheduled Sacri	fice				DAY DAY	1-DAY 185	184
581	Dark Material A Normal Normal Scheduled Sacri		Eyes			DAY DAY DAY DAY	1-DAY 179-DA	177 Y 184
582	Normal Scheduled Sacri	fice				DAY DAY	1-DAY 184	183
583	Normal Scheduled Sacri	fice				DAY DAY	1-DAY 185	184
584	Dark Material A Normal Normal Scheduled Sacri		Eyes			DAY DAY DAY DAY	1-DAY 179-DA	177 Y 1 83

0	A	E	77
Ju)	4		

						JU LA	и п п	
		INDIVID	UAL CLI	NICAL SIGNS				
STUDY: DAY 1-1	152 DAY 185	GROUP: DOSE:	4-F 9.0(mg	SEX: base/kg/day)	FEMALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCURRED	
585	Dark Material A Normal Normal Scheduled Sacr		lyes			DAY	178-DAY 180 1-DAY 177 181-DAY 184 185	
586	Normal Scheduled Sacr	ifice				DAY DAY	1-DAY 184 185	
587	Normal Normal Piloerection Scheduled Sacri	ifice				DAY	1-DAY 99 103-DAY 184 100-DAY 102 185	
588	Normal Normal Normal Piloerection Rough Coat Scheduled Sacr	ifice				DAY	132	ł
589	Normal Scheduled Sacra	ifice				DAY	1-DAY 183 184	
590	Normal Normal Piloerection Scheduled Sacri	ifice						
591	Normal Normal Piloerection Scheduled Sacri	ifice				DAY	1-DAY 125 129-DAY 184 126-DAY 128 185	
592	Normal Scheduled Sacra	ifice				DAY DAY	1-DAY 184 185	
593	Hunched Posture Normal	е					92-DAY 96 1-DAY 91	



INDIVIDUAL CLINICAL SIGNS

 STUDY: DAY 1-1	152 DAY 185	GROUP: DOSE:	4-F 9.0(mg	SEX: base/kg/day)	FEMALE			•
 ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	E OCCUP	RRED
593 (contd.)	Normal Normal Piloerection Rough Coat Scheduled Sacr:	ifice				DAY	98-DAY 103-DAY 100-DAY 92-DAY 185	AY 184 AY 102
594	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 185	184
595	Normal Scheduled Sacr:	ifice				DAY DAY	1-DAY 185	184
596	Normal Normal Piloerection Animal Removed	From St	tudy	,		DAY DAY DAY DAY		72 7 175
597	Normal Animal Removed	From St	tudy		*		1-DAY 176	175
598	Normal Animal Removed	From St	udy			DAY DAY	1-DAY 176	175
599	Dark Material A Normal Animal Removed		-			DAY DAY DAY	1-DAY	174

INDIVIDUAL CLINICAL SIGNS

STUDY: 152 GROUP: 4-F SEX: FEMALE DAY 1-DAY 185 DOSE: 9.0(mg base/kg/day)

ANIMAL # OBSERVATIONS

SEVERITY

LOC TIME OCCURRED

DAY 49

DAY 175

DAY 175

DAY 1-DAY 48

Normal

Normal

Normal

Normal

Piloerection
Piloerection
Piloerection
Animal Removed From Study

DAY 1-DAY 48

DAY 73-DAY 75

DAY 78-DAY 85

DAY 78-DAY 174

DAY 87-DAY 174

DAY 87-DAY 174

DAY 86

DAY 176

DRAFT

		MILESCOOS BOCK	CIMMIL	III ICII	9	
		INCIDENCE O	F OBSER	VATION	S	
STUDY: 152			SEX:	MALE		
	PERIOD	DOSE:(mg base/kg/day) GROUP:	0 1-M	0.5 2-M	2.0 3-M	9.0 4-M
	DAY 1 No. Observed Normal			25 25 100%		
	DAY 2 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 3 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 5 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 6 No. Observed Normal			25 25 100%		
	DAY 7 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 8 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%

DAY 9

DAY 10

Normal

No. Observed Normal

No. Observed

25 25 100%

25 25 100% 25 25 100%

25 25 100% 25 25 100%

25 25 100% 25 25 100%

25 25 100%

		WK230003 30C	CINAIL	IN KAI	3		L
		INCIDENCE O	F OBSE	RVATION	S		-
STUDY: 1	.52		SEX	: MALE			•
	PERIOD	DOSE:(mg base/kg/day; GROUP:) 0 1-M	0.5 2-M	2.0 3-M	9.0 4-M	
	DAY 11 No. Observed Normal Hunched Postur		25 25 100%	25 24 96% 1 4%	25 25 100%	25 25 100%	
	DAY 12 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 13 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 14 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 15 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 16 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 17 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 18 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 19 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	

DAY 20

No. Observed Normal 25 25 100% 25 25 100% 25 25 100% 25 25 100%

INCIDENCE OF OBSERVATIONS

		SEX	MALE		
PERIOD	DOSE:(mg base/ GROUP:	kg/day) 0 1-M	0.5 2-M	2.0 3-M	9.0 4-M
DAY 21 No. Observed Normal				25 25 100%	
DAY 22 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
DAY 23 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
DAY 24 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
DAY 25 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
DAY 26 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
DAY 27 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
DAY 28 No. Observed Normal Swollen Left		25 24 96% 1 4%	25 25 100% 0	25 25 100% 0	25 25 100% 0
DAY 29 No. Observed Normal Swollen Left		25 24 96% 1 4%	25 25 100% 0	25 25 100% 0	25 25 100% 0
DAY 30 No. Observed Normal Swollen Left I		24 96%	25 100%	25 25 100% 0	25 100%

STUDY: 152

INCIDENCE OF OBSERVATIONS

STUDY:	152	,	SEX	MALE		
		PERIOD	1-M	2-M	2.0 3-M	4-M
		DAY 31 No. Observed Normal	•		25 25 100%	
		DAY 32 No. Observed Normal	25 25 100%	25 25 100%	25 25 100%	25 25 100%
		DAY 33 No. Observed Normal	25 25 100%	25 25 100%	25 25 100%	25 25 100%
		DAY 34 No. Observed Normal	25 25 100%	25 25 100%	25 25 100%	25 25 100%
		DAY 35 No. Observed Normal			25 25 100%	
		DAY 36 No. Observed Normal	25 25 100%	25 25 100%	25 25 100%	25 25 100%
		DAY 37 No. Observed Normal	25 25 100%	25 25 100%	25 25 100%	25 25 100%
		DAY 38 No. Observed Normal			25 25 100%	
		DAY 39 No. Observed Normal	25 25 100%	25 25 100%	25 25 100%	25 25 100%
		DAY 40 No. Observed Normal			25 25 100%	

	A	3	7			
 	 			 	 	-

25 24 96% 1 4%

25 25 100% 0

		WR238605 SUC	CINATE	IN RAT	S		
		INCIDENCE O		RVATION	S		
STUDY: 152				MALE			 -
	PERIOD	DOSE:(mg base/kg/day GROUP:				9.0 4-M	
	DAY 41 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 42 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 43 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%		
	DAY 44 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 45 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 46 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 47 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 48 No. Observed Normal Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%	
	DAY 49 No. Observed Normal Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%	
	DAY 50		25	25		25	

No. Observed Normal

Rough Coat

25 25 100% 0 25 25 100% 0

	000	Λ	3	7				
-	 חח	1	-Ц		 	 -	 -	

							an tra H
		INCIDENCE (F OBSE	RVATION	IS		
STUDY: 152			SEX	: MALE			
	PERIOD	DOSE:(mg base/kg/da GROUP:	y) 0 1-m	0.5 2-M	2.0 3-M		9.0 4-M
	DAY 51 No. Observed Normal Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 1	96% 4%
	DAY 52 No. Observed Normal Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 1	96% 4%
	DAY 53 No. Observed Normal Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 1	96% 4%
	DAY 54 No. Observed Normal Rough Coat		25 25 100% 0	25 100%	25 25 100% 0	24	96%
	DAY 55 No. Observed Normal Rough Coat		25 25 100% 0	25 100%	25 25 100% 0	24	96%
	DAY 56 No. Observed Normal Rough Coat		25 25 100% 0	25 100%	25 25 100% 0	24	96%
	DAY 57 No. Observed Normal Dark Material Rough Coat	Around Eyes	25 25 100% 0	25 25 100% 0	25 25 100% 0	25 23 1 1	92%
	DAY 58 No. Observed Normal	Annual Con-	25 25 100%	25 100%	25 25 100%		92%

0 0

Dark Material Around Eyes

Rough Coat

0

0

1 4% 1 4%

		INCIDENCE O	F OBSE	RVATION	S		
STUDY: 152			SEX	MALE			
	PERIOD	DOSE:(mg base/kg/day GROUP:) 0 1-M	0.5 2-M	2.0 3-M	9.0 4-M	
	DAY 59 No. Observed Normal Dark Material Rough Coat	Around Eyes	25 25 100% 0	25 25 100% 0	25 25 100% 0	25 23 92% 1 4% 1 4%	
	DAY 60 No. Observed Normal Dark Material Rough Coat	Around Eyes	25 25 100% 0 0	25 25 100% 0 0	25 25 100% 0	25 23 92% 1 4% 1 4%	
	DAY 61 No. Observed Normal Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 23 92% 2 8%	
	DAY 62 No. Observed Normal Hunched Posture Rough Coat	e	25 25 100% 0	25 25 100% 0	25 25 100% 0 0	25 24 96% 1 4% 1 4%	
	DAY 63 No. Observed Normal Hunched Posture Rough Coat	e	25 25 100% 0	25 25 100% 0	25 25 100% 0	25 23 92% 1 4% 2 8%	
	DAY 64 No. Observed Normal Hunched Posture Rough Coat	е	25 25 100% 0 0	25 25 100% 0	25 25 100% 0 0	25 22 88% 1 4% 3 12%	
	DAY 65 No. Observed Normal Hunched Posture Rough Coat	e	25 25 100% 0	25 25 100% 0	25 25 100% 0	25 22 88% 1 4% 3 12%	

	*******		INCIDENCE C	F OBSE	RVATION	S	• • • • • • • •	
STUDY:	152			SEX	: MALE	• • • • • • • • • • • • • • • • • • • •		••••••
1		PERIOD	OOSE:(mg base/kg/day GROUP:	/) 0 1-M	0.5 2-M	2.0 3-M	9.0 4-M	
		DAY 66 No. Observed Normal Hunched Posture Rough Coat	,	25 25 100% 0 0	25 25 100% 0 0	25 25 100% 0	25 22 88% 1 4% 3 12%	
		No. Observed Normal Hunched Posture Rough Coat		25 25 100% 0 0	25 25 100% 0 0	25 25 100% 0 0	25 22 88% 1 4% 3 12%	
		DAY 68 No. Observed Normal Hunched Posture Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 22 88% 2 8% 3 12%	
		DAY 69 No. Observed Normal Hunched Posture Rough Coat		24 24 100% 0	25 25 100% 0	25 25 100% 0	25 22 88% 2 8% 3 12%	
		DAY 70 No. Observed Normal Hunched Posture Rough Coat	e.	25 25 100% 0	24 24 100% 0	25 25 100%, 0	25 22 88% 2 8% 3 12%	
		DAY 71 No. Observed Normal Hunched Posture Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 22 88% 2 8% 3 12%	
		DAY 72 No. Observed Normal Dark Material A Hunched Posture Rough Coat		25 24 96% 1 4% 0	25 25 100% 0 0	25 25 100% 0 0	25 22 88% 0 2 8% 3 12%	·

20	5	7
	1.1	4.4

	WR238605 SUC	LINATE	IN RATS		חח דען	ע ט ע	
	INCIDENCE OF	F OBSER	VATIONS	}			
STUDY: 152		SEX:	MALE				
PERIOD	DOSE:(mg base/kg/day) GROUP:	0 1-M	0.5 2-M	2.0 3-M	9.0 4-M		
Norm Hunci	Observed al hed Posture h Coat	25 25 100% 0	25 25 100% 0	25 100% 2 0	25 22 88% 2 8% 3 12%		
Norm Hunc	Observed	25 25 100% 0	25 25 100% 0	25 100% 2 0	25 22 88% 2 8% 3 12%		
Norm Hunc	Observed	25 25 100% 0	25 25 100% 0	25 100% 2 0	25 22 88% 2 8% 3 12%		
Norm Hunc	Observed	25 25 100% 0	25 25 100% 0	25 100% 2 0	25 23 92% 2 8% 2 8%		
Norm Hunc	Observed	25 25 100% 0	25 25 100% 0	25 100% 2	25 23 92% 2 8% 2 8%		
Norm Hunc	Observed .	25 25 100% 0	25 25 100% 0		25 23 92% 2 8% 2 8%		

	0		5	77
ال		Lal	1	

INCIDENCE OF OBSERVATIONS

STUDY: 152			SEX	: MALE		
	PERIOD	DOSE: (mg base/kg/da GROUP:	y) 0 1-M	0.5 2-M	2.0 3-M	9.0 4-M
						• • • • • • • • • • • • • • • • • • • •
	DAY 79 No. Observed Normal Hunched Posture Rough Coat	•	25 100%	25 100%	25 25 100% 0	24 96%
	DAY 80 No. Observed Normal Hunched Posture Rough Coat	•	25 25 100% 0	25 25 100% 0	25 25 100% 0	25 23 92% 1 4% 2 8%
	DAY 81 No. Observed Normal Hunched Posture Rough Coat	:	25 25 100% 0	25 25 100% 0	25 25 100% 0	25 23 92% 1 4% 2 8%
	DAY 82 No. Observed Normal Hunched Posture Rough Coat	•	25 25 100% 0	25 25 100% 0	25 25 100% 0	25 22 88% 1 4% 3 12%
	DAY 83 No. Observed Normal Hunched Posture Rough Coat	•	25 25 100% 0	25 25 100% 0	25 25 100% 0	25 22 88% 1 4% 3 12%
	DAY 84 No. Observed Normal Hunched Posture Rough Coat	•	25 25 100% 0	0	25 25 100% 0	1 4%
	DAY 85 No. Observed Normal Rough Coat		25 100%	25 100%	25 25 100% 0	

50	5	1
ШЦ	11	- 11

• • • • • • • • • • • • • • • • • • • •	Tatal			AMTONO			
	INCII	DENCE OF	OBSERV	WITONS) 		•••••
STUDY: 152			SEX:	MALE			
	DOSE: (ma	base/kg/day)	0	0.5	2.0	9.0	
	PERIOD GROUP:	base/kg/day)	1-M	2-M	3-M	4-M	
						• • • • • • •	•••••
	DAY 86						
	No. Observed	2"	5	25	25	25	
	Normal					24 96%	
	Dark Material Around Eye			0	1 4%	0	
	Rough Coat	0		0	0	1 4%	
	DAY 87						
	No. Observed	21	5	25	25	25	
	Normal					24 96%	
	Rough Coat					1 4%	
		-		-			
	DAY 88						
	No. Observed			25	25	25	
	Normal	25	100% 2	5 100%	25 100%	24 96%	
	Rough Coat	0		0	0	1 4%	
	DAY 89						
	No. Observed	25		25	25	25	
	Normal	25	100% 2	5 100%	25 100%	24 96%	
	Rough Coat	0		0	0	1 4%	
	DAY 90						
	No. Observed			25	25	25	
	Normal	25	100% 2			24 96%	
	Rough Coat	0		0	0	1 4%	
	DAY 91						
	No. Observed	25	5		25	25	
	Normal	25	100% 2	5 100%	25 100%	24 96%	
	Rough Coat	0		0	0	1 4%	
	DAY 92						
	No. Observed	25	5	25	25	25	
	Normal	25				24 96%	
	Rough Coat	0		0	0	1 4%	
	DAY 93						
	No. Observed	25	5	25	25	25	
	Normal				2E 400%		

Normal Rough Coat 25 100% 0

24 96%

25 100% 0

25 100%

25 25 100%

25

D

25 100%

25 25 100% 25

0

25

D

25 100%

25 100%

25 25 100% 0 25

0

25

0

25 100%

25 25 100%

25 100%

25

25

24 96%

25 24 96% 1 4%

4%

4%

50	$\left\langle \frac{\Lambda}{\Delta} \right\rangle$	5	7
uu	44	Ш	- 14

								20
			INCIDENCE O	F OBSE	RVATION	is		
 STUDY:	152		• • • • • • • • • • • • • • • • • • • •	SEX	: MALE			
 		PERIOD	DOSE:(mg base/kg/day) GROUP:) 0 1-M	0.5 2-M	2.0 3-M	9.1 4-1	0 M
		DAY 94 No. Observed Normal Rough Coat		25 100%	25 100%	25 25 100% 0		
		DAY 95 No. Observed Normal Rough Coat		25	25	25 25 100% 0	25	*
		DAY 96 No. Observed Normal Rough Coat				25 25 100% 0		
•		DAY 97 No. Observed Normal Rough Coat			25 25 100% 0		25 24 96 1 4	
		DAY 98 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 24 96	%

Rough Coat

No. Observed

No. Observed

No. Observed Normal Rough Coat

Rough Coat

Rough Coat

DAY 99

DAY 100

DAY 101

Normal

1	0	A	F	57
	M	(2)	17	

		INCIDENCE OF		VATIONS	3	
STUDY: 1	52		SEX:	MALE		
	PERIOD	DOSE: (mg base/kg/day) GROUP:	0 1-M	0.5 2-M	2.0 3-M	9.0 4-M
	DAY 102 No. Observed Normal Rough Coat		25 25 100%	25 25 100%	25 25 100% 0	25 24 96%
	DAY 103 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 104 No. Observed Normal Rough Coat				25 25 100% 0	
	DAY 105 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 106 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 107 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 108 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 109 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 110 No. Observed Normal				25 25 100%	
	DAY 111		25	25	25	25

No. Observed Normal 25 25 100% 25 25 100% 25 25 100% 25 25 100%

	(A)	7
لنا	A	il

		INCIDENCE O	F OBSE	RVATION	S		
STUDY: 152			SEX	MALE			
	PERIOD	DOSE:(mg base/kg/day) GROUP:) 0 1-M	0.5 2-M	2.0 3-M	9.0 4-M	
	DAY 112 No. Observed Normal				25 25 100%	25 25 100%	
,	DAY 113 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 114 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 115 No. Observed Normal		25 25 100%		25 25 100%		
	DAY 116 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 117 No. Observed Normal Rough Coat		25 100%		25 25 100% 0		
	DAY 118 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 119 No. Observed Normal		25 25 100%		25 25 100%		

Normal DAY 120

No. Observed Normal DAY 121

No. Observed Normal 25 25 100%

25 25 100% 25 25 100%

25 25 100% 25 25 100%

25 25 100% 25 25 100%

25 25 100%

25 100% 25 100% 25 100% 25 100%

			INCIDENCE O	F OBSER	CVATION	S		
 STUDY:	152			SEX:	MALE			
		PERIOD	DOSE: (mg base/kg/day GROUP:) 0 1-M	0.5 2-M	2.0 3-M	9.0 4-M	
		DAY 122 No. Observed Normal		25	25 25 100%	25	25 25 100%	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 124 No. Observed Normal Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%	
		DAY 125 No. Observed Normal Rough Coat		25 100%	25 25 100% 0	25 25 100% 0	24 96%	
		DAY 126 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 127 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		No. Observed Normal			25 25 100%			
		No. Observed Normal			25 25 100%			
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 131 No. Observed		25	25	25	25	

		INCIDENCE O	F OBSEF	CVATION	S	
STUDY: 152			SEX:	MALE		
	PERIOD	DOSE:(mg base/kg/day GROUP:	1-M	0.5 2-M	2.0 3-M	9.0 4-M
	DAY 132 No. Observed Normal		25	25 25 100%	25 25 100%	25 25 100%
	No. Observed		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 134 No. Observed Normal Dark Material Rough Coat	Around Nose	25 100%	25 25 100% 0	25 100%	24 96%
	DAY 135 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	No. Observed Normal Dark Material Hunched Posture Labored Breath	Around Nose e ing	25 100%	25 25 100% 0 0	25 25 100% 0 0	25 24 96% 1 4% 1 4% 1 4%
	DAY 137 No. Observed Animal Found Do Normal		25 0 25 100%	0	0	25 1 4% 24 96%
	DAY 138 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	24 24 100%
	DAY 139 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	24 24 100%
	DAY 140 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	24 24 100%

			INCIDENCE OF	OBSEF	NOITAV	S	
STUDY:	152			SEX:	MALE		
 		PERIOD	DOSE:(mg base/kg/day) GROUP:	0 1-M	0.5 2-M	2.0 3-M	9.0 4-M
		DAY 141 No. Observed Normal	*	25 25 100%	25 25 100%	25 25 100%	24 24 100%
		DAY 142 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	24 24 100%
		DAY 143 No. Observed Normal				25 25 100%	
		DAY 144 No. Observed Normal	•	25 25 100%	25 25 100%	25 25 100%	24 24 100%
		DAY 145 No. Observed Normal			25 25 100%	25 25 100%	24 24 100%
		DAY 146 No. Observed Normal		25 25 100%		25 25 100%	24 24 100%
		DAY 147 No. Observed Normal				25 25 100%	
		DAY 148 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	24 24 100%
		DAY 149 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	24 24 100%
		OAY 150 No. Observed Normal				25 25 100%	

SIX MONTH ORAL TOXICITY STUDY OF DATE OF WR238605 SUCCINATE IN RATS								
INCIDENCE OF OBSERVATIONS								
STUDY: 152		SEX	: MALE	• • • • • • • • • •				
PERIOD	DOSE:(mg base/kg/day GROUP:	') 0 1-M	0.5 2-M	2.0 3-M	9.0 4-M			
DAY 151 No. Observ Normal	ed	25 25 100%		25 25 100%				
DAY 152 No. Observ Normal	ed	25 25 100%	25 25 100%	25 25 100%	24 24 100%			
DAY 153 No. Observ Normal	ed	25 25 100%	25 25 100%	25 25 100%	24 24 100%			
DAY 154 No. Observ Normal	ed	25 25 100%	25 25 100%	25 25 100%	24 24 100%			
DAY 155 No. Observ Normal	ed	25 25 100%	25 25 100%	25 25 100%	24 24 100%			
DAY 156 No. Observ Normal Dark Mater	ed ial Around Eyes	25 24 96% 1 4%	25 25 100% 0	25 25 100% 0	24 24 100% 0			
DAY 157 No. Observ Normal	ed	25 25 100%	25 25 100%	25 25 100%				
DAY 158 No. Observ Normal	ed	25 25 100%	25 25 100%	25 25 100%	24 24 100%			
DAY 159 No. Observ Normal	ed	25 25 100%	25 25 100%	25 25 100%	24 24 100%			

25

25 100%

25

25 100%

25 25 100%

24 24 100%

DAY 160

Normal

No. Observed

		5	7
	μ	1.1	

INCIDENCE OF OBSERVATIONS

STUDY: 152			SEX	: MALE	• • • • • • • • • •	• • • • • • • • •
	PERIOD	DOSE:(mg base/kg/day GROUP:	') 0 1-M		2.0 3-M	9.0 4-M
	DAY 161 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	24 24 100%
	OAY 162 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	24 24 100%
	OAY 163 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	24 24 100%
	DAY 164 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	24 24 100%
	DAY 165 No. Observed Normal Dark Material	Around Eyes	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%	24 24 100% 0
	OAY 166 No. Observed Normal			25 25 100%		
	DAY 167 No. Observed Normal Dark Material Oark Material Labored Breat Nasal Dischar	Around Nose	25 25 100% 0 0 0 0	25 24 96% 1 4% 1 4% 0 1 4% 1 4%	0 0 0	24 23 96% 1 4% 1 4% 1 4% 0
	DAY 168 No. Observed Normal Dark Material Dark Material		25 25 100% 0 0	25 24 96% 0 1 4%	25 24 96% 1 4% 0	

0	A	P	57
111	101	17	

INCIDENCE OF OBSERVATIONS

STUDY: 152		SEX: MALE				
	PERIOD	DOSE:(mg base/kg/day GROUP:	′) 0 1-M		2.0 3-M	9.0 4- M
	DAY 169 No. Observed Normal Dark Material		0	25 24 96% 0	24 96% 1 4%	0
	Hunched Postur Dark Material		0	0 1 4%	0	1 4% 1 4%
	DAY 17D No. Observed Normal Dark Material Dark Material		25 25 1DD% 0	25 24 96% 0 1 4%	25 24 96% 1 4% 0	24 24 1D0% 0
	DAY 171 No. Observed Normal Dark Material Hunched Postur Dark Material	e	25 25 100% 0 D	25 24 96% 0 D 1 4%	25 24 96% 1 4% 0	24 23 96% 0 1 4%
	DAY 172 No. Observed Normal Dark Material Hunched Postur Dark Material	e	25 25 100% 0 0	25 24 96% 0 0 1 4%	25 24 96% 1 4% 0	24 23 96% D 1 4%
	DAY 173 No. Dbserved Normal Dark Material Hunched Postur Rough Coat Dark Material	e	25 25 100% D O D	25 24 96% 0 D 0 1 4%	25 24 96% 1 4% 0 D	24 23 96% D 1 4% 1 4%
	DAY 174 No. Dbserved Normal Dark Material Hunched Postur Rough Coat	·	25 25 100% 0 0	25 25 100% 0 0	25 24 96% 1 4% 0	24 23 96% 0 1 4% 1 4%

0	$\left\langle \begin{array}{c} A \\ A \end{array} \right\rangle$	3	7
	UU	H	3.1

			INCIDENCE	OF (OBSEI	RVA	TION	S			
 STUDY:	152				SEX	: M	ALE				
			DOSE:(mg base/kg/d	ay)	0		0.5		2.0		9.0
 		PERIOD	GROUP:		1-M		2-M		3-M		4-M
		DAY 175									
		No. Observed		25	i	25		25		24	
		Normal		24	96%	25	100%	21	84%	21	88%
		Dark Material	Around Eyes	1	4%	0		3	12%	2	8%
		Hunched Postur	e	0		0		0		1	4%
		Rough Coat		0		0		0		1	4%
		Dark Material	Around Mouth	0		0		1	4%	0	
		DAY 176									
		No. Observed		25		25		25		24	
		Normal		20	80%	_	80%		80%	18	75%
		Hunched Postur	e	0		0		0		1	
		Rough Coat		0		0	Lancing.	. 0		1	4%
		Animal Removed	From Study	5	20%	5	20%	5	20%	5	21%
		DAY 177									
		No. Observed		20				20		19	
		Normal			85%					_	84%
		Dark Material			15%		15%		20%		11%
		Hunched Postur	e	0		0		0		1	5%
		DAY 178									
		No. Observed		20		20		20		19	
		Normal		_	100%		95%				79%
		Dark Material	•	0			5%		20%	3	
		Hunched Postur		0		0		0	500	1	5%
		Swollen Left E	ye	0		0		1	5%	0	
		DAY 179		-		-		12.5			
		No. Observed		20		20		20		19	
		Normal	. minima e e e e		100%		100%				89%
		Dark Material		0		0		1	5%	1	
		Hunched Postur		0		0		0	===	1	5%
		Swollen Left E	ye	0		0		1	5%	0	
		DAY 180									
		No. Observed		20		20		20		19	
		Normal			100%		100%		95%		95%
		Hunched Postur		0		0		0		1	5%
		Swollen Left E	ye	0		0		1	5%	0	

	INCIDENCE	OF OBSE	RVATION	15		
STUDY: 152		SEX	: MALE			
	DOSE:(mg base/kg/ PERIOD GROUP:	day) 0 1-M	0.5 2-M	2.0 3-M	9.0 4-M	
	DAY 181 No. Observed Normal Dark Material Around Eyes Hunched Posture Swollen Left Eye	20 20 100% 0 0	20 20 100% 0 0	20 19 95% 0 0 1 5%	19 17 89% 1 5% 1 5% 0	
	No. Observed Normal	20 20 100%	20 20 100%	20 20 100%	19 19 100%	
	OAY 183 No. Observed Scheduled Sacrifice Normal	20 11 55% 9 45%	20 14 70% 6 30%	20 14 70% 6 30%	19 13 68% 6 32%	
	DAY 184 No. Observed Scheduled Sacrifice	9 9 100%	6 6 100%	6 6 100%	6 6 100%	

						J HIL LA	7
		INCIDENCE OF	OBSE	RVATION			
STUDY: 152		-	SEX:	FEMALE			
	PERIOD	DOSE:(mg base/kg/day) GROUP:	0 1-F	0.5 2-f	2.0 3-F	9.0 4-F	
	DAY 1 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 ° 25 100%	
	DAY 2 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 3 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 7 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 10 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	

T			F	5
	In	1-1	17	
	114		ш	u

			WR238605 SUC	CINATE	IN RAT	S		7 11 17
_			INCIDENCE O	F OBSER	RVATION			
-	STUDY: 152			SEX: E	EMALE			•••••••
		PERIOD	DOSE:(mg base/kg/day GROUP:					
• •		DAY 11 No. Observed Normal		25 25 100%	25 25 100%	25	25 25 100%	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		No. Observed Normal			25 25 100%	25 25 100%	25 25 100%	
		DAY 15 No. Observed Normal		25 25 100%	25 25 100%		25 25 100%	
		DAY 16 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 20 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	

25 25 100% 25 25 100% 25 25 100% 25 25 100%

DAY 21

No. Observed Normal

	Λ	E	57
	[2]	4	Ш

		INCIDENCE O	F OBSE	ERVATION	S		
STUDY: 152			SEX:	FEMALE			
Р	PERIOD	DOSE:(mg base/kg/day GROUP:) 0 1-F	0.5 2-F	2.0 3-F	9.0 4-F	
D	DAY 22 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
D	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
D	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
D	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
D	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%		
D	No. Observed Normal			25 25 100%		25 25 100%	
D	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
ם	DAY 29 No. Observed Normal	•	25 25 100%	25 25 100%	25 25 100%	25 25 100%	
C	DAY 30 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
C	No. Observed Normal		25 25 100%	25 25 100%		25 25 100%	

0	1	57
	in	

 			INCIDENCE OF	F OBSE	RVATION	S			
 STUDY:	152			SEX:	FEMALE				
		PERIOD	DOSE:(mg base/kg/day) GROUP:	0 1-F	0.5 2-F	2.0 3-F	9.0 4-F		
		DAY 32 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	•,	
		DAY 33 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%		
		No. Observed Normal			25 25 100%				
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%		
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%		
		DAY 37 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%		
		DAY 38 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%		
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%		
		No. Observed Normal			25 25 100%				
		DAY 41 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%			

		INCIDENCE O	F OBSI	ERVATION	S	
152			SEX:	FEMALE		
	PERIOD	DOSE:(mg base/kg/day: GROUP:	0 1-F	0.5 2-F	2.D 3-F	9.0 4-F
	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 45 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 46 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 47 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	No. Observed		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 49 No. Observed Normal Dark Material	Around Eyes	25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%
	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 51 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%

STUDY:

		3	7
	 	-	- 44

			WR238605 SUC	CINATE	IN RAT	S		
 			INCIDENCE C	F OBSE	RVATION	S		-
 STUDY:	152			SEX:	FEMALE			
 		PERIOD	DOSE:(mg base/kg/day GROUP:	y) 0 1-F	0.5 2-F	2.0 3-F	9.0 4-F	
		DAY 52 No. Observed Normal		25	25 25 100%	25	25	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 55 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 56 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 57 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	

DAY 61

No. Observed Normal 25 25 100% 25 25 100% 25 25 100% 25 25 100%

0	Λ	R	57
Π	W	5	

		INCIDENCE OF	OBSE	RVATION	S		
STUDY: 152			SEX:	FEMALE			
	PERIOD	DOSE:(mg base/kg/day) GROUP:		0.5 2-F	2.0 3-F	9.0 4-F	
	DAY 62 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 63 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 64 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 65 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 66 No. Observed Normal	3	25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 67 No. Observed Normal Piloerection		25 25 100% 0		25 25 100% 0	25 24 96% 1 4%	
	DAY 68 No. Observed Normal Piloerection		25 25 100% 0	25 25 100% 0		25 24 96% 1 4%	
	DAY 69 No. Observed Normal Piloerection		25 25 100% 0		25 25 100% 0	25 23 92% 2 8%	
	DAY 70 No. Observed Normal Piloerection		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%	
	DAY 71 No. Observed Normal Piloerection		25 25 100% 0	25 25 100% 0	25 100%		

-				5
1	1:3	111	3	
التا		LN	Ш	Ш

INCIDENCE OF OBSERVATIONS

			INCIDENCE OF	F OBSE	ERVATION	S		
 STUDY:	152			SEX:	FEMALE			
 		PERIOD	DOSE:(mg base/kg/day) GROUP:) 0 1-F	0.5 2-F	2.0 3-F	9.0 4-F	
		DAY 72 No. Observed Normal Piloerection		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%	
		DAY 73 No. Observed Normal Piloerection		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%	,
		DAY 74 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 75 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 76 No. Observed Normal Piloerection		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%	
		DAY 77 No. Observed Normal Piloerection		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%	
		DAY 78 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 79 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 80 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	

1:3	131	[]	
Lil	Lal	11	- 11

INCIDENCE	OF	OBSERVATIONS		

				INCIDENCE OF	F OBSE	RVATION	5	
-	STUDY:	152			SEX:	FEMALE		• • • • • • • • • • • • • • • • • • • •
			PERIOD	DOSE:(mg base/kg/day) GROUP:	0 1-F	0.5 2-F	2.0 3-F	9.0 4-F
-			DAY 81 No. Observed Normal			25 25 100%		25 25 100%
			DAY 82 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
			DAY 83 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
			No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
			DAY 85 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
			DAY 86 No. Observed Normal Piloerection		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%
			DAY 87 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
			DAY 88 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
			DAY 89 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
			DAY 90 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%

	n		
U	LIÚ	12	

		WK250005 50CC	TIMALE	IN WAI	3	שות חוד	7 11 11
		INCIDENCE OF	OBSE	RVATION	S		
STUDY: 152			SEX: I	FEMALE			
	PERIOD	OOSE:(mg base/kg/day) GROUP:	0 1-F	0.5 2-F	2.0 3-F	9.0 4-F	
		••••••					
	No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 92 No. Observed Normal Hunched Posture Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0 0	25 24 96% 1 4% 1 4%	
	DAY 93 No. Observed Normal Hunched Posture Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4% 1 4%	
	OAY 94 No. Observed Normal Hunched Posture Piloerection Rough Coat		25 25 100% 0 0	25 25 100% 0 0	25 25 100% 0 0	25 23 92% 1 4% 1 4% 1 4%	
	DAY 95 No. Observed Normal Hunched Posture Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4% 1 4%	
	DAY 96 No. Observed Normal Hunched Posture Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0 0	25 24 96% 1 4% 1 4%	
	DAY 97 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 24 96%	

0

0

0

1 4%

Normal Rough Coat

0	\Box		57
In		17	

INCIDENCE OF OBSERVATIONS STUDY: 152 SEX: FEMALE DOSE:(mg base/kg/day) 0 0.5 2.0 9.0 2-F 1-F 3-F 4-F PERIOD GROUP: DAY 98 No. Observed 25 25 100% 25 25 100% 25 25 100% 25 100% Normal **DAY 99** 25 25 100% No. Observed 25 25 25 100% 25 100% 25 100% Normal **DAY 100** 25 25 100% 25 25 100% No. Observed Normal Piloerection **DAY 101** No. Observed 25 25 25 25 100% 25 100% Normal 25 100% Piloerection DAY 102 No. Observed 25 25 Normal 25 100% 25 100% 25 100% Piloerection DAY 103 No. Observed 25 25 100% 25 25 100% 25 25 100% Normal 25 100% DAY 104 No. Observed 25 25 Normal 25 100% 25 100% 25 100% 25 100% **DAY 105** No. Observed 25 25 25 25 25 100% 25 100% 25 100% 25 100% Normal

25

25 100%

25 100%

25

25 100%

25

25 100%

DAY 106

Normal

No. Observed

	[P	57
	101	///	15	
L.		LO	ii	- 11

INCIDENCE O	F	OBSERVATIONS
-------------	---	--------------

STUDY: 152			SEX:	FEMALE		
	PERIOD	DDSE:(mg base/kg/day) GROUP:	0 1-F	0.5 2-F	2.0 3-F	9.0 4-F
	DAY 107 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 108 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 109 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 110 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 111 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 112 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 113 No. Dbserved Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 114 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 115 No. Dbserved Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 116 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%
	DAY 117 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%

INCIDENCE OF OBSERVATIONS										
STUDY: 152	SEX:	FEMALE				•				
PERIOD	DOSE:(mg base/kg/day) 0 GROUP: 1-F	0.5 2-F	2.0 3-F	9.0 4-F		-				
DAY 118 No. Observed Normal	25 25 100%	25 25 100%	25 25 100%	25 25 100%						
DAY 119 No. Observed Normal	25 25 100%	25 25 100%	25 25 100%	25 25 100%						
DAY 120 No. Observed Normal	25 25 100%		25 25 100%							
OAY 121 No. Observed Normal	25 25 100%	_								
DAY 122 No. Observed Normal	25 25 100%		25 25 100%	25 25 100%						
OAY 123 No. Observed Normal	25 25 100%	25 25 100%	25 25 100%	25 25 100%						
OAY 124 No. Observed Normal	25 25 100%		25 25 100%							
OAY 125 No. Observed Normal	25 25 100%		25 25 100%							
DAY 126 No. Observed Normal Piloerection	25 25 100% 0	25 100%	25 25 100% 0	24 96%						
DAY 127 No. Observed Normal Piloerection	25 25 100% 0	25 100%	25 25 100% 0	25 24 96% 1 4%						

[0		P	57
	103	151	17	11
	UU		Ш	U

		INCIDENCE OF	F OBSE	RVATION	S		
STUDY: 152			SEX:	FEMALE			
	PERIOD	DOSE:(mg base/kg/day GROUP:	1-F	0.5 2-f	3-F	4-F	
	DAY 128 No. Observed Normal Piloerection		25 25 100%	25 25 100% 0	25 25 100%	25 24 96%	
	DAY 129 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 130 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 131 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 132 No. Observed Normal Rough Coat		25 25 100% 0	25 25 100% 0	25 25 100% 0	25 24 96% 1 4%	
	DAY 133 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 134 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 135 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 136		25	25	25	25	

No. Observed Normal 25 25 100% 25 25 100% 25 25 100% 25 25 100%

			INCIDENCE OF	OBSE	RVATION	S		
•	STUDY: 152		•	SEX:	FEMALE			-
-		PERIOD	DOSE:(mg base/kg/day) GROUP:	0 1-F	0.5 2-F	2.0 3-F	9.0 4-F	
		DAY 137						
		No. Observed Normal	;	25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 138 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 139 No. Observed		25	25	35	25	
		Normal	:	25 100%	25 25 100%	25 100%	25 100%	
		DAY 140 No. Observed Normal	;	25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		0AY 141 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		OAY 142 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 143 No. Observed Normal			25 25 100%			
		DAY 144 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 145 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 146 No. Observed Normal		25 25 100%	25 25 100%			

n	n	A	13	57
L	IN	La		

				Witabooob Book		3 111 1011			и и и	
				INCIDENCE O	F OBSI	ERVATION	S			
	STUDY:	152			SEX:	FEMALE			• • • • • • • • • • • • • • •	*******
			252102	DOSE:(mg base/kg/day) GROUP:	0	0.5	2.0	9.0		
			PER10D	GROUP:	1-1	2-1	3-F	4-7		
-			DAY 147							
			No. Observed		25	25	25	25		
			Normal		25 100%	25 100%	25 100%	25 100%		
			DAY 148							
			No. Observed		24	25	25	25		
			Normal		24 100%	25 100%	25 100%	25 100%		
			DAY 149							
			No. Observed			25				
			Normal		25 100%	25 100%	25 100%	25 100%		
			DAY 150				70.2			
			No. Observed		25	25	25	25		
			Normal		25 100%	25 100%	25 100%	25 100%		
			DAY 151		25	25	25	25		
			No. Observed		25 25 100%	25 100%	25	25 100%		
					23 100%	23 100%	23 100%	25 100%		
			DAY 152		25	25	25	25		
			No. Observed Normal		25 100%	25 25 100%				
					23 100%	53 100%	23 100%	25 100%		
			DAY 153							
			No. Observed		25	25 25 100%	25	25		
			Normal		25 100%	25 100%	25 100%	25 100%		
			DAY 154							
			No. Observed			25				
			Normal		25 100%	25 100%	25 100%	25 100%		
			DAY 155					22		
			No. Observed		25	25	25	25		
			Normal		25 100%	25 100%	25 100%	25 100%		
			DAY 156					25		
			No. Observed		25 25 100%	25 24 96%	25	25		
			NOCEAL		/ TIIII/Z	JA VOZ	/3 111117	/ 111117		

25 24 96% 1 4%

25 25 100% 0

25 25 100% 0

Normal Rough Coat 25 25 100% 0

DRAFT

INCIDENCE OF OBSERVATIONS

 STUDY:	152			SEX:	FEMALE			
		PERIOD	DOSE:(mg base/kg/day) GROUP:	0 1-F	0.5 2-F	2.0 3-F	9.0 4-F	
		DAY 157 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 158 No. Observed Normal Rough Coat		25 25 100% 0	25 24 96% 1 4%	25 25 100% 0	25 25 100% 0	
		DAY 159 No. Observed Normal Rough Coat		25 25 100% 0	25 24 96% 1 4%	25 25 100% 0	25 25 100% 0	
		DAY 160 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 161 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 162 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 163 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 165 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
		DAY 166 No. Observed Normal	÷	25 25 100%	25 25 100%	25 25 100%	25 25 100%	

SIX MONTH ORAL TOXICITY STUDY OF D A F

		INCIDENCE OF	CLINIC	AL SIGN	s		
STUDY: 152			SEX:	FEMALE			
	PERIOD	DOSE:(mg base/kg/day) GROUP:	. 1-F	0.5 2-F	3-F	9.0 4-F	
	DAY 167 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 168 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 169 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 170 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 171 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 172 No. Observed Normal		. 25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 173 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 174 No. Observed Normal		25 25 100%	25 25 100%	25 25 100%	25 25 100%	
	DAY 175 No. Observed Normal Dark Material	Around Eyes	25 24 96% 1 4%	25 25 100% 0	25 24 96% 1 4%	25 23 92% 2 8%	
	DAY 176 No. Observed Normal Animal Removed	d From Study	25 20 80% 5 20%	25 20 80% 5 20%	25 20 80% 5 20%	25 20 80% 5 20%	

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY:	152				FEMALE			
		PERIOD	OOSE:(mg base/kg/day GROUP:) 0 1-F		2.0 3-F	9.0 4-F	
		DAY 177 No. Observed Normal		20 20 100%	20 20 100%	20 20 100%	20 20 100%	
		DAY 178 No. Observed Normal Dark Material Swollen Left E		20 18 90% 2 10% 0	20 16 80% 4 20% 0	20 17 85% 2 10% 1. 5%	20 16 80% 4 20% 1 5%	
		DAY 179 No. Observed Normal Dark Material Swollen Left E		20 18 90% 2 10% 0	20 19 95% 1 5% 0	20 16 80% 3 15% 1 5%	20 18 90% 2 10% 1 5%	
		OAY 180 No. Observed Normal Oark Material Swollen Left E		20 18 90% 2 10% 0	20 20 100% 0 0	20 20 100% 0	20 18 90% 1 5% 1 5%	
		OAY 181 No. Observed Normal Oark Material Swollen Left E		20 19 95% 1 5% 0	20 20 100% 0 0	20 19 95% 1 5% 0	20 18 90% 2 10% 1 5%	
		DAY 182 No. Observed Normal Dark Material Swollen Left E		20 20 100% 0 0	20 20 100% 0	20 20 100% 0 0	20 18 90% 1 5% 1 5%	
		OAY 183 No. Observed Normal Dark Material	Around Eyes	20 20 100% 0	20 20 100% 0	20 20 100% 0	20 19 95% 1 5%	

0	5	7
	ш	14

]	INCIDENCE OF C	CLI	INIC	IAL S	SIGNS	3				 	
STUDY:	152			SE	EX:	FEMA	LE						
		PERIOD	DOSE:(mg base/kg/day) GROUP:		0 1-F		0.5 2-F		2.0 3-F		9.0 4-F		
		DAY 184 No. Observed Scheduled Sacr Normal	ifice	20 9 11	45% 55%		35% 65%	20 7 13	35%	20 3 17	15% 85%	 	
		DAY 185 No. Observed Scheduled Sacr	ifice	11 11	100%	12 12 1	00%	13 13	100%	17 17	100%		

APPENDIX D

INDIVIDUAL BODY WEIGHTS AND BODY WEIGHT GAINS

DRAFT

STUDY: 152 GROUP: 1-M SEX: MALE DOSE: 0 (mg base/kg/day) ANIMAL # DAY 1 DAY 8 DAY 15 DAY 27 DAY 29 DAY 36 DAY 50 DAY 57 DAY 64 DAY 71 DAY 78													
STU	DY: 15	52		GR	OUP: 1	-M		SE	X:/MA	LE)			
		_		DO:	SE: 0	(mg b	ase/kg	/day)					
ANIMAL #	DAY 1	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
401	276	341	390	423	447	464	490	524	557	574	594	620	
402	246	298	345	394	413	436	481	504	524	555	573	591	
403	219	269	307	341	364	392	426	446	472	489	509	520	
404	238	290	334	374	399	420	476	502	529	552	576	491	
405	249	302	335	372	392	420	461	484	511	533	551	564	
406	258	308	356	402	433	471	509	548	569	591	622	637	
407	264	323	376	416	424	449	498	516	519	549	573	596	
408	258	318	368	410	426	467	514	543	579	589	620	641	
409	266	321	371	422	448	488	546	567	591	620	640	652	
410	244	299	339	377	390	422	458	477	502	519	547	572	
411	246	298	330	357	384	416	442	464	482	497	506	518	
412	246	299	343	383	398	427	466	487	507	517	533	544	
413	249	312	362	406	440	466	507	528	553	573	594	610	
414	260	317	360	390	424	455	490	511	537	518	583	604	
415	245	293	334	366	392	397	425	443	456	468	483	493	
416	265	328	380	423	466	491	538	558	586	607	621	648	
417	231	278	322	356	383	414	440	454	474	497	514	531	
418	267	330	383	419	454	476	527	538	567	581	602	617	
419	253	307	352	390	425	466	502	521	545	569	582	603	
420	242	285	328	365	401	419	449	468	495	514	531	549	
421	238	290	333	367	402	416	450	460	470	484	510	521	
/ 422	240	292	339	374	416	438	471	488	517	539	560	578	
423	232	276	318	343	367	380	414	424	443	456	478	492	
424	283	345	414	453	508	536	587	608	643	663	685	710	
425	289	338	397	434	478	515	556	584	616	638	657	682	
MEAN	252	306	353	390	419	446	485	506	530	548	570	583	
S.D.	16.6	20.7	26.9	29.6	34.9	38.5	44.1	46.8	51.0	53.3	54.2	60.7	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					: [ata Unav	ailable						

1	1			
	100	1:1	15	
	UU	6	Ü	

					DIVID	UAL BO	DY WE	IGHTS	(Grams)				
STU	JDY: 1	52		GR DO	OUP:	1-M 0 (mg b DAY 120	ase/ko	SE (dav)	EX: MA	LE			
ANIMAL #	DAY 85	DAY 92	0AY 99	DAY 106	DAY 113	DAY 120	OAY 127	OAY 134	OAY 141	0AY 148	DAY 155	DAY 162	
401	631	637	656	659	676	677	681	681	686	700	707	715	
402	603	606	616	621	636	646	649	658	669	680	689	699	
403	533	545	566	573	581	590	596	605	606	623	634	648	
404	515	545	579	588	619	630	642	652	667	673	684	699	
405	582	492	548	583	597	625	630	631	629	647	656	670	
406	659	675	691	711	728	657	668	714	732	748	769	776	
407	602	603	628	629	652	669	671	682	698	709	725	729	
408	655	623	638	652	665	677	676	682	702	706	719	724	
409	667	667	693	702	721	728	735	740	744	751	764	781	
410	598	606	617	627	649	658	665	672	695	705	721	732	
411	534	549	560	559	573	573	576	589	600	611	622	622	
412	567	573	580	592	611	610	605	619	629	642	640	653	
413	622	636	648	647	653	665	666	672	689	699	710	715	
414	613	622	633	654	656	661	663	687	704	704	722	716	
415	505	514	527	524	530	538	541	546	558	565	579	578	
416	665	684	692	696	706	714	722	743	741	746	769	779	
417	541	552	561	570	581	594	594	586	608	618	625	610	
418	635	640	663	668	682	690	695	705	720	726	732	744	
419	610	644	656	665	674	678	687	695	704	715	736	734	
420	554	574	584	590	601	611	613	602	609	629	646	653	
421	543	556	567	575	581	586	575	584	590	605	622	625	
422	597	612	624	630	654	667	664	669	680	691	698	701	
423	506	513	523	522	538	546	552	563	557	571	575	574	
424	729	751	768	773	780	795	790	793	808	820	830	851	
425	711	719	737	741	762	767	775	785	795	802	829	848	
MEAN	599	606	622	630	644	650	653	662	673	683	696	703	
S.D.	61.7	65.1	63.7	64.1	64.7	62.6	63.4	65.5	67.2	65.5	68.4	73.0	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					••:	Data Unav	ailable						

STUDY: 152

DRAFT

 INDIV	IDUAL	BODY	WEIGH:	CS (Gram	ns)	 	
 GROUE	: 1-M			SEX:	MALE		
DOSE:	0 (mg	base	/kg/da	v)			
ANITMAL #	DAV 140	DAY 174	DAY 192				
401	713	711	730				
402	700	716	718				
403	648	654	659				
404	696	715	720				
405	672	686	691				
406	785	787	792				
407	730	731	729				
408	726	739	742				
409	789	796	806				
410	733	746	747				
411	630	636	638				
412	655	674	679				
413	702	712	724				
414	723	730	733				
415	574	581	592				
416	779	801	805				
417	592	633	645				
418	748	757	762				
419	737	746	756				
420	664	668	673				
421	628	619					
422	702	708					
423	578	592					
424	857	858					
425	866	867					
MEAN	705	715	717				
S.D.	76.2	73.9	56.9				
N	25	25	20				
	: Data U	Inava i lab	le				

			5	
--	--	--	---	--

	INDIVIDUAL BODY WEIGHTS (Grams) STUDY: 152 GROUP: 2-M SEX: MALE DOSE: 0.5 (mg base/kg/day) ANIMAL # DAY 1 DAY 8 DAY 15 DAY 22 DAY 29 DAY 36 DAY 43 DAY 50 DAY 57 DAY 64 DAY 71 DAY 78													
STU	DY: 19	52		GRO	OUP: 2	-M	base/	SE kg/day	X: MA	LE				
ANIMAL #	DAY 1	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78		
451	244	303	348	383	401	436	483	518	540	563		605		
452	264	307	346	379	398	422	455	476	491	514	531	539		
453	243	294	338	369	381	405	447	467	495	522	544	564		
454	246	295	338	373	379	418	465	481	504	531	550	569		
455	245	297	346	388	423	463	497	529	562	587	614	615		
456	243	301	339	373	395	426	468	496	519	540	557	586		
457	266	332	385	432	463	496	543	564	590	613	642	655		
458	245	298	341	375	402	434	475	506	527	549	567	568		
459	249	308	350	382	414	437	477	496	522	541	558	568		
460	240	286	327	362	385	414	438	457	489	512	538	554		
461	254	306	339	376	415	446	469	493	513	540	552	567		
462	266	324	365	401	434	460	494	517	544	572	598	604		
463	264	318	363	403	438	467	493	509	531	552	577	591		
464	256	312	358	398	436	467	495	508	547	570	584	604		
465	232	282	335	358	392	417	452	469	487	512	534	547		
466	261	323	363	414	451	483	514	539	553	570	593	606		
467	240	213	242	258	295	323	353	386	414	436	458	482		
468	230	278	322	354	381	408	443	473	502	522	549	565		
469	234	276	317	356	385	412	443	476	503	526	546	565		
470	216	262	301	339	365	377	398	422	440	455	469	484		
471	251	301	346	379	424	447	475	496	529	549	575	591		
472	243	285	336	372	406	435	469	486	502	520	541	552		
473	274	326	379	422	468	499	531	554	586	612	632	663		
474	262	316	363	398	448	480	521	537	563	586	612	628		
475	251	300	357	399	434	471	511	543	582	604	636	652		
415	231	300	331	377	434	411	311	545	302	004	030	032		
MEAN	249	298	342	378	409	438	472	496	521	544	566	581		
S.D.	13.5	24.5	28.0	33.2	36.7	38.9	41.0	40.0	41.9	42.7	45.0	44.8		
N	25	25	25	25	25	25	25	25	25	25	25	25		
					: 0	ata Unava	ailable							

 					A	
INDIVIDUAL	BODY	WEIGHTS	(Grams)			

	THE TENED TO THE COLUMN TO THE												
STU	JDY: 1	52		GR DO	OUP: 2	2-M).5 (ma	base	SE kg/day DAY 134	X: MA	LE			
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 162	
451	629	643	663	670	678	701	711	717	737	751	745	749	
452	551	558	573	578	595	598	606	610	625	637	651	656	
453	581	591	608	618	628	641	649	659	670	684	698	708	
454	586	585	595	601	604	621	625	624	637	655	669	653	
455	629	640	660	665	663	682	689	697	712	729	742	748	
456	601	608	622	627	641	653	648	655	680	684	693	705	
457	666	673	690	699	706	718	734	735	749	757	771	781	
458	593	596	619	622	631	646	659	661	673	690	699	706	
459	580	557	600	597	808	621	624	631	641	641	647	651	
460	571	583	596	608	615	630	633	641	650	634	641	656	
461	592	602	618	622	636	649	641	655	676	686	686	695	
462	625	631	651	650	664	679	684	691	707	717	726	738	
463	603	618	615	641	643	643	653	667	676	692	685	688	
464	616	626	636	638	651	667	681	694	701	714	726	717	
465	558	570	585	601	612	623	633	649	659	661	672	688	
466	629	628	648	664	668	678	675	685	699	716	736	739	
467	497	501	510	514	520	535	526	531	545	560	561	564	
468	583	602	617	630	649	652	660	670	682	702	724	735	
469	588	514	590	597	618	633	642	648	668	676	684	698	
470	496	508	520	519	530	540	545	559	564	572	582	573	
471	621	624	642	655	667	676	680	693	719	732	750	755	
472	557	566	555	579	597	599	603	808	614	619	632	635	
473	685	710	741	756	768	776	766	785	816	830	852	878	
474	644	670	694	691	706	706	720	731	750	760	775	776	
475	673	585	694	731	762	770	790	799	810	826	833	844	
MEAN	598	600	622	631	642	653	659	668	682	693	703	709	
S.D.	46.7	50.6	53.5	56.1	57.4	56.9	59.4	60.4	63.4	65.5	67.6	71.4	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					:	Data Unav	ailable						



	IND	IVIDUAL BODY	WEIGHTS (Grams)	
STUDY: 1	DOSI	UP: 2-M E: 0.5 (mg ba # DAY 169 DAY 176	ase/kg/day)	IALE
	451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474	768 784 648 667 590 565 655 665 746 757 710 714 781 784 715 722 668 677 657 672 699 704 743 750 692 693 727 723 694 698 743 755 569 568 737 738 690 708 582 584 752 750 640 643 881 884 776 788 855 860	764 667 558 673 761 717 785 728 685 674 711 752 695 734 703 756 584 746 709 592	

MEAN

S.D.

709

75.7

25

714

78.1

25

--: Data Unavailable

700

62.2

20

	INDIVIDUAL BODY WEIGHTS (Grams) STUDY: 152 GROUP: 3-M SEX: MALE DOSE: 2.0 (mg base/kg/day) ANIMAL # DAY 1 DAY 8 DAY 15 DAY 22 DAY 29 DAY 36 DAY 43 DAY 50 DAY 57 DAY 64 DAY 71 DAY 78												
STU	DY: 19	52		GR(OUP: 3	-M 0 (mc	base	SE/kg/day	X: MA	LE			
ANIMAL #	DAY 1	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
501	235	284	326	360	385	419	438	453	475	498	512	530	
502	235	281	318	354	386	406	435	457	473	495	508	525	
503	238	296	344	379	407	432	472	489	508	527	545	554	
504	223	275	314	349	373	408	425	448	470	492	504	513	
505	254	308	359	396	421	448	466	474	494	508	526	539	
506	251	301	338	375	401	420	455	474	499	520	538	544	
507	263	325	374	413	451	483	507	527	544	566	566	587	
508	256	306	349	384	398	429	459	480	491	509	532	555	
509	284	335	377	411	431	444	471	477	495	513	523	542	
510	235	288	336	363	385	401	416	440	449	474	491	507	
511	238	286	321	357	390	416	443	475	500	525	542	566	
512	263	325	374	419	470	514	550	574	590	617	647	648	
513	242	300	347	388	426	457	493	509	532	558	566	581	
514	246	292	333	369	402	433	457	475	498	516	534	548	
515	253	311	362	404	448	492	522	536	558	580	598	618	
516	253	307	357	385	421	441	470	481	492	511	525	531	
517	244	292	339	377	414	445	478	492	512	532	546	560	
518	242	287	324	355	388	416	448	470	493	506	525	548	
519	257	311	353	384	416	440	457	472	492	502	509	515	
520	243	294	343	386	422	449	474	497	514	522	542	560	
521	263	310	354	393	437	454	483	480	498	520	534	552	
522	247	279	313	347	373	403	430	450	475	486	503	520	
523	262	304	352	393	429	464	498	508	541	559	580	609	
524	238	276	319	356	401	432	460	472	489	506	525	537	
525	246	293	335	373	406	394	434	447	476	490	506	513	
MEAN	248	299	342	379	411	438	466	482	502	521		552	
S.D.	12.8	15.7	18.9	20.6	24.8	29.3			30.9	32.6		34.7	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					:[ata Unav	ailable						



	INDIVIDUAL BODY WEIGHTS (Grams) STUDY: 152 GROUP: 3-M SEX: MALE DOSE: 2.0 (mg base/kg/day) ANIMAL # DAY 85 DAY 92 DAY 99 DAY 106 DAY 113 DAY 120 DAY 127 DAY 134 DAY 141 DAY 148 DAY 155 DAY 162													
ST	UDY: 1	52		GR	OUP:	3 - M		SE	EX: MA	LE				
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	2.0 (mg DAY 120	DAY 127	kg/day	DAY 141	DAY 148	DAY 155	DAY 162		
F01	F//	F 7 7	557	550	F.70	E04	F01	(00	/2/	440	(5)	450		
501 502	544 537	533 532	557 544	558 545	572 560	581 560	591 566	608 576	626 587	640 596	654 602	658 600		
503		570	570	572	582	568	557	571		593	598	596		
504	561	523	537	556	556		580		584	598	603	617		
505	523		568		572	569	587	585	589	619	637			
	553	555		569		577		592	612			624		
506	558	562	571	574	590	598	599	613	621	628	636	645		
507	597	577	592	606	627	629	621	633	632	639	658	668		
508	560	553	576	577	594	594	601	608	617	627	646	649		
509	542	537	556	541	556	560	551	561	574	587	592	595		
510	518	526	539	544	554	558	563	573	584	593	606 657	619		
511	577	586	591	604	599	614	620	623	638	650		667		
512	661	659	674	691	687	685	695	709	724	739	754	755		
513	595	595	616	605	616	621	627	635	642	660	676	669		
514	562	548	572	579	604	623	630	640	648	662	678	682		
515	643	652	671	682	683	700	667	682	707	731	752	755		
516	544	537	557	556	566	570	567	574	585	597	610	613		
517	562	569	591	584	596	595	596	606	614	621	634	645		
518	561	569	579	584	590	600	602	614	626	632	648	658		
519	516	528	538	538	544	533	539	550	562	573	590	580		
520	568	576	577	580	589	578	589	592	606	621	637	640		
521	559	564	571	575	584	596	604	612	625	634	656	666		
522	538	543	557	575	581	597	598	594	605	618	628	639		
523	622	630	649	653	666	661	663	675	680	679	688	703		
524	556	564	569	578	588	579	578	581	582	599	6D9	622		
525	524	521	513	529	534	552	561	572	576	575	597	617		
MEAN	563	564	577	582	592	596	598	607	618	628	642	647		
S.D.	36.5	37.4	39.4	40.9	39.4	40.4	37.8	39.0	40.3	42.1	43.8	44.1		
N	25	25	25	25	25			25	25	25	25	25		
					:	Data Unav	ailable							



					-	, ,,	LU	Li	U	
••••••	INDIV	IDUAL	BODY	WEIGHTS (Gr	ams)					
STUDY: 152	GROUP DOSE: ANIMAL#	2.0(mq bas	SEX: se/kg/day) DAY 182	MALE					
	501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525	659 603 602 623 623 651 679 653 592 607 676 757 676 679 770 618 647 660 587 645 660 649 719 632 626	664 618 604 614 642 654 672 664 603 604 683 772 674 692 771 629 646 660 597 660 655 719 617 636	672 613 598 617 638 648 673 660 599 616 681 780 674 698 786 632 650 674 602 676 						

--: Data Unavailable



INDIVIDUAL BODY WEIGHTS (Grams)													
 STU	DY: 19	52		GR DO:	OUP: 4	-M .0 (mg	base	SE /kg/day DAY 50	X: MAI	LE			
ANIMAL #	DAY 1	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
551	235	273	311	325	346	354	380	389	408	432	447	458	
552	235	274	302	318	329	344	366	375	388	400	415	423	
553	235	273	302	324	346	353	374	379	387	406	405	412	
554	241	293	327	355	378	396	419	426	441	448	459	479	
555	221	256	281	274	294	286	307	315	315	314	343	353	
556	262	302	324	346	360	369	381	382	391	413	425	428	
557	262	292	324	354	372	393	429	450	475	494	509	516	
558	253	291	324	344	361	351	348	330	303	287	292	352	
559	239	292	319	340	357	375	399	404	415	430	443	453	
560	243	278	296	302	325	354	365	369	377	377	383	387	
561	233	268	303	321	344	348	372	379	397	406	418	424	
562	244	294	331	340	376	394	419	431	442	450	471	473	
563	250	292	319	334	360	382	411	423	435	449	460	461	
564	236	272	296	313	330	342	357	367	367	388	404	413	
565	247	301	332	344	373	382	407	416	433	452	467	471	
566	246	291	318	342	352	361	398	399	415	432	445	436	
567	236	288	315	336	345	365	400	407	421	446	448	474	
568	241	273	294	312	332	337	342	346	360	334	291	308	
569	265	311	330	348	305	362	380	401	420	449	456	469	
570	261	312	343	374	404	423	454	460	485	505	535	545	
571	266	310	339	370	401	429	455	450	465	474	492	401	
572	268	320	361	376	413	422	442	433	456	465	476	495	
573	250	288	329	357	392	405	421	430	450	470	481	487	
574	287	336	359	367	386	407	429	440	449	457	478	488	
575	244	285	323	344	370	390	418	441	463	478	492	499	
MEAN	248	291	320	338	358	373	395	402	414	426	437	444	
S.D.	14.6	18.1	19.4	23.8	29.7	32.5	36.5	38.4	46.2	53.8	60.2	55.2	
N	25	25	25	25	25	25	25	25	25	25	25	25	
: Data Unavailable													



INDIVIDUAL BODY WEIGHTS (Grams)													
STU	STUDY: 152 GROUP: 4-M SEX: MALE DOSE: 9.0 (mg base/kg/day) ANIMAL # DAY 85 DAY 92 DAY 99 DAY 106 DAY 113 DAY 120 DAY 127 DAY 134 DAY 141 DAY 148 DAY 155 DAY 162												
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 162	
551	470	471	478	476	495	507	519	531	541	540		531	
552	427	427	435	447	457	449	454	460	471	485	473	481	
553	415	389	424	417	432	437	424	430	430	439	447	451	
554	471	460	477	480	497	505	510	515	522	536	544	533	
555	354	352	358	361	368	365	379	367	381	398	414	414	
556	426	428	433	448	454	464	469	470	480	489	496	505	
557	529	521	538	525	548	546	563	567	578	593	599	587	
558	386	416	428	435	449	450	443	415	С	C	С	С	
559	464	469	479	482	492	497	506	500	510	518	515	520	
560	393	386	389	409	409	420	417	422	423	433	432	438	
561	423	428	438	436	447	456	465	471	479	484	495	482	
562	473	464	474	484	493	492	499	502	517	524	540	535	
563	465	468	494	483	499	506	509	517	528	537	545	549	
564	414	423	431	429	435	444	446	459	471	484	491	487	
565	481	485	496	496	510	523	518	526	540	552	538	545	
566	463	454	453	453	475	457	457	481	487	501	510	489	
567	489	474	495	491	506	517	520	529	535	551	561	554	
568	367	396	414	424	427	420	422	423	420	435	459	447	
569	471	479	491	488	508	509	520	524	518	539	549	542	
570	558	554	580	579	600	588	592	613	609	630	654	654	
571	492	522	542	552	554	569	556	565	581	593	600	604	
572	503	501	524	518	538	547	525	547	559	569	575	569	
573	497	507	525	520	536	543	543	552	563	579	590	592	
574	493	502	521	519	538	539	537	541	548	570	590	588	
. 575	515	509	522	527	542	544	546	552	539	550	560	571	
MEAN	458	459	474		488	492	494	499 -	510	522	530	528	
S.D.	50.8	49.4	52.8	49.7	53.2	53.9	53.2	58.3		57.7	58.9	58.9	
N	25	25	25	25	25	25	25	25	24	24	24	24	
				: Data	Unavaila	ble c	:: Animal	Found Dea	d				

DRAFT

	INDIV	IDUAL 1	BODY	WEIGHTS (Gra	ms)
STUDY: 152	GROUP DOSE:	9.0 (t	ng bas	SEX: se/kg/day)	MALE
				••••••	
	551 552 553 554 555 556	552 488 438 541 411 506	566 510 453 549 416 519	579 513 457 553 428 524	
	557	588	603	616	
	558 559 560 561	519 441 495	533 450 503	535 449 501	
	562	546	526	543	
	563 564 565 566	552 492 449 498	555 498 445 507	563 502 495 519	
	567	551	570	581	
	568 569 570	464 538 662	464 551 681	463 572 680	
	571	598	598		
	572 573	564	578	• •	
	574	592 597	583 592	••	
	575	572	571		
	MEAN S.D.	527 61.1	534 61.5	530 61.7	
	N	24	24	19	
•	-: Data Unav	allable	c: Ani	mal Found Dead	

1		[]		52
12	1	131	13	
رت		LA	L	Li

INDIVIDUAL BODY WEIGHTS (Grams)												
STU	STUDY: 152 GROUP: 1-F SEX: FEMALE DOSE: 0 (mg base/kg/day) ANIMAL # DAY 1 DAY 8 DAY 15 DAY 22 DAY 29 DAY 36 DAY 43 DAY 50 DAY 57 DAY 64 DAY 71 DAY 78											
ANIMAL #	DAY 1	8 YAO	0AY 15	0AY 22	0AY 29	DAY 36	0AY 43	0AY 50	0AY 57	DAY 64	DAY 71	DAY 78
426	204	228	251	270	271	276	282	296	312	-318	321	332
427	179	203	230	251	250	261	279	288	304	314	320	333
428	181	210	227	246	256	260	267	272	285	287	297	308
429	169	196	213	225	231	239	264	263	273	278	285	287
430	194	227	240	253	263	268	299	296	313	326	335	332
431	183	197	218	235	241	240	267	265	280	292	292	299
432	183	205	222	231	250	249	272	275	290	299	300	309
433	178	211	228	248	257	259	291	291	297	314	322	328
434	186	205	219	234	239	241	257	269	277	294	297	299
435	198	225	236	258	280	282	290	303	324	333	335	347
436	199	217	236	254	270	281	295	310	321	331	339	351
437	190	219	235	244	260	272	274	291	294	310	319	323
438	178	196	215	227	227	248	246	248	265	281	295	305
439	188	213	224	232	245	251	266	267	277	290	291	291
440	162	189	205	218	230	234	251	252	254	258	263	257
441	178	193	216	225	238	254	265	268	276	287	296	306
442	178	205	222	229	246	255	266	268	282	293	295	297
443	170	192	204	222	229	230	247	248	261	273	277	282
444	190	199	224	236	250	257	271	281	286	291	301	307
445	169	186	197	215	230	230	249	250	261	270	275	277
446	192	216	219	239	253	263	273	283	298	300	300	309
447	184	203	228	240	251	256	281	289	293	311	319	329
448	177	193	208	225	237	234	253	253	259	261	268	278
449	175	188	204	213	216	227	242	249	246	255	259	262
450	176	191	218	224	243	240	253	261	269	272	274	283
MEAN	182	204	222	236	247	252	268	273	284	294	299	305
S.D.	10.2	12.6	12.7	14.4	15.4	16.1	16.0	18.5	20.9	22.2	22.7	24.9
N	25	25	25	25	25	25	25	25	25	25	25	25
	: Data Unavailable											

[0]				- ,-
	13	151	13	1
	uu	LN	L	Ü

INDIVIDUAL BODY WEIGHTS (Grams)													
STUDY: 152 GROUP: 1-F SEX: FEMALE DOSE: 0 (mg base/kg/day) ANIMAL # DAY 85 DAY 92 DAY 99 DAY 106 DAY 113 DAY 120 DAY 127 DAY 134 DAY 141 DAY 148 DAY 155 DAY 162													
				DO	SE: C) (mg b	ase/kg	g/day)					
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 162	
	71.4	~~~	770	7.07	70.	=	770	700			7.05	~	
426	341	335	332	323	356	366	372	382			385	364	
427	339	338	331	330	346	363	365	373	377	397	394	384	
428	311	314	344	333	322	323	333	336	340	367	374	347	
429	298	302	300	292	306	311	325	325	323	333	332	322	
430	344	340	339	328	349	346	355	362	366	372	384	378	
431	310	313	303	307	324	336	336	348	357	360	364	357	
432	323	333	323	326	341	351	349	370	371	377	377	373	
433	338	339	335	344	365	377	387	392	385	397	401	406	
434	312	317	304	303	319	328	326	335	336	346	338	339	
435	357	363	356	352	376	396	402	404	421	430	432	424	
436	345	363	349	352	369	381	388	399	413	432	452	462	
437	326	337	331	332	357	362	365	376	387	390	392	381	
438	325	331	333	336	351	355	366	378	389	396	407	409	
439	303	313	298	309	327	317	325		331	331	344	334	
440	257	263	267	273	287	297	301	295	302	308	302	307	
441	316	322	321	321	335	341	343	342	351	349	363	352	
442	301	306	296	307	331	321	331	342	342	338	346	339	
443	281	284	276	274	288	290	297	303	310	307	318	300	
444	308	301	318	337	315	346	337	340	337	341	342	343	
445	284	287	290	288	298	297	306	309	314	319	325	323	
446	318	327	323	328	345	346	350	356	367	365	384	375	
447	343	351	361	365	361	371	370	371	376	383	392	406	
448	277	277	278	274	291	291	284	293	299	288	292	294	
449	276	276	274	268	290	293	290	287	299	297	307	325	
450	282	283	294	293	300	310	312	321	337	341	357	361	
MEAN	313	317	315	316	330	337	341	347	353	358	364	360	
S.D.	26.2	27.5	26.7	27.2	27.6	30.9		33.8	34.7		40.0	40.7	
N	25	25	25	25	25	25	25	25	25	25	25	25	
						Data Unav							

10	[]			
1111	1	1:1	12	
		(2)		14

INDIVIDUAL BODY WEIGHTS (Grams)

SEX: FEMALE

STUDY: 152 GROUP: 1-F SE DOSE: 0 (mg base/kg/day) ANIMAL # DAY 169 DAY 176 DAY 182

				IN	DIVIDU	AL BO	DY WE	GHTS	(Grams)				
STU	JDY: 15	52		GR(DO:	OUP: 2 SE: 0 DAY 29	-F	base/	SE kg/day	X: FEI	MALE			
ANIMAL #	DAY 1	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
476	195	222	237	259	273	278	301	306	322	339	341	353	
477	177	197	214	228	234	239	264	264	273	279	278	289	
478	161	181	194	207	215	227	234	237	247	253	254	263	
479	196	220	241	252	262	272	290	302	316	317	319	335	
480	177	206	226	243	251	266	281	289	297	317	315	334	
481	186	210	233	239	252	263	284	294	309	323	339	353	
482	167	187	200	213	227	227	235	247	256	258	261	267	
483	160	169	188	199	208	206	217	222	239	244	241	251	
484	186	205	221	230	247	253	265	268	276	288	289	299	
485	180	200	212	224	234	237	257	261	273	279	288	290	
486	171	187	208	217	233	237	252	246	258	269	268	272	
487	192	221	242	250	265	267	286	291	294	304	308	317	
488	180	199	221	237	247	250	266	283	292	293	304	308	
489	186	204	216	231	238	245	252	259	270	272	274	280	
490	176	200	221	232	251	255	270	280	294	306	315	326	
491	190	213	234	248	266	275	292	314	329	316	325	334	
492	187	209	221	240	254	264	284	284	288	298	305	302	
493	190	206	223	238	252	257	278	281	288	292	296	306	
494	170	185	197	213	224	226	244	245	248	254	258	265	
495	186	208	232	241	250	258	278	286	296	298	306	317	
496	203	227	253	269	290	288	314	335	359	355	352	360	
497	194	216	236	252	267	272	292	295	310	310	324	328	
498	187	205	223	239	253	244	262	. 261	275	286	296	298	
499	180	198	210	226	244	262	259	272	285	292	296	309	
500	173	197	217	223	239	254	265	273	285	292	295	299	
MEAN	182	203	221	234	247	253	269	276	287	293	298	306	
S.D.	11.0	13.8	16.0	16.7	18.5	19.3	22.6	25.8	27.8	26.9	28.4	29.9	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					: 0	ata Unava							

0		\Box	F	57
	103	IA	12	- 11
[]			Ш	П

				IN	DIVID	JAL BO	DY WE	IGHTS	(Grams)				
STU	STUDY: 152 GROUP: 2-F SEX: FEMALE DOSE: 0.5 (mg base/kg/day) ANIMAL # DAY 85 DAY 92 DAY 99 DAY 106 DAY 113 DAY 120 DAY 127 DAY 134 DAY 141 DAY 148 DAY 155 DAY 162												
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 162	
476	375	378	372	369	397	404	423	424	434	441	442	433	
477	287	294	291	293	314	311	314	319	325	328	329	332	
478	265	267	262	266	279	287	285	291	297	298	290	293	
479	341	341	336	339	356	359	357	359	382	373	373	370	
480	342	336	335	333	355	366	371	382	378	383	377	379	
481	354	348	345	358	378	392	401	404	413	429	443	444	
482	270	270	273	277	277	281	287	290	292	287	269	267	
483	254	253	256	266	271	275	280	286	290	293	301	299	
484	306	309	297	289	316	321	326	336	343	343	344	329	
485	302	302	299	301	318	320	330	329	332	336	334	335	
486	278	284	281	282	295	305	310	320	323	331	334	339	
487	319	315	320	315	333	324	334	342	337	344	343	340	
488	316	308	311	315	341	334	347	351	366	370	364	361	
489	284	285	288	285	299	302	301	316	314	316	315	312	
490	335	332	342	348	367	369	378	379	390	397	400	399	
491	337	339	335	341	358	361	368	371	375	380	375	377	
492	307	310	308	315	333	331	326	337	345	355	363	363	
493	306	311	306	317	330	329	326	326	344	346	342	348	
494	267	272	268	269	283	286	282	292	297	302	298	296	
495	311	314	311	317	336	339	340	337	339	343	356	352	
496	368	367	367	360	376	385	374	382	378	379	389	395	
497	332	343	339	338	346	354	350	360	357	368	378	383	
498	308	314	304	310	321	321	328	328	332	336	340	346	
499	323	328	326	333	338	347	348	356	368	373	380	389	
500	307	313	316	320	323	333	331	332	341	352	356	353	
MEAN	312	313	312	314	330	333	337	342	348	352	353	353	
S.D.	32.0	31.1	30.8	30.3	33.5	34.7 25	36.5	35.5	36.9	38.7	42.1	42.4	
N	25	25	25	25				25	25	25	25	25	
					:	Data Unav	ailable						

DRAFT

						ШЦ	177	Ш	П
	INDIV	IDUAL B	ODY W	EIGHTS (Gram	ns)				
STUDY: 152	DOSE:	2: 2-F 0.5 (m DAY 169 DA	g base	AV 102	FEMAI				
	476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497	437 332 300 382 391 446 267 303 342 343 349 350 356 317 409 378 373 353 353 352 354 398 383	460 339 321 402 408 459 275 308 352 349 354 352 380 328 416 390 375 359 308 369 406 396	461 336 309 397 412 486 289 302 354 358 359 369 390 321 422 395 402 358 315 369					

352

398

359

369

44.5

25

--

--

370

51.9

20

354

391

360

359

42.3

25

498

499

500

MEAN

S.D.

N

	5	1
	-	44

				IN	DIVIDU	TAL BO	DY WE	IGHTS (Grams)				
STU	JDY: 19	52		GRO	OUP: 3	-F	hase/	SE: kg/day bay 50	X: FE	MALE			
ANIMAL #	DAY 1	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
526	198	221	249	265	287	300	307	329	351	358	363	372	
527	166	179	199	213	214	224	233	252	249	252	268	264	
528	183	205	222	231	243	249	271	281	280	292	297	301	
529	182	203	222	236	249	254	264	273	279	292	300	295	
530	180	201	213	223	239	234	246	263	268	282	282	280	
531	177	197	213	225	239	238	256	253	264	265	262	267	
532	196	224	250	258	280	280	310	320	341	357	362	369	
533	192	214	236	251	272	276	296	311	326	332	347	359	
534	189	213	233	256	272	271	288	303	311	329	337	340	
535	172	186	206	217	211	218	234	236	245	255	257	258	
536	182	197	217	232	249	240	266	265	274	283	272	265	
537	189	214	236	246	254	266	283	302	296	301	309	320	
538	179	209	229	250	266	275	284	298	297	305	316	315	
539	185	209	224	247	259	255	275	269	285	300	295	303	
540	187	214	233	244	259	264	288	288	304	316	325	328	
541	184	204	224	234	249	249	269	269	278	285	284	287	
542	162	180	198	217	224	231	246	260	260	276	281	285	
543	179	194	220	236	247	247	269	270	287	297	302	305	
544	191	207	223	236	253	268	266	282	289	288	296	305	
545	159	182	196	209	223	226	237	250	259	264	267	272	
546	190	209	227	249	268	264	286	305	312	328	339	343	
547	167	183	200	217	235	237	237	254	260	258	264	266	
548	193	209	222	236	252	255	274	278	291	301	306	306	
549	177	196	213	215	233	239	244	251	254	260	258	253	
550	186	203	214	237	251	243	250	261	269	273	269	276	
MEAN	182	202	221	235	249	252	267	277	285	294	298	301	
S.D.	10.3	12.6	14.5	15.4	19.4	20.0	22.4	24.4	27.6	29.8	32.3	34.9	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					: 1	Data Unava	ailable						

	INDIVIDUAL BODY WEIGHTS (Grams)												
STU ANIMAL#	JDY: 1	52		GR DO	OUP: 3	3-F	base/	SE kg/day	X: FE	MALE			
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 162	
526	379	371	371	378	397	397	411	419	415	419	435	424	
527	277	280	277	277	293	285	296	294	298	301	313	309	
528	306	307	299	302	322	325	328	339	343	352	348	341	
529	302	307	303	310	314	319	322	328	330	330	331	323	
530	290	298	287	294	305	309	306	326	327	335	333	339	
531	275	276	280	287	294	297	300	304	308	314	320	323	
532	381	373	374	378	390	410	421	438	449	455	465	468	
533	360	359	373	359	382	394	411	416	422	427	439	428	
534	344	342	338	335	349	355	361	369	371	380	378	378	
535	263	269	265	268	274	277	286	288	292	304	292	298	
536	273	288	278	284	305	316	326	334	331	341	341	336	
537	323	319	323	319	332	330	337	347	348	346	360	349	
538	326	332	328	336	343	338	344	353	355	362	369	364	
539	310	317	288	310	324	330	338	339	352	359	352	336	
540	336	338	324	329	345	353	366	375	380	387	402	398	
541	296	303	296	292	308	313	311	315	326	335	326		
542	288	293	281	290	309	322	328	344	348	360	370	360	
543	314	315	307	310	324	332	327	335	342	347	358	357	
544	310	308	304	319	327	335	344	353	358	373	380	379	
545	279	283	286	286	294	296	299	308	309	308	316	309	
546	340	348	350	331	351	371	376	387	395	407	416	421	
547	271	270	281	291	287	286	290	295	294	296	305	302	
548	319	328	327	337	353	367	364	365	372	371	378	389	
549	259	267	269	264	278	285	284	282	293	301	302	301	
550	289	289	291	286	302	305	305	314	318	321	317	329	
330	207	207	271	200	302	303	302	314	310	321	311	327	
MEAN	308	311	308	311	324	330	335	343	347	353	358	355	
S.D.	34.2	31.4	32.8	31.2	33.3	36.6	39.3 25	41.3	41.8	42.3	46.0	45.5	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					:	Data Unav	vailable						

DRAFT

INDIVIDUAL BODY WEIGHTS (Grams)

STUDY: 152

GROUP: 3-F SEX: FEMALE DOSE: 2.0 (mg base/kg/day)
ANIMAL # DAY 169 DAY 176 DAY 182

526	427	442	439
527	310	317	318
528	346	347	358
529	325	332	333
530	340	347	352
531	326	323	327
532	465	471	478
533	424	443	455
534	370	390	389
535	306	311	319
536	344	372	365
537	355	371	369
538	367	369	372
539	352	360	378
540	404	416	415
541	336	343	349
542	365	363	374
543	362	378	371
544	385	395	394
545	310	314	325
546	419	425	
547	296	292	
548	396	420	
549	308	305	-
550	331	338	
MEAN	359	367	374
S.D.	44.0	48.1	44.6
N	25	25	20
	- : Data l	Jnava i labl	e

								IGHTS (
STU	DY: 15	52		GRO	OUP: 4	-F	hace/	SE kg/day DAY 50	X: FE	MALE			
ANIMAL #	DAY 1	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	0AY 57	DAY 64	0AY 71	DAY 78	
576	187	209	228	237	250	239	262	262	281	282	280	288	
577	180	202	215	226	235	242	248	255	266	263	266	272	
578	201	215	235	244	255	263	275	275	284	290	295	298	
579	168	189	208	216	229	228	248	253	262	269	273	278	
580	184	204	222	229	245	237	251	260	262	269	275	279	
581	177	187	201	208	216	221	234	240	246	252	257	256	
582	175	199	198	211	226	225	240	242	245	253	249	258	
583	172	194	208	219	228	239	251	247	254	263	269	278	
584	168	183	195	211	222	231	232	240	248	253	254	257	
585	174	196	208	224	241	238	252	267	271	273	274	281	
586	172	192	209	226	241	242	259	268	276	279	283	290	
587	187	208	230	234	257	253	271	269	283	289	293	299	
588	187	202	209	217	231	222	244	242	248	258	261	262	
589	181	205	212	228	243	230	250	253	258	263	265	273	
590	184	208	224	223	235	241	259	253	259	267	269	267	
591	184	201	220	236	246	250	259	265	273	281	285	279	
592	164	180	192	197	209	214	227	227	233	236	243	247	
593	175	196	206	213	232	235	248	250	251	262	260	260	
594	191	211	217	231	245	245	257	258	261	267	272	272	
595	170	182	194	207	220	210	223	229	235	242	250	251	
596	199	208	231	247	263	256	278	281	286	293	299	303	
597	164	186	200	208	221	212	225	236	239	246	240	248	
598	163	191	201	211	225	218	244	236	250	255	261	264	
599	184	202	223	231	246	246	268	275	259	280	285	289	
600	192	204	226	246	255	255	274	270	280	284	289	295	
MEAN	179	198	212	223		236	251	254	260	267	270	274	
S.D.	10.6	9.8	12.6	13.3	14.0	14.4	15.6	15.1	15.7	15.4	16.2	16.6	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					: [ata Unava	ailable						

INDIVIDUAL BODY WEIGHTS (Grams)															
STUDY: 152 GROUP: 4-F SEX: FEMALE DOSE: 9.0 (mg base/kg/day) ANIMAL # DAY 85 DAY 92 DAY 99 DAY 106 DAY 113 DAY 120 DAY 127 DAY 134 DAY 141 DAY 148 DAY 155 DAY 162															
				DO	SE: 9	0.0 (mg	g base	/kg/da	y)						
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 162			
576	302	302	296	299	309	305	307	318	321	319	319	323			
577	281	280	275	275	287	282	288	292	294	291	293	291			
578	302	305	307	305	319	324	316	318	314	318	333	325			
579	287	285	285	275	291	292	296	280	290	300	304	298			
580	281	283	286	286	293	298	300	279	290	299	304	308			
581	257	259	268	267	275	270	280	289	285	287	303	304			
582 265 256 269 260 271 278 279 281 285 288 287 293 583 282 278 286 279 288 291 294 302 302 312 313 306															
583	583 282 278 286 279 288 291 294 302 302 312 313 306														
584	584 265 268 277 267 277 278 282 289 288 291 293 283														
585	585 285 282 288 287 300 300 304 307 303 310 314 313														
586															
587	305	303	301	294	311	312	303	321	321	331	321	322			
588	266	265	270	261	283	281	278	289	285	292	289	290			
589	284	271	275	275	285	290	290	293	295	295	309	300			
590	275	274	283	276	291	288	293	298	283	296	308	308			
591	286	289	290	295	301	303	297	298	299	305	319	316			
592	249	249	250	261	270	262	273	273	272	278	281	278			
593	265	216	262	267	272	275	275	274	278	285	284	289			
594	278	282	283	282	286	293	284	291	301	290	303	303			
595	254	252	248	254	267	268	268	273	273	278	287	289			
596	304	298	299	306	311	317	304	315	316	321	320	328			
597	247	250	246	241	252	256	249	257	257	249	263	248			
598	267	274	272	266	276	282	283	287	286	290	293	283			
599	296	299	299	306	304	313	306	. '311	311	309	318	331			
600	306	305	308	309	313	319	320	329	328	328	343	347			
MEAN	280	277	281	280	290	292	291	295	296	300	305	304			
S.D.	18.2	22.1	17.7	18.6	17.5	18.7	16.9	18.6	17.8	18.9	18.3	21.1			
N	25	25	25	25	25	25	25	25	25	25	25	25			
					: [Data Unav	ailable								

DRAFT

	INDIV	IDUAL	BODY 1	WEIGHTS (Grad	
STUDY: 152	GROUP DOSE: ANIMAL#	9.0(mg bas	SEX: se/kg/day) DAY 182	FEMALE
	576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600	326 299 338 306 306 310 291 315 293 316 330 328 288 301 314 318 289 286 305 286 325 250 280 321 348	346 296 346 310 314 300 300 315 304 332 341 333 296 308 321 316 295 287 313 290 335 250 289 322 347		
	N	25	25	20	
			tana and Label	_	

--: Data Unavailable

101	105	111	15	11
		LN	Ц	Ü

INDIVIDUAL WEIGHT GAIN (Grams)														
	STUDY:	152			GROUP	1-M		'kg/day	SEX:					
		b			DOSE:	0 (mg	base/	kg/day	7)					
	ANIMAL #			DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	0AY 57	0AY 64	DAY 71	0AY 78		
	401	65	49	33	24	17	26	34	33	17	20	26		
	402	52	47	49	19	23	45	23	20	31	18	18		
	403	50	38	34	23	28	34	20	26	17	20	11		
	404	52	44	40	25	21	56	26	27	23	24	-85		
	405	53	33	37	20	28	41	23	27	22	18	13		
	406	50	48	46	31	38	38	39	21	22	31	15		
	407	59	53	40	8	25	49	18	3	30	24	23		
	408	60	50	42	16	41	47	29	36	10	31	21		
	409	55	50	51	26	40	58	21	24	29	20	12		
	410	55	40	38	13	32	36	19	25	17	28	25		
	411	52	32	27	27	32	26	22	18	15	9	12		
	412	53	44	40	15	29	39	21	2D	10	16	11		
	413	63	50	44	34	26	41	21	25	20	21	16		
	414	57	43	30	34	31	35	21	26	- 19	65	21		
	415	48	41	32	26	5	28	18	13	12	15	10		
	416	63	52	43	43	25	47	20	28	21	14	27		
	417	47	44	34	27	31	26	14	20	23	17	17		
	418	63	53	36	35	22	51	11	29	14	21	15		
	419	54	53 45	38	35	41	36	19	24	24	13	21		
	420	43	43	37	36	18	30	19	27	19	17	18		
	421	52	43	34	35	14	34	10	10	14	26 -	11		
	422	52	47	35	42	22	33	17	29	22	21	18		
	423	44	42	25	24	13	34	10	19	13	22	14		
	424	62	69	39	55	28	51	21	35	20	22	25		
	425	49	59	37	44	37	41	28	32	22	19	25		
	MEAN	54	46	38	29	27	39	21	24	18	22	14		
		6.1	7.7	6.2	10.9	27		21 6.7						
	S.D.	25			25	9.2	9.3		7.6	9.6	10.4	21.2		
	N	20	25	25		25	25	25	25	25	25	25		
						: Data l	navaitab	le						

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period $^{\rm b}{\rm Baseline}$ is day 1

INDIVIDUAL WEIGHT GAIN (Grams) ^a														
STUDY:	152			GROUP	: 1-M		15 1 -	SEX:	MALE					
				DOSE:	0 (mg	base	/kg/da	У)						
ANIMAL #	DAY 85	DAY 92	0AY 99	0AY 106	0AY 113	0AY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155			
401	11	6	19	3	17	1	4	0	5	14	7			
402	12	3	10	5	15	10	4 3 6	9	11	11	9			
403	13	12	21	3 5 7	8	9	6	9	1	17	11			
404	24	30	34	9	31	11	12	10	15	6	11			
405	18	-90	56	35	14	28	5	1	-2	18	9			
406	22	16	16	20	17	-71	11	46	. 18	16	21			
407	6	1	25	1	23	17	2	11	16	11	16			
408	14	-32	15	14	13	12	-1	6	20	4	13			
409	15	0	26	9	19	7	7	5 7	4	7	13			
410	26	8	11	10	22	9	7		23	10	16			
411	16	15	11	-1	14	0		13	11	11	11			
412	23	6	7	12	19	-1	-5	14	10	13	-2			
413	12	14	12	-1	6	12	1	6	17	10	11			
414	9	9	11	21	2	5 8 8	1 2 3 8 0 5	24	17	0	18			
415	12	9	13	-3 4	6	8	3	5	12	7	14			
416	17	19	8	4	10	8	8	21	-2	5	23			
417	10	11	9	9	11	13	0	-8	22	10	7			
418	18	5	23	5	14	8	5	10	15	6	6			
419	7	34	12	9	9	4	9	8	9	11	21			
420	5	20	10	9 5 9 6 8	11	10	2	-11	7	20	17			
421	22	13	11	8	6	5	-11	9	6	15	17			
422	19	15	12	6	24	13	-3	5	11	11	7			
423	14	7	10	-1	16	8	6	11	-6	14	4			
424	19	22	17	5	7	15	-5	3	15	12	10			
425	29	8	18	4	21	5	8	10	10	7	27			
MEAN	16	6	17	8	14	6	3	9	11	11	13	*		
S.D.	6.3	23.4	10.5	8.2	6.9	17.1	5.3	10.7	7.6	4.7	6.5			
N	25	25	25	25	25	25	25	25	25	25	25			
					: Data	Unavailab	ole							

^aWeight gains compared to the previous period

INDIVIDUAL WEIGHT GAIN (Grams) ^a													
STUDY: 152	GR	OUP: 1	- M		SEX	: MALE							
	DO	SE: 0	(mg b	ase/kg	/day)								
						TOTAL							
	ANIMAL #	DAY 162	DAY 169	DAY 176	DAY 182	GAIN							
	/04		2	2	40	151							
	401	8	-2	-2	19	454							
	402	10	1	16	2	472							
	403	14	0	6	5	440							
	404	15	-3 2	19	5	482							
	405	14	2	14	5	442							
	406	7	9	2	5 -2	534							
	407	4	1	1	-2	465							
	408	5	2	13	3	484							
	409	17	8	7	10	540							
	410	11	1	13	1	503							
	411	0	8	6	2	392							
	412	13	2	19	5	433							
	413	5	- 13	10	12	475							
	414	-6	7	7	3	473							
	415	-1	-4	7	11	347							
	416	10	0	22	4	540							
	417	-15	- 18	41	12	414							
	418	12	4	9	5	495							
	419	-2	3	9	10	503							
	420	7	11	4	5	431							
	421	3	3	-9		381							
	422		1	6		468							
	423	-1	4	14		360							
	424	21	6	1		575							
	425	19	18	1		578							
	MEAN	7	2	9	6	467							
	S.D.	8.3	7.1	9.7	4.9	60.8							
	N	25	25	25	20	25							
		: D	ata Unav	ailable									

^aWeight gains compared to the previous period

DRAFT

INDIVIDUAL WEIGHT GAIN (Grams) ²														
STUDY:	152			GROUP DOSE:	: 2-M 0.5	(mg bas	se/kg/	SEX: day)	MALE					
ANIMAL #	DAY 8 b	0AY 15	DAY 22	0AY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78			
451	59	45	35	18	35	47	35	22	23	23	19			
452	43	39	33	19	24	33	21	15	23	17	8			
453	51	44	31	12	24	42	20	28	27	22	20			
454	49	43	35	6	39	47	16	23	27	19	19			
455	52	49	42	35	40	34	32	33	25	27	1			
456	58	38	34	22	31	42	28	23	21	17	29			
457	66	53	47	31	33	47	21	26	23	29	13			
458	53	43	34	27	32	41	31	21	22	18	1			
459	59	42	32	32	23	40	19	26	19	17	10			
460	46	41	35	23	29	24	19	32	23	26	16			
461	52	33	37	39	31	23	24	20	27	12	15			
462	58	41	36	33	26	34	23	27	28	26	6			
463	54	45	40	35	29	26	16	22	21	25	14			
464	56	46	40	38	31	28	13	39	23	14	20			
465	50	53	23	34	25	35	17	18	25	22	13			
466	62	40	51	37	32	31	25	14	17	23	13			
467	-27	29	16	37	28	30	33	28	22	22	24			
468	48	44	32	27	27	35	30	29	20	27	16			
469	42	41	39	29	27	31	33	27	23	20	19			
470	46	39	38	26	12	21	24	18	15	14	15			
471	50	45	33	45	23	28	21	33	20	26	16			
472	42	51	36	34	29	34	17	16	18	21	11			
473	52	53	43	46	31	32	23	32	26	20	31			
474	54	47	35	50	32	41	16	26	23	26	16			
475	49	57	42	35	37	40	32	39	22	32	16			
MEAN	49	44	36	31	29	35	24	25	23	22	15			
S.D.	17.0	6.4	7.0	10.3	5.9	7.5	6.5	6.8	3.3	5.0	7.1			
N	25	25	25	25	25	25	25	25	25	25	25			

--: Oata Unavailable

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period $^{\rm b}{\rm Baseline}$ is day 1

	1	[3]	F	
	In	10	17	- 11
الثا	UU	UU	ш	u

									ت	טע נ	Л	n		
	INDIVIDUAL WEIGHT GAIN (Grams) ^a													
STUDY:	152			GROUP DOSE:	2-M 0.5	(mg ba	se/kg/	SEX: 'day)	MALE					
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155			
451		14	20	7	8	23	10	6	20	14	-6			
452	12	7	15		17	3	8	4	15	12	14			
453	17	10	17		10	13	8	10	11	14	14			
454	17	-1	10	6	3 -2	17	4	-1 8 7 1 2 7 8	13	18				
455	14	11 7	20	5	-2	19	7	8	15	17	13			
456	15	7	14	5 9 3	14	12	-5	7	25	4	9			
457	11	7	17	9	7	12	16	1	14		14			
458	25	3	23	3	9	15	13	2	12	17	9			
459	12	- 23	43	-3	11	13	3	7	10	0	6			
460	17	12	13	12	7	15	3	8	9	-16	7			
461	25	10	16	4	14	13	-8	14	21	10	0			
462	21	6	20		14	15	5	7	16	10	9			
463	12	15	-3	26	2	0	10		9	16	-7			
464		10	10	2	13	16	14	13	7	13	12			
465	11	12	15	16	11	11	10	16	10	2	11			
466	23	-1	20	16	4	10	-3	10	14	17	20			
467	15	4	9	4	6	15	-9	5	14	15	1			
468	18		15		19	3		10	12	20	22			
469	23	-74	76	7	21	15	9	6	20	8	8			
470	12	12	12	-1	11	10	5	14	5	8	10			
471	30	3	18	13	12	9	4	13	26	13	18			
472	5	9	-11	24	18	2	4	5	6	5	13			
473	22	25	31		12	8	-10	19	31	14	22			
474	16	26	24		15	0	14	11	19	10	15			
475	21	-88	109	37	31	8	20	9	11	16	7			
	17	1	22	9	11	11	6	9	15	11	10			
S.D.	5.9	26.6	23.9	9.5		5.9	7.8	4.8	6.5	7.6	7.4			
N	25	25	25	25	25	25	25	25	25	25	25			
					: Data	Unavailab	ole							

^aWeight gains compared to the previous period

STUDY: 152

 I	NDIVID	UAL W	EIGHT	GAIN (Grams) ^a	 	
 GR	OUP: 2	-M	hace	SEX kg/day	K: MALE	 	
20	DD . 0	. 5 (1119	Dase	kg/ day	TOTAL		
ANIMAL #	DAY 162	DAY 169	DAY 176	DAY 182	GAIN		
451	4	19	16	-20	520		
452	5	-8	19	0	403		
453	10	-118	-25	-7	315		
454	- 16	2	10	8	427		
455	6	-2	11	4	516		
456	12	5	4	3	474		
457	10	0	3	1	519		
458	7	9	7	6	483		
459	4	17	9	8	436		
460	15	1	15	2	434		
461	9	4	5	2 7	457		
462	12	5	5 7	2	486		
463	3	4	1	2	431		
464	-9	10	-4	11	478		
465	16	6	4	5	471		
466	3	4	12	1	495		
467	3		-1	16	344		
468	11	5 2	1		516		
469	14	-8		8 1	475		
470	-9	9	18				
		-3	2	8	376		
471	5	-2	-2		499		
472	3	5	3		400		
473	26	3	3		610		
474	1	0	12		526		
475	11	11	5		609		
MEAN	6	-1	5	3	468		
S.D.	8.7	25.2	8.9	7.3	69.9		
N	25	25	25	20	25		
	: D	ata Unav	ailable				

^aWeight gains compared to the previous period

											JF	
				INDI	VIDUAI	WEIG	HT GA	I N (Gram	s) ^a			
STUDY:	152			GROUP DOSE:	: 3-M 2.0	(mg ba	se/kg/	SEX: day)	MALE	• • • • • • • • •		
ANIMAL #	DAY 8b	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
501	49	42	34	25	34	19	15	22	23	14	18	
502 503	46 58	37 48	36 35	32 28	20 25	29 40	22 17	16 19	22 19	13 18	17	
504	52	39	35	24	35	17	23	22	22	12	9	
505	54	51	37	25	27	18	8	20	14	18	13	
506	50	37	37	26	19	35	19	25	21	18	6	
507 508	62 50	49 43	39 35	38 14	32 31	24 30	20 21	17 11	22 18	0 23	21 23	
509	51	42	34	20	13	27	6	18	18	10	19	
510	53	48	27	22	16	15	24	9	25	17	16	
511	48	35	36	33	26	27	32	25	25	17	24	
512	62	49	45	51	44	36	24	16	27	30	1	
513	58	47	41	38	31	36	16	23	26	8	15	
514 515	46 58	41 51	36	33 44	31 44	24	18	23	18	18	14	
516	54	50	42 28	36	20	30 29	14 11	22 11	22 19	18 14	20 6	
517	48	47	38	37	31	33	14	20	20	14	14	
518	45	37	31	33	28	32	22	23	13	19	23	
519	54	42	31	32	24	17	15	20	10	7	6	
520	51	49	43	36	27	25	23	17	8	20	18	
521	47	44	39	44	17	29	-3	18	22	14	18	
522	32	34	34	26	30	27	20	25	11	17	17	
523	42	48	41	36	35	34	10	33	18	21	29	
524 525	38 47	43 42	37 38	45 33	31 -12	28 40	12 13	17 29	17 14	19 16	12 7	
JEJ	41	46	30	33	- 12	40	13	24	14	10	,	

26 11.1

25

32

8.6

25

28 7.0

25

--: Data Unavailable

17 7.2

25

20

5.5

25

19

5.0

25

16

5.8

25

15

6.8

25

44

5.2

25

36

4.3

25

MEAN

S.D.

50

6.9

25

 $^{^{\}mbox{\scriptsize d}}\mbox{\scriptsize Weight gains compared to the previous period}$ Baseline is day 1

 INDIVIDUAL WEIGHT GAIN (Grams)													
 STUDY:	152			GROUP	: 3-M		/-	SEX:	MALE				
				DOSE:	2.0	(mg ba	se/kg/	(day)					
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155		
501	14	-11	24	1	14	9	10	17	18	14	14		
502	12	-5	12	1	15	0	6	10	11	9	6		
503	7	9	0	2	10	-14	-11	14	13	9	5		
504	10	0	14	19	0	13	11	5	4	9	5		
505	14	2	13	1	3	5	10	5	20	7	18		
506	14	4	9	3	16	8	1	14	8	7	8		
507	10	-20	15	14	21	2	-8	12	-1 '	7	19		
508	5	-7	23	1	17	0	7	7	9	10	19		
509	0	-5	19	-15	15	4	-9	10	13	13	5		
510	11	8	13	5	10	4	. 5	10	11	9	13		
511	11	9	5	13	-5	15	6	3	15	12	7		
512	13	-2	15	17	-4	-2	10	14	15	15	15		
513	14	0	21	-11	11	5	6	8	7	18	16		
514	14	-14	24	7	25	19	7	10	8	14	16		
515	25	9	19	11	1	17	-33	15	25	24	21		
516	13	-7	20	-1	10	4	-3	7	11	12	13		
517	2	7	22	-7	12	-1	1	10	8	7	13		
518	13	8	10	5	6	10	2	12	12	6	16		
519	1	12	10	0	6	-11	6	11	12	11	17		
520	8	8	1	3	9	-11	11	3	14	15	16		
521	7	5	7	4	9	12	8	8	13	9	22		
522	18	5	14	18	6	16	1	-4	11	13	10		
523	13	8	19	4	13	-5	2	12	5	-1	9		
524	19	8	5	9	10	-9	-1	3	1	17	10		
525	11	-3	-8	16	5	18	9	11	4	-1	22		
MEAN	11	1	13	5	9	4	2	9	11	11	13		
S.D.	5.6	8.3	8.2	8.6	7.2	9.6	9.6	4.7	5.8	5.4	5.4		
N	25	25	25	25	25	25	25	25	25	25	25		
					: Data	Unavailab	ole						

^aWeight gains compared to the previous period



	I	NDIVID	UAL W	EIGHT	GAIN (G	rams) ^a		
STUDY: 152	GR DC	OUP: 3	-M .0 (mg	base/	SEX kg/day)	: MALE	 	
					J. 1	TOTAL		
	ANIMAL #	DAY 162	DAY 169	DAY 176	DAY 182	GAIN		
	501	4	1	5	8	437		
	502	-2	3	15	-5	378		
	503	-2		2	-6	360		
	504	14	6	-9	3	394		
	505	-13	- 1	19	-4	384		
	506	9	6	3	-6	397		
	507	10	11	-7	1	410		
	508	3	4	11	-4	404		
	509	3	-3	11	-4	315		
	510	13	-12	-3	12	381		
	511	10	9	7	-2	443		
	512	1	2	15	8	517		
	513	-7	7	-2	0	432		
	514	4	-3	13	6	452		
	515	3	15	1	15	533		
	516	3	5	11	3	379		
	517	11	2	-1	4	406		
	518	10	2 2 7	0	14	432		
	519	-10	7	10	5	345		
	520	3	5	15	16	433		
	521	10	-6	-4		393		
	522	11	10	6		408		
	523	15	16	0		457		
	524	13	10	-15		379		
	525	20	9	10		390		
	MEAN	5	4	5	3	410		
	S.D.	8.0	6.3	8.6	7.2	48.0		
	N	25	25	25	20	25		
				* * * *				

--: Data Unavailable

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period

	[2]			
	153	1:1	2	11
1	ШШ	La		- 11

										ם מ	u u	
INDIVIDUAL WEIGHT GAIN (Grams)												
STUDY:	152			GROUP DOSE:	: 4-M 9.0	(mg bas	se/kg/	SEX: day)	MALE			
ANIMAL #	DAY 8b	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
551	38	38	14	21	8	26	9	19	24	15	11	
552	39	28	16	11	15	22	9	13	12	15	8	
553	38	29	22	22	7	21	5	8	19	-1	7	
554	52	34	28	23	18	23	7	15	7	11	20	
555	35	25	-7	20	-8	21	8	0	-1	29	10	
556	40	22	22	14	9	12	1	9	22	12	3	
557	30	32	30	18	21	36	21	25	19	15	7	
558	38	33	20	17	-10	-3	-18	-27	-16	5	60	
559	53	27	21	17	18	24	5	11	15	13	10	
560	35	18	6	23	29	11	4	8	0	6	4	
561	35	35	18	23	4	24	7	18	9	12	5	
562	50	37	9	36	18	25	12	11	8	21	2	
563	42	27	15	26	22	29	12	12	14	11	.1	
564	36	24	17	17	12	15	10	0	21	16	9	
565	54	31	12	29	9	25	9	17	19	15	4	
566	45	27	24	10	9	37	1	16	17	13	-9	
567	52	27	21	9	20	35	7	14	25	2	26	
568	32	21	18	20	5	5	4	14	-26	-43	17	
569	46	19	18	-43	57	18	21	19	29	7	13	
570	51	31	31	30	19	31	6	25	20	30	10	
571	44	29	31	31	28	26	-5	15	9	18	-91	
572	52	41	15	37	9	20	-9	23	9	11	19	
573	38	41	28	35	13	16	9	20	20	11	6	
574	49	23	8	19	21	22	11	9	8	21	10	
575	41	38	21	26	20	28	23	22	15	14	7	
MEAN	43	29	18	20	15	22	7	13	12	_ 11	7	
S.D.	7.3	6.6	8.7	15.2	12.9	9.3		10.6	12.5	13.3	23.8	
N	25	25	25	25	25	25	25	25	25	25	25	
					: Data	Unavailab	le					

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period $^{\rm b}{\rm Baseline}$ is day 1

n		F	57
In'	101	17	- 11
LILI	101	11	- 1

											00	u u	
					INDI	VIDUA	L WEIG	HT GA	IN (Gram	rs) ^a			
	STUDY:	152			GROUP	: 4-M	· · · ·	se/kg/	SEX:	MALE			
					DOSE:	9.0	(mg ba	se/kg/	(day)				
A	NIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	
	551	12	1	7	-2	19	12	12	12	10	-1	-3	
	552	4	0	8	12	10	-8	5	6	11	14	-12	
	553	3	-26	35	-7	15	5	-13	6	0	9	8	
	554	-8	-11	17	3	17	8	5	5	7	14	8	
	555	1	-2	6	3	7	-3	14	-12	14	17	16	
	556	-2	2	5	15	6	10	5	1	1D	9	7	
	557	13	-8	17	- 13	23	-2	17	4	11	15	6	
	558	34	30	12	7	14	1	-7	-28	C	С	C	
	559	11	5	1D	3	1D	5	9	-6	10	8	-3	
	560	6	-7	3	20	0	11	-3	5	1	10	-1	
	561	- 1	5	10	-2	11	9	9	6	8	5	11	
	562	0	-9	10	10	9	-1	7	3	15	7	16	
	563	4	3	26	-11	16	7	3	8	11	9	8	
	564	1	9	8	-2	6	9	2	13	12	13	7	
	565	10	4	11	0	14	13	-5	8	14	12	-14	
	566	27	-9	-1	0	22	-18	0	24	6	14	9	
	567	15	- 15	21	-4	15	11	3	9	6	16	10	
	568	59	29	18	10	3	-7	2	1	-3	15	24	
	569	2	8	12	-3	20	1	11	4	-6	21	10	
	570	13	-4	26	-1	21	-12	4	21	-4	21	24	
	571	91	30	20	10	2	15	-13	9	16	12	7	
	572	8	-2	23	-6	20	9	-22	22	12	1D	6	
	573	1D	1D	18	-5	16	7	0	9	11	16	11	
	574	5	9	19	-2	19	1	-2	4	7	22	20	
	575	16	-6	13	5	15	2	2	6	- 13	11	1D	
	MEAN	13	2	14	2	13	3	2	6	7	12	8	
	S.D.	21.1	13.4	8.3	8.D	6.5	8.3	8.9	1D.4	7.4	5.3	9.4	
	N	25	25	25	25	25	25	25	25	24	24	24	
				:	Data Unav	ailable	c: Ani	mal Found	d Dead				

 $^{^{\}rm a}$ Weight gains compared to the previous period

STUDY: 152

I	NDIVII	UAL W	EIGHT	GAIN (G	rams) ^a		
 GR	OUP: 4	- M		SEX	: MALE	 	
DO	SE:	1.0 (mg	base/	(kg/day)			
					TOTAL		
ANIMAL #	DAY 162	DAY 169	DAY 176	DAY 182	GAIN		
551	-6	21	14	13	344		
552	8	7	22	3	278		
553	4	-13	15	4			
554	-11			4	222		
		8	8		312		
555	0	-3	5	12	207		
556	9	1	13	5	262		
557	-12	1	15	13	354		
558	С	С	С	С			
559	5	-1	14	2	296		
560	6	3	9	-1	206		
561		13	8	-2	268		
562	-5	11	-20	17	299		
563	4	3	3	8	313		
564	-4	5	6	4	266		
565	7	-96	-4	50	248		
566	-21	9	9	12	273		
567	-7	-3	19	11	345		
568	-12	17	0	-1	222		
569	-7	-4	13	21	307		
570	0	8	19	-1	419		
571	4	-6	0		332		
572	-6	-5	14		310		
573	2	0	-9		333		
574	-2	9	-5		305		
575	11	1	-1		327		
5.5		•			32.		
MEAN	-2	-1	7	9	294		
S.D.	8.3	21.7	10.0	11.9	51.3		
N	24	24	24	19	24		
: Data	Unavaila	ble o	:: Animal	Found Dead			

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period

										200	3 0	
				INDI	VIDUAL	WEIG	HT GAI	CN (Gram	s j			
STUDY:	152			GROUP DOSE:	: 1-F 0 (mg	j base,	/kg/da	SEX:	FEMAL	E		
ANIMAL #	DAY 8b	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
/2/	3/	27	40		· · · · · · · · · · · · · · · · · · ·	,	4/		,			
426	24	23	19	1	5	6	14	16	6	3 6	11	
427	24	27	21	-1	11	18	9	16	10	_	13	
428	29	17	19	10	4	7	5	13	2	10	11	
429	27	17	12	6	8	25	-1	10	5	7	2	
430	33	13	13	10	5	31	-3 -2	17	13	9	-3	
431	14	21	17	6	-1	27	- 2	15	12	0	7	
432	22	17	9	19	-1	23	3	15	9	1	9	
433	33	17	20	9	2	32	0	6	17	8	6	
434	19 27	14	15	5	2	16	12	8	17	3	2	
435		11	22	22		8	13	21	9	2	12	
436	18	19	18	16	11	14	15	11	10	8	12	
437	29	16	9	16	12	2	17	3	16	9	4	
438	18	19	12	0	21	-2	2	17	16	14	10	
439	25	11	8	13	6	15	1	10	13	1	0	
440	27	16	13	12	4	17	1	2	4	5	-6	
441	15	23	9	13	16	11	3 2	8	11	9	10	
442	27	17	7	17	9	11		14	11	2	2	
443	22	12	18	7		17	1	13	12	4	5	
444	9	25	12	14	7	14	10	5	5	10	6	
445	17	11	18	15	0	19	1	11	9	5	2	
446	24	3	20	14	10	10	1.0	15	2	0	9	
447	19	25	12	11	5	25	8	4	18	8	10	
448	16	15	17	12	-3	19	0	6	2	7	10	
449	13	16	9	3	11	15	7	-3	9	4	3	
450	15	27	6	19	-3	13	8	8	3	2	9	
MEAN	22	17	14	11	6	16	5	10	10	5	6	
S.D.	6.4	5.7	4.9	6.2	5.9	8.4	5.8	5.7	5.0	3.7	5.0	
N	25	25	25	25	25	25	25	25	25	25	25	
					: Data l	Jnava i lab	le					

 $^{\rm a}{\rm Weight}$ gains compared to the previous period $^{\rm b}{\rm Baseline}$ is day 1

 				INDI	VIDUA	WEIG	HT GA	IN (Gram	is j ^a			
 STUDY:	152			GROUP DOSE:	: 1-F 0 (mg	g base	/kg/da	SEX:	FEMAL	E		
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	
 426	9	-6	-3	-9	33	10	6	10	4	-2	1	
427	6	-1	-7	-1	16	17	2	8	4	20	-3	
428	3	3	30	-11	-11	1	10	3	4	27	7	
429	11	4	-2	-8	14	5	14	0	-2	10	- 1	
430	12	-4	-1	-11	21	-3	9	7	4	6	12	
431	11	3	-10	4	17	12	0	12	9	3	4	
432	14	10	-10	3	15	10	-2		1	6	0	
433	10	1	-4	9	21	12	10	5	-7	12	4	
434	13	5	-13	- 1	16	9	-2	9	1	10	-8	
435	10	6	-7	-4	24	20	6	2	17	9	2	
436	-6	18	-14	3	17	12	7	11	14	19	20	
437	3	11	-6	1	25	5	3	11	11	3	2	
438	20	6	2	3	15	4	11	12	11	7	11	
439	12	10	-15	11	18	-10	8	8	-2	0	13	
440	0	6	4	6	14	10	4	-6	7	6	-6	
441	10	6	-1	0	14	6	2	-1	9	-2	14	
442	4	5	-10	11	24	-10	10	11	0	-4	8	
443	-1	3	-8	-2	14	2	7	6	7	-3	11	
444	1	-7	17	19	-22	31	-9	3	-3	4	1	
445	7	3	3	-2	10	-1	9	3	5	5	6	
446	9	9	-4	5	17	1	4	6	11	-2	19	
447	14	8	10	4	-4	10	-1	1	5	7	9	
448	-1	0	1	-4	17	0	-7	9	6	-11	4	
449	14	0	-2	-6	22	3	-3	-3	12	-2	10	
450	-1	1	11	- 1	7	10	2	9	16	4	16	
MEAN	. 7	4	-2	1	14	7	4	6	6	5	6	
S.D.	6.3	5.6	10.2	7.2	11.6	8.9	5.8	5.8	6.1	8.3	7.3	
N	25	25	25	25	25	25	25	25	25	25	25	
					: Data	Unavailab	ole					

 $^{^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period

STUDY: 152

 I	NDIVII	OUAL W	EIGHT	GAIN	(Grams) ^a	 	
 GR	OUP: 1	L-F	/>	SE	X: FEMA		
DO	SE: ((mg r	ase/kg	g/day)	Object and Original I		
	2010/2012				TOTAL		
 ANIMAL #	DAY 162	DAY 169	DAY 176	DAY 182	GAIN	 	
426	-21	-3	28	11	196		
427	-10	8	5 2	11	229		
428	-27	5		30	203		
429	-10	7	18	3	181		
430	-6	5 2	9	-2	196		
431	-7	2	19	-2	193		
432	-4	10	11	18	229		
433	5	1	14	7	250		
434	1	4	20	-7	170		
435	-8	5	28	0	259		
436	10	16	14	2 3 -2	295		
437	-11	4	29	3	227		
438	2	5	12 7	-2	246		
439	-10	7	7	2	162		
440	5	8	11	19	183		
441	-11	8	- 1	-6	175		
442	-7	11		-8	181		
443	-18	3	2	8	143		
444	1	5	9	1	168		
445	-2	5 7	4	7	172		
446	-9	6	14		199		
447	14	-2	0		220		
448	2	6	1		124		
449	18	-25	2		127		
450	4	10	-3		192		
MEAN	-4	4	11	5	197		
S.D.	10.5	7.3	9.3	9.5	40.8		
N	25	25	25	20	25		
	:	Data Unav	ailable				

^aWeight gains compared to the previous period

											_	
INDIVIDUAL WEIGHT GAIN (Grams) ³												
STUDY:	152			GROUP	: 2-F	(mg ba		SEX:	FEMAL	E		
				DOSE:	0.5	(mg ba	se/kg/	day)				
ANIMAL #	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
								• • • • • • • • •	ji.			
476	27	15	22	14	5	23	5	16	17	2	12	
477	20	17	14	6	5	25	0	9	6	-1	11	
478	20	13	13	8	12	7	3	10	6	1	9	
479	24	21	11	10	10	18	12	14	1	2	16	
480	29	20	17	8	15	15	8	8	20	-2	19	
481	24	23	6	13	11	21	10	15	14	16	14	
482	20	13	13	14	0	8	12	9	2	3	6	
483	9	19	11	9	-2	11	5	17	5	-3	10	
484	19	16	9	17	6	12	3	8	12	1	10	
485	20	12	12	10	3 4 2 3 7	20	4	12	6	9	2	
486	16	21	9	16	4	15	-6	12	11	- 1	4	
487	29	21	8	15	2	19	5	3	10	4	9	
488	19	22	16	10	3	16	17	9	1	11	4	
489	18	12	15	7	7	7	7	11	2	2	6	
490	24	21	11	19	4	15	10	14	12	9	11	
491	23	21	14	18	9	17	22	15	-13	9	9	
492	22	12	19	14	10	20	0	4	10	7	-3	
493	16	17	15	14	5	21	3	7	4	4	10	
494	15	12	16	11	2	18	1	3	6	4	7	
495	22	24	9	9	5 2 8 -2	20	8	10	6 2	8	11	
496	24	26	16	21	-2	26	21	24	-4	-3	8	
497	22	20	16	15	5	20	3	15	0	14	4	
498	18	18	16	14	-9	18	-1	14	11	10	2	
499	18	12	16	18	18	-3	13	13	7	4	13	
500	24	20	6	16	15	11	8	12	7	3	4	
MEAN	21	18	13	13	6	16	7	11	6	5	8	
S.D.	4.5	4.3	4.0	4.1	6.0	6.5	6.7	4.7	6.9	5.2	4.9	
N	25	25	25	25	25	25	25	25	25	25	25	
					: Data	Unavailab	le					

 $^{^{\}rm a}\text{Weight gains compared to the previous period}$ $^{\rm b}\text{Baseline}$ is day 1

										RA	F	
				INDI	VIDUA	L WEIG	HT GA	IN (Gram	ns) ^a			
STUDY:	152			GROUP DOSE:	: 2-F 0.5	(mg ba	se/kg/	SEX: 'day)	FEMAL	Æ	* • • • • • • •	
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	
476 477	22 -2	3 7	-6 -3	-3 2	28 21	7 -3	19	1 5	10 6	7	1	
478 479	2	2	-5 -5	3	13 17	8	-2 -2	6 2	6 23	1 -9	-8 0	
480 481 482	8	-6 -6 0	-1 -3	-2 13	22 20	11 14	5	11	-4 9	5 16	-6 14	
483 484	3 3 7	-1 3	-12	4 10 -8	0 5 27	4 4 5	6 5 5	3 6 10	2 4 7	-5 3 0	-18 8 1	
485 486	12 6	0	-3 -3 5	2	17 13	2 10	10 5	-1 10	3	8	-2 3	
487 488 489	2 8 4	-4 -8 1	5 3 3	-5 4 -3	18 26 14	-9 -7 3	10 13 -1	8 4 15	-5 15 -2	7 4 2	-1 -6 -1	
490 491	9	-3 2	10 -4	6	19 17	2	9	1	11 4	7 5	3 -5	
492 493 494	5 0 2	3 5 5	-2 -5 -4	7 11 1	18 13 14	-2 -1 3	-5 -3 -4	11 0 10	8 18 5	10 2 5	8 -4 -4	
494 495 496	-6 8	3 -1	-3	6 -7	19 16	3 9	1 -11	-3 8	2 -4	4	13	
497 498	10	11	-4 -10	-1 6	8 11	8	-4 7	10	-3 4	11	10	
499 500	14 8	5	-2 3	7	5 3	9 10	1 -2	8	12 9	5 11	7	
MEAN S.D. N	6 5.6 25	4.6 25	-2 4.8 25	5.4 25	15 7.2 25	5.6 25	6.7 25	5 4.7 25	6.9 25	5.1 25	7.3 25	
					: Data	Unava i lab	ole					

^aWeight gains compared to the previous period

STUDY: 152

I	1	Λ	K	77
L		[2]		

INDIVIDUAL WEIGHT GAIN (Grams) GROUP: 2-F SEX DOSE: 0.5 (mg base/kg/day) SEX: FEMALE ANIMAL # DAY 162 DAY 169 DAY 176 DAY 182 GAIN -9 -3 -12 -5 -3 -2 -2 -6 -15 -3 -3 -5 -3 -7 -1 -2 -4 -2 - --3 MEAN

10.4

41.9

7.1

4.6

--: Data Unavailable

5.2

S.D.

^aWeight gains compared to the previous period

	INDIVIDUAL WEIGHT GAIN (Grams) ^a												
-	STUDY: 152 GROUP: 3-F SEX: FEMALE DOSE: 2.0 (mg base/kg/day)												
					DOSE:	2.0	(mg ba	se/kg/	day)				
		h											
	ANIMAL #	DAY 8D	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
	526	23	28	16	22	13	7	22	22	7	5	9	
	527	13	20	14	1	10	9	19	-3	3	16	-4	
	528	22	17	9	12	6	22	10	-1	12	5	4	
	529	21	19	14	13	5	10	9	6 5 .	13	8	-5	
	530	21	12	10	16	-5	12	17	5 .	14	0	-2 5	
	531	20	16	12	14	- 1	18	-3	11	1	-3	5	
	532	28	26	8	22	0	30	10	21	16	5	7	
	533	22	22	15	21	4	20	15	15	6	15	12	
	534	24	20	23	16	-1	17	15	8	18	8	3	
	535	14	20	11	-6	7	16	2	9	10	2	1	
	536	15	20	15	17	-9	26	-1	9	9	-11		
	537	25	22	10	8	12	17	19	-6	5	8	11	
	538	30	20	21	16	9	9	14	-1	8	11	-1	
	539	24	15	23	12	-4	20	-6	16	15	-5	8	
	540	27	19	11	15	5 0 7	24	0	16	12	9	3	
	541	20	20	10	15	0	20	0	9	7	-1	3	
	542	18	18	19	7	7	15	14	0	16	5	4	
	543	15	26	16	11	0	22	1	17	10	5	3	
	544	16	16	13	17	15	-2	16	7	-1	8	9	
	545	23	14	13	14	3	11	13	9	5	3	5	
	546	19	18	22	19	-4	22	19		16	11	4	
	547	16	17	17	18	2	D	17	6	-2	6	2	
	548	16	13	14	16	3	19	4	13	10	5	0	
	549	19	17	2	18	6	5	7	3 8	6	-2		
	550	17	11	23	14	-8	7	11	8	4	-4	7	
	MEAN	20	19	14	14	3	15	10	8	9	4	3	
	S.D.	4.5	4.2	5.3	6.3		8.0	8.0	7.2	5.5	6.3	5.1	
	N	25	25	25	25	25	25	25	25	25	25	25	
						: Data I	Jnavai lab	le					

 $^{^{\}mbox{\scriptsize a}}\mbox{\scriptsize Weight gains compared to the previous period}$ $^{\mbox{\scriptsize b}}\mbox{\scriptsize Baseline}$ is day 1

												u
				INDI	VIDUAI	WEIG	HT GA	IN (Gram	ıs j ²			
STUDY:	152			GROUP DOSE:	: 3-F		4-	SEX:	FEMAL	E		
				DOSE:	2.0	(mg ba	se/kg/	(day)				
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	
• • • • • • • • • • • • • • • • • • • •												
526	7	-8	0		19	0	14	8	-4	4	16	
527	13	3	-3	0	16	-8	11	-2	4	3	12	
528	5	1	-8	3	20	3	3	11	4	9	-4	
529	7	5	-4	3 7 7	4	3 5 4	3	6	2	0	1	
530	10	8	-11	7	11	4	-3	20	1	8	-2	
531	8	1	4	7	7	3	3	4	4	6	6	
532	12	-8	1	4	12	20	11	17	11		10	
533	1	-1	14	-14	23	12	17	5	6	5	12	
534	4 5 8 3	-2	-4	-3 3	14	6	6	8 2	2	9	-2	
535	5	6	-4	3	6	3	9	2	4	12	- 12	
536	8	15	-10	6	21		10	8	-3		0	
537		-4	4	-4	13	-2	7	10	1		14	
538	11	6	-4	8	7	-5	6	9	2		7	
539	7	7	-29	22	14	6	8	1	13	7	-7	
540	8	2	-14	5	16	8	13	9	5	7	15	
541	9	7		-4	16	5	-2	4	11	9	-9	
542	3	5		9	19	13	6	16		12	10	
543	9	1	_	3	14	8		8	7	5	11	
544	5	-2		15	8	8	9	9	5	15	7	
545	7	4	3	0	8	2	3	9	1		8	
546	-3	8	2	-19	20	20	5	. 11	8		9	
547	5	-1	11	10	-4	- 1		5	-1		9	
548	13	9	-1	10	16		-3		7		7	
549	6	8	2	-5	14	7		-2			1	
550	13	0	2	-5	16	3	0	9	4	3	-4	
MEAN	7	3	-3	3	13	6		7	4	_	5	
S.D.	3.9	5.4	8.6	8.6	6.2	6.8	5.7	5.4	4.3		7.9	
N	25	25	25	25	25	25	25	25	25	25	25	
					: Data	Unavailab	le					

^aWeight gains compared to the previous period

D	Λ	5	7
Π	W	5	

	I	NDIVIDU	AL W	EIGHT	GAIN (Gr	ams) ^a
STUDY: 152	GR DO:	OUP: 3- SE: 2.	F O (ma	base/	SEX kg/dav)	: FEMALE
						TOTAL
	ANIMAL #	DAY 162 DA	Y 169	DAY 176	DAY 182	GAIN
	526	- 11	3	15	-3	241
	527	-4	1	7	1	152
	528	-7	5 2	1	11	175
	529	-8	2	7	1	151
	530	6	1	7	5	172
	531	3	3	-3	5	150
	532	3	-3	6	7	282
	533	-11	-4	19	12	263
	534	0	-8	20	-1	200
	535	6	8	5	8	147
	536	-5	8	28	-7	183
	537	-11	6	16	-2	180
	538	-5	3	2	3	193
	539	-16	16	8	18	193
	540	-4	6	12	-1	228
	541	-4	14	7	6	165
	542	-10		-2	11	
	543	-10	5			212
			2	16	-7	192
	544	-1	6	10	-1	203
	545	-7	1	4	11	166
	546	5	-2	6		235
	547	-3	-6	-4		125
	548	11	7	24		227
	549	-1	7	-3		128
	550	12	2	7		152
	MEAN	-3	3	9	4	189
	S.D.	7.1	5.5	8.5	6.7	40.7
	N		25	25	20	25
	,,			ailable		
		. 040	Unida	0.10010		

³Weight gains compared to the previous period

[1			57
	153	111	17	11
		7	Ш	U

											_	
				INDI	VIDUAI	WEIG	HT GA	I N (Gram	s) ^a			
STUDY:	152			GROUP DOSE:	: 4-F 9.0	(mg ba	se/kg/	SEX: day)	FEMAL	E		
ANIMAL #	DAY 8	DAY 15		DAY 29					DAY 64	DAY 71	DAY 78	
-7.												
576	22	19	9	13	-11	23	0	19	1	-2	8	
577	22	13	11	9	7	6	7	11	-3	3	6	
578	14	20	9	11	8	12	0	9	6	5	3	
579	21	19	8	13	-1	20	5	9	7	4	5	
580	20	18	7	16	-8	14	9	2	7	6	4	
581	10	14	7	8	5	13	6	6	6	5	-1	
582	24	- 1	13	15	-1	15	2	3	8	-4	9	
583	22	14	11	9	11	12	-4	7	9	6	9	
584	15	12	16	11	9	1	8	8	5 2 3	1	3	
585	22	12	16	17	-3	14	15	4	2	1	7	
586	20	17	17	15	1	17	9	8	3	4	7	
587	21	22	4	23	-4	18	-2	14	6	4	6	
588	15	7	8	14	-9	22	-2	6	10	3	1	
589	24	7	16	15	-13	20	3	5	5	2	8	
590	24	16	-1	12	6	18	-6	6	8	2	-2	
591	17	19	16	10	4	9	6	8	8	4	-6	
592	16	12	5	12	5	13	0	6	3	7	4	
593	21	10	7	19	5	13	2	1	11	-2	0	
594	20	6	14	14	0	12	1	3	6	5	0	
595	12	12	13	13	-10	13	6	6	7	8	1	
596	9	23	16	16	-7	22	3	5	7	6	4	
597	22	14	8	13	-9	13	11	3	7	-6	8	
598	28	10	10	14	-7	26	-8	14	5	6	3	
599	18	21	8	15	0	22	7	-16	21	5	4	
600	12	22	20	9	0	19	-4	10	4	5	6	
MEAN	19	14	11	13	-1	15	3	6	6	3	4	
S.D.	4.9	5.9	4.9	3.4	6.9	5.7	5.6	6.2	4.3	3.5	3.8	
N	25	25	25	25	25	25	25	25	25	25	25	
					: Data	Unavailab	le					

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period $^{\rm b}{\rm Baseline}$ is day 1

CEED	R	5	7
		 ш	u

												0
				INDI	VIDUA	L WEIG	HT GA	IN (Gram	s) ^a			
STUDY:	152			GROUP	: 4-F			SEX:	FEMAL	E		
				DOSE:	9.0	(mg ba	se/kg/	(day)				
ANIMAL #	0AY 85	DAY 92	0AY 99	0AY 106	DAY 113	0AY 120	0AY 127	0AY 134	DAY 141	DAY 148	DAY 155	
 				_					_			
576	14	0	-6	3	10	-4	2	11	3	-2	0	
577	9	- 1	-5	0	12	-5	6	4	2	-3	2	
578	4	3	2	_	14	5	-8		-4	4	15	
579	9	-2 2 2	0		16	1		-16	10	10	4	
580	2	2	3	0	7	5	2	-21	11	9	5	
581	1	2	9	-1	8	-5	10	9	-4	2	16	
582	7	-9	13	-9	11	7	1	2	4	3	-1	
583	4	-4	8	-7	9	3	3	2 8 7	0	10	1	
584	8	3	9	-10	10	1	4		-1	3	2	
585	4	-3	6	-1	13	0	4	3	-4	7	4	
586	10	4	-3 -2	1	11	1	4	5	-4	9	-2	
587	6	-2	-2	-7	17	1	-9	18	0	10	- 10	
588	4	-1	5	-9	22	-2	-3	11	-4	7	-3	
589	11	-13	4	0	10	5 -3	0	3	2	0	14	
590	8	-1	9		15	-3	5	5	- 15	13	12	
591	7	3	1	5	6	2 -8	-6	1	1	6	14	
592	2	0	1	11	9	-8	11	0	-1	6	3	
593	5	-49	46	5	5	3	0	-1	4	7	-1	
594	6	4	1	-1	4	7	-9	7	10	-11	13	
595	3	-2	-4	6	13	1	0	5	0	5	9	
596	1	-6	1	7	5	6	-13	11	1	5	-1	
597	-1	3	-4	-5	11	4	-7	8	0	-8	14	
598	3	7	-2	-6	1D	6	1	4	-1	4	3	
599	7	3	0	7	-2	9	-7		0	-2	9	
600	11	-1	3	1	4	6	1	9	-1	0	15	
MEAN	6	- 2	4	-1	10	2	0	4	0	4	5	
S.D.	3.7	10.6	10.1	6.0	5.0	4.4	6.1	8.0	5.3	5.8	7.1	
N	25	25	25	25	25	25	25	25	25	25	25	
					: Data	Unavailab	le			=		

 $^{^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period

		R		5	7
--	--	---	--	---	---

 									ם ם	Щ	
		Ii	NDIVID	UAL W	EIGHT	GAIN (Grams) ^a				
 STUDY:	152	GRO	OUP: 4	-F	h /	SEX	K: FEM	IALE			
		DO	SE: 9	. U (mg	pase/	kg/day)	TOTAL				
 		ANIMAL #	DAY 162	DAY 169	DAY 176	0AY 182	GAIN				
		576	4	3	20	3	162	pie.			
		577	-2	8	-3	9	125				
		578	-8	13	8	-6	139				
		579	-6	8	4	4	146				
		580	4	-2	8	6	136				
		581	1	6	-10	0	123				
		582	6	-2	9	9	134				
		583	-7	9	0	12	155				
		584	-10	10	11	2	138				
		585	-1	3	16	-2	156				
		586	0	4	11	8	177				
		587	1	6	5	-4	142				
		588	1	-2	8	10	119				
		589	-9	1	7	13	140				
		590	0	6	7	0	137				
		591	-3	2	-2	3	135				
		592	-3	11	6	-3	128				
		593	5	-3	1	2	114				
		594	0	-3	8	-3	119				
		595	2	- 5	4	5	125				
		596	8	-3	10	••	136				
		597	-15	2	0		86				
		598	-10	-3	9		126				
		599	13	-10	1		138				
		600	4	1	-1	••	155				
		MEAN	-1	3	5	3	136				
		S.D.	6.5	5.5	6.4	5.5	18.0				
		N	25	25	25	20	25				
			: (Data Unav	ailable						

^aWeight gains compared to the previous period

DRAFT

APPENDIX E INDIVIDUAL FOOD CONSUMPTION DATA

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams) ²													
Cmr	STUDY: 152 GROUP: 1-M SEX: MALE DOSE: 0 (mg base/kg/day) ANIMAL # 0AY 1 b 0AY 8 DAY 15 DAY 22 0AY 29 0AY 36 0AY 43 0AY 50 0AY 57 DAY 64 0AY 71 0AY 78												
510	יותו: דסו	4		GRO	DOP: I	/ma h	200/100	/42	A: MA	LE			
ANTENAL A	any ab	044 0	DAY 4E	DO:	DE: U	(mg b	ase/kg	/day)	04V E7	DAY 41	0AV 71	04V 70	
ANIMAL #	UATI	UATO	CI TAU	DAT ZZ	UAT 29	UAT 30	UAT 43	UAT 50	UAT 37	UAT 04	UALTI	UM; 70	
401	24.7	27.9	30.3	27.3	26.6	22.9	24.6	28.4	30.0	29.3	29.7	30.6	
402	24.2	26.6	29.9	29.3	33.3	25.3	30.9	30.6	36.7	30.3	31.7	36.3	
403	22.8	27.4	25.0	26.1	25.7	23.4	30.7	28.0	33.0	26.7	27.3	27.9	
404	22.2	23.9	24.6	26.6	24.6	25.0	30.9	30.7	31.1	29.9	30.3	9.0	
405	23.8	25.3	25.4	25.7	24.9	25.4	28.9	29.7	30.7	30.0	29.9	30.4	
406	24.5	23.9	25.9	27.9	28.6	28.1	31.6	32.9	30.6	30.6	31.9	31.3	
407	23.5	24.9	26.9	26.9	25.1	23.0	28.0	28.6	24.4	26.7	28-4	29.3	
408	23.5	24.7	27.0	27.6	25.0	25.7	34.9	30.9	32.9	29.1	30.9	31.9	
409	27.0	26.7	27.6	28.4	27.6	33.9	33.1	32.9	32.6	33.0	32.3	31.4	
410	23.3	24.1	25.9	26.1	26.0	25.9	28.4	27.3	27.6	27.1	29.1	30.4	
411	26.2	25.7	24.3	23.7	23.3	23.9	26.3	26.1	26.1	25.3	24.7	25.7	
412	22.7	24.0	24.9	25.3	22.1	27.6	26.0	26.3	26.6	25.6	25.3	26.7	
413	23.2	24.9	26.1	27.0	26.7	26.4	28.6	28.1	27.7	30.6	28.4	33.1	
414	23.8	24.6	26.0	26.3	25.4	30.0	28.7	27.9	30.3	30.7	30.7	31.3	
415	23.7	24.0	24.0	25.0	23.7	25.1	24.7	24.1	23.9	23.6	23.6	25.0	
416	24.2	25.4	27.3	27.9	28.6	27.4	30.6	29.0	30.3	29.0	29.3	31.4	
417	33.0	21.0	22.4	23.3	23.9	28.3	26.0	22.3	25.0	25.0	24.4	26.6	
418	24.3	26.4	28.6	28.6	28.7	28.1	32.4	30.6	31.1	31.4	31.1	31.6	
419	24.8	25.6	25.6	25.3	26.3	26.3	28.1	27.4	28.7	28.0	28.1	28.6	
420	21.5	23.6	24.6	25.0	25.1	24.0	25.3	26.0	28.0	27.3	26.9	28.3	
421	21.7	23.4	24.4	25.4	24.0	22.6	25.0	25.9	24.7	24.1	26.4	27.1	
422	22.3	24.9	26.1	26.6	25.9	29.1	26.3	26.9	28.3	28.9	29.1	30.3	
423	25.2	22.9	23.3	23.6	22.4	22.0	24.0	23.4	25.4	23.3	23.7	25.6	
424	25.5	30.0	32.4	30.6	32.0	31.3	32.7	33.1	34.1	33.6	32.3	35.3	
425	25.5	25.7	27.3	28.1	27.7	29.1	30.9	34.0	34.0	33.1	34.1	35.1	
MEAN	24.3	25.1	26.2	26.5	26.1	26.4	28.7	28.4	29.4	28.5	28.8	29.2	
S.D.	2.26	1.81	2.28	1.80	2.67	2.92	3.06	3.06	3.44	2.96	2.90	5.19	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					: (ata Unav	ailable						

 $^{^{\}rm a}{\rm Calculated}$ daily food consumption for successive periods $^{\rm b}{\rm Baseline}$ is day -6

0	Λ	R	77
Π	Li	4	Ц

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams) ^a													
STUDY: 152 GROUP: 1-M SEX: MALE DOSE: 0 (mg base/kg/day) ANIMAL # DAY 85 DAY 92 DAY 99 DAY 106 DAY 113 DAY 120 DAY 127 DAY 134 DAY 141 DAY 148 DAY 155 DAY 162													
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 162	
401	28.0	26.6	26.4	24.3	23.7	23.9	24.1	22.0	23.0	26.1		23-4	
402	30.4	30.4	28.7	27.0	27_4	28_9	27.6	26.1	27.3	28.9	28.3	26.9	
403	28.1	28.1	26.7	29.6	25.9	27.1	24.7	24.6	24.4	27.7	27.0	25.9	
404	18.0	29.6	28.6	26.9	30_0	30.6	27.9	26.6	26.1	26.7	27.9	25.4	
405	29_0	14.4	20.7	29.9	30.0	29.7	26.9	26.6	24.4	27.4	28.1	28.1	
406	31_4	30.9	29.0	30.1	31.7	15.7	19.6	30.6	30.3	29.6	31.7	28.7	
407	26.3	25.7	25.7	26.4	28.1	28.9	27.3	26.4	28.9	28.4	29.4	26.0	
408	30.1	23.1	24.4	23.6	24.7	27.3	23.6	24.7	26.0	26.7	27.9	25.1	
409	30.7	29.3	30.7	29.6	30.1	30.3	30.4	30.1	25.7	29.7	30.1	29.6	
410	30.6	28.6	29.0	27.9	29.1	29.7	27.0	27.6	28.0	29.0	29.6	27.6	
411	25.3	25.7	25.1	23.1	23.4	23.7	22.9	24.3	23.1	25.3	25.6	23.3	
412	27.3	26.1	25.3	25.4	27.3	25.7	23.6	25.3	26.3	26.1	26.7	24.1	
413	28.3	28.1	27.4	25.4	26.3	27.7	26.1	28.3	27.9	28.9	28.6	26.3	
414	29.7	28.1	28.1	27.6	27.0	27.1	25.4	28.9	29.4	28.0	29.4	25.6	
415	24.9	24.7	23.9	22.7	22.3	22.9	21.9	22.1	22.0	22.7	23.1	21.7	
416	29.7	29.9	28.0	26.4	27.0	28.0	26.6	28.9	25.3	27.6	30.4	27.3	
417	26.1	24.9	24.7	24.1	23.7	24.0	23.3	22.7	23.4	22.7	24.7	18_1	
418	32.0	30.7	31.4	29.7	30.6	31.7	29.1	30.7	30.7	30.9	29.9	29.0	
419	27.0	28.0	28.6	26.7	26.0	26.9	26.0	26.1	26.9	27.3	28.4	25.1	
420	26.3	25.4	26.1	25.0	24.7	25.4	23.9	21.9	20.7	26.9	26.9	26.0	
421	27.9	26.4	27.3	26.3	24.9	25.7	23.4	23.6	24.3	26.0	25.4	24.7	
422	30.3	29.6	28.0	29.1	28.6	28.7	27.6	26.1	27.6	29.9	28.1	23.1	
423	25.6	23.9	23.7	23.9	24.1	25.0	24.6	24.4	22.7	23.9	23.7	25.1	
424	32.9	33.3	33.7	31.1	29.4	31.7	30.3	28.0	28.3	30.6	30.9	30.4	
425	34.3	32.1	32.6	30.0	31.3	32.0	30.0	30.9	30.3	32.7	32.9	32.6	
MEAN	28.4	27.3	27.4	26.9	27.1	27.1	25.8	26.3	26.1	27.6	28.0	26.0	
S.D.	3.27	3.75	2.94	2.51	2.72	3.55	2.73	2.78	2.77	2.43	2.41	2.98	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					:	Data Unav	vailable						

^aCalculated daily food consumption for successive periods

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY:	152	GROUP:		SEX:	MALE
		DOSE:	0 (mg	base/kg/day)	
		ANIMAL # D.	AY 169 D	AY 176 DAY 182	

401 21.9 20.4 23.5 402 28.7 26.0 28.9 403 24.0 24.9 25.0 404 25.3 26.6 26.8 405 26.1 27.9 28.0 406 27.9 27.3 27.5 407 26.4 23.6 26.5 408 25.4 27.7 27.3 409 29.9 30.0 30.5 410 27.7 28.0 27.7 23.3 411 23.4 23.3 412 25.1 26.7 27.8 29.0 413 24.3 26.4 414 28.2 26.4 26.0 415 20.1 20.6 22.3 416 25.6 29.6 29.8 417 19.6 24.7 26.0 418 28.9 29.9 31.0 23.7 25.0 419 27.8 420 26.6 24.6 26.3 421 23.3 23.6 422 26.3 27.9 423 22.1 24.3 424 32.1 30.7 30.7 30.1 425 MEAN 25.6 26.3 27.2 3.03 2.84 2.30 S.D. 25 25 20 --: Data Unavailable

^aCalculated daily food consumption for successive periods

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams) a OY: 152 GROUP: 2-M SEX: MA DOSE: 0.5 (mg base/kg/day) DAY 1^b DAY 8 DAY 15 DAY 22 DAY 29 DAY 36 DAY 43 DAY 50 DAY 57 STUDY: 152 SEX: MALE ANIMAL # DAY 64 DAY 71 DAY 78 30.0 30.9 25.1 25.6 25.9 24.7 25.1 28.4 28.4 28.6 23.4 23.7 25.6 25.1 452 23.4 25.3 26.3 23.3 22.4 20.6 24.1 25.6 453 23.8 25.4 25.7 25.6 23.6 22.4 25.9 27.3 29.9 29.0 29.4 30.3 29.1 454 24.8 26.9 29.9 29.1 31.0 31.3 26.3 23.4 28.7 26.4 26.3 455 23.0 23.7 25.3 26.9 26.3 25.3 27.3 31.0 33.0 31.3 33.0 30.0 456 22.2 25.0 25.1 24.9 25.3 28.1 28.6 29.0 28.0 28.7 28.9 24.3 457 22.8 29.3 30.3 30.1 28.7 28.6 30.6 32.0 31.9 31.4 32.6 30.6 458 23.8 25.6 30.9 30.9 30.9 27.7 26.6 25.6 25.6 26.3 30.0 30.1 459 22.5 23.3 23.9 27.3 27.4 27.6 24.3 24.4 23.4 26.1 26.1 26.0 460 26.5 23.4 26.0 28.9 29.9 24.4 25.4 24.6 24.7 27.9 28.6 30.4 461 25.6 24.8 23.9 25.1 28.0 28.4 28.4 27.3 29.6 28.7 26.1 25.0 462 24.8 27.7 27.7 27.0 26.1 26.9 28.0 30.6 32.9 32.1 32.4 33.6 463 23.8 27.7 27.3 27.3 33.3 27.3 28.3 28.9 29.3 30.0 27.3 30.4 25.3 464 25.9 27.1 27.4 29.4 27.4 28.3 27.7 31.9 30.6 30.7 31.6 465 20.8 21.9 23.0 23.6 24.7 24.1 25.1 25.6 26.3 26.3 26.6 26.4 29.4 466 26.2 28.3 27.3 28.1 29.3 26.7 30.1 28.9 29.4 29.6 31.0 467 23.0 10.9 13.3 18.9 18.1 20.0 22.0 23.7 24.7 24.3 24.4 26.6 468 25.3 25.7 23.9 26.9 28.9 28.6 24.7 25.1 24.9 30.4 29.6 29.7 469 23.7 22.9 23.1 24.0 25.6 24.1 25.9 27.6 29.1 28.0 29.7 30.0 23.8 19.1 19.4 470 21.1 21.6 20.3 22.6 23.1 22.0 21.9 23.6 471 23.0 25.1 26.9 23.3 28.4 28.6 27.7 24.0 26.4 25.9 27.1 27.0 472 22.3 23.4 25.1 26.7 26.6 25.0 27.1 27.6 28.6 27.1 28.4 27.7 473 25.2 26.1 28.4 30.7 32.1 31.0 32.0 31.6 33.4 33.7 34.0 36.3 474 25.2 26.4 26.1 26.3 27.3 27.4 28.6 28.6 28.6 28.4 30.4 29.6 475 25.8 22.7 29.1 24.1 26.1 26.3 34.7 30.7 30.0 32.0 32.1 33.1 24.3 29.4 MEAN 24.3 24.9 25.8 27.1 29.2 28.5 29.3 26.2 25.3 28.4 S.O. 2.01 3.58 3.15 2.32 3.56 2.71 2.63 2.59 2.56 2.52 2.85 2.63 25 25 25 25 25 25 25 25 25 25 24 25 --: Data Unavailable

 $^{^{\}rm d}\text{Calculated daily food consumption for successive periods }^{\rm b}\text{Baseline}$ is day -6

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)a													
STUDY: 152 GROUP: 2-M SEX: MALE DOSE: 0.5(mg base/kg/day) ANIMAL# DAY 85 DAY 92 DAY 99 DAY 106 DAY 113 DAY 120 DAY 127 DAY 134 DAY 141 DAY 148 DAY 155 DAY 162													
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 162	
451	31.0	29.4	28.9	27.7	26.4	28.6	28.6	26.0	29.0	29.3	25.3	25.4	
452	25.3	24.3	25.7	24.3	25.4	24.0	25.3	24.3	25.3	26.4	25.6	24.7	
453	30.0	27.6	28.4	26.6	27.3	28.4	28.1	26.9	27.1	27.6	28.0	26.3	
454	31.7	27.4	26.7	28.0	25.3	29.0	27.1	26.7	26.3	28.7	29.3	25.6	
455	31.6	28.6	28.6	27.7	25.1	30.3	29.1	29.4	33.0	31.7	32.6	27.1	
456	28.6	24.9	25.9	24.1	24.0	24.6	24.3	24.0	27.4	26.9	25.7	26.9	
457	28.9	28.0	29.0	27.3	27.0	28.9	29.1	26.6	27.6	28.6	28.6	28.0	
458	29.7	26.4	29.0	27.1	26.6	27.1	27.7	27.3	26.6	29.0	28.3	28.0	
459	26.0	22.9	26.1	23.6	24.9	25.4	24.7	25.3	25.1	19.6	27.4	23.1	
460	29.1	27.7	27.6	27.0	27.6	27.6	26.7	27.9	28.6	18.4	26.4	24.3	
461	28.4	27.9	27.9	24.7	25.1	26.0	24.7	25.4	27.3	27.7	27.0	23.7	
462	31.0	31.1	29.1	28.4	29.7	29.0	28.7	28.0	30.0	29.9	29.3	28.1	
463	29.6	37.4	27.1	30.7	28.7	27.1	27.1	28.1	28.6	29.0	27.0	22.9	
464	30.4	28.7	28.0	26.6	28.4	29.6	29.6	29.1	28.4	29.3	29.6	26.3	
465	25.3	25.0	25.4	24.4	26.1	25.9	25.1	26.7	25.9	26.0	24.3	23.9	
466	31.4	28.4	29.9	30.3	28.9	28.0	26.4	27.6	27.9	29.6	30.7	26.9	
467	25.7	24.6	23.7	23.4	23.7	23.9	21.0	22.9	24.9	26.0	23.1	21.4	
468	29.6	28.9	29.3	29.1	29.4	27.3	26.9	27.4	27.7	29.3	31.1	28.3	
469	30.1	13.7	30.3	25.9	28.7	27.9	27.0	26.6	26.9	27.3	28.1	25.6	
470	22.4	22.9	22.0	21.1	21.9	22.9	22.0	21.9	21.9	22.6	22.4	18.7	
471	27.4	23.1	26.4	26.6	27.6	26.4	24.3	27.1	30.4	27.9	28.4	28.9	
472	25.7	27.9	24.3	24.7	26.9	27.3	27.1	23.9	25.3	26.0	26.4	24.6	
473	35.4	35.1	37.1	34.0	32.3	32.4	30.7	29.0	37.0	36.4	36.4	37.3	
474	29.4	29.1	30.0	27.1	28.0	26.3	27.3	26.3	27.3	28.3	28.4	25.1	
475	32.1	14.4	33.1	37.0	36.0	33.3	32.0	29.7	29.1	33.1	29.9	31.4	
MEAN	29.0	26.6	28.0	27.1	27.2	27.5	26.8	26.6	27.8	27.8	28.0	26.1	
S.D.	2.80	5.07	3.04	3.39	2.87	2.47	2.53	2.01	2.89	3.72	2.98	3.51	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					:	Data Unav	ailable						

 $^{{}^{\}rm a}{\rm Calculated}$ daily food consumption for successive periods

						الا	JL
	INDIVIDUA	DAIL					is)a
STUDY: 152	GROUP DOSE: ANIMAL #	0.5 (mg ba	se/kg/d DAY 18 2	SEX:	MALE	
				10000			
	451 452 453	27.4	28.6	20.8			
	452	22.7	25.4	26.0			
	453	13.7	9.0	14.5			
	454	22.3	27.3	27.8			
	455	26.0	28.3	29.2			
		26.3					
		26.4 28.6					
		24.9					
		24.9		29.0			
	461	23.6	22.3	26.2			
	462	28.0	27 9	29.5			
	463	28.0 26.4 27.9	24.4	26.7			
	464	27.9	26.4	27.8			
	465	25.0	25.7	26.5			
	466	27.4	26.9	27.5			
		23.7	22.9				
	468	28.7	24.7	28.0			
	469	25.9	26.4	25.8			
	470	20.6	19.6	22.2			
	471	26.0	24.9				
	472	24.7	25.0				
	473	34.1 25.9	33.4				
	474	25.9					
	475	30.4	30.0	• •			
	MEAN	25.7	25.2	25.9			
	S.D.	3.70	4.29	3.49			
	N	25	25	20			
		·-: Data Ur	nava i labl	.e			

^aCalculated daily food consumption for successive periods

	 				B.		
		CONSUMPTION	(Grams)	а		G	

STUDY: 152 GROUP: 3-M DOSE: 2.0 (mg base/kg/day) ANIMAL# DAY 1 ^b DAY 8 DAY 15 DAY 22 DAY 29 DAY 36 DAY 43 DAY 50 DAY 57 DAY 64 DAY 71 DAY 78 501 20.8 21.4 22.9 24.3 23.9 23.0 24.7 26.6 26.0 25.6 27.3 28.3 502 23.7 22.6 21.6 28.4 24.7 23.4 25.6 25.4 27.3 26.1 25.7 31.4 503 23.2 24.4 24.9 26.3 25.6 24.6 27.7 27.4 28.6 29.1 28.9 29.6 504 22.0 23.9 23.7 24.6 23.3 25.6 24.6 27.7 27.4 28.6 29.1 28.9 29.6 505 23.0 25.0 26.3 26.9 25.7 24.3 25.6 24.7 25.9 27.0 26.3 25.7 26.4 506 24.5 24.6 24.7 27.0 26.3 25.6 29.1 27.1 28.9 29.6 28.3 28.7 507 25.0 26.3 27.0 28.4 28.7 27.4 30.0 28.7 29.7 29.3 27.1 28.9 508 22.5 24.1 25.4 26.4 24.3 23.1 25.1 25.4 26.0 26.7 28.6 29.6 509 24.8 25.6 26.1 26.6 24.1 22.0 24.7 26.0 26.7 26.4 25.9 510 22.2 24.4 25.9 24.7 23.7 20.9 24.4 24.1 22.0 24.7 24.0 24.3 26.1 27.1 511 26.0 24.0 24.3 25.1 25.6 26.1 26.6 24.1 22.0 24.7 24.0 24.3 26.1 27.1 512 26.7 27.4 29.0 30.1 31.3 33.0 33.0 31.0 31.9 30.7 32.0 33.4 31.1 513 22.7 24.0 25.1 27.3 26.6 27.3 29.0 29.0 30.0 30.1 29.4 31.3 514 27.3 24.0 24.4 27.9 28.0 28.7 30.7 29.4 28.6 28.9 29.7 29.7 516 24.0 23.4 27.9 28.0 28.7 30.7 29.4 28.6 28.9 29.7 29.7 517 22.0 22.6 26.1 26.6 26.1 26.6 27.3 29.0 29.0 30.0 30.1 29.4 31.3 518 22.7 24.0 25.1 27.3 26.6 27.3 29.0 29.0 30.0 30.1 29.4 31.3 519 22.2 24.4 27.9 28.0 28.7 30.7 29.4 28.6 28.9 28.9 29.7 29.7 516 24.0 23.4 25.9 25.0 24.6 27.3 26.1 27.1 27.3 27.6 27.1 517 22.0 22.6 26.4 27.9 28.0 28.7 30.7 29.4 28.6 28.9 28.9 29.7 29.7 518 22.0 23.6 26.1 24.6 25.1 27.6 25.1 25.6 26.9 27.1 27.3 27.6 27.1 519 24.8 26.3 26.3 26.3 26.3 25.6 39.0 26.3 25.7 28.0 27.7 27.7 27.7 28.0 27.7 27.7 28.0 27.7 27.7 28.0 27.7 28.0 27.7 29.7 52.2 28.5 25.1 28.5 26.7 27.1 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 28.8 28.8 28.0 27.7 23.4 25.1 24.6 26.7 27.4 26.1 27.0 27.7 28.0 27.7 28.0 27.7 29.7 522 28.5 25 25 25 25 25 25 25 25 25 25 25	INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)													
ANIMAL # DAY 1 D DAY 8 DAY 15 DAY 22 DAY 29 DAY 36 DAY 43 DAY 50 DAY 57 DAY 64 DAY 71 DAY 78 501 20.8 21.4 22.9 24.3 23.9 23.0 24.7 24.6 25.6 25.4 27.3 26.1 25.7 31.4 503 23.2 24.4 24.9 26.3 25.6 24.6 27.7 27.4 28.6 29.1 28.9 29.6 504 22.0 23.9 23.7 24.6 23.3 25.6 24.7 25.9 27.0 26.3 25.7 26.4 505 23.0 25.0 26.3 26.9 25.7 24.3 25.9 27.0 26.3 25.7 26.4 506 24.5 24.6 24.7 27.0 26.3 25.6 29.1 27.1 28.9 29.6 28.3 28.7 507 25.0 26.3 27.0 28.4 28.7 27.4 30.0 28.7 29.7 29.2 20.3 27.1 28.9 508 22.5 24.1 25.4 26.4 24.3 25.1 25.1 25.1 25.4 26.0 26.7 28.6 29.6 509 24.8 25.6 26.1 26.6 24.1 22.0 24.7 24.0 24.7 24.7 25.9 25.9 510 22.2 24.4 25.9 24.7 23.7 20.9 22.4 24.1 24.0 24.3 26.1 27.1 511 26.0 24.0 24.3 25.1 25.6 25.4 28.7 30.1 30.3 32.3 512 26.7 27.4 29.0 30.1 31.3 33.0 33.0 31.9 30.7 32.0 33.4 31.1 513 22.7 24.0 24.4 25.9 28.0 28.7 27.3 29.0 29.0 30.0 30.1 29.4 31.3 514 27.3 24.0 24.4 25.9 28.0 28.7 29.0 29.0 29.0 30.0 30.1 29.4 31.3 514 27.3 24.0 24.4 25.9 28.0 28.7 29.0 29.0 29.0 30.0 30.1 29.4 31.3 514 27.3 24.0 24.4 25.9 28.0 28.7 29.0 29.0 29.0 30.0 30.1 29.4 31.3 514 27.3 24.0 24.4 25.9 25.0 24.6 25.1 27.3 26.6 27.3 29.0 29.0 30.0 30.1 29.4 31.3 514 27.3 24.0 24.4 25.9 25.0 24.6 27.7 29.4 28.6 28.9 28.9 29.7 29.7 29.7 516 24.0 23.4 25.1 24.3 24.7 24.0 25.7 24.6 27.1 27.3 27.6 27.1 515 25.0 26.4 27.9 28.0 28.7 30.7 29.4 28.6 28.9 28.9 29.7 29.7 29.7 516 24.0 23.4 25.1 24.6 25.1 24.0 25.7 29.4 28.6 28.9 28.9 29.7 29.7 29.7 516 24.0 23.4 25.1 24.6 25.1 25.6 26.9 27.1 27.0 27.3 27.4 28.0 27.4 28.0 27.3 27.4 28.0 27.4 28.0 27.3 27.4 28.0 27.3 27.4 28.0 27.4 28.0 27.3 27.4 28.0 27.7 28.0 27.3 27.4 28.0 27.3 27.4 28.0 27.4 28.0 27.3 27.4 28.0 27.3 27.4 28.0 27.7 28.0 27.3 27.4 28.0 27.7 29.7 29.7 52.3 26.5 25.9 26.7 30.9 27.9 30.0 28.6 28.6 28.7 28.9 30.0 31.4 25.0 27.7 29.3 52.0 23.5 24.3 27.0 29.0 25.3 23.4 25.1 27.7 28.0 27.7 26.7 27.1 28.0 27.4 28.0 27.7 29.3 25.0 22.9 25.1 23.6 26.7 27.4 26.4 26.4 27.0 26.7 27.4 28.0 27.7 29.3 25.0 27.4 28.0 27.7 28.0 27.7 28.0 27.7 29.7 29.7 29.7 29.3 20.2 23.5 24.3 25.9	STUDY: 152 GROUP: 3-M SEX: MALE													
501 20.8 21.4 22.9 24.3 23.9 23.0 24.7 24.6 26.0 25.6 27.3 28.3 502 23.7 22.6 21.6 28.4 24.7 23.4 25.6 25.4 27.3 26.6 29.1 28.9 29.6 504 22.0 23.9 23.7 24.6 25.3 23.3 23.6 24.7 25.9 27.0 26.3 25.7 26.4 505 23.0 25.0 26.3 26.9 25.7 24.3 25.9 24.3 27.1 26.0 27.9 28.3 506 24.5 24.6 24.7 27.0 26.3 25.6 24.7 27.0 26.3 25.0 26.3 26.9 25.7 24.3 25.9 24.3 27.1 28.9 29.6 28.3 28.7 507 25.0 26.3 27.0 28.4 28.7 27.4 30.0 28.7 29.7 29.3 27.1 28.9 508 22.5 24.1 25.4 26.4 24.3 23.1 25.1 25.4 26.0 26.7 28.6 29.6 509 24.8 25.6 26.1 25.4 26.4 24.1 22.0 24.7 24.0 24.7 24.7 25.4 25.9 510 22.2 24.4 25.9 24.7 25.9 24.7 24.0 24.7 24.0 24.7 25.4 25.9 510 22.2 24.4 25.9 24.7 25.1 25.4 26.0 26.7 28.6 29.6 509 24.8 25.6 26.1 25.1 25.6 25.4 28.7 30.1 29.7 30.1 30.3 32.3 512 26.7 27.4 29.0 30.1 31.3 33.0 33.0 31.9 30.7 32.0 33.4 31.1 513 22.7 24.0 24.3 25.1 25.6 26.6 26.7 28.6 29.6 26.7 28.6 29.6 26.7 28.6 26.1 26.6 26.1 25.6 26.1 25.6 26.1 25.6 26.1 25.6 26.1 25.6 26.1 25.6 26.1 25.6 26.1 25.6 26.1 25.6 25.4 28.7 30.1 29.7 30.1 30.3 32.3 512 26.7 27.4 29.0 30.1 31.3 33.0 33.0 31.9 30.7 32.0 33.4 31.1 513 22.7 24.0 24.0 24.3 25.1 25.1 25.6 25.4 28.7 30.1 29.7 30.1 30.3 32.3 514 27.3 24.0 24.4 25.9 25.0 26.6 27.3 29.0 29.0 30.0 30.1 29.4 31.3 514 27.3 24.0 24.4 25.9 25.0 26.6 27.3 29.0 29.0 30.0 30.1 29.4 31.3 514 27.3 24.0 24.4 25.9 25.0 26.6 27.3 29.0 29.0 30.0 30.1 29.4 31.3 514 27.3 24.0 24.4 25.9 25.0 26.6 27.1 24.0 23.4 25.1 24.3 24.0 24.6 27.9 28.0 28.7 30.7 29.4 28.6 28.9 28.9 29.7 29.7 516 24.0 23.4 25.1 24.3 24.0 24.6 25.1 25.6 26.9 29.4 28.6 28.9 29.7 29.7 29.7 516 24.0 23.4 25.1 24.6 25.1 24.6 25.1 25.6 26.9 27.4 24.0 25.7 24.0 25.7 24.0 25.7 24.0 25.3 27.6 26.9 29.6 519 24.8 26.3 26.3 26.3 26.3 26.3 26.7 24.0 25.7 24.0 25.7 24.0 25.7 24.0 25.7 24.0 25.7 24.0 25.3 27.0 27.4 28.0 27.3 27.4 28.0 27.7 28.0 27.3 27.4 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 28.0 27.7 29.7 29.7 29.7 25.3 26.5 25.0 22.9 25.1 23.6 26.7 26.4 26.7 27.1 26.4 26.9 29.1 27.6 29.3 22.3 23.0 22.3 23.0 25.1 26.4 26.7 27.	ANTMAL #	DAY 1b	DAY S	DAY 15	DO:	SE: Z	. U (mg	base/	kg/day	7) DAY 57	DAY 64	DAY 71	DAY 78	
502 23.7 22.6 21.6 28.4 24.7 23.4 25.6 25.4 27.3 26.1 25.7 31.4 503 23.2 24.4 24.9 26.3 25.6 24.6 27.7 27.4 28.6 29.1 28.9 29.6 504 22.0 23.9 23.7 24.3 25.9 27.0 26.3 25.7 26.4 505 23.0 25.0 26.3 26.9 25.7 24.3 25.9 24.3 27.1 26.0 27.9 28.3 506 24.5 24.6 24.7 27.0 26.3 25.6 29.1 27.1 28.9 29.6 28.3 28.7 507 25.0 26.3 27.0 28.4 28.7 29.1 27.1 28.9 29.6 28.3 28.7 508 22.5 24.1 25.4 26.4 24.3 23.1 25.1 25.1 25.1 25.1 26.7 24.0 26														
502 23.7 22.6 21.6 28.4 24.7 23.4 25.6 25.4 27.3 26.1 25.7 31.4 503 23.2 24.4 24.9 26.3 25.6 24.6 27.7 27.4 28.6 29.1 28.9 29.6 504 22.0 23.9 23.7 24.6 24.7 25.9 27.0 26.3 25.7 26.4 505 23.0 25.0 26.3 26.9 25.7 24.3 25.9 24.3 27.1 26.0 27.9 28.3 506 24.5 24.6 24.7 27.0 26.3 25.6 29.1 27.1 28.9 29.6 28.3 28.7 507 25.0 26.3 27.0 28.4 28.7 29.7 29.3 27.1 28.9 29.6 28.3 28.7 508 22.5 24.1 25.4 26.4 24.3 23.1 25.1 25.1 25.1 26.1 22														
\$\begin{array}{c c c c c c c c c c c c c c c c c c c	501	20.8	21.4	22.9	24.3	23.9	23.0	24.7	24.6	26.0	25.6	27.3	28.3	
504	502	23.7	22.6	21.6	28.4	24.7	23.4	25.6	25.4	27.3	-26.1	25.7	31.4	
505 23.0 25.0 26.3 26.9 25.7 24.3 25.9 24.3 27.1 26.0 27.9 28.3 506 24.5 24.6 24.7 27.0 28.4 28.7 27.4 30.0 28.7 29.7 29.3 27.1 28.9 29.6 28.3 28.7 508 22.5 24.1 25.4 26.4 24.3 23.1 25.1 25.4 26.0 26.7 28.6 29.6 509 24.8 25.6 26.1 26.6 24.1 22.0 24.7 24.0 24.7 25.4 25.9 26.7 25.9 26.7 26.7 24.0 24.7 24.7 25.4 25.9 26.7 25.4 28.7 30.1 30.0 26.7 28.6 29.6 29.6 510 22.2 24.4 25.9 24.7 23.7 20.9 22.4 24.1 24.1 24.1 24.1 25.9 25.0 28.4 28.7	503	23.2	24.4	24.9		25.6	24.6	27.7	27.4	28.6	29.1	28.9	29.6	
506	504	22.0			24.6		23.6			27.0		25.7		
507	505	23.0		26.3	26.9		24.3	25.9		27.1	26.0	27.9		
508	506				27.0	26.3	25.6			28.9	29.6			
509	507	25.0		27.0	28.4		27.4	30.0		29.7	29.3	27.1		
510												28.6		
511 26.0 24.0 24.3 25.1 25.6 25.4 28.7 30.1 29.7 30.1 30.3 32.3 512 26.7 27.4 29.0 30.1 31.3 33.0 33.0 31.9 30.7 32.0 33.4 31.1 513 22.7 24.0 25.1 27.3 26.6 27.3 29.0 29.0 30.0 30.1 29.4 31.3 514 27.3 24.0 24.4 25.9 25.0 24.6 27.3 26.1 27.1 27.3 27.6 27.1 515 25.0 26.4 27.9 28.0 28.7 30.7 29.4 28.6 28.9 28.9 29.7 29.7 516 24.0 23.4 25.1 24.3 24.7 24.0 25.7 24.6 24.0 30.1 25.0 25.3 517 22.0 22.6 26.1 24.6 25.1 25.6 26.9 27.1 27.0 27.3 27.4 28.0 25.3 518 20.7 23.4 25.1 24.1 24.0 24.9 29.4 26.7 28.3 27.6 26.9 29.6 519 24.8 26.3 26.3 26.3 25.6 39.0 26.3 25.7 28.0 27.3 27.0 27.4 520 23.5 24.3 27.0 29.0 28.1 27.3 27.7 28.0 27.7 26.7 27.1 28.0 521 28.5 26.1 26.0 26.7 27.4 26.1 27.0 25.7 26.4 29.1 27.6 29.3 521 28.5 26.1 26.0 26.7 27.4 26.1 27.0 25.7 26.4 29.1 27.6 29.3 522 30.7 25.0 22.9 25.1 23.6 26.7 26.4 26.4 27.0 26.9 27.7 29.7 523 26.5 25.9 26.7 30.9 27.9 30.0 28.6 28.6 28.9 30.0 31.4 28.9 30.0 31.4 28.0 524 23.3 22.3 23.0 25.1 26.4 26.7 27.4 26.1 27.0 25.7 26.4 29.1 27.6 29.3 524 23.3 22.3 23.0 25.1 23.6 26.7 26.4 26.4 27.0 26.9 27.7 29.7 29.7 523 26.5 25.9 26.7 30.9 27.9 30.0 28.6 28.6 28.7 28.9 30.0 31.4 52.4 26.3 25.9 24.9 29.0 25.3 23.4 25.1 27.7 29.1 26.4 26.9 26.4 30.1 525 25.9 24.3 25.9 24.9 29.0 25.3 23.4 25.1 27.7 29.1 26.4 26.9 26.4 30.1 525 25.9 24.3 25.9 24.9 29.0 25.3 23.4 25.1 27.7 29.1 26.4 26.9 26.4 30.1 525 25.0 25.9 26.5 25.9 26.5 25.9 26.7 30.9 27.9 27.0 27.6 27.7 29.1 26.4 26.9 26.4 30.1 525 25.0 25.9 26.7 30.9 27.9 27.0 25.3 27.0 27.6 28.4 30.1 525 25.0 25.9 26.7 30.9 27.9 27.9 30.0 28.6 28.6 28.7 28.9 30.0 31.4 52.4 26.7 27.7 29.1 26.4 26.9 26.4 26.4 26.9 26.4 26.4 26.9 26.4 26.4 26.9 26.4 26.4 26.9 26.4 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.9 26.9 26.9 26.9 26.9 26.9 26.9					26.6	24.1						25.4	25.9	
512						23.7								
513						25.6								
514														
515						26.6								
516						25.0			26.1				27.1	
517						28.7								
518														
519 24.8 26.3 26.3 25.6 39.0 26.3 25.7 28.0 27.3 27.0 27.4 520 23.5 24.3 27.0 29.0 28.1 27.3 27.7 28.0 27.7 26.7 27.1 28.0 521 28.5 26.1 26.0 26.7 27.4 26.1 27.0 25.7 26.4 29.1 27.6 29.3 522 30.7 25.0 22.9 25.1 23.6 26.7 26.4 26.4 27.0 26.9 27.7 29.7 523 26.5 25.9 26.7 30.9 27.9 30.0 28.6 28.6 28.7 28.9 30.0 31.4 524 23.3 22.3 23.0 25.1 26.4 26.7 27.6 27.7 28.0 27.6 28.4 30.1 525 24.3 25.9 24.9 29.0 25.3 23.4 25.1 27.7 29.1 26.4 26.9 26.4 MEAN 24.3 24.5 25.3 26.6 25.8 26.1 27.1 26.8 27.6 27.8 27.8 28.8 S.D. 2.36 1.47 1.68 <td></td>														
520 23.5 24.3 27.0 29.0 28.1 27.3 27.7 28.0 27.7 26.7 27.1 28.0 521 28.5 26.1 26.0 26.7 27.4 26.1 27.0 25.7 26.4 29.1 27.6 29.3 522 30.7 25.0 22.9 25.1 23.6 26.7 26.4 26.4 27.0 26.9 27.7 29.7 523 26.5 25.9 26.7 30.9 27.9 30.0 28.6 28.6 28.7 28.9 30.0 31.4 524 23.3 22.3 23.0 25.1 26.4 26.7 27.6 27.7 28.0 27.6 28.4 30.1 525 24.3 25.9 24.9 29.0 25.3 23.4 25.1 27.7 29.1 26.4 26.9 26.4 MEAN 24.3 24.5 25.3 26.6 25.8 26.1 27.1 26.8 27.6 27.8 27.8 28.8 S.D. 2.36 1.47 1.68 1.91 1.96 3.84 2.25 1.98 1.77 1.89 1.83 1.88 N 25 25			23.4											
521 28.5 26.1 26.0 26.7 27.4 26.1 27.0 25.7 26.4 29.1 27.6 29.3 522 30.7 25.0 22.9 25.1 23.6 26.7 26.4 26.4 27.0 26.9 27.7 29.7 523 26.5 25.9 26.7 30.9 27.9 30.0 28.6 28.6 28.7 28.9 30.0 31.4 524 23.3 22.3 23.0 25.1 26.4 26.7 27.6 27.7 28.0 27.6 28.4 30.1 525 24.3 25.9 24.9 29.0 25.3 23.4 25.1 27.7 29.1 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.9 26.4 26.9 26.9 26.4 26.9 26.9 26.4 26.9 26.9 26.4 26.9 26.9 26.9 26.9 26.9 26.9 26.9 26.9						25.6								
522 30.7 25.0 22.9 25.1 23.6 26.7 26.4 26.4 27.0 26.9 27.7 29.7 25.3 26.5 25.9 26.7 30.9 27.9 30.0 28.6 28.6 28.7 28.9 30.0 31.4 25.4 23.3 22.3 23.0 25.1 26.4 26.7 27.6 27.7 28.0 27.6 28.4 30.1 25.5 24.3 25.9 24.9 29.0 25.3 23.4 25.1 27.7 29.1 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.0 26.0 26.0 26.0 26.0 26.0 26.0 26.0						28.1								
523														
524 23.3 22.3 23.0 25.1 26.4 26.7 27.6 27.7 28.0 27.6 28.4 30.1 25.5 24.3 25.9 24.9 29.0 25.3 23.4 25.1 27.7 29.1 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.4 26.9 26.0 26.0 26.4 26.9 26.0 26.0 26.0 26.0 26.0 26.0 26.0 26.0														
525 24.3 25.9 24.9 29.0 25.3 23.4 25.1 27.7 29.1 26.4 26.9 26.4 MEAN 24.3 24.5 25.3 26.6 25.8 26.1 27.1 26.8 27.6 27.8 27.8 28.8 S.D. 2.36 1.47 1.68 1.91 1.96 3.84 2.25 1.98 1.77 1.89 1.83 1.88 N 25 25 25 25 25 25 25 25 25 25 25 25 25												30.0		
MEAN 24.3 24.5 25.3 26.6 25.8 26.1 27.1 26.8 27.6 27.8 27.8 28.8 S.D. 2.36 1.47 1.68 1.91 1.96 3.84 2.25 1.98 1.77 1.89 1.83 1.88 N 25 25 25 25 25 25 25 25 25 25 25 25 25						26.4								
S.D. 2.36 1.47 1.68 1.91 1.96 3.84 2.25 1.98 1.77 1.89 1.83 1.88 N 25 25 25 25 25 25 25 25 25 25 25 25 25	525	24.3	25.9	24.9	29.0	25.3	23.4	25.1	27.7	29.1	26.4	26.9	26.4	
S.D. 2.36 1.47 1.68 1.91 1.96 3.84 2.25 1.98 1.77 1.89 1.83 1.88 N 25 25 25 25 25 25 25 25 25 25 25 25 25	MEAN	24.3	24.5	25.3	26.6	25.8	26.1	27.1	26.8	27.6	27.8	27.8	28.8	
N 25 25 25 25 25 25 25 25 25 25 25 25 25														

 $^{^{\}rm a}{\rm Calculated}$ daily food consumption for successive periods $^{\rm b}{\rm Baseline}$ is day -6

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)2													
STUDY: 152 GROUP: 3-M SEX: MALE DOSE: 2.0 (mg base/kg/day) ANIMAL # DAY 85 DAY 92 DAY 99 DAY 106 DAY 113 DAY 120 DAY 127 DAY 134 DAY 141 DAY 148 DAY 155 DAY 162													
	DAY 05	DAY 02	00	DO	SE:	2.0 (mg	base/	kg/day	T)	DAY 4/0	DAY 455	DAY 4/3	
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 102	
501	28.0	24.0	25.4	25.1	27.3	25.9	24.7	27.6	27.4	28.1	29.6	24.1	
502	28.9	25.6	24.9	32.7	27.9	27.1	24.9	29.4	29.4	26.1	26.6	22.6	
503	27.4	28.1	25.9	26.3	29.1	22.3	22.1	24.7	25.9	28.4	25.4	23.3	
504	24.9	24.1	25.6	25.7	23.7	25.0	24.3	24.1	24.0	26.4	26.0	24.1	
505	28.1	25.7	25.3	25.6	25.9	25.7	25.7	26.3	27.7	28.1	29.6	22.7	
506	30.3	27.4	26.7	26.1	28.7	28.3	26.1	28.1	28.6	27.3	29.9	25.9	
507	28.7	24.1	25.7	28.0	29.0	28.3	25.1	26.7	27.0	27.7	29.6	26.3	
508	28.0	24.7	27.6	25.4	29.9	25.9	25.1	28.3	27.9	27.6	28.9	25.9	
509	24.9	22.0	23.0	21.1	23.7	23.6	23.4	23.9	26.1	25.6	25.9	21.4	
	25.9	24.9	25.0	25.7	25.0	24.1	23.6	25.1	25.9	26.4	26.1	25.3	
	31.7	28.4	27.7	28.4	27.9	27.1	27.4	28.1	29.0	28.7	27.3	27.3	
512	30.7	27.4	28.7	27.9	27.7	28.0	29.3	30.6	30.1	31.0	30.7	27.1	
513	30.9	27.4	28.3	25.4	26.3	25.9	26.1	27.7	27.1	29.6	29.9	25.9	
514	29.4	25.6	27.7	28.0	31.9	30.3	28.4	28.1	27.9	27.7	28.6	26.9	
515	31.4	27.1	29.3	29.0	29.1	30.0	21.7	26.3	32.4	33.4	32.1	30.0	
516	24.3	21.0	22.7	21.1	22.9	23.0	21.1	23.3	24.0	24.4	24.9	22.9	
517	26.1	24.6	31.0	24.1	27.0	24.4	24.3	25.1	25.7	24.7	25.4	25.4	
518	37.4	26.4	26.4	28.9	28.7	28.3	26.7	27.0	28.0	28.0	27.6	25.1	
519	27.3	26.3	25.0	24.7	24.7	19.7	24.0	25.6	25.9	25.4	27.0	23.9	
520	27.0	25.3	25.4	23.4	26.3	21.7	24.4	25.9	27.1	27.1	27.4	26.3	
521	31.7	28.3	28.1	31.1	29.0	29.6	26.1	30.3	29.1	29.7	29.9	28.9	
522	31.4	30.3	27.1	31.6	27.3	27.4	25.9	25.3	26.1	28.9	27.9	27.6	
523	31.9	29.7	29.1	29.1	27.6	27.3	27.9	27.6	29.4	27.7	27.7	29.4	
524	31.0	28.0	25.9	25.6	25.3	24.7	22.0	22.9	24.7	27.3	26.7	25.7	
525	26.7	25.0	20.9	26.0	27.7	27.7	26.6	28.0	25.4	27.1	27.6	27.6	
MEAN	29.0	26.1	26.3	26.6	27.2	26.1	25.1	26.6	27.3	27.7	27.9	25.7	
S.D.													
N	25	25	25	25		25	25	25	25	25	25	25	
					:	Data Unav	ailable						

^aCalculated daily food consumption for successive periods

		A	5	7
_		00	U	LI

	INDIVIDUAL	DAILY	FOOD (CONSUMPTI	ON (Grams) ^a
STUDY: 152	GROUP: DOSE: ANIMAL # DAY			SEX: 'kg/day) 182	MALE
	501	24.1 2	5.0 2	7.5	

25.9 23.9 31.2 502 23.9 25.7 503 22.5 504 24.1 22.9 25.2 505 23.6 27.1 28.2 506 27.9 26.4 24.5 507 27.0 26.9 26.7 508 27.3 27.4 28.3 509 21.1 23.4 22.7 510 22.4 23.3 25.7 511 28.4 26.7 30.2 512 26.3 30.0 31.2 513 25.7 25.3 26.5 514 25.6 29.3 26.6 515 30.7 29.3 31.7 23.4 516 22.9 25.2 23.7 517 25.1 24.0 518 24.7 27.3 30.2 519 24.7 25.3 26.7 520 26.1 26.7 30.8 521 26.1 28.0 --26.0 522 26.6 523 28.4 28.3 26.9 524 24.1 525 27.1 29.1 MEAN 25.6 27.4 26.2 2.02 S.D. 2.09 2.92 25 25 N 20 --: Data Unavailable

^aCalculated daily food consumption for successive periods

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams) ^a												
STUDY: 152 GROUP: 4-M SEX: MALE DOSE: 9.0 (mg base/kg/day) ANIMAL # DAY 1 DAY 8 DAY 15 DAY 22 DAY 29 DAY 36 DAY 43 DAY 50 DAY 57 DAY 64 DAY 71 DAY 78												
ANIMAL #	DAY 1 b	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78
551	21.8	19.1	20.3	19.1	20.0	17.1	21.6	20.3	21.9	22.6	23.1	23.4
552	23.2	20.7	18.3	19.7	18.4	19.4	19.7	19.9	20.6	19.4	22.1	22.4
553	22.8	19.7	19.7	20.6	18.6	17.6	19.7	19.4	20.7	22.9	18.7	21.9
554	21.3	22.4	21.6	22.4	22.6	21.4	23.6	24.9	23.4	22.4	24.0	27.1
555	23.3	20.3	19.4	15.9	16.9	13.0	16.6	16.7	15.0	14.1	19.0	20.7
556	24.8	24.3	19.7	20.3	21.0	17.9	20.3	20.7	19.9	20.6	21.1	20.9
557	23.3	21.0	20.3	21.4	21.1	21.1	24.4	25.1	26.9	24.9	26.3	25.7
558	23.8	20.6	20.7	21.6	20.9	17.3	17.3	12.4	10.3	8.1	10.4	22.1
559	24.7	23.0	20.3	21.3	21.0	21.1	24.7	22.1	22.6	22.1	24.0	24.1
560	21.2	20.1	17.3	17.1	17.9	20.1	19.0	21.3	19.1	17.1	19.0	17.0
561	23.0	21.0	21.6	20.3	21.0	20.0	22.9	22.6	22.0	22.0	22.0	25.6
562	22.8	22.7	22.4	19.7	22.1	21.9	22.7	23.3	23.1	21.9	23.0	24.1
563	25.3	23.3	22.0	20.4	20.7	22.6	25.7	26.1	24.1	24.9	23.9	26.0
564	22.0	20.7	18.7	18.4	19.1	18.6	21.0	21.6	18.9	20.1	21.1	22.4
565	25.5	25.3	22.0	20.6	22.0	22.3	24.3	23.6	25.0	24.1	25.1	23.9
566	23.3	21.4	19.4	18.7	18.4	18.9	22.6	21.7	20.0	21.1	21.4	20.9
567	24.0	25.6	20.6	19.7	19.0	20.6	23.1	24.0	21.9	22.0	21.4	25.6
568	27.0	21.4	18.1	17.0	17.4	17.3	18.3	17.4	17.6	11.9	5.1	12.7
569	29.2	24.9	20.0	22.1	12.6	23.7	22.1	26.6	23.6	24.0	24.0	26.0
570	23.2	23.0	22.1	22.9	22.9	21.3	24.9	26.0	26.4	25.7	28.0	29.3
571	25.7	25.3	22.6	24.7	24.3	25.6	26.7	24.9	24.3	24.9	26.9	12.4
572	23.8	25.6	23.6	22.3	23.7	23.3	21.4	23.4	22.4	22.4	23.4	25.6
573	22.3	21.4	21.9	22.0	22.3	21.9	21.1	24.0	23.4	23.9	25.1	23.6
574	27.2	27.7	23.9	19.3	19.3	22.0	23.3	27.4	22.7	22.7	24.7	25.6
575	20.3	21.6	21.0	20.0	19.6	20.6	26.6	24.6	23.7	22.0	23.0	24.1
MEAN	23.8	22.5	20.7	20.3	20.1	20.3	22.1	22.4	21.6	21.1	21.8	22.9
S.D.	2.05	2.25	1.68	1.99	2.51		2.74	3.44	3.56	4.22	4.90	4.00
N	N 25 25 25 25 25 25 25 25 25 25 25 25 25											
					: (Data Unava	ailable					

 $^{^{\}text{8}}\text{Calculated daily food consumption for successive periods}$ Baseline is day -6

											A F	7	
•••••]	INDIVI	DUAL	DAILY	FOOD	CONSU	APTION	(Grams)			
STU	JDY: 1	52		GR	OUP:	4-M 9.0 (mg DAY 120	haga	SI	EX: MA	LE			
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 162	
554													
551	24.0	21.0	20.6	19.9	23 - 9	23.7	23.9	23.9	23.6	24.6	21.4	21.0	
552	24.0	19.7	19.7	19.7	21.4	21.6	20.1	20.9	22.0	27.4	19.9	22.0	
553	20.6	15.4	19.1	18.3	23.1	22.4	19.0	18.1	18.7	21.0	20.1	18.7	
554	24.0	18.9	22.1	21.3	25.9	25.7	22.7	24.0	24.4	26.6	24.7	23.0	
555	19.1	16.0	17.6	16.7	18.4	16.7	20.7	4.0	17.6	20.1	21.6	22.6	
556 557	21.4	18.4	19.7	21.4	21.0	21.0	20.9	20.4	21.4	25.3	22.1	21.4	
557	28.3	22.6	26.0	20.9	25.9	24.0	26.3	25.4	26.1	28.0	27.6	23.1	
558	25.9	20.7	20.3	19.0	22.0	20.1	18.6	16.1	C	25 4	C	C 24 7	
559	23.1	21.1	22.3	20.9	24.4	23.3	23.0	22.3	23.0	25.1	19.9	21-3	
560	20.1	15.4	16.9	17.3	18.1	19.9	17.9	18.9	16.4	20.3	19.0	17.9	
561 562	22.4 25.7	20.4 17.9	29.4	25.7	22.9	22.9	23.4	23.0	23.7	29.3	24.3	21-4	
			20.7	28.9	21.7	21.7	21.6	22.1	25.1	24.1	24.4	23.6	
563 564	24.7	21.7	24.9	20.6	26.4	26.4	24.1	23.7	26.4	32.9	26.9	23.3	
565	21.6 25.1	20.1	20.7	25.6	19.9	22.0	20.4	22.3	21.6	23.1	23.4	20.0	
566	23.9	22.0 18.7	24.9	23.4	24.1	25.6	23.0	24.6	24.6	28.0		22.4	
567	25.0		17.6	19.0	21.7	15.6	16.6	23.6	21.0	22.7	22.3	18.0	
568	26.4	19.7 21.0	24.7	25.6	23.6	23.4	21.6	21.0	23.7	27.0	24.7	20.9	
			19.7	20.4	19.7	17.7	18.3	18.3	16.0	17.7	22.9	17.6	
569	23.7	23.4	23.7	25.6	25.9	24.7	23.9	24.1	21.7	29.6	26.7	22.7	
570	29.9	24.4	26.6	25.9	29.0	24.1	25.4	28.1	27 - 4	29.9	31.3	25.7	
571	30.6	30.4	29.0	26.9	26.1	27.4	25.7	26.4	27.3	29.3	29.3	26.7	
572	24.3	24.0	24.9	23.7	27.3	25.9	21.7	24.3	25.1	27.0	26.4	21.6	
573	24.6		23.7	22.1	25.4	25.1	23.3	25.1	25.3	27.6	27.1	24.9	
574	23.9	24.1	24.7	25.0	26.0	25.1	23.7	23.1	25.4	28.1	28.9	24.6	
575	23.4	21.1	23.0	21.0	23.6	23.9	23.4	21.9	18.0	23.0	25.4	23.1	
MEAN	24.2	20.9	22.5	22.2	23.5	22.8	22.0	21.8	22.7	25.7	24.3	22.0	
S.D.	2.72	3.27	3.41	3.24	2.82	3.01	2.55	4.61	3.36	3.68	3.30	2.38	
N	25	25	25	25	25	25	25	25	24	24	24	24	
				and Date	. Ilmaunii.	hla c	. Animal	Found Dos	d				

25 25 25 25 25 -: Data Unavailable c: Animal Found Dead

 $^{^{\}rm d}$ Calculated daily food consumption for successive periods

***************************************		INDIVIDUA	L DAIL	Y F00	D CONSUMP	TION (Grams)	1	
STUDY:	152	ANIMAL #	9.0(mg bas	se/kg/day)			
		551	22.9	24.9	26.3			
		552	21.7	24.6	23.8			
		553	18.0	21.1	23.0			
		554	22.4	23.3	24.8			
		555	18.3	18.6	27.2			
		556	22.3	22.9	23.7			
		557	23.7	25.4	28.2			
		558	С	С	С			
		559	22.1	23.9	25.0			
		560	19.4	19.1	19.8			
		561	22.9	22.6	24.8			
		562	24.7	19.6	24.5			
		563	22.6	25.0	29.7			
		564	21.9	22.0	23.5			
		565	13.6	11.1	28.2			
		566	19.9	20.6	24.5			
		567	21.9	23.9	26.0			
		568	20.4	20.7	22.7			
		569	21.0	24.9	30.5			
		570	27.4	29.3	33.3			
		571	25.0	26.7				
		572	22.4	25.6	• •			
		573	23.1	24.3				
		574	25.6	25.7				
		575	21.D	22.D	• •			
		MEAN	21.8	22.8	25.8			
		S.D.	2.80	3.58	3.17			
		N	24	24	19			
		: Data Unava	ailable	c: Anir	mal Found Dead			

^aCalculated daily food consumption for successive periods

			I	NDIVI	DUAL I	AILY	FOOD (CONSUM	PTION	(Grams) ^a			
STU	DY: 15	2		GRO	OUP: 1	-F	200/k0	SE (day)	X: FE	MALE			
ANIMAL #	DAY 1 b	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
426	22.2	20.9	19.0	18.6	17.1	17.0	18.1	18.3	20.1	19.3	19.6	24.0	
427	27.0	18.9	20.0	34.0	22.1	16.1	18.4	20.9	20.4	20.7	19.3	26.6	
428	19.0	18.0	18.6	18.7	17.6	17.7	16.9	18.6	19.6	19.9	18.7	23.9	
429	18.0	22.6	19.3	20.3	16.7	16.1	17.4	18.6	19.6	20.3	20.0	23.4	
430	17.2	19.0	18.6	19.9	18.7	18.6	21.6	20.6	21.9	21.9	19.7	25.9	
431	32.3	21.6	19.7	19.3	16.6	15.0	17.6	17.6	19.4	18.1	17.6	18.7	
432	18.8	18.1	16.9	17.9	19.1	24.7	17.6	19.1	20.0	19.4	19.1	22.4	
433	18.0	23.1	17.4	18.9	18.7	16.7	19.4	19.6	19.3	21.0	21.7	20.0	
434	16.2	17.7	16.6	16.6	14.6	15.1	16.1	18.4	19.1	18.0	18.7	18.3	
435	22.3	21.4	18.1	19.9	20.1	16.4	17.4	19.9	21.6	19.9	20.1	20.4	
436	24.7	20.1	22.6	22.1	19.7	27.7	19.1	23.6	22.3	21.4	20.0	22.3	
437	18.2	17.3	17.4	17.3	17.1	15.4	15.7	18.3	19.3	20.0	18.3	17.7	
438	16.0	15.3	16.1	16.0	15.4	17.1	15.6	15.3	17.6	19.7	20.3	20.7	
439	18.5	18.9	16.7	17.1	17.1	16.3	16.7	17.9	18.0	18.3	17.4	18.7	
440	14.5	15.9	16.0	17.6	17.1	16.7	17.1	16.6	15.6	17.0	15.4	14.7	
441	48.5	24.4	27.9	21.4	21.3	20.9	- •	34.7	29.6	27.6	29.1		
442	18.2	20.4	19.0	16.9	18.3	18.4	24.6	18.1	20.9	19.7	18.1	19.0	
443	14.8	15.9	15.3	16.9	14.4	17.4	14.9	15.7	17.6	16.9	16.3	17.3	
444	19.8	19.3	17.6	22.0	16.9	18.0	18.0	18.0	20.4	20.3	17.0	18.1	
445	14.7	14.9	14.7	16.6	15.3	14.3	15.0	16.0	17.4	17.0	16.6	17.0	
446	16.5	16.7	16.7	18.1	15.6	18.3	17.0	18.3	20.1	17.4	17.0	19.1	
447	20.0	15.6	17.6	18.0	16.1	16.6	17.9	19.7	18.7	19.4	19.1	19.9	
448	17.8	15.4	15.9	16.6	15.3	16.0	16.7	15.7	16.3	16.1	17.1	17.4	
449	25.5	17.3	17.3	18.0	20.1	22.9	18.0	18.3	18.0	18.0	18.0	22.3	
450	15.5	15.6	17.9	16.0	17.0	16.4	17.3	16.3	18.3	16.6	17.7	19.0	
MEAN	20.6	18.6	18.1	19.0	17.5	17.8	17.7	19.0	19.6	19.4	18.9	21.2	
S.D.	7.21	2.69	2.65	3.59	2.05	3.14	2.07	3.77	2.65	2.34	2.59	5.52	
N	25	25	25	25	25	25	24	25	25	25	25	25	
					: 1	Data Unav	ailable						

 $^{^{\}rm a}{\rm Calculated}$ daily food consumption for successive periods $^{\rm b}{\rm Baseline}$ is day -6

				INDIVI	DUAL :	DAILY	FOOD	CONSU	IPTION	(Grams) ^a			
CTIT	IDV. 1	E 0		CD.	OIID.	1 0		CI	v. pp	MATE			
510	JDY: 1	52		DO	CE.	0 (mar h	350 /ke	7/30.0	SA: FE	MALLE			
ANIMAL #	DAY OF	044 03	DAY 00	04Y 106	OAY 117	0 (1119 1	044 127	SI g/day) DAY 134	DAY 1/1	DAY 4/9	04V 1EE	0AV 163	
ANIMAL #	DAT 65	DAT 92	DAT 99	UAT 100	UAT 113	UAT 120	UAT 127	DAT 134	DAT 141	DAT 140	UAT 133	UAT 102	
426	19.4	16.4	17.9	16.1	20.7	20.9	22.3	20.0	18.6	17.7	17.6	10.7	
427	18.7	20.6	16.4	16.1	21.1	21.0	19.3	22.9	21.3	22.0	20.3	15.0	
428	19.4	19.0	20.3	19.9	14.1	17.0	18.1	18.7	19.3	22.9	22.0	13.7	
429	19.6	24.3	21.9	18.6	18.7	18.1	18.7	19.1	18.3	20.0	16.6	14.4	
430	20.9	22.9	18.6	16.6	20.4	19.4	19.3	19.0	19.3	21.0	21.0	16.7	
431	18.7	16.0	14.7	13.7	16.1	18.9	18.3	18.3	18.3	18.4	17.6	12.9	
432	22.1	17.7	16.9	17.7	19.3	21.0	19.1	22.1	19.3	20.4	19.6	15.4	
433	21.3	19.6	18.0	18.3	20.6	22.3	22.1	21.9	17.6	22.4	20.7	18.9	
434	20.1	16.1	14.1	14.0	18.0	17.7	16.9	16.3	17.1	16.7	15.4	13.9	
435	19.7	18.0	18.0	14.0	19.7	22.3	20.6	19.7	21.0	21.3	19.3	14.1	
436	19.7	19.1	16.3	18.6	20.4	21.9	22.1	22.1	24.7	25.6	25.0	22.3	
437	19.9	17.1	15.6	14.4	19.3	19.6	17.9	18.7	18.4	18.7	17.0	13.0	
438	23.6	19.6	19.4	17.1	19.7	19.0	19.9	20.3	20.6	20.3	20.6	17.9	
439	20.7	18.3	16.4	16.7	19.1	17.7	17.6	18.0	17-1	18.6	18.9	14.3	
440	20.1	15.6	15.7	17.7	18.0	17.0	15.9	16.3	16.0	16.6	15.0	14.6	
441	35.7	45.9	35.3	40.3	37.9	26.3	20.7	28.0	26.7	33.9	39.3	28.9	
442	20.7	21.3	16.7	17.6	21.4	18.6	18.1	19.7	17.7	18.0	17.6	14.3	
443	17.6	13.9	13.6	12.6	15.1	16.0	15.1	15.3	16.6	15.6	15.3	11.1	
444	18.9	14.0	17.6	22.4	10.7	21.0	19.7	18.1	15.9	17.1	16.7	15.6	
445	17.9	16.6	15.0	14.4	15.4	16.4	16.3	15.7	16.7	17.4	17.0	15.6	
446	20.9	20.3	16.7	19.6	18.0	18.4	18.1	31.6	23.6	18.9	17.7	14.4	
447	20.3	20.3	18.9	16.9	16.1	17.7	17.0	18.1	14.0	16.4	20.7	16.7	
448	17.0	16.3	15.0	14.9	15.9	17.1	16.4	15.6	15.6	16.0	15.0	15.0	
449	22.4	19.4	17.4	18.7	19.3	19.4	18.3	16.6	17.7	21.3	19.7	19.7	
450	20.1	15.4	19.4	18.1	18.4	19.3	20.4	19.6	22.3	21.4	21.1	19.9	
MEAN	20.6	19.3	17.8	17.8	18.9	19.4	18.7	19.7	18.9	19.9	19.5	16.0	
S.D.	3.47	6.11	4.14	5.21	4.69	2.33	1.95	3.74	3.00	3.83	4.81	3.81	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					:	Data Unav	ailable						

 $^{{}^{\}rm d}\text{Calculated daily food consumption for successive periods}$

STUDY: 152

 INDIVIDUAL	DAILY	FOOD	CONSUMPT	ION (Grams)
 GROUP: DOSE: ANIMAL # D	1-F 0 (mg AY 169 DA	base/k	SEX: g/day) ay 182	FEMALE
 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441	12.7 16.7 16.0 15.7 17.6 14.3 18.0 19.4 15.4 17.3 23.7 16.9 19.1 16.7 16.1 33.6	19.6 19.4 17.3 18.1 20.3 17.0 20.7 21.3 17.9 20.7 24.6 19.0 20.1 18.0 19.0 29.0	25.2 22.8 23.8 21.8 21.5 19.5 22.7 24.0 17.7 21.3 22.2 18.7 19.2 18.3 20.3 31.8 18.2	24
448 449 450 MEAN S.D. N	15.7 15.9 17.0 14.9 15.0 13.0 18.6	15.6 19.4 14.6 16.0 16.9 20.4 19.0 3.14 25	21.1	

^aCalculated daily food consumption for successive periods

_				I	NDIVI	DUAL I	AILY	FOOD (CONSUM	PTION	(Grams)			
-	COLL	DV. 10	2		CD	OTID. C			SE	יסק .	MATE:			
	510.	DY: 15	2		DO	DOP: 2	5 (ma	hage /	7 le ce / cl a se	A: PEI	MUE			
	ANIMAL #	DAY 1b	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	kg/day	DAY 57	DAY 64	DAY 71	DAY 78	
	476	25.0	19.6	18.3	19.1	20.1	18.3	22.1	21.1	21.7	24.7	20.6	23.3	
	477	16.8	17.1	16.3	17.6	16.4	16.0	24.4	18.3	18.3	17.3	17.4	21.6	
	478	14.8	15.3	14.4	15.9	15.1	15.9	17.9	16.0	17.0	15.7	16.1	17.9	
	479	22.3	18.4	19.0	18.3	18.7	18.0	21.0	20.7	21.0	19.4	18.9	22.0	
	480	19.0	19.4	16.6	18.1	18.1	16.4	19.7	18.6	19.3	20.6	19.1	23.0	
	481	18.0	18.6	18.6	17.9	19.6	20.1	22.0	20.3	23.0	23.1	24.9	26.0	
	482	21.7	15.3	14.1	15.0	16.9	13.7	14.7	15.3	16.1	15.4	14.9	16.7	
	483	18.0	14.1	15.1	15.6	15.3	16.0	17.1	17.6	17.7	16.3	17.7	17.0	
	484	17.2	16.0	15.6	16.6	16.9	15.3	18.1	16.9	17.6	17.6	17.0	18.7	
	485	16.8	18.6	21.1	15.1	14.6	15.0	17.7	17.0	17.9	16.4	17.1	18.1	
	486	19.0	18.6	16.9	17.0	16.0	15.1	17.0	15.3	16.9	15.3	15.1	18.3	
	487	24.5	19.4	19.3	19.7	19.7	17.1	19.6	20.7	20.9	19.9	20.4	21.9	
	488	19.8	17.0	18.0	18.4	18.0	16.4	19.6	21.6	21.0	20.0	21.1	21.3	
	489	18.5	16.3	16.6	17.7	17.1	16.1	18.0	17.0	19.6	17.6	17.7	19.3	
	490	17.0	18.1	17.9	17.0	16.7	15.7	19.1	19.3	20.4	22.9	20.7	22.3	
	491	24.7	17.7	20.4	19.0	18.4	17.3	20.1	20.4	22.4	16.7	16.6	18.7	
	492	17.3	18.3	17.3	18.9	18.1	18.0	20.6	23.7	20.6	19.6	18.1	24.6	
	493	20.3	20.0	19.0	30.3	17.4	17.3	20.1	19.9	18.7	18.9	18.9	20.4	
	494	17.0	17.4	16.6	17.0	19.1	19.4	17.9	17.3	17.9	19.7	16.6	24.4	
	495	18.3	16.1	16.9	17.9	17.9	16.3	18.6	18.9	19.6	18.9	18.6	18.7	
	496	18.0	18.7	20.6	21.3	20.7	18.7	20.4	22.9	24.9	23.4	18.6	21.1	
	497	19.8	18.4	19.0	19.3	19.0	17.7	19.3	19.0	20.4	18.9	20.3	19.7	
	498	24.8	21.3	20.7	23.6	20.3	18.9	20.0	18.7	19.6	19.1	20.9	22.0	
	499	17.7	17.1	17.1	18.1	19.0	18.1	18.9	18.6	18.3	19.7	19.9	20.6	
	500	18.0	16.7	16.0	16.7	16.7	16.4	19.9	20.1	19.7	20.6	17.3	21.1	
	MEAN	19.4	17.7	17.7	18.4	17.8	16.9	19.4	19.0	19.6	19.1	18.6	20.7	
	S.D.	2.87	1.67	1.94	3.10	1.66	1.53	1.95	2.18	2.08	2.55	2.22	2.44	
	N	25	25	25	25	25	25	25	25	25	25	25	25	
						: (ata Unava	ilable						

 $^{^{\}text{d}}\text{Calculated daily food consumption for successive periods}$ $^{\text{b}}\text{Baseline is day -6}$

]	NDIVI	DUAL	DAILY	FOOD	CONSU	APTION	(Grams)			
STU	JDY: 1	52		GR	OUP:	2-F 0.5(mg DAY 120	base	SI /kg/day	EX: FE	MALE		**********	
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 162	
									• • • • • • • • • • • • • • • • • • • •				
476	21.6	19.1	19.3	16.6	21.9	22.0	21.9	21.0	19.3	22.3			
477	17.9	17.1	15.7	18.3	20.0	18.6	18.3	18.1	18.9	18.6	17.9	18.9	
478	16.4	14.6	14.6	17.0	17.7	17.4	16.7	17.3	17.1	16.7	15.7	15.0	
479	22.3	20.4	18.0	18.0	20.7	21.6	18.0	19.9	21.9	19.6	17.7	15.7	
480	20.9	17.0	17.1	20.3	21.1	22.3	19.0	19.4	19.1	19.4	16.6	16.6	
481	24.7	22.3	17.7	28.1	23.4	23.3	23.0	22.3	22.0	24.1	24.3	22.7	
482	14.7	15.3	14.1	19.1	13.7	14.6	15.0	14.3	14.4	15.1			
483	18.7	15.9	17.3	19.3	17.1	16.9	17.9	18.3	19.3	19.1	19.0	18.9	
484	17.0	15.6	14.4	13.9	17.4	17.0	18.1	18.0	16.9	17.3	17.0	11.3	
485	18.4	16.1	15.0	15.7	18.0	16.1	17.1	16.4	17.6	17.4	15.1	16.7	
486	18.1	15.0	15.4	16.3	16.1	17.9	19.0	17.6	18.1	19.1	16.7	17.9	
487	20.9	17.3	19.3	18.7	21.0	18.7	19.1	20.3	19.7	19.9	19.3	17.4	
488	21.0	17.9	16.9	19.0	22.0	22.1	21.3	21.9	22.4	22.3	18.1	16.0	
489	18.1	16.4	17.3	16.0	17.9	18.4	17.0	20.1	18.1	18.9	16.4	14.7	
490	21.7	19.9	19.7	19.4	20.7	21.0	18.3	20.9	21.7	21.6	20.4	18.3	
491	18.6	17.3	16.1	17.3	20.0	19.1	17.6	19.1	17.9	18.9	16.0	14.0	
492	21.7	18.7	18.4	21.9	21.6	18.3	17.3	19.0	21.0	21.4	23.6	19.3	
493	18.4	18.0	16.7	17.0	19.1	18.7	17.3	17.3	19.3	18.9	17.0	17.1	
494	22.3	28.9	16.6	19.0	17.7	18.7	16.7	19.1	18.3	19.0	19.7	14.4	
495	19.0	19.0	16.6	17.3	20.0	19.4	18.4	17.1	19.3	19.3	18.4	16.9	
496	21.3	21.4	18.7	19.7	20.9	20.1	17.4	19.6	19.4	18.3	21.4	18.7	
497	20.4	20.6	17.6	18.7	18.6	19.9	18.9	19.9	19.6	21.4	22.0	19.6	
498	23.1	24.7	18.1	19.1	20.9	19.7	18.6	20.0	18.6	20.6	17.3	18.6	
499	21.3	20.6	18.3	19.6	18.9	18.1	19.1	17.7	18.6	20.4	19.3	20.0	
500	18.9	21.6	17.6		17.4	18.1	17.0	18.4	18.9	20.3	19.3	16.9	
MEAN	19.9	18.8	17.1	18.6	19.4	19.1	18.3	18.9	19.1	19.6	18.6	17.2	
S.D.	2.32	3.30	1.56	2.67	2.20	2.08	1.72	1.80	1.78	1.95	2.44	2-42	
N	25	25	25	24	25	25	25	25	25	25	23	23	
					:	Data Unav	ailable						

^aCalculated daily food consumption for successive periods

STUDY: 152



INDIVIDUA	L DAIL	Y FOO	D CONSUMP	TION (Grams)a
ANIMAL #	0.5(DAY 169	DAY 176	se/kg/day) DAY 182	: FEMALE
	16.4 17.4 15.9 18.0 18.3 19.9 7.6 17.1 16.3 18.0 18.7 14.9 15.7 14.9 15.7	20.7	22.7 19.3 18.0 23.8 22.2 24.7 16.2 17.8 18.5 18.5 19.0 24.3 24.7 18.0 21.8 20.0 26.3 19.3	
499 500	18.3 18.3	17.3 16.7		

20.9

2.92

20

19.0 1.90

25

--: Data Unavailable

17.5

2.52

MEAN

S.D.

N

 $^{^{\}rm a}\text{Calculated daily food consumption for successive periods}$

			I	NDIVI	DUAL I	AILY	FOOD (CONSUM	PTION	(Grams)			
STI	mv . 15	2		GR	י סוור	- F		SE	x FE	AT.E.			•
010	DI. 13	-		DOS	SE:	0 (mg	hase/	ka/day	1				
STU	DAY 1b	DAY 8	DAY 15	DAY 22	DAY 29	DAY 36	DAY 43	DAY 50	DAY 57	DAY 64	DAY 71	DAY 78	
526	18.3	17.7	20.4	21.9	20.4	19.3	20.7	22.4	22.3	24.1	22.3	21.9	
527	19.2	16.0	18.1	26.9	16.7	17.4	16.6	18.3	17.0	16.7	18.4	18.3	
528	15.8	16.1	16.9	16.7	17.6	16.1	18.7	19.0	17.0	17.9	16.3	18.0	
529	18.5	16.4	17.4	18.1	18.6	17.7	18.3	18.6	18.4	18.1	18.6	17.7	
530	18.2	17.0	17.6	17.6	17.7	16.3	17.4	18.6	19.4	19.7	18.3	18.4	
531	14.8	16.1	17.3	17.4	16.1	16.4	17.1	18.3	18.7	20.1	18.1	21.6	
532	20.8	24.0	20.3	20.6	21.0	16.3	20.1	22.9	22.9	21.3	20.4	22.7	
533	18.3	17.3	18.1	19.1	20.0	17.1	19.7	21.6	21.9	21.4	21.1	20.0	
534	18.0	18.1	18.6	20.3	19.3	17.4	20.7	21.9	21.4	22.9	21.4	22.0	
535	17.2	15.7	17.1	18.9	15.1	27.7	16.6	17.4	17.3	16.6	16.1	17.4	
536	27.3	20.6	17.9	16.7	17.4	20.9	18.9	18.9	20.0	19.7	15.7	17.6	
537	16.8	17.3	17.9	17.6	17.7	19.6	20.4	21.4	17.4	18.4	19.9	21.6	
538	18.2	29.9	37.7	32.9	26.3	27.9	24.4	30.0	23.3	22.9	25.0	30.3	
539	17.8	17.3	17.1	18.9	18.3	17.7	21.1	16.6	19.9	19.6	17.6	20.9	
540	17.8	17.9	18.4	18.4	18.6	17.3	19.6	21.4	21.1	20.0	18.9	21.3	
541	16.2	16.6	16.1	17.4	15.9	15.0	17.0	18.1	17.7	17.3	16.7	20.4	
542	23.0	15.9	16.6	23.6	17.4	16.4	21.4	18.7	19.9	20.3	17.7	22.6	
543	17.8	16.6	19.7	18.9	18.4	17.7	20.4	18.7	20.7	19.3	20.0	20.9	
544	20.0	16.1	17.7	18.7	18.6	18.3	18.1	21.0	20.0	18.9	19.1	21.6	
545	16.3	16.6	15.9	16.7	16.3	15.1	19.3	17.4	18.1	18.1	18.0	20.6	
546	17.0	17.1	18.3	20.4	20.3	18.4	20.7	20.7	21.7	22.1	20.3	21.6	
547	17.8	16.3	15.7	17.6	16.4	15.1	16.6	16.6	16.6	16.3	17.1	16.7	
548	17.0	18.0	16.6	18.9	17.0	30.6	20.7		19.7	19.3	18.0	19.1	
549	18.2	16.6	17.0	17.0	17.3	16.9	18.1	17.1	18.1	17.3	17.4	22.6	
550	17.2	17.9	16.0	19.6	18.6	15.4	18.3	18.4	18.4	17.3	17.7	19.1	
MEAN	18.3	17.8	18.4	19.6	18.3	18.6	19.2	19.7	19.6	19.4	18.8	20.6	
S.D.	2.49	3.06	4.21	3.62		4.12	1.89	2.86	1.97	2.12	2.13	2.73	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					:	Data Unav	ailable						

 $^{^{\}rm a}{\rm Calculated}$ daily food consumption for successive periods $^{\rm b}{\rm Baseline}$ is day -6

]	INDIVI	DUAL 1	DAILY	FOOD	CONSUM	PTION	(Grams) ^a			
CTT	IDV. 1	52		CP	OTTD.	2 _ 🗜		CI	y. PP	MATE			
510	יועני	J 2		70	CE.	3 - L (mc	t hace	/ka/da	in.	PLALIE			
STU ANIMAL #	DAY RS	DAY 02	DAY OO	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	Y / DAY 141	DAY 148	DAY 155	DAY 162	
VILLIUF A		UNI 72	· · · · · · · · · · · · · · · · · · ·									ON1 102	
526	23.6	17.7	16.7	17.7	19.3	19.9	20.0	20.9	19.6	19.9	20.0	16.7	
527	21.1	19.6	18.9	19.3	21.6	16.9	17.9	18.1	18.3	22.7	19.3	17.6	
528	20.9	15.9	13.4	14.9	18.6	16.9	16.7	18.6	16.6	18.9	17.6	13.1	
529	18.4	17.3	16.4	17.0	17.9	18.0	17.3	18.1	16.9	17.6	17.4	13.3	
530	20.6	20.1	16.6	18.7	19.9	18.3	18.4	20.9	19.7	20.7	19.9	18.1	
531	21.6	25.4	27.0	22.7	32.3	17.9	18.1	19.6	32.6	33.7	26.4	28.7	
532	23.1	17.6	16.1	19.4	20.3	23.7	22.1	25.0	23.9	22.7	23.3	20.4	
533	18.6	17.3	19.0	15.9	18.7	21.4	21.7	20.1	20.4	21.0	19.0	15.7	
534	21.1	16.7	15.9	16.6	18.7	19.1	18.7	19.0	19.0	20.9	18.9	16.7	
535	17.7	15.4	17.0	16.0	18.4	18.7	16.6	18.1	17.0	19.1	17.1	16.7	
536	18.3	19-6	17.3	18.0	23.0	22.3	.20.9	22.0	20.6	22.7	2D.1	14.6	
537	18.1	17.7	18.4	17.3	19.4	20.4	18.1	19.7	18.3	20.6	20.6	16.7	
538	22.3	31.6	19.9	25.0	25.1	22.1	20.1	25.0	23.1	28.0	23.9	18.1	
539	20.3	18.3	15.3	16.9	18.6	18.4	18.7	18.1	18.9	21.9	21.7	13.4	
540	21.1	17.0	15.0	14.9	19.7	19.6	21.9	23.0	22.0	23.9	21.7	18.6	
541	19.1	18.7	17.3	20.6	19.4	18.7	17.0	17.6	22.9	22.4	18.4		
542	20.0	17.3	17.7	16.6	20.4	21.1	21.1	22.3	20.4	24.7	23.1	15.9	
543	25.7	17.7	17.9	17.7	20.1	21.6	19.6	18.6	22.9	22.6	23.1	19.3	
544	20.6	22.9	16.3	21.1	24.6	26.4	22.9	24.4	22.6	30.7	21.3	21.6	
545	19.1	16.9	16.9	19.4	18.7	19.3	18.4	18.3	19.1	10.7	19.7	16.D	
546	21.3	18.3	19.1	14.3	18.3	23.9	23.6	22.9	23.6	27.6	24.1	22.1	
547	17.3	16.1	17.0	19.6	16.0	15.7	16.6	17.6	17.7	17.9	16.0	15.4	
548	20.7	19.1	17.9	19.6	21.4	22.7	19.0	16.1	19.9	18.1	18.4	18.9	
549	17.3	19.6	16.6	20.7	17.4	18.1	16.6	17.1	19.4	18.4	18.0	17.9	
550	19.7	18.3	17.0	17.6	17.9	19.3	18.4	19.3	20.3	21.4	18.4	19.1	
MEAN	20.3	18.9	17.5	18.3	20.2	20.0	19.2	20.0	20.6	22.0	20.3	17.6	
S.D.	2.05	3.41	2.44	2.52	3.28		2.09	2.55	3.29	4.63	2.58	3.31	
N	25	25	25	25		25		25	25	25	25	25	
					:	Data Unav	/ailable						

 $^{^{\}rm d}\text{Calculated}$ daily food consumption for successive periods

STUDY: 152

INDIVIDUAL	DAIL	FOOD	CONSUMPT	ION (Grams)
GROUP:	3-F		SEX:	FEMALE
DOSE:	2.0 (m	o base	e/kg/day)	
ANIMAL # D	AY 169 D	AY 176 D.	AY 182	
F2/	40.0	20. /	20.7	
		20.4		
527	10.1	19.0	22.0	
528	15.3	15.3	19.3	
529 530	15.7 17.7	16.1 19.1 24.3 19.4	18.5	
531	24.6	2/ 7	21.2 30.8 23.3	
532	19.0	10 /	27.7	
533	16.0	19.1	22.8	
534	16.3	19.4	20.3	
535	17.6	18.7		
536	17.9	22.6	25 8	
537		21.6		
538		20.3		
539		20.0		
540		19.7	23.7	
541	18.4	18.1	25.7	
542	21.9	16.6	19.8	
543	20.0	22.4	23.0	
	20.3	20.1	28.2	
545	15.3	22.4 20.1 16.9	23.3	
546	19.3	22.3	4 6	
547		15.9		
548	20.4	25.3	••	
549	17.1	17.4		
550	19.6			
MEAN	18.3	19.6	23.1	
		2.53	3.17	
N	25	25	20	
	: Data Ur	available		

 $^{^{\}rm a}{\rm Calculated}$ daily food consumption for successive periods

n		\Box		57
	N	/A\	12	- 11
ريا	ШЦ	101		- 11

			3	INDIVI	DUAL :	DAILY	FOOD	CONSU	APTION	(Grams)	3		
STU	JDY: 1	52		GR	OUP:	4-F	n hase	SI /kg/da DAY 134	EX: FE	MALE			
ANIMAL #	DAY 85	DAY 92	DAY 99	DAY 106	DAY 113	DAY 120	DAY 127	DAY 134	DAY 141	DAY 148	DAY 155	DAY 162	
		_											
576	20.3	16.3	17.4	16.3	16.4	17.6	16.9	17.6	17.6	18.1	18.0	17.0	
577	17.4	15.3	15.0	15.3	16.6	15.7	16.4	16.0	16.9	17.0	15.9	14.6	
578	18.6	15.1	16.9	21.1	19.9	18.6	15.4	15.4	15.7	17.6	20.7	15.7	
579	19.4	20.9	14.0	15.6	21.0	20.6	16.4	10.6	18.6	22.4	17.1	15.9	
580	17.3	14.9	15.7	14.9	18.0	16.3	16.3	14.7	11.7	16.3	18.0	14.7	
581	13.1	13.1	15.1	14.3	15.3	14.6	15.3	15.7	13.7	21.1	18.7	17.1	
582	17.7	10.7	16.0	14.0	16.6	15.6	15.0	15.6	16.7	15.9	17.0	14.7	
583	20.4	14.7	16.9	15.4	17.4	17.6	18.6	18.1	19.7	19.9	18.4	15.9	
584	16.3	14.7	16.4	15.1	17.9	17.7	16.0	16.7	16.4	18.4	16.7	13.6	
585	15.9	14.7	16.3	17.9	17.3	16.1	16.0	17.1	15.3	18.0	15.6	16.6	
586	17.3	16.3	14.7	14.9	17.1	17.3	16.4	16.1	15.9	18.0	17.0	14.1	
.587	19.4	16.3	15.4	16.0	21.1	17.3	17.0	20.1	19.7	21.9	17.0	19.9	
588	17.6	12.9	13.7	13.0	16.3	14.6	14.4	15.9	14.7	17.3	13.7	12.6	
589	18.7	13.9	16.6	16.7	18.3	18.3	16.6	17.4	17.7	19.3	19.6	15.9	
590	17.0	12.9	15.4	12.3	18.6	15.7	15.3	16.1	12.0	18.1	17.6	15.0	
591	19.4	19.0	18.0	16.0	21.6	26.1	16.6	15.7	17.7	22.7	19.9	18.7	
592	26.1	13.7	13.4	15.6	16.6	14.7	16.4	15.3	14.1	17.7	13.7	13.3	
593	16.6	13.1	13.6	16.1	17.4	20.7	14.9	15.4	15.1	30.1	15.1	15.3	
594	28.9	15.1	15.4	15.1	15.6	15.1	15.1	15.9	18.3	16.9	17.3	15.0	
595	15.7	12.6	13.4	14.1	16.0	15.4	14.6	14.6	14.4	16.3	15.3	14.6	
596	17.9	12.7	17.1	16.9	17.6	17.4	14.6	17.7	16.6	19_1	16.7	16.3	
597	16.9	16.9	14.6	19.0	15.6	15.3	12.9	15.9	14.7	21.3	16.6	13.4	
598	22.6	16.1	16.0	19.7	21.0	25.4	17.7	25.0	24.3	36.7	21.9	18.1	
599	19.1	17.9	15.4	16.9	17.0	18.3	16.9	16.6	17.0	19.6	18.7	17.3	
600	18.3	16.9	17.9	17.9	17.6	19.1	18.0	20.0	18.7	20.3	20.4	19.0	
MEAN	18.7	15.1	15.6	16.0	17.8	17.6	16.0	16.6	16.5	20.0	17.5	15.8	
S.D.	3.25	2.25	1.37	2.01	1.83	2.99	1.26	2.52	2.67	4.57	2.05	1.87	
N	25	25	25	25	25	25	25	25	25	25	25	25	
					:	Data Unav	ailable						

 $^{^{\}rm a}$ Calculated daily food consumption for successive periods

STUDY: 152



 INDIVIDUAL	DAILY	FOOD	CONSUMP	IION (Grams) ^a
 GROUP: DOSE: ANIMAL# D	9.0 (m	AY 176 D	e/kg/day) AY 182	: FEMALE
576	18.3	20.1	21.5	
577	15.1	16.3	17.3	
578 579	17.3	18.6 17.3	18.3	
580	16.6 15.3			
581	17.4	16.1 13.4	20.5 17.0	
582	14.4	16.4	18.7	
583	17.1	17.3	20.5	
584	15.3	16.9	19.8	
585	15.9	18.6	23.8	
586	16.3	18.3	20.7	
587	17.7	18.9	18.8	
588	14.3	15.4	17.7	
589	17.7	17.7	23.3	
590	17.3	17.9	18.3	
591	17.3	16.9	23.8	
592	16.1	19.1	18.3	
593	14.6	16.3	24.8	
594	15.7	17.9	18.8	
595	12.6	14.4	15.8	
596	16.0	19.7		
597		15.0		
598	21.3	21.3		
599	14.4	16.1		
600	17.7	19.3		
MEAN	16.2	17.4	20.1	
S.D.		1.86	2.64	
N	25 .	25	20	
	: Data Un	available		

^aCalculated daily food consumption for successive periods

DRAFT

Clinical Chemistry Test Directory

STU	DY: UIC-	5B				• • • • • • • • • • • • • • • • • • • •			
	ABBR. UNITS	DESCRIPTION PRECISION	CALCULATED	OPERAND A	OPERAND B		FEMALE	UPPER	FEMALE
	ALT [U/L	Alanine Amino Integer				30	30	70	70
2.	SDH	Sorbitol Dehy	drogenase						
	IU/L	0.0	NO			10	10	30	30
3.	TP	Total Protein							
	g/dL	0.0	NO			6.0	6.0	9.5	9.5
4.	ALB	Albumin							
	g/dL	0.0	NO			3.4	3.4	5.6	5.6
5.	TBA	Total Bile Ac	ids						
	umol/L	0.0	NO			25.0	25.0	75.0	75. 0
6.	ALKP	Alkaline Phos							
	IU/L	Integer	NO		-	60	40	500	250
7.	LDH	Lactate Dehyd							
	IU/L	Integer	NO			100	100	400	400
8.	CK	Creatine Kinas	se						
	IU/L	Integer	NO			100	100	400	400
9.	BUN	Blood Urea Ni	trogen						
	mg/dL	0.0	NO			12.0	12.0	22.0	22.0
10.	CREAT	Creatinine							
	mg/dL	0.00	NO			0.40	0.40	0.80	0.80
11.	NA	Sodium							
	mEq/L	Integer	NO			140	140	148	148
12.	K	Potassium							
	mEq/L	0.00	NO			5.00	5.00	7.00	7.00
13.		Chloride							
	mEq/L	Integer	NO			95	95	115	115
14.	CA	Calcium							
	mg/dL	0.0	NO			9.0	9.0	12.0	12.0
15.		Inorganic Pho	· ·						
	mg/dL	0.0	NO			5.5	5.5	11.0	11.0

(REPORT CONTINUED)

			5	7
--	--	--	---	---

Clinical Chemistry Test Directory

STU	DY: UIC-15	3								_
NO.	ABBR. UNITS	DESCRIPTION PRECISION	CALCULATED	OPERAND A	OPERAND B	LOWER L	IMIT FEMALE	UPPER L MALE	IMIT FEMALE	
	GLU mg/dL	Glucose Integer	NO			80	80	175	175	
17.	GLOB g/dL	Globulin 0.0	Operand A - Operand B	TP	ALB	2.5	2.5	5.0	5.0	
18.	A/G t	A/G Ratio 0.00	Operand A / Operand B	ALB	GL08	0.75	0.75	1.50	1.50	

(END OF REPORT)

UIC/TRL - CLINICAL CHEMISTRY

0		F	57
M	Li		

HISTORICAL DATABASE REPORT

 		ALB	ALKP	ALT	AST	BUN	CA	CHOL	CK
 RAT CD Male						• • • • • • • • • • • • • • • • • • • •			
control data1	MEAN	4.0	304	59	121	16.7	11.2	57	46
	SD	0.33	101.3	15.4	44.7	2.82	0.59	16.1	104.9
	N	140	140	140	45	140	140	80	175
RAT CD Femal	e								٠
control data1	MEAN	4.3	222	61	140	17.8	11.2	60	41
	SD	0.46	92.0	14.5	67.8	3.14	0.57	11.8	93.9
	N	140	140	140	45	140	140	80	4 175
RAT CD Both									
control data1	MEAN	4.1	263	60	130	17.2	11.2	59	43
	SD	0.42	105.0	14.9	57.9	3.03	0.58	14.2	99.4
	N	280	280	280	90	280	280	160	350
RAT CD Male									
control data2	MEAN	4.1	213	58	91	16.9	11.1	67	86
	SD	0.34	78.4	16.4	15.3	3.06	0.50	18.0	218.6
	N	80	80	80	40	80	80	60	100
RAT CD Femal	e								
control data2	MEAN	4.6	137	71	103	17.2	11.0	68	95
	SD	0.39	65.7	31.4	25.5	3.35	0.60	15.1	236.0
	N	60	60	60	20	60	60	40	80
RAT CD Both									
control data2	MEAN	4.3	181	64	95	17.0	11.0	68	90
	SD	0.43	82.2	24.7	19.8	3.18	0.54	16.8	225.9
	N	140	140	140	60	140	140	100	180
	N	140	140	140	00	140	140	100	

......

control data1-40-120 days

control data2-120-300 days

LABCAT CC4.32

UIC/TRL - CLINICAL CHEMISTRY



HISTORICAL DATABASE REPORT

		CL	CREAT	GLU	IP	K	LDH	NA	SDH
RAT CD Male									
control data1	MEAN	111	0.50	159	10.1	5.95	168	144	14.
	SD	6.3	0.060	36.9	1.11	0.503	134.5	1.7	5.7
	N	140	120	140	140	140	35	140	7
RAT CD Fema	e								
control data1	MEAN	112	0.56	157	9.2	5.71	179	144	14.
	SD	6.9	0.079	38.9	1.41	0.567	155.1	4.7	5.3
	N	140	120	140	140	140	35	140	7
RAT CD Both									
control data1	MEAN	111	0.53	158	9.6	5.83	174	144	14.
	SD	6.6	0.076	37.9	1.35	0.549	144.2	3.5	5.5
	N	280	240	280	280	280	70	280	14
RAT CD Male									
control data2	MEAN	108	0.53	164	8.8	5.90	495	145	15.
	SD	4.9	0.069	38.8	1.13	0.499	433.0	1.6	7.6
	N	80	70	80	80	80	20	80	4
RAT CD Fema	le								
control data2	MEAN	107	0.59	147	7.9	5.56	463	145	13.
	SD	6.4	0.080	30.4	1.15	0.493	231.3	1.8	4.8
	N	60	60	60	60	60	20	60	3
RAT CD Both									
control data2		108	0.56	157	8.4	5.76	479	145	14.
	SD	5.6	0.080	36.3	1.22	0.524	343.0	1.7	6.5
	N	140	130	140	140	140	40	140	7

control data1-40-120 days

control data2-120-300 days

LABCAT CC4.32



UIC/TRL - CLINICAL CHEMISTRY

HISTORICAL DATABASE REPORT

			TBA	TBILI	TP	TRIG	
RAT CD	Male						
control	data1	MEAN	40.9	0.11	7.7	129	
		SD	24.58	0.026	0.65	49.5	
		N	90	25	140	5	
RAT CD	Female						
	data1		34.6	0.17	7.8	70	
00110101	44.4	SD		0.093			
		N	90				
RAT CD	Both						
	data1	MEAN	37 7	0.14	7 7	100	
00.11.101	00.01	SD		0.074			
		N		50	280	10	
RAT CD	Male						
control		MEAN	45.6	0.11	7.9		
00110101		SD		0.023			
		N	40				
RAT CD	Female						
		MEAN	51.0	0.11	8.4		
		SD		0.018			
		N	40	20	60		
RAT CD	Both						
control		MEAN	48.3	0.11	8.1		
		SD		0.021			
		N	80	60	140		

(--)-Data Unavailable control data1-40-120 days

control data2-120-300 days

LABCAT CC4.32



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alanine Aminotransferase

STUDY NO: 152

SEX: MALE

 Animal ID	Week 4		Week 26	
GROUP: 1 M:0				
401	57	62	58	
402	39	64	94	
403	55	70	70	
404	47	54	73	
405	63	56	71	
406	51	52	63	
407	68	60	69	
408	44	102	111	
409	49	70	76	
410	56	61	68	
MEAN	53	65	75	
SD	8.7	14.3	15.7	
N	10	10	10	
				• • • • • • • • • • • • • • • • • • • •
 GROUP: 2-M:0	.5 mg base/	kg/day		• • • • • • • • • • • • • • • • • • • •
 GROUP: 2-M:0 451	0.5 mg base/ 65	kg/day 70	81	• • • • • • • • • • • • • • • • • • • •
 GROUP: 2-M:0 451 452	0.5 mg base/ 65 45	kg/day 70 46	81 47	• • • • • • • • • • • • • • • • • • • •
 GROUP: 2-M:0 451 452 453	65 45 49	kg/day 70 46 57	81 47 44	• • • • • • • • • • • • • • • • • • • •
 GROUP: 2-M:0 451 452 453 454	65 45 49	70 46 57 66	81 47 44 193	• • • • • • • • • • • • • • • • • • • •
 GROUP: 2-M:0 451 452 453 454 455	65 45 49 49	70 46 57 66 41	81 47 44 193 52	•
 GROUP: 2-M:0 451 452 453 454 455	0.5 mg base/ 65 45 49 49 40 60	70 46 57 66 41	81 47 44 193 52 82	•
GROUP: 2-M:0 451 452 453 454 455 456 457	0.5 mg base/ 65 45 49 49 40 60 66	70 46 57 66 41 70 86	81 47 44 193 52 82 91	•
GROUP: 2-M:0 451 452 453 454 455 456 457	0.5 mg base/ 65 45 49 49 40 60 66 45	70 46 57 66 41 70 86 54	81 47 44 193 52 82 91 70	
GROUP: 2-M:0 451 452 453 454 455 456 457 458	0.5 mg base/ 65 45 49 49 40 60 66 45 43	70 46 57 66 41 70 86 54	81 47 44 193 52 82 91 70	
GROUP: 2-M:0 451 452 453 454 455 456 457	0.5 mg base/ 65 45 49 49 40 60 66 45	70 46 57 66 41 70 86 54	81 47 44 193 52 82 91 70	
GROUP: 2-M:0 451 452 453 454 455 456 457 458	0.5 mg base/ 65 45 49 49 40 60 66 45 43	70 46 57 66 41 70 86 54	81 47 44 193 52 82 91 70	
GROUP: 2-M:0 451 452 453 454 455 456 457 458 459	65 45 49 49 40 60 66 45 43	70 46 57 66 41 70 86 54 68	81 47 44 193 52 82 91 70 70	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alanine Aminotransferase

STUDY ID: UIC-15B STUDY NO. 152

SEX: MALE

ABBR: ALT					UNITS: IU/L
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 3-M:				
	501	52	69	72	
	502	57	58	63	
	503	47	55	80	
	504	42	55	43	
	505	46	48	45	
	506	50	52	67	
	507	55	64	53	
	508	65	80	73	
	509	53	65	87	
	510	62	57	65	
	MEAN	53	60	65	
	SD	7.2	9.4	14.4	
	N	10	10	10	
				•••••	
	GROUP: 4-M:	9.0 mg base/	kg/day		
	551	46	69	138	
	552	40	113	111	
	553	56	63	111	
	554	56	81	79	
	555	43	73	70	
	556	51	102	119	
	557	38	50	60	
	558	48	62		
	559	45	59	45	
	560	52	96	84	
	561		••	69	
	MEAN	48	77	89	
	SD	6.3	20.7	29.7	
	N	10	10	10	

(--) - Data Unavailable



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sorbitol Dehydrogenase

STUDY ID: UIC-15B

SEX: MALE

STUDY NO: 152

 Animal ID	Week 4	Week 13	Week 26	
GROUP: 1 M	0 mg base/kg	/day		
401	27.4	20.8	12.6	
402	23.1	7.5	7.1	
403	12.2	17.4	10.8	
404	25.2	30.2	11.5	
405	7.3	13.4	18.8	
406	5.2	44.2	13.2	
407	15.0	8.3	17.2	
408	22.6	36.6	15.0	
409	10.8	19.2	18.2	
410	6.3	3.1	5.7	
MEAN	15.5	20.1	13.0	
SD	8.40	13.31	4.44	
N	10	10	10	
	:0.5 mg base/			
451	10.5	11.9	23.1	
452	24.7	9.3	26.4	
453	37.2	10.6	15.8	
454	18.0	17.7	21.7	
455	18.1	5.4	5.2	
456	19.1	17.5	21.4	
457	20.7	20.8	19.3	
458	5.4	18.5	5.4	
459	13.5	24.7	12.1	
460	19.6	27.8	9.3	
MEAN	18.7	16.4	16.0	
SD	8.53	7.08	7.60	
N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sorbitol Dehydrogenase

STUDY ID: UIC-158

STUDY NO: 152

ABBR: SDH

SEX: MALE

UNITS: IU/L

ABBR: SDH					UNITS: IU/L
	Animal ID	Week 4	Week 13	Week 26	
		2.0 mg base/	kg/day		••••••
	501	4.6	35.6	7.8	
	502	15.7	20.3	4.5	
	503	6.5	18.0	19.1	
	504	36.0	9.6	12.8	
	505	28.4	7.2	6.9	
	506	13.2	24-5	16.9	
	507	27.1	24.5	23.5	
	508	6.9	11.6	10.3	
	509	15.0	18.3	17.5	
	510	9.4	12.5	4.9	
	MEAN	16.3	18.2	12.4	
	SD	10.71	8.55	6.57	
	N	10	10	10	
	CPOUD. /-M-	9.0 mg base/	'ka/day		
	551		19.7	7.0	
	552	7.0	18.8	19.9	
	553	16.2	7.9	17.9	
	554	16.8	25.0	30.3	
	555	29.6	18.3	6.4	
	556	23.7	11.2	15.9	
	557	24.1	19.3	24.4	
	558	18.6		24.4	
	559	17.0	6.2 20.7	13.7	
	560 561	17.0	19.7	12.9 9.6	
	201			y.0	
	MEAN	19.0	16.7	15.8	
	SO	6.02	6.10	7.62	
	N	10	10	10	

(--) - Data Unavailable

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Protein

STUDY ID: UIC-158

SEY - MALE

STUDY NO: 152

STUDY NO: 152 ABBR: TP						UNITS: g/dL
	Animal ID			Week 26	۽ منشر	
	GROUP: 1 M:0	mg base/kg				
	401	7.7	8.6	6.8		
	402	8.4	8.3	7.1		
	403	8.2	9.4	7.5		
	404	7.8	7.5	7.2		
	405	6.0	8.8	8.2		
	406	8.0	8.5	8.2		
	407	8.4	8.8	7.3		
	408	6.8	7.8	7.8		
	409	7.6	7.8	8.5		
	410	8.4	7.8	7.3		
	MEAN	7.7	8.3	7.6		
	SD	0.78	0.60	0.56		
	N	10	10	10		
	CDOUD. 2.M.		La Iday			
	GROUP: 2-M:(7 7		
	451	6.8	7.8	7.3		
	452	8.0	7.5	7.7		
	453	7.5	7.8	6.4		
	454	8.6	7.7	6.4		
	455	7.6	7.5	7.4		
	456	7.9	7.7	8.0		
	457	7.	8.7	8.3		
	458	7.8	8.1	7.3		
	459	8.3	7.9	7.5		
	460	8.0	8.3	7.0		
	MEAN	7.8	7.9	7.3		
	SD	0.48	0.37	0.61		
	N	10	10	10		

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Protein

STUDY ID: UIC-15B

STUDY NO: 152

SEX: MALE

		Week 13		
 GROUP: 3-M:				• • • • • • • • • • • • • • • • • • • •
501	7.8	8.4	8.2	
502	7.8	7.0	8.2	
503	8.0	8.3	6.9	
504	7.5	8.3	7.5	
505	8.1	7.3	7.8	
506	7.4	7.6	7.9	
507	7.4	7.6	7.5	
508	8.3	8.7	7.7	
509	6.9	8.5	7.3	
510	7.7	8.1	7.0	
MEAN	7.7	8.0	7.6	
SD N	0.41 10	0.57 10	0.45 10	
GROUP: 4-M:9				
551	7.4	6.9	7.4	
552	7.3	8.1	6.8	
553	8.5	7.5	7.8	-
554	8.2	7.7	7.2	
555	7.8	8.2	6.7	
556	8.0	7.7	6.8	
557	7.9	7.9	6.7	
558	7.4	8.0		
559	8.4	8.7	7.9	
560	8.4	8.3	7.7	
561			7.6	
MEAN	7.9	7.9	7.3	
SD	0.45	0.49	0.48	

(--) - Data Unavailable



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Albumin

STUDY ID: UIC-15B

STUDY NO: 152

SEX: MALE

ABBR: ALB					UNITS: g/dL
	Animal ID	Week 4	Week 13	Week 26	
		:0 mg base/kg			• • • • • • • • • • • • • • • • • • • •
	401	4.0	4.9	4.5	
	402	4.0	4.2	4.0	
	403	4.2	4.8	4.4	
	404	4.0	3.7	4.5	
	405	3.3	4.5	4.2	
	406	4.1	4.2	3.9	
	407	4.6	4.6	4.5	
	408	3.5	4.2	3.8	
	409	4.0	3.9	3.9	
	410	4.1	3.9	4.4	
	MEAN	4.0	4.3	4.2	
	SD	0.36	0.40	0.28	
	N	10	10	10	
	GROUP: 2-M	:0.5 mg base/	ka/day		
			4.2	4 1	
	452		3.9		
	453	3.6		3.9	
	454	4.3		4.1	
	455	4.0	4.1	4.3	
	456	3.9	4.1	4.0	
	457	3.8	4.4	3.7	
	458	4.0	4.4	4.1	
	459	4.3	3.9	3.8	
	460	4.0	4.3	4.3	
	MEAN	3.9	4.1	4.0	
	SD	0.23	0.21	0.24	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Albumin

STUDY ID: UIC-15B SEX: MALE

STUDY NO: 152
ABBR: ALB
UNITS: 9/d

ABBR: ALB					UNITS: g/dL
			Week 13		
		2.0 mg base/			
	501	3.9	4.7	4.3	
	502	4.0	3.8	4.2	
	503	3.9	4.2	4.5	
	504	3.9	4.6	3.8	
	505	4.0	3.7	3.9	
	506	3.8	3.9	3.7	
	507	4.3	3.9	3.9	
	508	4.6	4.3	4.0	
	509	4.2	4.6	4.5	
	510	3.9	4.3	4.5	
	MEAN	4.1	4.2	4.1	
	SD	0.25	0.36	0.31	
	N	10	10	10	
		9.0 mg base/			*****
	551	3.9	3.9	3.8	
	552	3.9	4.5	4.3	
	553	4.3	4.1	4.1	
	554	4.2	4.3	3.9	
	555	4.2	4.4	4.3	
	556	4.0	4.3	4.1	
	557	4.2	3.9	4.3	
	558	4.3	4.5		
	559	4.2	4.7	4.3	
	560	4.0	4.3	4.0	
	561			3.8	
	MEAN	4.1	4.3	4.1	
	SD	0.15	0.26	0.21	
	N	10	10	10	

(--) - Data Unavailable



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Globulin

STUDY ID: UIC-15B

ABBR: GLOB					UNITS: g/dL
			Week 13		
***************************************	GROUP: 1 M:				
	401	3.7	3.7	2.3	
	402	4.4	4.1	3.1	
	403	4.0	4.6	3.1	
	404	3.8	3.8	2.7	
	405	2.7	4.3	4.0	
	406	3.9	4.3	4.3	
	407	3.8	4.2	2.8	
	408	3.3	3.6	4.0	
	409	3.6	3.9	4.6	
	410	4.3	3.9	2.9	
	MEAN	3.8	4.0	3.4	
	SD	0.49	0.31	0.78	
	N	10	10	10	
	GROUP: 2-M:	0.5 mg base/	kg/day		
	451	3.1	3.6	3.2	
	452	4.2	3.6	4.1	
	453	3.9	4.0	2.5	
	454	4.3	3.7	2.3	
	455	3.6	3.4	3.1	
	456	4.0	3.6	4.0	
	457	3.9	4.3	4.6	
	458	3.8	3.7	3.2	
	459	4.0	4.0	3.7	
	460	4.0	4.0	2.7	
		_	_		
	MEAN	3.9	3.8	3.3	
	SD	0.34	0.27	0.75	
	N	10	10	10	
	2.3	· -		• •	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Globulin

STUDY ID: UIC-15B

ABBR: GLOB					UNITS: g/dL
			Week 13		
		2.0 mg base/			
	501	3.9	3.7	3.9	
	502	3.8	3.2	4.0	
	503	4.1	4.1	2.4	
	504	3.6	3.7	3.7	
	505	4.1	3.6	3.9	
	506	3.6	3.7	4.2	
	507	3.1	3.7	3.6	
	508	3.7	4.4	3.7	
	509	2.7	3.9	2.8	
	510	3.8	3.8	2.5	
	MEAN	3.6	3.8	3.5	
	SD	0.44	0.32	0.65	
	N	10	10	10	
					•••••••••••••••••••••••••••••••••••••••
		9.0 mg base/			
	551	3.5	3.0	3.6	
	552	3.4	3.6	2.5	
	553	4.2	3.4	3.7	
	554	4.0	3.4	3.3	
	555	3.6	3.8	2.4	
	556	4.0	3.4	2.7	
	557	3.7	4.0	2.4	
	558	3.1	3.5		
	559	4.2	4.0	3.6	
	560	4.4	4.0	3.7	
	561		* *	3.8	
	MEAN	3.8	3.6	3.2	
	SD N	0.41	0.33	0.60	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: A/G Ratio

STUDY ID: UIC-15B

Animal ID	Week 4	Week 13	Week 26	
 GROUP: 1 M:	0 mg base/kg	/day		
401	1.08	1.32	1.96	
402	0.91	1.02	1.29	
403	1.05	1.04	1.42	
404	1.05	0.97	1.67	
405	1.22	1.05	1.05	
406	1.05	0.98	0.91	
407	1.21	1.10	1.61	
408	1.06	1.17	0.95	
409	1.11	1.00	0.85	
410	0.95	1.00	1.52	
MEAN	1.07	1.07	1.32	
SD	0.097	0.108	0.375	
N	10	10	10	
GROUP: 2-M:0	1 5 mg hace/	ka/day		
451	1.19	1.17	1.28	
451 452	1.19	1.17 1.08	0.88	
451	1.19	1.17		
451 452	1.19	1.17 1.08	0.88	
451 452 453	1.19 0.90 0.92	1.17 1.08 0.95	0.88 1.56	
451 452 453 454	1.19 0.90 0.92 1.00	1.17 1.08 0.95 1.08	0.88 1.56 1.78	
451 452 453 454 455	1.19 0.90 0.92 1.00 1.11	1.17 1.08 0.95 1.08 1.21	0.88 1.56 1.78 1.39	
451 452 453 454 455	1.19 0.90 0.92 1.00 1.11 0.98	1.17 1.08 0.95 1.08 1.21 1.14	0.88 1.56 1.78 1.39 1.00	
451 452 453 454 455 456 457	1.19 0.90 0.92 1.00 1.11 0.98 0.97	1.17 1.08 0.95 1.08 1.21 1.14	0.88 1.56 1.78 1.39 1.00 0.80	
451 452 453 454 455 456 457	1.19 0.90 0.92 1.00 1.11 0.98 0.97	1.17 1.08 0.95 1.08 1.21 1.14 1.02	0.88 1.56 1.78 1.39 1.00 0.80 1.28	
451 452 453 454 455 456 457 458 459	1.19 0.90 0.92 1.00 1.11 0.98 0.97 1.05 1.08	1.17 1.08 0.95 1.08 1.21 1.14 1.02 1.19	0.88 1.56 1.78 1.39 1.00 0.80 1.28 1.03 1.59	
451 452 453 454 455 456 457 458 459	1.19 0.90 0.92 1.00 1.11 0.98 0.97 1.05 1.08	1.17 1.08 0.95 1.08 1.21 1.14 1.02 1.19 0.98 1.08	0.88 1.56 1.78 1.39 1.00 0.80 1.28 1.03	x



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: A/G Ratio

STUDY ID: UIC-15B

SEX: MALE

STUDY NO: 152

Animal ID	Week 4	Heat 17	Heate 26	
		Week 13		
GROUP: 3-M:	2.0 mg base/	kg/day		
501	1.00	1.27	1.10	
502	1.05	1.19	1.05	
503	0.95	1.02	1.88	
504	1.08	1.24	1.03	
505	0.98	1.03	1.00	
506	1.06	1.05	0.88	
507	1.39	1.05	1.08	
508	1.24	0.98	1.08	
509	1.56	1.18	1.61	
510	1.03	1.13	1.80	
MEAN	1.13	1.11	1.25	
SD	0.200	0.101	0.365	
N	10	10	10	
 	0.0 1			
	9.0 mg base/		4.04	
551	1.11	1.30	1.06	
552	1.15	1.25	1.72	
553	1.02	1.21	1.11	
554	1.05	1.26	1.18	
555	1.17	1.16	1.79	
556	1.00	1.26	1.52	
557	1.14	0.98	1.79	
558	1.39	1.29		
559	1.00	1.18	1.19	
560	0.91	1.08	1.08	
561	••		1.00	
MEAN	1.09	1.20	1.34	. *
SD	0.132	0.101	0.324	
N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Bile Acids

STUDY ID: UIC-15B

SEX: MALE

STUDY NO: 152

UNITS: umol/L

ABBR: TBA					UNITS: umol/L
	Animal ID	Week 4	Week 13	Week 26	
· · · · · · · · · · · · · · · · · · ·	GROUP: 1 M:	0 mg base/kg			
	401	19.5	22.6	20.4	
	402	23.8	68.8	89.0	
	403	20.1	39.9	39.0	
	404	23.2	58.7	35.8	
	405	45.8	44.1	140.6	
	406	23.2	23.4	66.6	
	407	22.9	22.7	34.5	
	408	23.6	73.9	68.9	
	409	23.8	62.1	64.1	
	410	21.0	27.8	38.9	
	MEAN	24.7	44.4	59.8	
	SD	7.58	20.18	35.22	
	N	10	10	10	
	GROUP: 2-M:	0.5 mg base/	kg/day		
	451	102.9	50.7	48.5	
	452	38.6	38.8	67.8	
	453	29.0	24.8	16.4	
	454	22.7	23.7	32.7	•
	455	31.4	53.4	38.4	
	456	21.2	43.9	61.1	
	457	22.9	41.9	51.5	
	458	32.1	28.3	30.4	
	459	18.9	110.5	83.0	
	460	21.6	47.1	52.4	
	MEAN	34.1	46.3	48.2	
	SD	24.94	24.88	19.59	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Bile Acids

STUDY ID: UIC-15B STUDY NO: 152

SEX: MALE

ABBR: TBA					UNITS: umol/L
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 3-M:	2.0 mg base/	'kg/day		•
	501	19.9	111.0	89.1	
	502	16.8	77.0	57.0	
	503	22.1	49.2	122.9	
	504	26.2	60.8	24.2	
	505	54.5	69.4	26.8	
	506	22.6	26.7	86.4	
	507	24.5	103.2	58.4	
	508	27.3	53.5	37.6	
	509	44.3	42.8	33.5	
	510	80.0	79.2	66.7	
	MEAN	33.8	67.3	60.3	
	SD	20.01	26.35	31.87	
	N	10	10	10	
			••••••		
	GROUP: 4-M:	9.0 mg base/	'kg/day		
	551	50.9	69.0	116.1	
	552	27.6	60.7	156.9	
	553	17.8	39.0	128.0	
	554	32.7	36.7	72.8	
	555	24.2	113.4	44.7	
	556	52.1	84.6	95.1	
	557	20.9	43.7	42.0	
	558	40.9	90.7	••	
	559	31.1	43.2	102.3	
	560	31.9	40.8	72.5	
	561		••	119.5	
	MEAN	33.0	62.2	95.0	
	SD	11.72	26.53	37.05	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alkaline Phosphatase

STUDY ID: UIC-15B

SEX: MALE

ABBR: ALKP					UNITS: IU/L
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 1 M:	0 mg base/kg	/day		
	401	456	313	232	
	402	312	192	166	
	403	499	335	313	
	404	316	200	182	
	405	339	250	223	
	406	328	168	121	
	407	282	148	146	
	408	264	167	118	
	409	331	205	193	
	410	555	383	343	
	MEAN	368	236	204	
	SD	98.7	80.9	76.0	
	N	10	10	10	

		0.5 mg base/			
	451	424	334	269	
	452	336	205	154	
	453	296	196	70	
	454	329	200	198	
	455	318	192	160	
	456	354	238	137	
	457	380	224	238	
	458	287	178	169	
	459	319	189	136	
	460	361	261	202	
	MEAN	340	222	173	
	SD	41.0	46.8	56.5	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alkaline Phosphatase

STUDY 10: UIC-158

SEX: MALE

ABBR: ALKP					UNITS: IU/
	Animal IO	Week 4		Week 26	
	GROUP: 3-M:		ka/day		
	501	314	201	134	
	502	349	215	168	
	503	227	142	134	
	504	256	147	78	
	505	524	366	330	
	506	258	177	125	
	507	347	195	156	
	508	554	400	334	
	509	289	163	176	
	510	517	353	279	
	310	J.,	323	217	
	MEAN	364	236	191	
	SD	122.7	98.0	90.1	
	N	10	10	10	
		9.0 mg base/			
	551	219	193	170	
	552	404	311	305	
	553	312	224	200	
	554	529	299	272	
	555	285	165	152	
	556	354	268	242	
	557	328	190	197	
	558	221	177		
	559	369	226	194	
	560	226	166	125	
	561			170	
	MEAN	325	222	203	
	MEAN SD	325 96.8	222 54.0	203 55.5 10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Lactate Dehydrogenase

STUDY ID: UIC-15B

.....

STUDY NO: 152 ABBR: LDH					UNITS: IU/L
		Week 4	Week 13	Week 26	
	GROUP: 1 M:	0 mg base/kg	ı/day		•••••••••••
	401	157	262	573	
	402	225	248	586	
	403	165	319	349	
	404	113	167	506	
	405	558	659	403	
	406	70	156	133	
	407	66	639	230	
	408	167	220	959	
	409	56	214	158	
	410	129	1845	1266	
	MEAN	171	473	516	
	SD	146.3	515.2	359.7	
	N	10	10	10	
	GROUP: 2-M:	0.5 mg base/			
	451	383	533	146	
	452	71	373	149	
	453	236	418	189	
	454	42	255	425	
	455	159	1177	526	
	456	193	414	237	
	457	96	175	211	
	458	166	278	696	
	459	73	204	467	
	460	211	300	1168	
	400	211	300	1100	
	MEAN	163	413	421	
	SD	101.5	289.8	321.1	

10

10

10



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Lactate Dehydrogenase

STUDY ID: UIC-15B

SEX: MALE

STUDY NO: 152

HMITS: III/I

ABBR: LDH					UNITS: IU/L
	Animal ID				
		2.0 mg base/	kg/day		
	501	50	236	449	
	502	119	252	555	
	503	97	318	239	
	504	175	501	325	
	505	155	571	736	
	506	485	214	288	
	507	80	137	188	
	508	95	483	366	
	509	54	258	166	
	510	454	356	741	
	MEAN	176	333	405	
	SD	159.6	142.3	210.9	
	N	10	10	10	
	N	10	10	10	
		9.0 mg base/		510	
	551	335	518	549	
	552	245	620	503	
	553	133	498	484	
	554	76	176	225	
	555	170	426	1072	
	556	84	482	617	
	557	141	336	307	
	558	79	880		
	559	399	323	252	
	560	217	344	312	
	561			277	
	MEAN	188	460	460	
	SD	111.1	193.4	255.3	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatine Kinase

STUDY ID: UIC-15B

SEX: MALE

STUDY NO: 152					
ABBR: CK					UNITS: IU/L
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 1 M:	0 mg base/kg	/day		
	401	256	119	181	
	402	273	415	276	
	403	99	127	219	
	404	360	342	1012	
	405	661	181	163	
	406	44	131	326	
	407	153	201	387	
	408	163	129	814	
	409	164	831	336	
	410	250	644	1304	
	MEAN	242	312	502	*
	SD	173.4	249.1	397.4	
	N	10	10	10	
	GROUP: 2-M:	0.5 mg base/	kg/day		
	451	856	178	60	
	452	71	930	87	
	453	182	203	138	
	454	55	373	169	
	455	401	983	179	
	456	270	218	642	
	457	221	91	1094	
	458	131	274	350	
	459	64	1119	210	
	460	790	192	846	
	MEAN	304	456	378	
	SD	293.8	392.0	358.6	
	N	10	10	10	
			10	.0	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatine Kinase

STUDY ID: UIC-15B

SEX: MALE

STUDY NO: 152

ABBR: CK					UNITS: IU/L
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 3-M:	2.0 mg base/	kg/day		
	501	88	225	999	
	502	69	812	200	
	503	88	137	99	
	504	207	141	124	
	505	78	604	339	
	506	459	125	107	
	507	83	516	140	
	508	85	1021	139	
	509	162	130	97	
	510	382	98	1084	
	MEAN	170	381	333	
	SD	140.2	335.6	380.8	
	N	10	10	10	
	GROUP: 4-M:	9.0 mg base/	kg/day		
	551	646	208	1841	
	552	99	122	171	
	553	105	308	1791	
	554	77	81	384	
	555	61	135	286	
	556	90	639	461	
	557	108	212	102	
	558	63	233		
	559	307	177	139	
	560	109	141	309	
	561			577	
	MEAN	167	226	606	
	SD	182.7	159.0	654.3	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Blood Urea Nitrogen

STUDY ID: UIC-15B

SEX: MALE

ABBR: BUN					UNITS: mg/dL
	Animal ID	Week 4	Week 13	Week 26	A.
	GROUP: 1 M:				
	401	21.9	22.1	20.1	
	402	16.3	26.4	20.1	
	403	18.5	24.2	18.6	
	404	18.6	17.3	17.3	
	405	17.5	23.3	14.9	
	406	16.9	16.8	15.1	
	407	19.6	23.9	18.2	
	408	16.9	21.5	15.3	
	409	17.7	18.3	22.5	
	410	19.5	16.1	18.5	
	MEAN	18.3	21.0	18.1	
	SD	1.67	3.61	2.48	
	N	10	10	10	
	GROUP: 2-M:	0 5 mg baco	······································		
	451	17.5	17.1	13.2	
	452				
		15.4	15.D	17.4	
	453	16.5	14.7	8.2	
	454	18.1	14.9	15.2	
	455	17.3	17.1	16.8	
	456	18.7	18.0	15.4	
	457	19.1	23.6	20.7	
	458	17.7	14.5	14.6	
	459	14.0	16.7	14.7	
	460	19.2	18.5	18.7	
	MEAN	17.3	17.0	15.5	
	SD	1.62	2.73	3.38	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Blood Urea Nitrogen

STUDY NO: 152

SEX: MALE

ABBR: BUN					UNITS: mg/dL
	Animal		Week 13	Week 26	
		3-M:2.0 mg base/			
	501	16.9	22.3	18.4	
	502	16.7	15.9	15.8	
	503	16.1	20.4	19.3	
	504	17.2	19.2	13.4	
	505	16.6	18.2	15.2	
	506	18.0	13.6	16.4	
	507	19.3	14.2	15.0	
	508	14.4	18.3	16.1	
	509	16.5	17.1	13.1	
	510	18.0	21.4	15.0	
	MEAN	17.0	18.1	15.8	
	SD	1.31	2.91	1.95	
	N	10	10	10	
	GROUP:	4-M:9.0 mg base/	kg/day		
	551	14.8	12.7	12.8	
	552	16.0	20.4	15.6	
	553	17.8	15.7	17.8	
	554	12.9	17.4	13.3	
	555	19.5	16.6	17.9	
	556	16.5	15.5	12.8	
	557	15.2	11.7	12.6	
	558	19.2	16.1		
	559	14.6	14.4	12.9	
	560	11.8	13.1	12.5	
	561	••		12.1	
	MEAN	15.8	15.4	14.0	
	SD	2.52	2.54	2.23	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatinine

STUDY ID: UIC-15B

SEX: MALE

STUDY NO: 152 ABBR: CREAT					UNITS: mg/dL
		Week 4			
		0 mg base/kg	/day		• • • • • • • • • • • • • • • • • • • •
	401	0.60	0.59	0.58	
	402	0.46	0.64	0.64	
	403	0.54	0.59	0.68	
	404	0.50	0.51	0.61	
	405	0.59	0.54	0.55	
	406	0.47 .	0.51	0.54	
	407	0.62	0.59	0.60	
	408	0.64	0.73	0.56	
	409	0.48	0.54	0.61	
	410	0.48	0.50	0.65	
	MEAN	0.54	0.57	0.60	
	SD	0.069	0.071	0.046	
	N	10	10	10	
	GROUP: 2-M:	0.5 mg base/	kg/dav		
	451	0.57	0.50	0.54	
	452	0.54	0.52	0.69	
	453	0.81	0.51	0.61	
	454	0.54	0.53	0.58	
	455	0.49	0.46	0.56	
	456	0.48	0.49	0.59	
	457	0.51	0.58	0.53	
	458	0.52	0.52	0.53	
	459	0.55	0.61	0.54	
	460	0.54	0.49	0.56	
	400	0.54	0.47	0.30	
	MEAN	0.56	0.52	0.57	
	SD	0.094	0.044	0.049	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatinine

STUDY ID: UIC-15B STUDY NO: 152

Animal ID	Week 4	Week 13	Week 26	
	2.0 mg base/	kg/dav		
501	0.54	0.75	0.62	
502	0.46	0.59	0.54	
503	0.54	0.63	0.88	
504	0.53	0.55	0.53	
505	0.49	0.49	0.56	
506	0.51	0.48	0.54	
507	0.52	0.60	0.64	
508	0.61	0.61	0.60	
509	0.48	0.56	0.62	
510	0.54	0.52	0.63	
MEAN	0.52	0.58	0.62	
SD	0.042			
N	10	10	10	
	9.0 mg base/			5965
551	0.93	0.51	0.61	
552	0.55	0.60	0.61	
553	0.60	0.55	0.64	
554	0.56	0.55	0.54	
555	0.61	0.62	0.60	
556	0.53	0.69	0.61	
557	0.53	0.50	0.52	
558	0.59	0.55		
559	0.54	0.56	0.52	
560	0.48	0.57	0.57	
561		••	0.60	
MEAN	0.59	0.57	0.58	
MEAN				
SD	0.125	0.055	0.042	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sodium

STUDY ID: UIC-15B STUDY NO: 152

ABBR: NA					UNITS: mEq/L
	Animal ID		Week 13	Week 26	
	GROUP: 1 M:0	mg base/kg	ı/day		
	401	152	145	147	
	402	143	143	148	
	403	143	146	147	
	404	142	144	148	
	405	148	145	145	
	406	143	146	148	
	407	146	145	148	
	408	141	146	145	
	409	144	147	145	
	410	141	144	145	
	MEAN	144	145	147	
	SD	3.5	1.2	1.4	
	N	10	10	10	
	GROUP: 2-M:0		The second secon		
	451	149	145	148	
	452	154	145	146	
	453	151	146	148	
	454	145	145	144	
	455	144	142	146	
	456	144	144	146	
	457	145	147	148	
	458	145	147	146	
	459	146	145	145	
	460	146	146	147	
	MEAN	147	145	146	
	SD	3.3	1.5	1.3	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sodium

STUDY ID: UIC-15B

STUDY NO: 152

		Week 13		
	:2.0 mg base/	kg/day		•••••••
501	144	146	146	
502	145	146	147	
503	146	145	147	
504	143	146	145	
505	144	143	142	
506	151	147	148	
507	146	145	144	
508	145	144	145	
509	145	147	149	
510	144	144	145	
MEAN	145	145	146	
SO SO	2.2	1.3	2.0	
N	10	10	10	
	110 100			
	:9.0 mg base/	kg/day		
551	149	kg/day 143	146	
551 552		kg/day	146 144	
551	149	kg/day 143	146	
551 552	149 150	kg/day 143 141	146 144	
551 552 553	149 150 145	kg/day 143 141 144	146 144 144	
551 552 553 554	149 150 145 147	kg/day 143 141 144 145	146 144 144 144	
551 552 553 554 555	149 150 145 147 148	kg/day 143 141 144 145 145	146 144 144 144 144	2
551 552 553 554 555 556	149 150 145 147 148 154	kg/day 143 141 144 145 145	146 144 144 144 144	9
551 552 553 554 555 556 557	149 150 145 147 148 154	kg/day 143 141 144 145 145 145	146 144 144 144 145 145	
551 552 553 554 555 556 557 558	149 150 145 147 148 154 146 153	kg/day 143 141 144 145 145 145 146	146 144 144 144 145 146	
551 552 553 554 555 556 557 558 559	149 150 145 147 148 154 146 153	kg/day 143 141 144 145 145 145 146 145	146 144 144 144 145 144 	
551 552 553 554 555 556 557 558 559 560	149 150 145 147 148 154 146 153 144	kg/day 143 141 144 145 145 146 145 145	146 144 144 144 145 145 144 142	
551 552 553 554 555 556 557 558 559 560 561	149 150 145 147 148 154 146 153 144 143	kg/day 143 141 144 145 145 146 145 146 145 146	146 144 144 144 145 146 142 146	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Potassium

STUDY ID: UIC-158

	Animal ID	Week 4	Week 13	Week 26	
,	GROUP: 1 M:	0 mg base/kg	/day		
	401	6.98	5.73	5.78	
	402	6.10	5.38	5.85	
	403	6.30	5.95	6.17	
	404	6.29	7.01	6.01	
	405	6.38	5.87	6.27	
	406	6.07	6.21	5.25	
	407	6.54	6.34	6.28	
	408	5.14	5.47	5.73	
	409	5.79	5.73	5.28	
	410	6.45	6.42	6.26	
	MEAN	6.20	6.01	5.89	
	SD	0.489	0.493	0.387	
	N	10	10	10	
		0.5 mg base/			
	451	6.17	6.10	5.92	
	452	5.80	6.25	5.51	
	453	6.90	5.94	5.20	
	454	5.79	5.97	5.90	
	455	5.79	5.57	5.73	
	456	5.76	5.83	5.68	
	430	3.10	7.03	3100	
	457	7.06	5.67	6.12	
	457	7.06	5.67	6.12	
	457 458	7.06 6.20	5.67 6.51	6.12 6.22	
	457 458 459 460	7.06 6.20 6.80 5.52	5.67 6.51 4.54 6.41	6.12 6.22 5.61 6.11	
	457 458 459	7.06 6.20 6.80	5.67 6.51 4.54	6.12 6.22 5.61	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Potassium

STUDY ID: UIC-15B

STUDY NO: 152

 				UNITS: mEq/
Animal IO	Week 4			
	2.0 mg base/			
501	4.98	4.65	6.27	
502	5.85	6.09	6.23	
503	6.32	6.03	5.47	
504	5.49	5.77	5.92	
505	5.92	6.21	6.17	
506	6.13	6.46	5.09	
507	5.92	5.55	5.34	
508	4.83	5.12	5.77	
509	5.49	5.78	5.86	
510	5.73	5.79	6.25	
MEAN	5.67	5.75	5.84	
SD	0.476	0.533	0.418	
N	10	10	10	
GROUP: 4-M:	9.0 mg base/	kg/day		
551	6.65	6.68	5.74	
552	5.65	5.85	5.47	
553	6.34	6.28	5.31	
554	6.01	4.96	5.52	
555	6.62	5.92	5.86	
556	7.57	6.01	5.68	
557	6.23	5.97	5.90	
558	6.59	5.78	••	
559	6.11	6.26	5.85	
560	6.21	5.78	5.57	
561		••	5.14	
	6.40	5.95	5.60	
MEAN	0.40	3.73	3.00	
MEAN SD	0.515	0.446	0.251	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Chloride

STUDY ID: UIC-158

SEX: MALE

	Animal ID	Week 4	Week 13	Week 26	23
	GROUP: 1 M:0	mg base/kg	/dav	• • • • • • • • • • • • • • • • • • • •	
	401	105	111	103	
	402	105	109	101	
	403	105	108	103	
	404	107	104	101	
	405	103	110	107	
	406	106	98	102	
	407	110	108	99	
	408	103	109	103	
	409	101	104	108	
	410	107	96	104	
	MEAN	105	106	103	
	SD	2.5	5.1	2.7	
	N	10	10	10	
	N GROUP: 2-M:0		10		
			10	10 	
	GROUP: 2-M:0).5 mg base/	10 kg/day		
	GROUP: 2-M:0 451).5 mg base/	10 kg/day 97	, [.] 97	
	GROUP: 2-M:0 451 452	0.5 mg base/ 102 100	10 kg/day 97 100		
	GROUP: 2-M:0 451 452 453	0.5 mg base/ 102 100 106	10 kg/day 97 100 99	. 97 108 108	
••••••	GROUP: 2-M:0 451 452 453 454	0.5 mg base/ 102 100 106 104	10 kg/day 97 100 99 102	97 108 108 103	
	GROUP: 2-M:0 451 452 453 454 455	102 106 104 102	10 kg/day 97 100 99 102 101	. 97 108 108 103 102	
	GROUP: 2-M:0 451 452 453 454 455	0.5 mg base/ 102 100 106 104 102 107	10 kg/day 97 100 99 102 101 97	108 108 108 103 102 102	
••••••	GROUP: 2-M:0 451 452 453 454 455 456 457	102 100 106 104 102 107	10 kg/day 97 100 99 102 101 97 110	108 108 103 102 102 105	
	GROUP: 2-M:0 451 452 453 454 455 456 457	102 100 106 104 102 107 102 114	10 kg/day 97 100 99 102 101 97 110	108 108 103 102 102 105 99	
	GROUP: 2-M:0 451 452 453 454 455 456 457 458	102 100 106 104 102 107 102 114	10 kg/day 97 100 99 102 101 97 110 94 102	108 108 103 102 102 105 99	
	GROUP: 2-M:0 451 452 453 454 455 456 457 458 459	102 100 106 104 102 107 102 114 101	10 kg/day 97 100 99 102 101 97 110 94 102 97	108 108 103 102 102 105 99 106	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Chloride

STUDY ID: UIC-15B STUDY NO: 152

ABBR: CL					UNITS: mEq/L
		Week 4	Week 13	Week 26	
		2.0 mg base/			
	501	112	114	107	
	502	105	100	104	
	503	104	109	106	
	504	104	108	108	
	505	106	100	104	
	506	106	97	108	
	507	106	101	110	
	508	110	110	103	
	509	109	110	100	
	510	103	109	103	
	MEAN	107	106	105	
	SD	2.9	5.7	3.0	
	N	10	10	10	
		9.0 mg base/			
	551	104	101	116	
	552	106	112	103	
	553	102	100	104	
	554	102	112	110	
	555	103	109	102	
	556	104	115	103	
	557	103	102	102	
	558	107	109		
	559	108	111	104	
	560	108	115	105	
	561			107	
	MEAN	105	109	106	
	SD	2.4	5.6	4.4	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Calcium

STUDY ID: UIC-15B STUDY NO: 152

SEX: MALE

	Week 4	Week 13	Week 26	
 GROUP: 1 M:		/dav		•
401	11.7	10.3	11.5	4
402	11.1	10.7	11.3	
403	11.1	11.3	12.5	
404	11.3	11.4	11.6	
405	12.3	11.0	11.7	
406	11.3	10.9	11.1	
407	11.6	10.5	11.8	
408	10.7	10.7	10.8	
409	10.8	11.4	11.4	
410	10.8	10.4	11.1	
MEAN	11.3	10.9	11.5	
SD	0.49	0.41	0.47	
N N	10	10	10	
	0.5 mg base/			
451	12.2	10.8	11.9	
452	11.1	10.6	11.9	
453	10.7	10.4	11.7	
454	11.0	10.6	11.3	
455		10.6 10.6	11.3 11.6	
	11.0			
455	11.0 11.2	10.6	11.6	
455 456	11.0 11.2 11.5	10.6 11.3	11.6 11.8	
455 456 457	11.0 11.2 11.5 11.5	10.6 11.3 10.9	11.6 11.8 11.5	
455 456 457 458	11.0 11.2 11.5 11.5 10.9	10.6 11.3 10.9 11.1	11.6 11.8 11.5 11.3	
455 456 457 458 459	11.0 11.2 11.5 11.5 10.9 11.2	10.6 11.3 10.9 11.1 11.3	11.6 11.8 11.5 11.3	
455 456 457 458 459 460	11.0 11.2 11.5 11.5 10.9 11.2	10.6 11.3 10.9 11.1 11.3	11.6 11.8 11.5 11.3 11.3	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Calcium

STUDY ID: UIC-15B STUDY NO: 152 SEX: MALE

APPD: CA

ABBR: CA					UNITS: mg/dL
	Animal ID	Week 4			
	GROUP: 3-M:	2.0 mg base/			
	501	11.2	11.3	11.4	
	502	10.7	10.8	11.2	
	503	10.9	11.3	12.3	
	504	10.7	10.8	11.0	
	505	11.1	10.9	11.3	
	506	11.0	10.5	11.5	
	507	11.6	11.2	11.8	
	508	11.1	10.6	11.8	
	509	11.7	10.8	11.6	
	510	11.4	10.0	11.6	
	MEAN	11.1	10.8	11.6	
	SD	0.34	0.40	0.37	
	N	10	10	10	
	GROUP · 4-M·	9.0 mg base/	'ko/dav		
	551	10.6	10.2	11.7	
	552	10.9	10.2	11.5	
	553	11.6	10.5	11.4	
	554	11.1	10.6	10.7	
	555	10.9	10.4	11.2	
	556	11.6	10.3	11.4	
	557	11.4	10.8	11.5	
	558	10.9	10.4		
	559	11.0	10.9	11.2	
	560	11.1	10.6	10.8	
	561	11.1	10.6	11.4	
	JO 1			11.4	
	MEAN	11.1	10.5	11.3	
	SD	0.33	0.24	0.32	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Inorganic Phosphorus

STUDY ID: UIC-15B

SEX: MALE

STUDY NO: 152 ABBR: IP					UNITS: mg/dL
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 1 M:				
	401	9.6	7.5	8.1	
	402	9.0	9.8	10.2	
	403	10.0	7.2	7.7	
	404	8.9	8.0	8.8	
	405	9.5	7.7	9.5	
	406	9.8	5.9	7.0	
	407	9.6	7.6	8.7	
	408	9.9	8.4	8.3	
	409	9.0	8.0	9.0	
	410	10.8	7.6	8.6	
	MEAN	9.6	7.8	8.6	
	SD	0.57	0.98	0.90	
	N	10	10	10	
	GROUP: 2-M:		kg/day		• • • • • • • • • • • • • • • • • • • •
	451	9.6	7.3	8.3	
	452	8.0	7.4	10.5	
	453	9.6	7.6	8.3	
	454	10.0	6.8	8.1	
	455	9.7	7.8	8.8	
	456	9.0	5.9	7.4	
	457	9.0	8.2	8.8	
	458	9.7	7.3	9.3	
	459	9.7	8.6	6.6	
	460	9.5	7.4	8.9	
	MEAN	9.4	7.4	8.5	
	SD	0.58	0.74	1.06	

10 10

10



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Inorganic Phosphorus

STUDY ID: UIC-15B

SEX: MALE

STUDY NO: 152

Animal ID	Week 4	Week 13		
 GROUP: 3-M	:2.0 mg base/	kg/day		
501	9.9	8.2	8.3	
502	9.2	7.5	7.1	
503	9.8	7.9	11.3	
504	9.5	7.3	7.8	
505	10.2	8.2	8.0	
506	10.5	7.8	8.4	
507	9.0	8.3	10.7	
508	9.5	8.5	9.2	
509	8.7	8.7	7.9	
510	9.7	7.8	9.1	
MEAN	9.6	8.0	8.8	
SD	0.54	0.44	1.33	
N	10	10	10	
	:9.0 mg base/	kg/day		••••
551	8.3	7.5	8.4	
552	8.2	9.0	9.3	
553	8.4	6.7	10.0	•
554	9.3	7.2	7.5	
555	10.3	8.0	8.4	
556	8.4	9.6	9.1	
557	10.6	7.1	8.4	
	0 7	8.8		
558	8.7			
559	9.2	8.5	7.9	
559 560			6.9	
559	9.2	8.5		
559 560	9.2 10.1	8.5 8.2	6.9	
559 560 561	9.2 10.1	8.5 8.2	6.9 8.0	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Glucose

STUDY ID: UIC-15B STUDY NO: 152

SEX: MALE

STUDY NO: 152 ABBR: GLU					UNITS: mg/c
	Animal ID				
	GROUP: 1 M:0		/day		
	401	134	156	157	
	402	168	268	277	
	403	163	147	180	
	404	146	176		
	405	160	139	193	
	406	138	115	135	
	407	141	143	175	
	408	265	254	170	
	409	129	167	257	
	410	165	131	184	
	MEAN	161	170	192	
	SD	39.1	51.3	43.4	
	N	10	10	10	
	GROUP: 2-M:0	7 5 ma hase/	kg/day		
	451	149	118	147	
	452	141	117	280	
	453	147	109	233	
		136	120	110	
	455	144	140	148	
	456	131	122	228	
	457	140	191	188	
	458	137	118	130	
	459	154	260	183	
	460	170	136	196	
	MEAN	145	143	184	
	SD	11.1	47.3	52.5	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Glucose

STUDY ID: UIC-15B STUDY NO: 152

ABBR: GLU					UNITS: mg/dL
,			Week 13		
	GROUP: 3-M:				•••••
	501	185	236	186	
	502	133	177	123	
	503	146	147	248	
	504	141	134	142	
	505	147	133	142	
	506	157	142	267	
	507	120	197	263	
	508	168	184	158	
	509	125	163	146	
	510	190	132	188	
	MEAN	151	165	186	
	SD	23.8	34.2	54.3	
	N	10	10	10	
	GROUP: 4-M:	0 on boss (
	551	160	111	161	
	552	126	140	174	
	553	135	110	219	
	554	134	137	136	
	555	128	139	165	
	556	122	176	163	
	557	140	112	145	
	558	135	138		
	559	121 144	140	138	
	560 561		134	106 201	
	MEAN	135	134	161	
	SD	11.7	19.6	32.6	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alanine Aminotransferase

STUDY ID: UIC-15B

SEX: FEMALE

STUDY NO: 152						
ABBR: ALT					UNITS	: IU/L
	Animal ID	Week 4	Week 13	Week 26	20	
	GROUP: 1-F:	0 mg base/kg	/day			
	426	42	47	87		
	427	58	61	225		
	428	57	80	95		
	429	45	53	65		
	430	64	71	76		
	431	55	63	83		
	432	50	80	144		
	433	42	55	70		
	434	50	83	117		
	435	49	50	168		
	MEAN	51	64	113		
	SD	7.3	13.4	51.6		
	N	10	10	10		
	GROUP: 2-F:	0.5 mg base/	kg/day			
	476	48	74	128		
	477	49	69	103		
	478	60	49	45		
	479	38	58	59		
	480	55	49	283		
	481	75	57	33		
	482	38	52	86		
	483	46	63	60		
	484	57	61	123		
	485	51	68	64		
	40)	21	00	04		
	MEAN	48	60	98		
		8.4	8.6	72.3		
	SD	10	10	10		
	N	111	111	10		



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alanine Aminotransferase

STUDY ID: UIC-15B

SEX: FEMALE

Animal ID	Week 4	Week 13	Week 26	
 				•••••
	2.0 mg base/		400	
526	51	70	108	
527	49	71	80	
528	53	66	66	
529	49	50	132	
530	51	57	99	
531	48	87	45	
532	54	63	93	
533	44	72	251	
534	49	82	243	
535	43	57	54	
MEAN	49	68	117	
SD	3.5	11.4	73.2	
N	10	10	10	
 				• • • • • • • • • • • • • • • • • • • •
GROUP: 4-F:	9.0 mg base/	kg/day		
576	47	41	99	
577	57	53	60	
578	51	65	156	
579	78	97	96	
580	54	71	75	
581	54	79	71	
582	64	82	86	
583	66	77	67	
584	52	74	70	
585	51	66	111	
MEAN	57	71	89	
SD N	9.3 10	15.6 10	28.6	

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sorbitol Dehydrogenase

STUDY ID: UIC-15B

ABBR: SDH					UNITS: IU/L
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 1-F:0				
	426	6.9	6.5	0.0	
	427	18.9	19.0	13.1	
	428	12.9	14.8	15.7	
	429	12.9	7.1	6.5	
	430	16.5	14.1	11.6	
	431	17.3	8.3	14.2	
	432	15.2	16.5	5.0	
	433	16.3	12.3	15.8	
	434	14.3	9.7	5.5	
	435	18.1	13.7	0.0	
	MEAN	14.9	12.2	8.7	
	SD	3.48	4.18	6.12	
	N	10	10	10	
	GROUP: 2-F:	0.5 mg base/	kg/day		
	476	11.4	15.7	9.3	
	477	16.1	15.7	5.8	
	478	15.8	11.4	10.2	
	479	16.6	18.3	11.1	
	480	15.3	9.1	11.5	
	481	15.4	7.7	7.4	
	482	14.8	6.8	0.0	
	483	12.9	9.6	5.3	
	484	15.5	28.6	13.6	
	485	13.8	8.4	13.2	
	MEAN	14.8	13.1	8.7	
	SD	1.60	6.69	4.19	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sorbitol Dehydrogenase

STUDY ID: UIC-15B

CTUDY NO AFS					
STUDY NO: 152 ABBR: SDH					UNITS: IU/L
		Week 4	Week 13		
	GROUP: 3-F:	2.0 mg base/	kg/day		
	526	15.9	33.0	3.9	
	527	19.0	22.5	0.0	
	528	20.4	14.5	12.5	
	529	10.8	6.5	7.4	
	530	11.3	29.2	9.9	
	531	10.3	14.6	4.3	
	532	26.9	18.6	15.8	
	533	16.8	16.9	0.0	
	534	17.0	20.7	11.2	
	535	4.0	10.2	4.9	
	MEAN	15.2	18.7	7.0	
	SD	6.40	8.11	5.30	
	SD N	6.40	8.11 10	5.30 10	
	N	10	10	10	
	N	10	10	10	
	N GROUP: 4-F:	10 9.0 mg base/	10 kg/day	10	
•••••	R GROUP: 4-F: 576	10 9.0 mg base/ 19.0	10 kg/day 16.5	0.0	
	GROUP: 4-F: 576 577	10 9.0 mg base/ 19.0 22.1	10 kg/day 16.5 19.5	0.0	
	GROUP: 4-F: 576 577 578	9.0 mg base/ 19.0 22.1 15.5	10 kg/day 16.5 19.5 17.5	0.0 6.2 0.0	
	GROUP: 4-F: 576 577 578 579	9.0 mg base/ 19.0 22.1 15.5 21.8	10 kg/day 16.5 19.5 17.5	0.0 6.2 0.0 4.3	
	GROUP: 4-F: 576 577 578 579 580	9.0 mg base/ 19.0 22.1 15.5 21.8 16.9	10 kg/day 16.5 19.5 17.5 19.0	0.0 6.2 0.0 4.3 8.0	
	GROUP: 4-F: 576 577 578 579 580	9.0 mg base/ 19.0 22.1 15.5 21.8 16.9 18.9	10 kg/day 16.5 19.5 17.5 19.0 19.2 20.1	0.0 6.2 0.0 4.3 8.0 13.2	
	GROUP: 4-F: 576 577 578 579 580 581 582	9.0 mg base/ 19.0 22.1 15.5 21.8 16.9 18.9 18.2	10 kg/day 16.5 19.5 17.5 19.0 19.2 20.1	0.0 6.2 0.0 4.3 8.0 13.2 0.0	
	GROUP: 4-F: 576 577 578 579 580 581 582 583	9.0 mg base/ 19.0 22.1 15.5 21.8 16.9 18.9 18.2 15.2	10 kg/day 16.5 19.5 17.5 19.0 19.2 20.1 15.2 12.1	0.0 6.2 0.0 4.3 8.0 13.2 0.0	
	GROUP: 4-F: 576 577 578 579 580 581 582	9.0 mg base/ 19.0 22.1 15.5 21.8 16.9 18.9 18.2	10 kg/day 16.5 19.5 17.5 19.0 19.2 20.1	0.0 6.2 0.0 4.3 8.0 13.2 0.0	
	ROUP: 4-F: 576 577 578 579 580 581 582 583 584 585	9.0 mg base/ 19.0 22.1 15.5 21.8 16.9 18.9 18.2 15.2 21.6 18.4	10 kg/day 16.5 19.5 17.5 19.0 19.2 20.1 15.2 12.1 18.2 17.0	0.0 6.2 0.0 4.3 8.0 13.2 0.0 10.1 0.9	
	ROUP: 4-F: 576 577 578 579 580 581 582 583 584 585	9.0 mg base/ 19.0 22.1 15.5 21.8 16.9 18.9 18.2 15.2 21.6 18.4	10 kg/day 16.5 19.5 17.5 19.0 19.2 20.1 15.2 12.1 18.2 17.0	0.0 6.2 0.0 4.3 8.0 13.2 0.0 10.1 0.9 15.1	
•	ROUP: 4-F: 576 577 578 579 580 581 582 583 584 585	9.0 mg base/ 19.0 22.1 15.5 21.8 16.9 18.9 18.2 15.2 21.6 18.4	10 kg/day 16.5 19.5 17.5 19.0 19.2 20.1 15.2 12.1 18.2 17.0	0.0 6.2 0.0 4.3 8.0 13.2 0.0 10.1 0.9	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Protein

STUDY ID: UIC-158

STUDY NO: 152 ABBR: TP					UNITS: g/dL
	Animal ID		Week 13	Week 26	
	GROUP: 1-F:	0 mg base/kg	/day		
	426	7.3	6.8	9.2	
	427	7.7	7.9	10.0	
	428	7.2	7.3	9.4	
	429	6.8	7.7	9.4	
	430	8.1	8.8	9.1	
	431	6.9	7.7	9.4	
	432	7.1	6.8	9.3	
	433	6.9	7.7	10.3	
	434	7.5	8.5	11.7	
	435	7.5	8.1	10.8	
	MEAN	7.3	7.7	9.9	
	SD	0.41	0.65	0.85	
	N	10	10	10	
					• • • • • • • • • • • • • • • • • • • •
	GROUP: 2-F:				
	476	6.7	8.0	9.2	
	477	6.9	8.4	9.5	
	478	7.4	7.7	10.0	,
	479	7.5	8.4	8.6	
	480	8.3	8.1	9.4	
	481	7.2	9.2	9.6	
	482	6.3	7.4	8.4	
	483	6.9	7.9	8.7	
	484	7.5	7.3	9.3	
	485	7.6	8.0	8.8	
	MEAN	7.2	8.0	9.2	
	SD	0.56	0.55	0.51	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Protein

STUDY ID: UIC-15B

STUDY NO: 152 ABBR: TP					UNITS: g/dL
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 3-F:			0.5	
	526	7.3	7.5	9.5	
	527	7.0	7.5	9.2	
	528	7.7	8.1	9.8	
	529	6.8	7.7	10.2	
	530	7.1	6.9	9.5	
	531	7.8	9.3	9.9	
	532	8.0	8.2	11.1	
	533	7.5	8.1	9.7	
	534	6.9	7.0	9.9	
	535	7.4	7.0	9.2	
	MEAN	7.4	7.7	9.8	
	SD	0.40	0.73	0.56	
	N	10	10	10	
	GROUP: 4-F:				
	576	6.8	6.9	8.2	
	577	7.7	8.7	8.9	
	578	7.0	8.5	10.0	
	579	7.8	8.0	9.7	
	580	7.0	7.2	9.1	
	581	7.1	7.6	8.3	
	582	7.3	6.7	9.5	
	583	6.8	7.3	9.3	
	584	7.9	7.8	9.1	
	585	7.0	7.9	8.7	
	MEAN	7.2	7.7	9.1	
	SD	0.41	0.65	0.58	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Albumin

STUDY ID: UIC-15B STUDY NO: 152

 Animal ID		Week 13		
GROUP: 1-F:0				
426	4.1	4.2	4.2	
427	4.3	4.5	4.4	
428	3.9	4.4	4.7	
429	4.1	4.6	4.7	
430	4.6	5.1	4.5	
431	3.7	4.2	4.4	
432	3.8	4.4	4.8	
433	3.9	4.7	5.1	
434	3.9	5.0	4.7	
435	4.4	4.5	5.0	
MEAN	4.1	4.6	4.7	
SD	0.29		0.28	
N	10	10	10	
GROUP: 2-F:0 476	.5 mg base/	kg/day	4.3	,
GROUP: 2-F:0	.5 mg base/	kg/day		
GROUP: 2-F:0 476	3.8 mg base/	kg/day 4.4	4.3	
GROUP: 2-F:0 476 477	3.8 3.5	kg/day 4.4 4.4	4.3	
GROUP: 2-F:0 476 477 478	3.8 3.5 4.1	kg/day 4.4 4.4 4.3	4.3 4.5 5.0	
GROUP: 2-F:0 476 477 478 479 480	3.8 3.5 4.1 4.2 4.3	kg/day 4.4 4.3 4.7 4.4	4.3 4.5 5.0 4.7 4.7	,
GROUP: 2-F:0 476 477 478 479 480 481	3.8 3.5 4.1 4.2 4.3 4.0	kg/day 4.4 4.3 4.7 4.4 5.5	4.3 4.5 5.0 4.7 4.7 4.5	,
GROUP: 2-F:0 476 477 478 479 480 481 482	3.8 3.5 4.1 4.2 4.3 4.0 3.6	kg/day 4.4 4.3 4.7 4.4 5.5	4.3 4.5 5.0 4.7 4.7 4.5	
GROUP: 2-F:0 476 477 478 479 480 481 482 483	3.8 3.5 4.1 4.2 4.3 4.0 3.6 3.9	kg/day 4.4 4.3 4.7 4.4 5.5 4.1 4.6	4.3 4.5 5.0 4.7 4.7 4.5 4.4	
GROUP: 2-F:0 476 477 478 479 480 481 482	3.8 3.5 4.1 4.2 4.3 4.0 3.6	kg/day 4.4 4.3 4.7 4.4 5.5	4.3 4.5 5.0 4.7 4.7 4.5	
GROUP: 2-F:0 476 477 478 479 480 481 482 483 484	3.8 3.5 4.1 4.2 4.3 4.0 3.6 3.9 4.3	kg/day 4.4 4.3 4.7 4.4 5.5 4.1 4.6 4.5	4.3 4.5 5.0 4.7 4.7 4.5 4.4 4.4 4.9	
GROUP: 2-F:0 476 477 478 479 480 481 482 483 484 485	3.8 3.5 4.1 4.2 4.3 4.0 3.6 3.9 4.3 4.2	kg/day 4.4 4.3 4.7 4.4 5.5 4.1 4.6 4.5 5.0	4.3 4.5 5.0 4.7 4.7 4.5 4.4 4.4 4.9 4.8	
GROUP: 2-F:0 476 477 478 479 480 481 482 483 484	3.8 3.5 4.1 4.2 4.3 4.0 3.6 3.9 4.3	kg/day 4.4 4.3 4.7 4.4 5.5 4.1 4.6 4.5	4.3 4.5 5.0 4.7 4.7 4.5 4.4 4.4 4.9	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Albumin

STUDY ID: UIC-15B STUDY NO: 152

 				UNITS: g/dL
Animal ID		Week 13		
	2.0 mg base/			
526	4.2	4.6	4.9	
527	3.9	5.0	4.6	
528	4.3	4.7	4.4	
529	3.6	4.1	5.0	
530	3.8	3.9	4.7	
531	4.2	5.3	4.9	
532	4.4	4.4	4.9	
533	4.2	4.6	4.5	
534	3.8	4.1	4.8	
535	4.1	4.3	4.6	
MEAN	4.1	4.5	4.7	
SD	0.26	0.43	0.20	
N	10	10	10	
 	.0.0 == b=== /			
	9.0 mg base/			
 576	3.6	4.2	4.2	
 576 577	3.6 4.3	4.2 5.1	4.6	
 576 577 578	3.6 4.3 3.7	4.2 5.1 4.6	4.6 5.1	
 576 577 578 579	3.6 4.3 3.7 4.4	4.2 5.1 4.6 4.5	4.6 5.1 4.6	,
 576 577 578 579 580	3.6 4.3 3.7 4.4 4.0	4.2 5.1 4.6 4.5 4.5	4.6 5.1 4.6 4.7	,
 576 577 578 579 580 581	3.6 4.3 3.7 4.4 4.0 3.7	4.2 5.1 4.6 4.5 4.5	4.6 5.1 4.6 4.7 4.3	
576 577 578 579 580 581 582	3.6 4.3 3.7 4.4 4.0 3.7 3.9	4.2 5.1 4.6 4.5 4.5 4.0	4.6 5.1 4.6 4.7 4.3 4.8	······································
576 577 578 579 580 581 582 583	3.6 4.3 3.7 4.4 4.0 3.7 3.9 3.8	4.2 5.1 4.6 4.5 4.5 4.0 4.0	4.6 5.1 4.6 4.7 4.3 4.8 5.1	
576 577 578 579 580 581 582 583	3.6 4.3 3.7 4.4 4.0 3.7 3.9 3.8 4.3	4.2 5.1 4.6 4.5 4.5 4.0 4.0 4.5	4.6 5.1 4.6 4.7 4.3 4.8 5.1	
576 577 578 579 580 581 582 583	3.6 4.3 3.7 4.4 4.0 3.7 3.9 3.8	4.2 5.1 4.6 4.5 4.5 4.0 4.0	4.6 5.1 4.6 4.7 4.3 4.8 5.1	<u>, </u>
576 577 578 579 580 581 582 583	3.6 4.3 3.7 4.4 4.0 3.7 3.9 3.8 4.3 3.9	4.2 5.1 4.6 4.5 4.5 4.0 4.0 4.5 4.7 4.3	4.6 5.1 4.6 4.7 4.3 4.8 5.1 4.9 4.4	
576 577 578 579 580 581 582 583 584 585	3.6 4.3 3.7 4.4 4.0 3.7 3.9 3.8 4.3 3.9	4.2 5.1 4.6 4.5 4.5 4.0 4.0 4.5 4.7	4.6 5.1 4.6 4.7 4.3 4.8 5.1 4.9	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Globulin

STUDY ID: UIC-158

STUDY NO: 152

			Week 26	,
				• • • • • • • • • • • • • • • • • • • •
	:0 mg base/kg		F 0	
426	3.2	2.6		
427	3.4	3.4	5.6	
428	3.3	2.9	4.7	
429	2.7	3.1	4.7	
430	3.5	3.7	4.6	
431	3.2	3.5	5.0	
432	3.3	2.4	4.5	
433	3.0	3.0	5.2	
434	3.6	3.5	7.0	
435	3.1	3.6	5.8	
MEAN	3.2	3.2	5.2	
SD	0.26	0.44	0.76	
N	10	10	10	
 			10	
 GROUP: 2-F	:0.5 mg base/	kg/day		
 GROUP: 2-F 476	:0.5 mg base/	kg/day 3.6	4.9	
 GROUP: 2-F 476 477	:0.5 mg base/ 2.9 3.4	kg/day 3.6 4.0	4.9 5.0	
 GROUP: 2-F 476 477 478	:0.5 mg base/ 2.9 3.4 3.3	kg/day 3.6 4.0 3.4	4.9 5.0 5.0	
 GROUP: 2-F 476 477 478 479	:0.5 mg base/ 2.9 3.4 3.3 3.3	kg/day 3.6 4.0 3.4 3.7	4.9 5.0 5.0 3.9	
 GROUP: 2-F 476 477 478 479 480	:0.5 mg base/ 2.9 3.4 3.3 3.3 4.0	kg/day 3.6 4.0 3.4 3.7 3.7	4.9 5.0 5.0 3.9 4.7	
 GROUP: 2-F 476 477 478 479 480 481	:0.5 mg base/ 2.9 3.4 3.3 3.3 4.0 3.?	kg/day 3.6 4.0 3.4 3.7 3.7	4.9 5.0 5.0 3.9 4.7 5.1	
 GROUP: 2-F 476 477 478 479 480 481 482	:0.5 mg base/ 2.9 3.4 3.3 3.3 4.0 3.2 2.7	kg/day 3.6 4.0 3.4 3.7 3.7 3.7 3.7	4.9 5.0 5.0 3.9 4.7 5.1 4.0	
 GROUP: 2-F 476 477 478 479 480 481 482 483	:0.5 mg base/ 2.9 3.4 3.3 3.3 4.0 3.7 2.7 3.0	kg/day 3.6 4.0 3.4 3.7 3.7 3.7 3.3	4.9 5.0 5.0 3.9 4.7 5.1 4.0	
 GROUP: 2-F 476 477 478 479 480 481 482 483	:0.5 mg base/ 2.9 3.4 3.3 3.3 4.0 3.7 2.7 3.0 3.2	kg/day 3.6 4.0 3.4 3.7 3.7 3.7 3.3 2.8	4.9 5.0 5.0 3.9 4.7 5.1 4.0 4.3	
 GROUP: 2-F 476 477 478 479 480 481 482 483	:0.5 mg base/ 2.9 3.4 3.3 3.3 4.0 3.7 2.7 3.0	kg/day 3.6 4.0 3.4 3.7 3.7 3.7 3.3	4.9 5.0 5.0 3.9 4.7 5.1 4.0	
 GROUP: 2-F 476 477 478 479 480 481 482 483	:0.5 mg base/ 2.9 3.4 3.3 3.3 4.0 3.7 2.7 3.0 3.2	kg/day 3.6 4.0 3.4 3.7 3.7 3.7 3.3 2.8	4.9 5.0 5.0 3.9 4.7 5.1 4.0 4.3	
 GROUP: 2-F 476 477 478 479 480 481 482 483 484	:0.5 mg base/ 2.9 3.4 3.3 3.3 4.0 3.7 2.7 3.0 3.2 3.4	kg/day 3.6 4.0 3.4 3.7 3.7 3.7 3.3 3.3 2.8 3.0	4.9 5.0 5.0 3.9 4.7 5.1 4.0 4.3 4.4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Globulin

			 CPOLID	3-5-2 (ma	hasa/k	a/day				 				-
			Animal	1D	Week	4	Week	13	Week	26					
ABBR:			 								 		ITS:	-	
STUDY	NO: 1	152													
STUDY	ID: L	JIC-15B										SE	X: FE	MALE	

Animal ID	week 4	week 13	week 20	
 GROUP: 3-F:2	2.0 mg base/	kg/dav		
526	3.1	2.9	4.6	
527	3.1	2.5	4.6	
528	3.4	3.4	5.4	
529	3.2	3.6	5.2	
530	3.3	3.0	4.8	
531	3.6	4.0	5.0	
532	3.6	3.8	6.2	
533	3.3	3.5	5.2	
534	3.1	2.9	5.1	
535	3.3	2.7	4.6	
MEAN	3.3	3.2	5.1	
SD	0.19	0.50	0.49	
N	10	10	10	
GROUP: 4-F:9	0.0 mg base/	kg/day		
576	3.2	2.7	4.0	
577	3.4	3.6	4.3	
578	3.3	3.9	4.9	
579	3.4	3.5	5.1	

GROUP: 4-	F:9.0 mg base/i	cg/day	
576	3.2	2.7	4.0
577	3.4	3.6	4.3
578	3.3	3.9	4.9
579	3.4	3.5	5.1
580	3.0	2.7	4.4
581	3.4	3.6	4.0
582	3.4	2.7	4.7
583	3.0	2.8	4.2
584	3.6	3.1	4.2
585	3.1	3.6	4.3
MEAN	3.3	3.2	4.4
SD	0.20	0.47	0.37
M	10	10	10



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: A/G Ratio

STUDY ID: UIC-158

ABBR: A/G					UNITS: -
	Animal ID	Week 4	Week 13		
	GROUP: 1-F:0	mg base/kg	/day		••••••
	426	1.28	1.62	0.84	
	427	1.26	1.32	0.79	
	428	1.18	1.52	1.00	
	429	1.52	1.48	1.00	
	430	1.31	1.38	0.98	
	431	1.16	1.20	0.88	
	432	1.15	1.83	1.07	
	433	1.30	1.57	0.98	
	434	1.08	1.43	0.67	
	435	1.42	1.25	0.86	
	MEAN	1.27	1.46	0.91	
	SD	0.133	0.188	0.121	
	N	10	10	10	
			1000		
					• • • • • • • • • • • • • • • • • • • •
	GROUP: 2-F:0				
	476	1.31	1.22	0.88	
	477	1.03	1.10	0.90	
	478	1.24	1.26	1.00	
	479	1.27	1.27	1.21	
	480	1.08	1.19	1.00	
	481	1.25	1.49	0.88	
	482	1.33	1.24	1.10	
	483	1.30	1.39	1.02	
	484	1.34	1.61	1.11	
	485	1.24	1.67	1.20	
	MEAN	1.24	1.34	1.03	
	SD	0.104	0.189	0.123	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: A/G Ratio

STUDY ID: UIC-158 STUDY NO: 152

ABBR: A/G					UNITS: -
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 3-F:	2.0 mg base/	kg/day		
	526	1.35	1.59	1.07	
	527	1.26	2.00	1.00	
	528	1.26	1.38	0.81	
	529	1.13	1.14	0.96	
	530	1.15	1.30	0.98	
	531	1.17	1.33	0.98	
	532	1.22	1.16	0.79	
	533	1.27	1.31	0.87	
	534	1.23	1.41	0.94	
	535	1.24	1.59	1.00	
	MEAN	1.23	1.42	0.94	
	SD	0.065	0.253	0.089	
	N	10	10	10	
	GROUP: 4-F:	9.0 mg base/	kg/day		
	576	1.13	1.56	1.05	
	577	1.26	1.42	1.07	
	578	1.12	1.18	1.04	
	579	1.29	1.29	0.90	
	580	1.33	1.67	1.07	
	581	1.09	1.11	1.08	
	582	1.15	1.48	1.02	
	583	1.27	1.61	1.21	
	584	1.19	1.52	1.17	
	585	1.26	1.19	1.02	
	MEAN	1.21	1.40	1.06	
	SD	0.083	0.198	0.085	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Bile Acids

STUDY ID: UIC-15B

STUDY NO: 152

ABBR: TBA					
		Week 4	Week 13	Week 26	2.
	GROUP: 1-F:		/day		
	426	26.0	35.1	78.5	
	427	13.2	27.4	124.3	
	428	36.4	47.2	38.0	
	429	21.9	42.3	151.5	
	430	19.9	24.6	94.3	
	431	22.1	34.4	59.3	
	432	18.9	39.3	83.5	
	433	59.8	128.3	84.5	
	434	20.2	29.0	47.6	
	435	17.3	43.8	177.3	
	MEAN	25.6	45.1	93.9	
	SD	13.51	30.14	44.84	
	N	10	10	10	
	N	10	10	10	
	GROUP: 2-F:	0.5 mg base/	kg/day		
			kg/day 30.7		
	GROUP: 2-F:	0.5 mg base/	kg/day		
	GROUP: 2-F::	0.5 mg base/ 19.0	kg/day 30.7	41.8	
	GROUP: 2-F: 476 477	0.5 mg base/ 19.0 27.6	kg/day 30.7 97.6	41.8 73.2	
	GROUP: 2-F: 476 477 478	0.5 mg base/ 19.0 27.6 16.1	kg/day 30.7 97.6 40.2	41.8 73.2 96.1	
	GROUP: 2-F: 476 477 478 479	0.5 mg base/ 19.0 27.6 16.1 19.3	30.7 97.6 40.2 31.5	41.8 73.2 96.1 82.7	
	GROUP: 2-F: 476 477 478 479 480	0.5 mg base/ 19.0 27.6 16.1 19.3 20.2	30.7 97.6 40.2 31.5 23.7	41.8 73.2 96.1 82.7 156.4	
	GROUP: 2-F: 476 477 478 479 480 481	0.5 mg base/ 19.0 27.6 16.1 19.3 20.2 24.5	30.7 97.6 40.2 31.5 23.7 43.1	41.8 73.2 96.1 82.7 156.4 45.1	
	GROUP: 2-F: 476 477 478 479 480 481 482	0.5 mg base/ 19.0 27.6 16.1 19.3 20.2 24.5	kg/day 30.7 97.6 40.2 31.5 23.7 43.1 52.8 46.8	41.8 73.2 96.1 82.7 156.4 45.1 65.7 64.5	
	GROUP: 2-F: 476 477 478 479 480 481 482 483	0.5 mg base/ 19.0 27.6 16.1 19.3 20.2 24.5 18.6 20.0	kg/day 30.7 97.6 40.2 31.5 23.7 43.1 52.8	41.8 73.2 96.1 82.7 156.4 45.1 65.7	
	GROUP: 2-F: 476 477 478 479 480 481 482 483	19.0 27.6 16.1 19.3 20.2 24.5 18.6 20.0 21.0	kg/day 30.7 97.6 40.2 31.5 23.7 43.1 52.8 46.8 277.8	41.8 73.2 96.1 82.7 156.4 45.1 65.7 64.5 81.9	
	GROUP: 2-F: 476 477 478 479 480 481 482 483 484	19.0 27.6 16.1 19.3 20.2 24.5 18.6 20.0 21.0 40.8	kg/day 30.7 97.6 40.2 31.5 23.7 43.1 52.8 46.8 277.8 222.2	41.8 73.2 96.1 82.7 156.4 45.1 65.7 64.5 81.9	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Bile Acids

STUDY ID: UIC-15B

STUDY NO: 152

Animal ID	Week 4	Week 13	Week 26	
GROUP: 3-F:	2.0 mg base/	kg/day		
526	71.2	93.8	62.0	
527	16.2	58.3	121.3	
528	30.9	46.6	53.4	
529	19.0	69.6	44.9	
530	23.4	21.2	115.4	
531	35.1	87.3	84.4	
532	24.3	35.4	50.2	
533	21.0	36.3	75.4	
534	15.7	56.8	54.8	
535	37.7	91.7	163.1	
MEAN	29.5	59.7	82.5	
SD	16.51	25.49	38.92	
N	10	10	10	
 				•••••
GROUP: 4-F:	9.0 mg base/	kg/day		
GROUP: 4-F:	9.0 mg base/ 31.5	kg/day 33.4	159.6	
			159:6 82:4	
576	31.5	33.4		
576 577	31.5 22.6	33.4 145.4	82.4	
576 577 578	31.5 22.6 55.9	33.4 145.4 102.8	82.4 596.7	
576 577 578 579	31.5 22.6 55.9 71.7	33.4 145.4 102.8 63.6	82.4 596.7 221.0	
576 577 578 579 580	31.5 22.6 55.9 71.7 27.0	33.4 145.4 102.8 63.6 127.0	82.4 596.7 221.0 47.3	
576 577 578 579 580 581	31.5 22.6 55.9 71.7 27.0 37.3	33.4 145.4 102.8 63.6 127.0 101.0	82.4 596.7 221.0 47.3 130.5	
576 577 578 579 580 581 582	31.5 22.6 55.9 71.7 27.0 37.3 12.5	33.4 145.4 102.8 63.6 127.0 101.0 26.9	82.4 596.7 221.0 47.3 130.5 85.7	
576 577 578 579 580 581 582 583	31.5 22.6 55.9 71.7 27.0 37.3 12.5 38.5	33.4 145.4 102.8 63.6 127.0 101.0 26.9 101.5	82.4 596.7 221.0 47.3 130.5 85.7 66.4	
576 577 578 579 580 581 582 583 584	31.5 22.6 55.9 71.7 27.0 37.3 12.5 38.5 52.5	33.4 145.4 102.8 63.6 127.0 101.0 26.9 101.5 87.2	82.4 596.7 221.0 47.3 130.5 85.7 66.4 79.6	
576 577 578 579 580 581 582 583 584 585	31.5 22.6 55.9 71.7 27.0 37.3 12.5 38.5 52.5 18.9	33.4 145.4 102.8 63.6 127.0 101.0 26.9 101.5 87.2	82.4 596.7 221.0 47.3 130.5 85.7 66.4 79.6 69.4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alkaline Phosphatase

STUDY ID: UIC-15B

STUDY NO: 152

Animal ID	Week 4	Week 13	Week 26	
 GROUP: 1-F:0	ma base/ka	/day		
426	167	105	118	
427	237	147	111	
428	168	105	86	
429	232	126	121	
430	301	189	205	
431	191	113	77	
432	217	119	86	
433	234	149	106	
434	153	115	102	
435	233	112	89	
103	255		0,	
MEAN	213	128	110	
SD	44.4	26.5	36.5	
N	10	10	10	
 GROUP: 2-F:0	.5 mg base/	kg/day		
476	201	129	79	
477	312			
	316	232	170	
		232 112	175 99	
478	206	112	99	
478 479	206 136	112 100	99 74	
478 479 480	206 136 260	112 100 111	99 74 82	
478 479 480 481	206 136 260 147	112 100 111 114	99 74 82 105	
478 479 480 481 482	206 136 260 147 228	112 100 111 114 351	99 74 82 105 78	
478 479 480 481 482 483	206 136 260 147 228 299	112 100 111 114 351	99 74 82 105 78 134	
478 479 480 481 482 483	206 136 260 147 228 299 224	112 100 111 114 351 180 124	99 74 82 105 78 134 89	
478 479 480 481 482 483	206 136 260 147 228 299	112 100 111 114 351	99 74 82 105 78 134	
478 479 480 481 482 483	206 136 260 147 228 299 224	112 100 111 114 351 180 124	99 74 82 105 78 134 89	
478 479 480 481 482 483 484	206 136 260 147 228 299 224 355	112 100 111 114 351 180 124 308	99 74 82 105 78 134 89 225	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alkaline Phosphatase

STUDY ID: UIC-158 STUDY NO: 152

ABBR: ALKP					UNITS: IU/L
	Animal ID	Week 4	Week 13	Week 26	
		2.0 mg base/			
	526	212	84	85	
	527	511	344	382	
	528	147	103	73	
	529	195	155	133	
	530	155	107	88	
	531	134	90	59	
	532	367	229	179	
	533	236	145	137	
	534	268	120	125	
	535	193	134	103	
	MEAN	242	151	136	
	SD	116.7	79.6	93.3	
	N	10	10	10	
	CDOUD. / - E-	9.0 mg base/	ka (dou		
				104	
	576 577	162 255	86 168	106 129	
	578	204	122	122	
	579	437	277	258	
	580	153	90	111	
	581	314	224	176	
	582	175	104	99	
	583	309	267	237	
	584	395	249	209	
	585	191	119	84	
	MEAN	260	171	153	
		100 /	76.5	12.7	
	SD	100.6 10	10	62.3 10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Lactate Dehydrogenase

STUDY ID: UIC-158

SEX: FEMALE

STUDY NO: 152

ABBR: LOH					UNITS: IU/L
	Animal ID	Week 4	Week 13	Week 26	
***************************************	GROUP: 1-F	:0 mg base/kg	ı/day		
	426	810	853	505	
	427	223	187	1103	
	428	374	318	366	
	429	108	460	318	
	430	154	292	250	
	431	209	555	242	
	432	181	391	505	
	433	123	453	273	
	434	113	639	513	
	435	230	287	756	
	MEAN	253	444	483	
	SD	211.0	197.3	270.4	
	N	10	10	10	
		0.5 1			•••••
		:0.5 mg base/		070	
	476	407	138	839	
	477	336	722	356	
	478	265	367	487	
	479	62	152	437	
	480	343	471	1042	
	481	188	815	293	
	482	100	388	442	
	483	215	544	755	
	484	180	249	544	
	485	302	727	302	
	MEAN	240	457	550	
	SO	110.8	242.7	249.7	

10

10



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Lactate Dehydrogenase

STUDY ID: UIC-15B

STUDY NO: 152 ABBR: LDH					UNITS: IU/L
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 3-F:	2.0 mg base/	kg/day		
	526	315	164	662	
	527	170	187	592	
	528	637	322	127	
	529	518	703	510	
	530	466	344	378	
	531	529	403	484	
	532	113	156	149	
	533	169	328	968	
	534	131	207	455	
	535	872	386	534	
	MEAN	392	320	486	
	SD	254.2	163.4	243.2	
	N	10	10	10	
	CROUD. 4-E-	9.0 mg base/			
	576	64	340	/17	
				417	
	577	229	212	248	
	578	228	311	999	
	579	244	402	539	
	580	356	290	300	
	581	119	217	267	
	582	137	852	522	
	583	212	521	596	
	584	127	280	432	
	585	109	327	545	
	MEAN	183	375	487	
	SD	86.7	190.0	218.5	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatine Kinase

STUDY ID: UIC-15B

DUITE. THE
UNITS: IU/L
<u> </u>



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatine Kinase

STUDY ID: UIC-15B

SEX: FEMALE

STUDY NO: 152

STUDY NO: 152 ABBR: CK					UNITS: IU/L
ADDR. UK					ONITS: TO/L
	Animal ID		Week 13	Week 26	
		2.0 mg base/			
	526	350	216	237	
	527	119	831	1818	
	528	273	159	187	
	529	337	346	468	
	530	212	336	136	
	531	212	166	366	
	532	99	181	71	
	533	103	648	2834	
	534	82	577	142	
	535	808	619	267	
	MEAN	260	408	653	
	SD	216.3	242.1	921.2	
	N	10	10	10	
	GROUP: 4-F:	9.0 mg base/	kg/day		
	576	131	173	170	
	577	233	134	604	
	578	152	513	2514	
	579	130	119	156	
	580	233	400	432	
	581	92	176	126	
	582	116	384	276	
	583	126	250	326	
	584	111	120	548	
	585	163	131	736	
	MEAN	149	240	589	
	SD	48.7	142.1	707.0	

10

10

10



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Blood Urea Nitrogen

STUDY ID: UIC-158					SEX: FEMALE
STUDY NO: 152					
ABBR: BUN					UNITS: mg/dL
	Animal ID	Week 4	Week 13	Week 26	24
	GROUP: 1-F:				
	426	18.4	15.3	23.1	
	427	16.5	14.8	17.7	
	428	19.9	19.1	19.6	
	429	20.8	14.5	17.1	
	430	17.5	19.6	18.9	
	431	19.0	14.6	17.5	
	432	17.5	18.4	17.7	
	433	18.6	15.8	16.3	
	434	16.1	23.0	19.5	
	435	19.6	12.4	20.1	
	MEAN	18.4	16.8	18.8	
	SD	1.50	3.18	1.96	
	N	10	10	10	
					•••••
		0.5 mg base/			
	476	18.3	21.3	15:0	
	477	15.9	13.3	19.2	
	478	19.9	16.3	20.2	
	479	16.4	15.7	15.9	
	480	16.4	15.8	18.1	
	481	16.5	15.2	14.7	
	482	19.4	21.2	20.5	
	483	20.6	16.7	19.3	
	484	20.4	23.0	18.4	
	485	19.3	24.8	20.1	
	MEAN	18.3	18.3	18.1	
	SD	1.85	3.89	2.18	
	N	10	10	10	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Blood Urea Nitrogen

STUDY ID: UIC-15B STUDY NO: 152

SEX: FEMALE

STUDY NO: 152

Animal ID	Week 4	Week 13		
 GROUP: 3-F:	2.0 mg base/	kg/day	•	•••••••••••
526	22.2	21.7	21.7	
527	17.6	18.1	19.5	
528	21.9	21.5	18.1	
529	18.1	18.4	21.2	
530	17.8	18.8	20.0	
531	20.4	16.6	17.6	
532	17.9	15.1	15.0	
533	19.9	19.4	17.8	
534	18.6	17.0	16.6	
535	20.4	21.5	20.0	
MEAN	19.5	18.8	18.8	
SD	1.72	2.26	2.10	
N	10	10	10	
 GROUP: 4-F:	9.0 mg base/	ka/dav		**********
576	18.4	14.2	18.5	
577	19.3	13.5	15.5	
578	14.9	13.0	16.7	
579	17.1	14.3	18.3	
580	15.7	19.0	15.5	
581	18.1	12.4	15.4	
582	19.9	20.5	16.7	
583	14.6	18.2	15.9	
584	22.4	14.7	13.0	
585	19.3	16.0	13.9	
MEAN	18.0	15.6	15.9	
SD	2.44	2.76	1.72	
N	10	10	10	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatinine

STUDY ID: UIC-158

STUDY ID: UIC-15B					SEX: FEMALE
STUDY NO: 152 ABBR: CREAT					UNITS: mg/dL
	Animal IO	Week 4	Week 13	Week 26	
	GROUP: 1-F:	0 mg base/kg	ı/day		
	426	0.59	0.57	0.81	
	427	0.57	0.52	0.67	
	428	0.53	0.57	0.63	
	429	0.53	0.50	0.54	
	430	0.52	0.59	0.64	
	431	0.53	0.54	0.67	
	432	0.59	0.80	0.68	
	433	0.51	0.64	0.46	
	434	0.55	0.67	0.65	
	435	0.55	0.57	0.73	
	MEAN	0.55	0.60	0.65	
	SD	0.028	0.088	0.096	
	N	10	10	10	
	GROUP: 2-F:	0.5 mg base/	kg/day		
	476	0.57	0.31	0.65	
	477	0.48	0.52	0.60	
	478	0.55	0.55	0.63	
	479	0.57	0.54	0.61	
	480	0.61	0.58	0.72	
	481	0.49	0.48	0.69	
	482	0.61	0.62	0.70	
	483	0.53	0.58	0.62	
	484	0.61	0.71	0.53	
	485	0.55	0.63	0.75	
	MEAN	0.56	0.55	0.65	
	SD	0.047	0.107	0.066	
	N	10	10	10	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatinine

STUDY ID: UIC-158 STUDY NO: 152

ABBR: CREAT					UNITS: mg/dL
	Animal ID	Week 4			
	GROUP - 3-F-	2.0 mg base/	kg/day		•••••
	526	0.64	0.73	0.66	
	527	0.56	0.70	0.69	
	528	0.61	0.63	0.71	
	529	0.50	0.56	0.73	
	530	0.64	0.55	0.60	
	531	0.53	0.52	0.57	
	532	0.59	0.61	0.66	
	533	0.55	0.61	0.79	
	534	0.62	0.74	0.68	
	535	0.50	0.62	0.62	
	737	0.50	0.62	0.02	
	MEAN	0.57	0.63	0.67	
	SD	0.054	0.075	0.065	
	N	10	10	10	
	GROUP: 4-F:	9.0 mg base/	kg/day		***************************************
	576				
		U.DI	0.65	0.73	
	577	0.61	0.65	0.73 0.68	
	577 578	0.59	0.53	0.68	
	578	0.59 0.54	0.53 0.54	0. 68 0.79	
	578 579	0.59 0.54 0.58	0.53 0.54 0.59	0.68 0.79 0.54	
	578 579 580	0.59 0.54 0.58 0.54	0.53 0.54 0.59 0.46	0.68 0.79 0.54 0.61	
	578 579 580 581	0.59 0.54 0.58 0.54 0.57	0.53 0.54 0.59 0.46 0.57	0.68 0.79 0.54 0.61 0.59	
	578 579 580 581 582	0.59 0.54 0.58 0.54 0.57	0.53 0.54 0.59 0.46 0.57 0.56	0.68 0.79 0.54 0.61 0.59 0.59	
	578 579 580 581 582 583	0.59 0.54 0.58 0.54 0.57 0.58 0.59	0.53 0.54 0.59 0.46 0.57 0.56 0.73	0.68 0.79 0.54 0.61 0.59 0.59	
	578 579 580 581 582 583 584	0.59 0.54 0.58 0.54 0.57 0.58 0.59	0.53 0.54 0.59 0.46 0.57 0.56 0.73 0.53	0.68 0.79 0.54 0.61 0.59 0.59 0.65	
	578 579 580 581 582 583	0.59 0.54 0.58 0.54 0.57 0.58 0.59	0.53 0.54 0.59 0.46 0.57 0.56 0.73	0.68 0.79 0.54 0.61 0.59 0.59	
	578 579 580 581 582 583 584	0.59 0.54 0.58 0.54 0.57 0.58 0.59	0.53 0.54 0.59 0.46 0.57 0.56 0.73 0.53	0.68 0.79 0.54 0.61 0.59 0.59 0.65	
	578 579 580 581 582 583 584 585	0.59 0.54 0.58 0.54 0.57 0.58 0.59 0.57	0.53 0.54 0.59 0.46 0.57 0.56 0.73 0.53	0.68 0.79 0.54 0.61 0.59 0.59 0.65 0.58	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sodium

STUDY ID: UIC-15B

ABBR: NA					UNITS: mEq/L
	Animal ID		Week 13	Week 26	
	GROUP: 1-F:0	mg base/kg			
	426	144	143	147	
	427	145	146	146	
	428	143	145	143	
	429	145	143	143	
	430	145	144	145	
	431	144	144	147	
	432	144	148	145	
	433	143	144	143	
	434	146	147	149	
	435	142	144	147	
	MEAN	144	145	146	
	SD	1.2	1.7	2.1	
	N	10	10	10	
	GROUP: 2-F:0				
	476	142	146	145	
	477	4/0	142	146	
	478	143	145	146	
	479	146	145	145	
		140	173	170	
	ሬጸበ	145	147	147	
	480 481	145	147	147	
	481	144	145	147	
	481 482	144 144	145 146	147 150	
	481 482 483	144 144 144	145 146 144	147 150 144	
	481 482 483 484	144 144 144 144	145 146 144 143	147 150 144 146	
	481 482 483	144 144 144	145 146 144	147 150 144	
	481 482 483 484 485	144 144 144 144 145	145 146 144 143 146	147 150 144 146 147	
	481 482 483 484 485	144 144 144 144 145	145 146 144 143 146	147 150 144 146 147	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sodium

STUDY ID: UIC-15B

STUDY NO: 152					
ABBR: NA					UNITS: mEq/L
	Animal ID				
		2.0 mg base/	kg/day		
	526	143	144	145	
	527	145	147	146	
	528	143	146	148	
	529	144	143	146	
	530	142	144	143	
	531	142	147	145	
	532	146	151	147	
	533	142	148	147	
	534	144	142	147	
	535	147	149	147	
	MEAN	144	146	146	
	SD	1.8	2.8	1.4	
	N	10	10	10	
		9.0 mg base/			
	576	144	144	145	
	577	144	142	144	
	578	144	146	148	
	579	144	146	144	
	580	144	144	145	
	581	145	146	144	
	582	144	138	144	
	583	141	144	144	
	584	144	144	144	
	585	143	144	144	
	MEAN	144	144	145	
	SD	1.1	2.4	1.3	
	N	10	10	10	

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Potassium

STUDY ID: UIC-15B

				UNITS: mEq/
Animal ID	Week 4	Week 13	Week 26	
	0 mg base/kg	/day		
426	5.50	5.89	5.37	
427	5.64	5.40	6.21	
428	5.81	6.24	6.33	
429	5.46		6.20	
430	5.08	5.73	5.68	
431	5.10	5.93	4.34	
432	5.71	5.54	4.68	
433	5.36	5.97	5.70	
434	5.60	6.67	6.12	
435	5.42	5.15	5.50	
MEAN	5.47	5.81	5.61	
SD	0.241	0.438	0.671	
N	10	10	10	
 GROUP: 2-F:	0.5 mg base/	kg/day		
476	5.44	5.01	5.08	
477	5.83		6.44	
478	5.22	5.61	5.68	
479	5.35	5.72	5.09	
480	5.04	5.67	5.02	
481	5.16	5.90	5.51	
482	5.58	5.58	6.06	
483	5.35	5.14	5.62	
484	5.71	4.64	5.70	
485	5.89	5.61	5.57	
MEAN	5.46	5.45	5.58	
MEAN				
SD	0.288	0.391	0.448	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Potassium

STUDY ID: UIC-15B

SEX: FEMALE

ABBR: K					UNITS: mEq/L
	Animal ID	Week 4	Week 13	Week 26	•
	CPOUD+ 3-F+	2.0 mg base/	ka/day		•••••
	526	5.27	4.92	6.04	
	527	5.38	5.01	5.42	
	528	6.35	5.90	4.86	
	529	5.82	5.45	5.82	
	530	5.66	6.03	6.06	
	531	5.99	5.84	5.24	
	532	5.82	5.85	6.12	
	533	5.16	5.69	5.32	
	534	5.24	4.76	5.28	
	535	6.19	5.29	4.96	
	222	0.19	3.29	4.70	
	MEAN	5.69	5.47	5.51	
	SD	0.417	0.457	0.465	
	N	10	10	10	
	GROUP: 4-F:	9.0 mg base/	kg/dav		
	576	5.04	5.32	5.08	
	577	6.02	5.23	5.90	
	578	5.77	5.54	5.39	
	579	5.43	5.67	6.05	
	580	5.75	5.48	5.59	
	581	5.53	5.92	5.72	
	582	5.85	5.80	6.07	
	583	5.79	5.55	6.28	
	584	5.55	5.36	5.19	
	585	5.58	5.49		
	202	3.30	3.47	6.10	
	MEAN	5.63	5.54	5.74	
	SD	0.272	0.214	0.413	

10

10

10

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Chloride

STUDY IO: UIC-15B STUDY NO: 152

	Animal IO	Week 4	Week 13	Week 26	,
	GROUP: 1-F:0	mg base/kg	/day		
	426	107	101	106	
	427	109	100	109	
	428	108	102	102	
	429	102	101	97	
	430	100	102	101	
	431	103	97	108	
	432	101	99	104	
	433	102	94	102	
	434	98	99	107	
	435	105	99	108	
	MEAN	10/	00	10/	
	MEAN	104	99	104	
	SO	3.6 10	2.5 10	3.9 10	
	N				
	GROUP: 2-F:0).5 mg base/	kg/day		
••••••	GROUP: 2-F:0 476).5 mg base/	kg/day 105	100	
	GROUP: 2-F:0 476 477	0.5 mg base/ 105 102	kg/day	100 101	
	GROUP: 2-F:0 476	0.5 mg base/ 105 102 105	kg/day 105	100	
	GROUP: 2-F:0 476 477	0.5 mg base/ 105 102	kg/day 105 99	100 101	
	GROUP: 2-F:0 476 477 478	0.5 mg base/ 105 102 105 97 108	kg/day 105 99 100	100 101 101	
	GROUP: 2-F:0 476 477 478 479	0.5 mg base/ 105 102 105 97	kg/day 105 99 100 97	100 101 101 104	
	GROUP: 2-F:0 476 477 478 479 480	0.5 mg base/ 105 102 105 97 108	kg/day 105 99 100 97 100	100 101 101 104 103	
	GROUP: 2-F:0 476 477 478 479 480 481	0.5 mg base/ 105 102 105 97 108 10;	kg/day 105 99 100 97 100 98	100 101 101 104 103 104	
	GROUP: 2-F:0 476 477 478 479 480 481 482 483	0.5 mg base/ 105 102 105 97 108 10: 103 105	kg/day 105 99 100 97 100 98 103	100 101 101 104 103 104 105	
	GROUP: 2-F:0 476 477 478 479 480 481 482	0.5 mg base/ 105 102 105 97 108 10: 103	kg/day 105 99 100 97 100 98 103	100 101 101 104 103 104 105	
	GROUP: 2-F:0 476 477 478 479 480 481 482 483 484	0.5 mg base/ 105 102 105 97 108 10: 103 105 110	kg/day 105 99 100 97 100 98 103 99 105	100 101 101 104 103 104 105 102 103	
	GROUP: 2-F:0 476 477 478 479 480 481 482 483	0.5 mg base/ 105 102 105 97 108 10: 103 105	kg/day 105 99 100 97 100 98 103 99	100 101 101 104 103 104 105 102	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Chloride

STUDY ID: UIC-15B STUDY NO: 152

	Week 4		Week 26	
GROUP: 3-F:	2.0 mg base/	kg/day		
526	107	103	102	
527	108	101	104	
528	104	104	105	
529	102	101	102	
530	108	106	103	
531	104	97	97	
532	103	102	107	
533	104	99	118	
534	99	104	104	
535	107	106	105	
MEAN	105	102	105	
SD	2.9	2.9	5.4	
N	10	10	10	
GROUP: 4-F:	9.0 mg base/	kg/day		
576	101	104	103	
577	107	97	104	
578	102	101	105	
579	103	103	103	
580	110	105	100	
581	100	103	104	
582	106	101	100	
583	103	104	101	
584	107	97	101	
585	103	102	100	
MEAN	104	102	102	
SD	3.2	2.8	1.9	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Calcium

STUDY ID: UIC-158

SEX: FEMALE

STUDY NO: 152

ABBR: CA					UNITS: mg/dL
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 1-F:	0 mg base/kg	/day		
	426	10.6	11.0	11.0	
	427	10.4	10.3	11.1	
	428	11.1	10.8	10.9	
	429	10.3	10.4	10.7	
	430	11.0	11.1	11.5	
	431	10.3	10.7	10.9	
	432	11.0	11.0	10.9	
	433	11.0	11.0	11.6	
	434	10.8	12.7	10.9	
	435	11.1	10.9	11.5	
	MEAN	10.8	11.0	11.1	
	SD	0.33	0.66	0.32	
	N	10	10	10	
		0.5 mg base/			
	476	10.4	11.2	10.7	
	477	10.6	10.9	10.8	
	478	10.9	10.4	11.3	
	479	11.1	11.2	11.0	
	480	10.9	10.3	11.0	
	481	10.8	11.8	11.0	
	482	10.6	10.4	11.2	
	483	10.7	10.5	10.5	
	484	11.1	11.0	11.3	
	485	11.0	11.8	11.6	
	485				
		11.0 10.8 0.23	11.8 11.0 0.56	11.6 11.0 0.32	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Calcium

STUDY ID: UIC-15B

 				• • • • • • • • • • • • • • • • • • • •
Animal ID	Week 4	Week 13		
 GROUP: 3-F:	2.0 mg base/	kg/day		
526	10.9	11.5	11.5	
527	10.3	11.4	10.8	
528	11.5	11.5	10.7	
529	10.8	10.7	10.7	
530	11.1	10.7	11.0	
531	10.9	11.3	10.8	
532	11.5	12.1	11.1	
533	11.2	11.3	10.9	
534	10.7	11.0	11.0	
535	10.4	10.6	10.8	
MEAN	10.9	11.2	10.9	*
SD	0.41	0.47	0.24	
N	10	10	10	
 N	10	10	10	
 R GROUP: 4-F:			10	
 			10	
 GROUP: 4-F:	9.0 mg base/ 11.0	kg/day		
 GROUP: 4-F:\ 576	9.0 mg base/ 11.0	kg/day 10.5	11.0	a
 GROUP: 4-F: 576 577	9.0 mg base/ 11.0 11.1	kg/day 10.5 11.1	11.0 11.1	3
 GROUP: 4-F:9 576 577 578	9.0 mg base/ 11.0 11.1 10.6	kg/day 10.5 11.1 11.1	11.0 11.1 11.7	
 GROUP: 4-F:9 576 577 578 579	9.0 mg base/ 11.0 11.1 10.6 11.1	kg/day 10.5 11.1 11.1	11.0 11.1 11.7 10.9	
 GROUP: 4-F:9 576 577 578 579 580	9.0 mg base/ 11.0 11.1 10.6 11.1 11.5	kg/day 10.5 11.1 11.1 11.1	11.0 11.1 11.7 10.9 10.7	
 GROUP: 4-F:9 576 577 578 579 580 581	9.0 mg base/ 11.0 11.1 10.6 11.1 11.5	kg/day 10.5 11.1 11.1 11.3 11.6	11.0 11.1 11.7 10.9 10.7 10.8	
GROUP: 4-F:9 576 577 578 579 580 581 582	9.0 mg base/ 11.0 11.1 10.6 11.1 11.5 10.2	kg/day 10.5 11.1 11.1 11.3 11.6 10.8	11.0 11.1 11.7 10.9 10.7 10.8 10.9	
GROUP: 4-F:9 576 577 578 579 580 581 582 583	9.0 mg base/ 11.0 11.1 10.6 11.1 11.5 10.2 10.8 10.5	kg/day 10.5 11.1 11.1 11.3 11.6 10.8 11.6	11.0 11.1 11.7 10.9 10.7 10.8 10.9	
GROUP: 4-F:9 576 577 578 579 580 581 582 583 584	9.0 mg base/ 11.0 11.1 10.6 11.1 11.5 10.2 10.8 10.5 11.1	kg/day 10.5 11.1 11.1 11.3 11.6 10.8 11.6	11.0 11.1 11.7 10.9 10.7 10.8 10.9 10.8	
GROUP: 4-F:9576 577 578 579 580 581 582 583 584	9.0 mg base/ 11.0 11.1 10.6 11.1 11.5 10.2 10.8 10.5 11.1	kg/day 10.5 11.1 11.1 11.3 11.6 10.8 11.6 11.0	11.0 11.1 11.7 10.9 10.7 10.8 10.9 10.8 10.6	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Inorganic Phosphorus

STUDY ID: UIC-15B

SEX: FEMA

STUDY NO: 152

		Week 13	Week 26	
		/day		
426	7.3	7.9	8.8	
427	9.0	6.9	10.6	
428	9.3	8.1	8.8	
429	6.9	7.2	9.2	
430	7.1	7.0	8.3	
431				
435	8.2	7.0	9.3	
MEAN	7.8	7.0	0.2	
N N	10	10	10	
GROUP: 2-F:	0.5 mg base/	kg/day		
476	7.9	8.1	7.5	
477	7.8	7.8	8.2	
478	8.0	6.9	8.7	
479	7.3	7.3	8.4	
480				
485	8.0	9.0	10.7	
MEAN	8.0	7 7	8.6	
	GROUP: 1-F: 426 427 428 429 430 431 432 433 434 435 MEAN SD N GROUP: 2-F: 476 477 478 479 480 481 482 483 484	GROUP: 1-F:0 mg base/kg 426 7.3 427 9.0 428 9.3 429 6.9 430 7.1 431 7.6 432 7.1 433 8.4 434 7.0 435 8.2 MEAN 7.8 SD 0.88 N 10 GROUP: 2-F:0.5 mg base/ 476 7.9 477 7.8 478 8.0 479 7.3 480 8.4 481 7.7 482 7.6 483 7.9 484 9.2 485 8.0 MEAN 8.0 SD 0.52	GROUP: 1-F:0 mg base/kg/day 426 7.3 7.9 427 9.0 6.9 428 9.3 8.1 429 6.9 7.2 430 7.1 7.0 431 7.6 7.3 432 7.1 10.1 433 8.4 9.0 434 7.0 8.9 435 8.2 7.0 MEAN 7.8 7.9 SD 0.88 1.08 N 10 10 GROUP: 2-F:0.5 mg base/kg/day 476 7.9 8.1 477 7.8 7.8 478 8.0 6.9 479 7.3 7.3 480 8.4 7.4 481 7.7 7.5 482 7.6 7.5 483 7.9 6.6 484 9.2 8.6 485 8.0 9.0 MEAN 8.0 7.7 SD 0.52 0.73	GROUP: 1-F:0 mg base/kg/day 426



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Inorganic Phosphorus

STUDY ID: UIC-15B

SEX: FEMALE

STUDY ID: UIC-158 STUDY NO: 152					SEX: FEMALE
ABBR: IP					UNITS: mg/dL
	Animal ID	Week 4	Week 13	Week 26	
		2.0 mg base/	kg/day		
	526	9.5	8.1	9.7	
	527	7.4	7.6	9.0	
	528	9.6	8.4	11.3	
	529	7.4	8.4	8.2	
	530	9.0	7.3	8.4	
	531	8.8	7.8	7.9	
	532	7.6	9.1	9.3	
	533	8.2	8.1	10.1	
	534	7.0	8.3	7.6	
	535	9.2	8.8	9.1	
	MEAN	8.4	8.2	9.1	
	SD	0.97	0.54	1.12	
	N	10	10	10	
		9.0 mg base/	-	12.1	
	576	8.6	7.7		
	577	8.3	7.4	10.5	
	578	7.4	7.2	10.5	
	579	8.8	8.0	9.3	
	580	9.2	9.3	8.7	
	581	7.1	7.9	8.3	
	582	8.4	7.4	7.6	
	583	8.3	10.2	8.7	
	584	8.1	7.6	8.8	
	585	8.7	7.7	8.5	
	MEAN	8.3	8.0	9.0	
	SD	0.63	0.96	0.91	
			4.0	4.0	

10

10

10



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Glucose

STUDY ID: UIC-15B

STUDY ID: UIC-158 STUDY NO: 152					SEX: FEMALE
ABBR: GLU					UNITS: mg/dL
	Animal ID	Week 4	Week 13	Week 26	
	GROUP: 1-F:	0 mg base/kg			
	426	166	154	196	
	427	149	124	156	
	428	141	129	115	
	429	114	129	131	
	430	127	116	132	
	431	131	114	182	
	432	112	199	180	
	433	112	188	131	
	434	116	150	114	
	435	119	118	194	
	MEAN	129	142	153	
	SD	18.2	30.3	32.5	
	N	10	10	10	
	CROUD. 2-E-	0 5 mg basa			
	GROUP: 2-F:	132	162	127	
	477	116	123	110	
	478	136	128	117	
	479	120	140		
	480	149	143	131 187	
	481	147	148	135	
	482				
	483	114 138	126 135	120 141	
	484	155	204	138	
	485	121	135	185	
	MEAN	133	144	139	
	SD	14.7	23.9	26.5	
	N	10	10	10	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Glucose

STUDY ID: UIC-15B

 Animal ID				
	Week 4	Week 13	Week 26	
	2.0 mg base/			
526	183	261	193	
527	141	193	144	
528	132	130	216	
529	126	145	105	
530	195	133	151	
531	141	120	136	
532	129	168	130	
533	121	146	202	
534	141	204	112	
535	149	157	184	
MEAN	146	166	157	
SD	24.4	43.0	38.9	
N	10	10	10	
 GROUP: 4-F:	9.0 mg base/	'kg/dav		
576	191	152	173	
577	145	113	201	
578	123	118	154	
579	131	116	127	
580	166	163	127	
581	116	142	151	
582	124	139	112	
583	131	266	104	
584	123	120	111	
585	144	136	113	
MEAN	139	147	137	
SD	23.3	45.1	31.7	
N	10	10	10	